-- phpMyAdmin SQL Dump
-- version 5.2.1
-- https://www.phpmyadmin.net/
--
-- Host: localhost:3306
-- Generation Time: Jan 17, 2024 at 05:33 PM
-- Server version: 10.6.16-MariaDB
-- PHP Version: 8.1.25

SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
START TRANSACTION;
SET time_zone = "+00:00";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8mb4 */;

--
-- Database: `bpcc`
--

-- --------------------------------------------------------

--
-- Table structure for table `articles`
--

CREATE TABLE `articles` (
  `id` int(10) UNSIGNED NOT NULL,
  `member_id` bigint(20) UNSIGNED DEFAULT NULL,
  `article_type_id` bigint(20) UNSIGNED DEFAULT NULL,
  `image` varchar(255) NOT NULL,
  `file_one` varchar(255) DEFAULT NULL,
  `file_one_name` varchar(255) DEFAULT NULL,
  `file_two` varchar(255) DEFAULT NULL,
  `file_two_name` varchar(255) DEFAULT NULL,
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `articles`
--

INSERT INTO `articles` (`id`, `member_id`, `article_type_id`, `image`, `file_one`, `file_one_name`, `file_two`, `file_two_name`, `order_by`, `created_at`, `updated_at`) VALUES
(5, 24, 5, 'uploads/Article/916091701786999.webp', 'uploads/Article/600731701786999.pdf', 'BPC-Arabic-Signed-Report-March-2023.pdf', 'uploads/Article/800991701787160.pdf', 'BPC-English-Signed-Report-March-2023-1.pdf', NULL, '2023-12-05 12:36:39', '2023-12-05 12:39:20'),
(6, 24, 5, 'uploads/Article/600601704629767.png', 'uploads/Article/940021701787295.pdf', 'Newsletter-2022.pdf', NULL, NULL, NULL, '2023-12-05 12:41:35', '2024-01-07 10:16:07'),
(7, 24, 2, 'uploads/Article/747501702112182.webp', NULL, NULL, NULL, NULL, NULL, '2023-12-09 06:56:22', '2023-12-09 06:56:22'),
(8, 24, 1, 'uploads/Article/81921702117777.jpg', NULL, NULL, NULL, NULL, NULL, '2023-12-09 08:29:37', '2023-12-09 08:29:37'),
(9, 24, 5, 'uploads/Article/175581704965217.jpeg', NULL, NULL, NULL, NULL, NULL, '2024-01-11 07:26:57', '2024-01-11 07:26:57');

-- --------------------------------------------------------

--
-- Table structure for table `article_translations`
--

CREATE TABLE `article_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `article_id` int(10) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `title` varchar(255) NOT NULL,
  `description` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `article_translations`
--

INSERT INTO `article_translations` (`id`, `article_id`, `locale`, `title`, `description`, `created_at`, `updated_at`) VALUES
(5, 5, 'en', 'Exciting News: Introducing BPC Reports For First Quarter 2023!', '<p>Birzeit Pharmaceutical Company Is Thrilled To Announce The Launch Of BPC Reports For The First Quarter Of 2023. Our Innovative Reporting Solution Is Designed To Elevate Data Analysis And Empower Decision-Making Within Our Organization. With Its Seamless Integration And Advanced Features, BPC Reports Will Revolutionize How We Harness Insights And Drive Success.</p>', NULL, NULL),
(6, 6, 'en', 'BPC Annual Newsletter 2022', '<h2>You can download BPC\'s Annual Newsletter for the year 2022:</h2>', NULL, NULL),
(7, 7, 'en', 'Relying 100% On Solar Energy To Meet Our Energy Needs', '<p>Birzeit Pharmaceutical Company and Masader Company -which is Owned by the Palestine Investment Fund- have signed an agreement to acquire a stake in the \"Noor Jericho\" solar power plant. This strategic move aims to fulfill the entirety of Birzeit Pharmaceutical Company\'s electricity requirements through renewable energy sources. By harnessing the power generated by the 2.21 megawatt-capacity station, the company is taking a significant step towards becoming environmentally friendly and fully reliant on renewable energy. This decision holds great significance on multiple fronts, including environmental preservation, national interests, and investment prospects.</p>\r\n<p>&nbsp;By embracing solar energy sources, the company is actively reducing its dependency on Israel for energy and electricity, while simultaneously aligning with its commitment to safeguarding the environment and utilizing clean energy sources. Moreover, this transition will lead to a decrease in production costs, as the company will benefit from reduced operational expenses, thereby enhancing its competitiveness in both local and international markets.</p>', NULL, NULL),
(8, 8, 'en', 'Ownership Structure', '<div class=\"elementor-element elementor-element-324f0b4 elementor-widget elementor-widget-heading\" data-id=\"324f0b4\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h4 class=\"elementor-heading-title elementor-size-default\">The company\'s shareholders are distributed according to the classes of shares they own as follows as of 31/12/2021:</h4>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-03f6de4 elementor-widget elementor-widget-jet-table\" data-id=\"03f6de4\" data-element_type=\"widget\" data-widget_type=\"jet-table.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-jet-table jet-elements\">\r\n<div class=\"jet-table-wrapper jet-table-responsive-mobile\">\r\n<table class=\"jet-table jet-table--sorting jet-table--fa5-compat tablesorter tablesorter-default tablesorter202a16c4432e7\" role=\"grid\">\r\n<thead class=\"jet-table__head\">\r\n<tr class=\"jet-table__head-row tablesorter-headerRow\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-34e2934 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"0\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Category: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Category</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-31e3760 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"1\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Number of Shareholders: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Number of Shareholders</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-66fd0ac jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"2\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Number of Shares: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Number of Shares</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-25c6a86 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"3\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Contribution percentage: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Contribution percentage</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n</tr>\r\n</thead>\r\n<tfoot class=\"jet-table__foot\">\r\n<tr class=\"jet-table__foot-row\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-4788968 jet-table__foot-cell\" scope=\"col\" data-column=\"0\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Total:</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-2165f09 jet-table__foot-cell\" scope=\"col\" data-column=\"1\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1319</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-38bb64b jet-table__foot-cell\" scope=\"col\" data-column=\"2\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">19382449</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-250a6c7 jet-table__foot-cell\" scope=\"col\" data-column=\"3\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">100.00%</div>\r\n</div>\r\n</div>\r\n</th>\r\n</tr>\r\n</tfoot>\r\n<tbody class=\"jet-table__body jet-table__body_no-border-radius\" aria-live=\"polite\" aria-relevant=\"all\">\r\n<tr class=\"jet-table__body-row elementor-repeater-item-059f6ca\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-68d1181 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">From 100,001 shares or more</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-1b9dd6e jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">31</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6896003 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">12818137</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-9535c92 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">66.13%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-45ca317\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-1132ab8 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">From 50001 to 100,000 shares</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-6859aa7 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">27</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-7b76fc0 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1769986</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-7dc6e6d jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">9.13%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-4aceda9\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-114db24 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">From 10.001 to 50,000 shares</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-8bd7a1a jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">147</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-29703b6 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">3074464</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a9a1aa1 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">15.86%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-e5706cc\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-c66c3e0 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">From 5001 to 10,000 shares</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-2b186f9 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">97</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-fe0af22 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">709976</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-1fc3f19 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">3.66%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-9c860af\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-9da97e3 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">From 1001 to 5000 shares</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-95127b2 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">341</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6402ded jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">795561</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-d5bc4e4 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">4.10%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-629813a\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-7305958 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">From 501 to 1000 shares</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-aec3cb7 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">162</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-884d10a jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">123574</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-e411238 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">0.64%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-3d21a4a\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-035c79b jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">From 101 to 500 shares</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-7c4df48 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">315</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-dea8c14 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">81435</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-12b2996 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">0.42%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-a1408dc\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-d35cdc6 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Less than 100 shares</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-c4c6f16 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">199</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-f2ce77c jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">9316</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-187f7c5 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">0.05%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n</div>\r\n</div>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-eaed594 elementor-widget elementor-widget-heading\" data-id=\"eaed594\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h4 class=\"elementor-heading-title elementor-size-default\">Shareholders owning more than 5% of the company&rsquo;s shares as on 31/12/2021:</h4>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-8bc6253 elementor-widget elementor-widget-jet-table\" data-id=\"8bc6253\" data-element_type=\"widget\" data-widget_type=\"jet-table.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-jet-table jet-elements\">\r\n<div class=\"jet-table-wrapper jet-table-responsive-mobile\">\r\n<table class=\"jet-table jet-table--sorting jet-table--fa5-compat tablesorter tablesorter-default tablesorterb03c07739a6b9\" role=\"grid\">\r\n<thead class=\"jet-table__head\">\r\n<tr class=\"jet-table__head-row tablesorter-headerRow\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-34e2934 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"0\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Contributor: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Contributor</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-31e3760 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"1\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Number of shares as in 2020: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Number of shares as in 2020</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-66fd0ac jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"2\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Percentage of capital in 2020: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Percentage of capital in 2020</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-25c6a86 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"3\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Number of shares as in 2021: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Number of shares as in 2021</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-83e9f21 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"4\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Percentage of the capital in 2021: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Percentage of the capital in 2021</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n</tr>\r\n</thead>\r\n<tbody class=\"jet-table__body\" aria-live=\"polite\" aria-relevant=\"all\">\r\n<tr class=\"jet-table__body-row elementor-repeater-item-059f6ca\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-68d1181 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Orchid Investment Company</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-1b9dd6e jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,511,476</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6896003 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">7.95</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-9535c92 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,573,820</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-08a9963 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">8.11</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-45ca317\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-1132ab8 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Rozan Center&nbsp;</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-6859aa7 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,390,124</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-7b76fc0 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">7.32</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-7dc6e6d jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,417,926</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a71fd56 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">7.32</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-4aceda9\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-114db24 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Firas Kazem Abdullah Nassereddin</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-8bd7a1a jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,153,500</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-29703b6 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">6.07</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a9a1aa1 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,211,500</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-ec90bc8 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">6.25</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-e5706cc\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-c66c3e0 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Iyad Kazem Abdullah Nassereddin</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-2b186f9 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,090,262</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-fe0af22 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">5.73</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-1fc3f19 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,112,067</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a441c9d jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">5.73</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-9c860af\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-9da97e3 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Aswaaq Investment Company</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-95127b2 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,011,421</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6402ded jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">5.32</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-d5bc4e4 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,057,248</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a11c43d jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">5.45</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n</div>\r\n</div>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-b68f437 elementor-widget elementor-widget-heading\" data-id=\"b68f437\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h4 class=\"elementor-heading-title elementor-size-default\">The trading volume of the company&rsquo;s shares in the Palestine Stock Exchange during the year 2021 was as follows:</h4>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-a50b0f9 elementor-widget elementor-widget-jet-table\" data-id=\"a50b0f9\" data-element_type=\"widget\" data-widget_type=\"jet-table.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-jet-table jet-elements\">\r\n<div class=\"jet-table-wrapper jet-table-responsive-mobile\">\r\n<table class=\"jet-table jet-table--fa5-compat\">\r\n<thead class=\"jet-table__head\">\r\n<tr class=\"jet-table__head-row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-34e2934 jet-table__head-cell\" scope=\"col\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Shares</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-0d757cc jet-table__head-cell\" scope=\"col\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Value</div>\r\n</div>\r\n</div>\r\n</th>\r\n</tr>\r\n</thead>\r\n<tbody class=\"jet-table__body\">\r\n<tr class=\"jet-table__body-row elementor-repeater-item-059f6ca\">\r\n<td class=\"jet-table__cell elementor-repeater-item-08a9963 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Number of Traded shares&nbsp;</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-d60b167 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">459,514 shares</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-ea048c6\">\r\n<td class=\"jet-table__cell elementor-repeater-item-f50f959 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">The value of the traded Shares</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-11896c1 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">2,515,759 USD</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-368effa\">\r\n<td class=\"jet-table__cell elementor-repeater-item-348f1c2 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Number of executed contracts</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6359cac jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">206 knots</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-9fc9f59\">\r\n<td class=\"jet-table__cell elementor-repeater-item-f583d01 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Share opening price</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-bcc7d5a jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">$5.40</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-c52b031\">\r\n<td class=\"jet-table__cell elementor-repeater-item-a08e31b jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Share closing price</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-b4a1aba jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">$5.65</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-e7cddfe\">\r\n<td class=\"jet-table__cell elementor-repeater-item-15bff08 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Highest traded price</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-8459d40 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">$5.90</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-f48f384\">\r\n<td class=\"jet-table__cell elementor-repeater-item-14871ec jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">Lowest traded price</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6bd3391 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">$5.06</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-86d581f\">\r\n<td class=\"jet-table__cell elementor-repeater-item-1d1dd9e jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">stock turnover rate</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-efbadce jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">2.37%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n</div>\r\n</div>\r\n</div>\r\n</div>', NULL, NULL);
INSERT INTO `article_translations` (`id`, `article_id`, `locale`, `title`, `description`, `created_at`, `updated_at`) VALUES
(9, 8, 'ar', 'هيكل الملكية \"كيفية توزيع المساهمين في الشركة\"', '<p>ويتوزع مساهمو الشركة حسب فئات الأسهم التي يملكونها على النحو التالي اعتباراً من 31/12/2021:</p>\r\n<p>&nbsp;</p>\r\n<table class=\"jet-table jet-table--sorting jet-table--fa5-compat tablesorter tablesorter-default tablesorter202a16c4432e7\" style=\"height: 504px; width: 101.438%;\" role=\"grid\">\r\n<thead class=\"jet-table__head\">\r\n<tr class=\"jet-table__head-row tablesorter-headerRow\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-34e2934 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" style=\"width: 28.3316%;\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"0\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Category: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">الفئة</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-31e3760 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" style=\"width: 23.5318%;\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"1\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Number of Shareholders: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">عدد المساهمين</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-66fd0ac jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" style=\"width: 17.2999%;\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"2\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Number of Shares: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">عدد الأسهم</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-25c6a86 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" style=\"width: 23.5925%;\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"3\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Contribution percentage: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">نسبة المساهمة</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n</tr>\r\n</thead>\r\n<tfoot class=\"jet-table__foot\">\r\n<tr class=\"jet-table__foot-row\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-4788968 jet-table__foot-cell\" style=\"width: 28.3316%;\" scope=\"col\" data-column=\"0\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">الإجمالي الكلي:</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-2165f09 jet-table__foot-cell\" style=\"width: 23.5318%;\" scope=\"col\" data-column=\"1\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1319</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-38bb64b jet-table__foot-cell\" style=\"width: 17.2999%;\" scope=\"col\" data-column=\"2\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">19382449</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-250a6c7 jet-table__foot-cell\" style=\"width: 23.5925%;\" scope=\"col\" data-column=\"3\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">100.00%</div>\r\n</div>\r\n</div>\r\n</th>\r\n</tr>\r\n</tfoot>\r\n<tbody class=\"jet-table__body jet-table__body_no-border-radius\" aria-live=\"polite\" aria-relevant=\"all\">\r\n<tr class=\"jet-table__body-row elementor-repeater-item-059f6ca\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-68d1181 jet-table__head-cell\" style=\"width: 28.3316%;\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">من 100.001 سهم فأكثر</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-1b9dd6e jet-table__body-cell\" style=\"width: 23.5318%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">31</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6896003 jet-table__body-cell\" style=\"width: 17.2999%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">12818137</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-9535c92 jet-table__body-cell\" style=\"width: 23.5925%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">66.13%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-45ca317\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-1132ab8 jet-table__head-cell\" style=\"width: 28.3316%;\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">من 50001 إلى 100000 سهم</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-6859aa7 jet-table__body-cell\" style=\"width: 23.5318%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">27</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-7b76fc0 jet-table__body-cell\" style=\"width: 17.2999%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1769986</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-7dc6e6d jet-table__body-cell\" style=\"width: 23.5925%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">9.13%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-4aceda9\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-114db24 jet-table__head-cell\" style=\"width: 28.3316%;\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">من 10.001 إلى 50.000 سهم</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-8bd7a1a jet-table__body-cell\" style=\"width: 23.5318%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">147</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-29703b6 jet-table__body-cell\" style=\"width: 17.2999%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">3074464</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a9a1aa1 jet-table__body-cell\" style=\"width: 23.5925%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">15.86%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-e5706cc\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-c66c3e0 jet-table__head-cell\" style=\"width: 28.3316%;\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">من 5001 إلى 10000 سهم</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-2b186f9 jet-table__body-cell\" style=\"width: 23.5318%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">97</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-fe0af22 jet-table__body-cell\" style=\"width: 17.2999%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">709976</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-1fc3f19 jet-table__body-cell\" style=\"width: 23.5925%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">3.66%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-9c860af\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-9da97e3 jet-table__head-cell\" style=\"width: 28.3316%;\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">من 1001 إلى 5000 سهم</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-95127b2 jet-table__body-cell\" style=\"width: 23.5318%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">341</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6402ded jet-table__body-cell\" style=\"width: 17.2999%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">795561</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-d5bc4e4 jet-table__body-cell\" style=\"width: 23.5925%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">4.10%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-629813a\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-7305958 jet-table__head-cell\" style=\"width: 28.3316%;\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">من 501 إلى 1000 سهم</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-aec3cb7 jet-table__body-cell\" style=\"width: 23.5318%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">162</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-884d10a jet-table__body-cell\" style=\"width: 17.2999%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">123574</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-e411238 jet-table__body-cell\" style=\"width: 23.5925%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">0.64%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-3d21a4a\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-035c79b jet-table__head-cell\" style=\"width: 28.3316%;\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">من 101 إلى 500 سهم</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-7c4df48 jet-table__body-cell\" style=\"width: 23.5318%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">315</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-dea8c14 jet-table__body-cell\" style=\"width: 17.2999%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">81435</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-12b2996 jet-table__body-cell\" style=\"width: 23.5925%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">0.42%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-a1408dc\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-d35cdc6 jet-table__head-cell\" style=\"width: 28.3316%;\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">أقل من 100 سهم</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-c4c6f16 jet-table__body-cell\" style=\"width: 23.5318%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">199</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-f2ce77c jet-table__body-cell\" style=\"width: 17.2999%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">9316</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-187f7c5 jet-table__body-cell\" style=\"width: 23.5925%;\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">0.05%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<p>&nbsp;</p>\r\n<p>المساهمون الذين يملكون ما يزيد عن 5% من أسهم الشركة كما في 31/12/2021:</p>\r\n<table class=\"jet-table jet-table--sorting jet-table--fa5-compat tablesorter tablesorter-default tablesorterb03c07739a6b9\" role=\"grid\">\r\n<thead class=\"jet-table__head\">\r\n<tr class=\"jet-table__head-row tablesorter-headerRow\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-34e2934 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"0\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Contributor: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">المساهم</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-31e3760 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"1\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Number of shares as in 2020: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">عدد الاسهم في عام 2020</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-66fd0ac jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"2\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Percentage of capital in 2020: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">نسبة رأس المال في عام 2020</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-25c6a86 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"3\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Number of shares as in 2021: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">عدد الاسهم في عام 2021</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-83e9f21 jet-table__head-cell tablesorter-header jet-table-header-sort tablesorter-headerUnSorted\" tabindex=\"0\" role=\"columnheader\" scope=\"col\" data-column=\"4\" aria-disabled=\"false\" aria-sort=\"none\" aria-label=\"Percentage of the capital in 2021: No sort applied, activate to apply an ascending sort\">\r\n<div class=\"tablesorter-header-inner\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">نسبة رأس المال في عام 2021</div>\r\n</div>\r\n</div>\r\n</div>\r\n</th>\r\n</tr>\r\n</thead>\r\n<tbody class=\"jet-table__body\" aria-live=\"polite\" aria-relevant=\"all\">\r\n<tr class=\"jet-table__body-row elementor-repeater-item-059f6ca\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-68d1181 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">شركة اوركيد للاستثمار</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-1b9dd6e jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,511,476</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6896003 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">7.95</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-9535c92 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,573,820</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-08a9963 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">8.11</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-45ca317\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-1132ab8 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">م. روزان متخصص في الطب والعقم وعلاج أطفال الأنابيب</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-6859aa7 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,390,124</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-7b76fc0 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">7.32</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-7dc6e6d jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,417,926</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a71fd56 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">7.32</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-4aceda9\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-114db24 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">فراس كاظم عبدالله ناصر الدين</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-8bd7a1a jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,153,500</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-29703b6 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">6.07</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a9a1aa1 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,211,500</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-ec90bc8 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">6.25</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-e5706cc\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-c66c3e0 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">إياد كاظم عبدالله ناصر الدين</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-2b186f9 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,090,262</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-fe0af22 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">5.73</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-1fc3f19 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,112,067</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a441c9d jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">5.73</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-9c860af\" role=\"row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-9da97e3 jet-table__head-cell\" scope=\"row\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">شركة أسواق للمحفظة الاستثمارية</div>\r\n</div>\r\n</div>\r\n</th>\r\n<td class=\"jet-table__cell elementor-repeater-item-95127b2 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,011,421</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6402ded jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">5.32</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-d5bc4e4 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">1,057,248</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-a11c43d jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">5.45</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<p>&nbsp;</p>\r\n<p>وبلغ حجم تداول أسهم الشركة في بورصة فلسطين خلال العام 2021 كما يلي:</p>\r\n<table class=\"jet-table jet-table--fa5-compat\">\r\n<thead class=\"jet-table__head\">\r\n<tr class=\"jet-table__head-row\">\r\n<th class=\"jet-table__cell elementor-repeater-item-34e2934 jet-table__head-cell\" scope=\"col\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">أسهم</div>\r\n</div>\r\n</div>\r\n</th>\r\n<th class=\"jet-table__cell elementor-repeater-item-0d757cc jet-table__head-cell\" scope=\"col\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">القيمة</div>\r\n</div>\r\n</div>\r\n</th>\r\n</tr>\r\n</thead>\r\n<tbody class=\"jet-table__body\">\r\n<tr class=\"jet-table__body-row elementor-repeater-item-059f6ca\">\r\n<td class=\"jet-table__cell elementor-repeater-item-08a9963 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">عدد الأسهم المتداولة</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-d60b167 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">459,514 سهم</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-ea048c6\">\r\n<td class=\"jet-table__cell elementor-repeater-item-f50f959 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">قيمة الأسهم المتداولة</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-11896c1 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">2,515,759 USD</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-368effa\">\r\n<td class=\"jet-table__cell elementor-repeater-item-348f1c2 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">عدد العقود المنفذة</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6359cac jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">206 عقد</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-9fc9f59\">\r\n<td class=\"jet-table__cell elementor-repeater-item-f583d01 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">سعر افتتاح السهم</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-bcc7d5a jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">$5.40</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-c52b031\">\r\n<td class=\"jet-table__cell elementor-repeater-item-a08e31b jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">سعر إغلاق السهم</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-b4a1aba jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">$5.65</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-e7cddfe\">\r\n<td class=\"jet-table__cell elementor-repeater-item-15bff08 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">أعلى سعر للتداول</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-8459d40 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">$5.90</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-f48f384\">\r\n<td class=\"jet-table__cell elementor-repeater-item-14871ec jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">أقل سعر تداول</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-6bd3391 jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">$5.06</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n<tr class=\"jet-table__body-row elementor-repeater-item-86d581f\">\r\n<td class=\"jet-table__cell elementor-repeater-item-1d1dd9e jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">معدل دوران الأوراق المالية</div>\r\n</div>\r\n</div>\r\n</td>\r\n<td class=\"jet-table__cell elementor-repeater-item-efbadce jet-table__body-cell\">\r\n<div class=\"jet-table__cell-inner\">\r\n<div class=\"jet-table__cell-content\">\r\n<div class=\"jet-table__cell-text\">2.37%</div>\r\n</div>\r\n</div>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>', NULL, NULL),
(10, 7, 'ar', 'الاعتماد بنسبة 100% على الطاقة الشمسية لتلبية احتياجاتنا من الطاقة', '<p>وقعت شركة بيرزيت للأدوية وشركة مصادر التابعة لصندوق الاستثمار الفلسطيني اتفاقية لشراء حصة في محطة &ldquo;نور أريحا&rdquo; للطاقة الشمسية لتلبية احتياجاتها من الكهرباء بنسبة 100%. وبموجب الاتفاقية، تم تزويد شركة بيرزيت للأدوية بالطاقة الكهربائية من المحطة بقدرة إنتاجية تبلغ 2.21 ميغاواط، لتصبح الشركة خضراء وتعتمد على مصادر الطاقة المتجددة بنسبة 100%. وتعتبر هذه الخطوة خطوة بيئية ووطنية واستثمارية، حيث أن الاعتماد على مصادر الطاقة الشمسية هو أحد الحلول نحو فك الارتباط التدريجي عن إسرائيل في ملف الطاقة والكهرباء، بالإضافة إلى أن الشركة أصبحت خضراء في أعمالها ولن التسبب في الإضرار بالبيئة تماشياً مع توجهاتها بالمحافظة على البيئة والاعتماد على مصادر الطاقة. متجددة ونظيفة. أما تكلفة الإنتاج فستنخفض من خلال تزويد الشركة بمصاريف التشغيل مما يدعم قدرتها التنافسية في الأسواق المحلية والخارجية.</p>', NULL, NULL),
(11, 6, 'ar', 'النشرة الإخبارية السنوية 2022 لـ BPC', '<p>يمكنكم تحميل \"النشرة السنوية 2022 لشركة بيرزيت للأدوية\" تحت الرابط أدناه</p>', NULL, NULL),
(12, 5, 'ar', 'آخر الأخبار : تقديم تقارير BPC للربع الأول 2023!', '<p>يسر شركة بيرزيت للأدوية أن تعلن عن إطلاق تقارير BPC للربع الأول من عام 2023. وقد تم تصميم حل التقارير المبتكر لدينا لرفع مستوى تحليل البيانات وتمكين اتخاذ القرار داخل مؤسستنا. بفضل تكاملها السلس وميزاتها المتقدمة، ستحدث تقارير BPC ثورة في كيفية تسخير الرؤى وتحقيق النجاح.</p>', NULL, NULL),
(13, 9, 'en', 'Birzeit Pharmaceutical Company and Higher Council for Youth and Sports Sign Sponsorship Agreement.', '<p>Birzeit Pharmaceutical Company and Higher Council for Youth&nbsp;and Sports Sign Sponsorship Agreement for the 10th Palestine International Marathon.</p>\r\n<p>BPC represented by its chairman and CEO Talal Nassereddin and the Higher Council for Youth and Sports, represented by the General Director of the Palestine Marathon Etidal Abdel Ghani have signed an agreement to sponsor the Palestine International Marathon in its tenth edition, scheduled to be held on May 10th 2024. This will be in parallel to BPC\'s celebration of its 50 years anniversary.</p>', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `article_types`
--

CREATE TABLE `article_types` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `article_types`
--

INSERT INTO `article_types` (`id`, `order_by`, `created_at`, `updated_at`) VALUES
(1, NULL, '2023-12-04 08:00:04', '2023-12-04 08:00:04'),
(2, NULL, '2023-12-04 08:00:04', '2023-12-04 08:00:04'),
(3, NULL, '2023-12-04 08:00:04', '2023-12-04 08:00:04'),
(5, NULL, '2023-12-05 12:33:16', '2023-12-05 12:33:16');

-- --------------------------------------------------------

--
-- Table structure for table `article_type_translations`
--

CREATE TABLE `article_type_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `article_type_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `title` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `article_type_translations`
--

INSERT INTO `article_type_translations` (`id`, `article_type_id`, `locale`, `title`, `created_at`, `updated_at`) VALUES
(1, 1, 'en', 'Corporate Governance', NULL, NULL),
(2, 2, 'en', 'Factory', NULL, NULL),
(3, 3, 'en', 'Social Responsibility', NULL, NULL),
(5, 1, 'ar', 'حوكمة الشركات', NULL, NULL),
(6, 2, 'ar', 'مصنع', NULL, NULL),
(7, 3, 'ar', 'مسؤولية اجتماعية', NULL, NULL),
(9, 5, 'en', 'Updates', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `branches`
--

CREATE TABLE `branches` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `order_by` varchar(255) DEFAULT NULL,
  `image` varchar(255) DEFAULT NULL,
  `phone` varchar(255) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `branches`
--

INSERT INTO `branches` (`id`, `order_by`, `image`, `phone`, `created_at`, `updated_at`) VALUES
(1, '1', 'assets/img/general/branch-3.webp', '+970 (2) 2956581', '2023-12-04 08:00:04', '2023-12-06 09:39:59'),
(2, '2', 'assets/img/general/branch-2.webp', '+970 (2) 2987573', '2023-12-04 08:00:05', '2023-12-06 09:40:31'),
(3, '3', 'assets/img/general/branch-1.webp', '+970 (2) 2987572', '2023-12-04 08:00:05', '2023-12-06 09:41:00');

-- --------------------------------------------------------

--
-- Table structure for table `branch_translations`
--

CREATE TABLE `branch_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `branch_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `title` varchar(255) DEFAULT NULL,
  `title_color` varchar(255) DEFAULT NULL,
  `address` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `branch_translations`
--

INSERT INTO `branch_translations` (`id`, `branch_id`, `locale`, `title`, `title_color`, `address`, `created_at`, `updated_at`) VALUES
(1, 1, 'en', 'Department', 'Marketing', 'Ramallah/ Betunia Industrial Area 4 Hittin Street/ Palestine', NULL, NULL),
(2, 1, 'ar', 'قسم ', 'التسويق ', 'رام الله/ بيتونيا الصناعية 20 شارع شاتيلا/ فلسطين', NULL, NULL),
(3, 2, 'en', 'Branch', 'Beitunia', 'Ramallah/ Betunia Industrial Area 20 Shatella Street/ Palestine', NULL, NULL),
(4, 2, 'ar', 'فرع ', 'بيتونيا  ', 'رام الله/ بيتونيا الصناعية 20 شارع شاتيلا/ فلسطين', NULL, NULL),
(5, 3, 'en', 'Branch', 'Birzeit', 'Ramallah, Birzeit city, Near Birzeit Girls Elementary School', NULL, NULL),
(6, 3, 'ar', 'فرع ', 'بيرزيت ', 'رام الله، مدينة بيرزيت، قرب مدرسة بنات بيرزيت الأساسية', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `careers`
--

CREATE TABLE `careers` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `image` varchar(255) DEFAULT NULL,
  `full_name` varchar(255) DEFAULT NULL,
  `position` varchar(255) DEFAULT NULL,
  `address` varchar(255) DEFAULT NULL,
  `mobile` varchar(255) DEFAULT NULL,
  `email` varchar(255) DEFAULT NULL,
  `place_of_birth` varchar(255) DEFAULT NULL,
  `date_of_birth` date DEFAULT NULL,
  `gender` tinyint(4) NOT NULL COMMENT '0 male , 1 female',
  `passport_no` varchar(255) DEFAULT NULL,
  `marital_status` varchar(255) DEFAULT NULL,
  `has_suffer` tinyint(4) NOT NULL COMMENT '0 no , 1 yes',
  `desc_suffer` text DEFAULT NULL,
  `has_allergy` tinyint(4) NOT NULL COMMENT '0 no , 1 yes',
  `smoke` tinyint(4) NOT NULL COMMENT '0 no , 1 yes',
  `is_agree` tinyint(4) NOT NULL COMMENT '0 no , 1 yes',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `careers`
--

INSERT INTO `careers` (`id`, `image`, `full_name`, `position`, `address`, `mobile`, `email`, `place_of_birth`, `date_of_birth`, `gender`, `passport_no`, `marital_status`, `has_suffer`, `desc_suffer`, `has_allergy`, `smoke`, `is_agree`, `created_at`, `updated_at`) VALUES
(1, 'uploads/InvestorService/52461701783747.jpg', 'Raghad', 'HR', 'رام الله البيرة', '0592675429', 'raghad@fis.ps', 'Palestine', '1999-12-01', 1, '6567656789', 'Single', 0, NULL, 0, 0, 1, '2023-12-05 11:42:27', '2023-12-05 11:42:27');

-- --------------------------------------------------------

--
-- Table structure for table `career_computer_skills`
--

CREATE TABLE `career_computer_skills` (
  `id` int(10) UNSIGNED NOT NULL,
  `career_id` bigint(20) UNSIGNED DEFAULT NULL,
  `name` varchar(255) DEFAULT NULL,
  `Experience` tinyint(4) NOT NULL COMMENT '0 weak 1 good 2 Excellent',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `career_computer_skills`
--

INSERT INTO `career_computer_skills` (`id`, `career_id`, `name`, `Experience`, `created_at`, `updated_at`) VALUES
(1, 1, '---', 2, '2023-12-05 11:42:27', '2023-12-05 11:42:27');

-- --------------------------------------------------------

--
-- Table structure for table `career_educational`
--

CREATE TABLE `career_educational` (
  `id` int(10) UNSIGNED NOT NULL,
  `career_id` bigint(20) UNSIGNED DEFAULT NULL,
  `degree` varchar(255) DEFAULT NULL,
  `degree_specialization` varchar(255) DEFAULT NULL,
  `degree_university` varchar(255) DEFAULT NULL,
  `degree_date` date DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `career_educational`
--

INSERT INTO `career_educational` (`id`, `career_id`, `degree`, `degree_specialization`, `degree_university`, `degree_date`, `created_at`, `updated_at`) VALUES
(1, 1, 'Bachelor\'s degree', '----', 'Birzeit University', '2017-02-07', '2023-12-05 11:42:27', '2023-12-05 11:42:27');

-- --------------------------------------------------------

--
-- Table structure for table `career_languages`
--

CREATE TABLE `career_languages` (
  `id` int(10) UNSIGNED NOT NULL,
  `career_id` bigint(20) UNSIGNED DEFAULT NULL,
  `language` varchar(255) DEFAULT NULL,
  `reading` tinyint(4) NOT NULL COMMENT '0 weak 1 good 2 Excellent',
  `writing` tinyint(4) NOT NULL COMMENT '0 weak 1 good 2 Excellent',
  `speaking` tinyint(4) NOT NULL COMMENT '0 weak 1 good 2 Excellent',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `career_languages`
--

INSERT INTO `career_languages` (`id`, `career_id`, `language`, `reading`, `writing`, `speaking`, `created_at`, `updated_at`) VALUES
(1, 1, 'Arabic', 2, 2, 2, '2023-12-05 11:42:27', '2023-12-05 11:42:27');

-- --------------------------------------------------------

--
-- Table structure for table `career_training_courses`
--

CREATE TABLE `career_training_courses` (
  `id` int(10) UNSIGNED NOT NULL,
  `career_id` bigint(20) UNSIGNED DEFAULT NULL,
  `name` varchar(255) DEFAULT NULL,
  `training_institute` varchar(255) NOT NULL,
  `Period` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `career_training_courses`
--

INSERT INTO `career_training_courses` (`id`, `career_id`, `name`, `training_institute`, `Period`, `created_at`, `updated_at`) VALUES
(1, 1, '---', '--', '3', '2023-12-05 11:42:27', '2023-12-05 11:42:27');

-- --------------------------------------------------------

--
-- Table structure for table `career_work_experience`
--

CREATE TABLE `career_work_experience` (
  `id` int(10) UNSIGNED NOT NULL,
  `career_id` bigint(20) UNSIGNED DEFAULT NULL,
  `company_name` varchar(255) DEFAULT NULL,
  `company_address` varchar(255) DEFAULT NULL,
  `company_tel` varchar(255) DEFAULT NULL,
  `salary_start` varchar(255) DEFAULT NULL,
  `salary_end` varchar(255) DEFAULT NULL,
  `period_from` date DEFAULT NULL,
  `period_to` date DEFAULT NULL,
  `reason_for_leaving` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `categories`
--

CREATE TABLE `categories` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `product_type_id` bigint(20) UNSIGNED DEFAULT NULL,
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `categories`
--

INSERT INTO `categories` (`id`, `product_type_id`, `order_by`, `created_at`, `updated_at`) VALUES
(5, 2, NULL, '2023-12-06 04:41:57', '2023-12-06 09:15:49'),
(6, 2, NULL, '2023-12-06 04:42:08', '2023-12-06 09:15:56'),
(7, 2, NULL, '2023-12-06 04:42:25', '2023-12-06 09:16:13'),
(8, 2, NULL, '2023-12-06 04:42:40', '2023-12-06 09:38:13'),
(9, 2, NULL, '2023-12-06 04:42:55', '2023-12-09 10:23:02'),
(10, 2, NULL, '2023-12-06 04:43:11', '2023-12-09 10:23:30'),
(11, 2, NULL, '2023-12-06 04:43:29', '2023-12-07 04:48:43'),
(12, 2, NULL, '2023-12-06 04:44:13', '2023-12-07 04:48:03'),
(13, 2, NULL, '2023-12-06 04:44:36', '2023-12-07 04:49:32'),
(14, 1, NULL, '2023-12-06 06:21:01', '2023-12-09 10:24:53'),
(15, 1, NULL, '2023-12-06 07:29:25', '2023-12-09 10:17:51'),
(16, 2, NULL, '2023-12-06 07:56:27', '2023-12-09 10:26:45'),
(17, 1, NULL, '2023-12-06 07:57:55', '2023-12-09 09:57:17'),
(18, 1, NULL, '2023-12-06 07:59:24', '2023-12-09 09:57:08'),
(19, 1, NULL, '2023-12-06 07:59:41', '2023-12-09 09:56:53'),
(20, 1, NULL, '2023-12-06 07:59:55', '2023-12-09 09:56:39'),
(21, 1, NULL, '2023-12-06 08:01:08', '2023-12-09 09:56:29'),
(22, 1, NULL, '2023-12-06 08:01:18', '2023-12-09 09:56:17'),
(23, 1, NULL, '2023-12-06 08:01:40', '2023-12-09 09:56:10'),
(24, 1, NULL, '2023-12-06 08:01:53', '2023-12-09 09:55:27'),
(25, 1, NULL, '2023-12-06 08:02:49', '2023-12-09 09:55:21'),
(26, 1, NULL, '2023-12-06 08:03:10', '2023-12-09 09:55:13'),
(27, 1, NULL, '2023-12-06 08:03:21', '2023-12-06 09:12:47'),
(28, 1, NULL, '2023-12-06 08:03:33', '2023-12-06 09:10:34');

-- --------------------------------------------------------

--
-- Table structure for table `category_translations`
--

CREATE TABLE `category_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `category_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `name` varchar(255) NOT NULL,
  `description` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `category_translations`
--

INSERT INTO `category_translations` (`id`, `category_id`, `locale`, `name`, `description`, `created_at`, `updated_at`) VALUES
(9, 5, 'en', 'Multivitamins & Minerals', NULL, NULL, NULL),
(10, 6, 'en', 'Skin / Topical Care', NULL, NULL, NULL),
(11, 7, 'en', 'Digestion & Gastrointestinal', NULL, NULL, NULL),
(12, 8, 'en', 'Allergy & Cold', NULL, NULL, NULL),
(13, 9, 'en', 'Pain & Fever', NULL, NULL, NULL),
(14, 10, 'en', 'Oral Mouth Care', NULL, NULL, NULL),
(15, 11, 'en', 'Supplements', NULL, NULL, NULL),
(16, 12, 'en', 'Nasal(Nose) Care', NULL, NULL, NULL),
(17, 13, 'en', 'Eye Care', NULL, NULL, NULL),
(18, 14, 'en', 'Antibiotics', NULL, NULL, NULL),
(19, 15, 'en', 'Infections', NULL, NULL, NULL),
(20, 15, 'ar', 'الالتهابات', NULL, NULL, NULL),
(21, 16, 'en', 'Anti-Allergic &amp; Cold Preparations', NULL, NULL, NULL),
(22, 17, 'en', 'Central Nervous System', NULL, NULL, NULL),
(23, 18, 'en', 'Alimentary System', NULL, NULL, NULL),
(24, 19, 'en', 'Cardio-vascular System', NULL, NULL, NULL),
(25, 20, 'en', 'Musculo -Skeletal System', NULL, NULL, NULL),
(26, 21, 'en', 'Ear, Nose & Oropharynx', NULL, NULL, NULL),
(27, 22, 'en', 'Endocrines', NULL, NULL, NULL),
(28, 23, 'en', 'Genito-Urinary System', NULL, NULL, NULL),
(29, 24, 'en', 'Obstetrics & Gynecology', NULL, NULL, NULL),
(30, 25, 'en', 'Affecting Nutrition & Metabolism', NULL, NULL, NULL),
(31, 26, 'en', 'Respiratory System', NULL, NULL, NULL),
(32, 27, 'en', 'Ophthalmic Drugs', NULL, NULL, NULL),
(33, 28, 'en', 'Dermatological Preparations', NULL, NULL, NULL),
(34, 18, 'ar', 'النظام الغذائي', NULL, NULL, NULL),
(35, 19, 'ar', 'نظام القلب والأوعية الدموية', NULL, NULL, NULL),
(36, 17, 'ar', 'الجهاز العصبي المركزي', NULL, NULL, NULL),
(37, 20, 'ar', 'العضلات - الجهاز الهيكلي', NULL, NULL, NULL),
(38, 21, 'ar', 'الأذن والأنف والبلعوم', NULL, NULL, NULL),
(39, 22, 'ar', 'الغدد الصماء', NULL, NULL, NULL),
(40, 23, 'ar', 'نظام الجهاز البولي التناسلي', NULL, NULL, NULL),
(41, 24, 'ar', 'أمراض النساء والولادة', NULL, NULL, NULL),
(42, 25, 'ar', 'التأثير على التغذية والتمثيل الغذائي', NULL, NULL, NULL),
(43, 26, 'ar', 'الجهاز التنفسي', NULL, NULL, NULL),
(44, 27, 'ar', 'أدوية العيون', NULL, NULL, NULL),
(45, 28, 'ar', 'الاستعدادات الجلدية', NULL, NULL, NULL),
(46, 5, 'ar', 'فيتامينات ومعادن متعددة', NULL, NULL, NULL),
(47, 6, 'ar', 'العناية بالبشرة / الموضعية', NULL, NULL, NULL),
(48, 7, 'ar', 'الهضم والجهاز الهضمي', NULL, NULL, NULL),
(49, 8, 'ar', 'الحساسية والبرد', NULL, NULL, NULL),
(50, 9, 'ar', 'الألم والحمى', NULL, NULL, NULL),
(51, 10, 'ar', 'العناية بالفم', NULL, NULL, NULL),
(52, 11, 'ar', 'المكملات الغذائية', NULL, NULL, NULL),
(53, 12, 'ar', 'العناية بالأنف', NULL, NULL, NULL),
(54, 13, 'ar', 'العناية بالعيون', NULL, NULL, NULL),
(55, 14, 'ar', 'المضادات الحيوية', NULL, NULL, NULL),
(56, 16, 'ar', 'مستحضرات مضادة للحساسية والبرد', NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `certificates`
--

CREATE TABLE `certificates` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `icone` varchar(255) NOT NULL,
  `order_by` int(11) DEFAULT NULL,
  `name` varchar(255) NOT NULL,
  `description_ar` text DEFAULT NULL,
  `description_en` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `certificates`
--

INSERT INTO `certificates` (`id`, `icone`, `order_by`, `name`, `description_ar`, `description_en`, `created_at`, `updated_at`) VALUES
(1, 'uploads/Certificate/455351701780988.webp', 1, 'ISO 9001', 'حصلت شركة BPC على شهادة الأيزو في إدارة الجودة.', 'BPC company obtained the ISO certificate in quality management.', '2023-12-04 08:00:04', '2023-12-05 10:56:28'),
(2, 'uploads/Certificate/340571701781010.svg', 2, 'ISO 14001', 'حصلت BPC على شهادة الإدارة البيئية.', 'BPC has obtained Environmental Management Certification.', '2023-12-04 08:00:04', '2023-12-05 10:56:50'),
(3, 'uploads/Certificate/750281701781026.svg', 3, 'GMP', 'حصلت شركة BPC على شهادة GMP الفلسطينية.', 'BPC has obtained the Palestinian GMP certificate.', '2023-12-04 08:00:04', '2023-12-05 10:57:06');

-- --------------------------------------------------------

--
-- Table structure for table `constants`
--

CREATE TABLE `constants` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `title_ar` varchar(255) NOT NULL,
  `title_en` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `constants`
--

INSERT INTO `constants` (`id`, `title_ar`, `title_en`, `created_at`, `updated_at`) VALUES
(1, 'الدرجة العلمية', 'Degree', '2023-12-04 08:00:05', '2023-12-04 08:00:05'),
(2, 'الجامعة', 'The University', '2023-12-04 08:00:05', '2023-12-04 08:00:05'),
(3, 'اللغات', 'Languages', '2023-12-04 08:00:05', '2023-12-04 08:00:05'),
(4, 'مكان الميلاد', 'Place Of Birth', '2023-12-04 08:00:05', '2023-12-04 08:00:05'),
(5, 'الحالة الاجتماعية', 'marital status', '2023-12-04 08:00:05', '2023-12-04 08:00:05');

-- --------------------------------------------------------

--
-- Table structure for table `constant_options`
--

CREATE TABLE `constant_options` (
  `id` int(10) UNSIGNED NOT NULL,
  `constant_id` bigint(20) UNSIGNED DEFAULT NULL,
  `name_ar` varchar(255) DEFAULT NULL,
  `name_en` varchar(255) DEFAULT NULL,
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `constant_options`
--

INSERT INTO `constant_options` (`id`, `constant_id`, `name_ar`, `name_en`, `order_by`, `created_at`, `updated_at`) VALUES
(1, 1, 'ليسانس', 'Bachelor\'s degree', NULL, '2023-12-04 08:00:05', '2023-12-04 08:00:05'),
(2, 1, 'الماستر', 'Master', NULL, '2023-12-04 08:00:05', '2023-12-04 08:00:05'),
(3, 2, 'جامعة بيرزيت', 'Birzeit University', NULL, '2023-12-05 11:38:59', '2023-12-05 11:38:59'),
(4, 4, 'فلسطين', 'Palestine', NULL, '2023-12-05 11:39:26', '2023-12-05 11:39:26'),
(5, 3, 'العربية', 'Arabic', NULL, '2023-12-05 11:39:44', '2023-12-05 11:39:44'),
(6, 3, 'الانجليزية', 'English', NULL, '2023-12-05 11:40:02', '2023-12-05 11:40:02'),
(7, 5, 'أعزب/عزباء', 'Single', NULL, '2023-12-05 11:40:35', '2023-12-05 11:40:35'),
(8, 4, 'الأردن', 'jordan', NULL, '2024-01-04 07:47:23', '2024-01-04 07:47:23'),
(9, 4, 'أخرى', 'other', NULL, '2024-01-04 07:48:27', '2024-01-04 07:48:27'),
(10, 5, 'متزوج/ة', 'married', NULL, '2024-01-04 07:49:31', '2024-01-04 07:49:31');

-- --------------------------------------------------------

--
-- Table structure for table `contacts`
--

CREATE TABLE `contacts` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) NOT NULL,
  `email` varchar(255) NOT NULL,
  `subject` varchar(255) NOT NULL,
  `message` text NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `contacts`
--

INSERT INTO `contacts` (`id`, `name`, `email`, `subject`, `message`, `created_at`, `updated_at`) VALUES
(2, 'raghad', 'raghad@fis.ps', 'test 1', 'test fis', '2023-12-06 09:50:08', '2023-12-06 09:50:08'),
(3, 'raghad', 'raghadd@fis.ps', 'any', 'test', '2023-12-09 07:55:13', '2023-12-09 07:55:13'),
(4, 'raghad', 'admin@admin.com', 'any', 'test', '2023-12-09 07:56:06', '2023-12-09 07:56:06'),
(5, 'test test', 'raghad@fis.ps', 'test', 'test', '2024-01-11 06:28:13', '2024-01-11 06:28:13');

-- --------------------------------------------------------

--
-- Table structure for table `failed_jobs`
--

CREATE TABLE `failed_jobs` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `uuid` varchar(255) NOT NULL,
  `connection` text NOT NULL,
  `queue` text NOT NULL,
  `payload` longtext NOT NULL,
  `exception` longtext NOT NULL,
  `failed_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `file_reports`
--

CREATE TABLE `file_reports` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `file` varchar(255) DEFAULT NULL,
  `file_name` varchar(255) DEFAULT NULL,
  `type` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'zero to annual and number one for qurater',
  `quarter` tinyint(4) NOT NULL DEFAULT 0 COMMENT '1 firtt 2 second ... 4 fourth',
  `order_by` int(11) DEFAULT NULL,
  `date` timestamp NOT NULL DEFAULT '2023-12-04 07:59:58',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `file_reports`
--

INSERT INTO `file_reports` (`id`, `file`, `file_name`, `type`, `quarter`, `order_by`, `date`, `created_at`, `updated_at`) VALUES
(5, 'uploads/FileReport/249601701781384.pdf', '2014.pdf', 0, 0, 5, '2023-12-04 07:59:58', '2023-12-05 11:03:04', '2024-01-10 11:30:21'),
(6, 'uploads/FileReport/600771701781393.pdf', '2015.pdf', 0, 0, 4, '2023-12-04 07:59:58', '2023-12-05 11:03:13', '2024-01-10 11:30:21'),
(7, 'uploads/FileReport/82581701781404.pdf', '2016.pdf', 0, 0, 3, '2023-12-04 07:59:58', '2023-12-05 11:03:24', '2024-01-10 11:30:08'),
(8, 'uploads/FileReport/942561701781516.pdf', '2017.pdf', 0, 0, 2, '2023-12-04 07:59:58', '2023-12-05 11:05:16', '2024-01-10 11:30:05'),
(17, 'uploads/FileReport/847901704719757.pdf', 'Annual Report 2018.pdf', 0, 0, 1, '2023-12-04 07:59:58', '2024-01-08 11:15:57', '2024-01-10 11:30:05'),
(23, 'uploads/FileReport/855871704890755.pdf', 'Financial Info 2014.pdf', 1, 4, 12, '2023-12-04 07:59:58', '2024-01-10 10:45:55', '2024-01-10 12:07:40'),
(24, 'uploads/FileReport/315691704890767.pdf', 'Financial Info 2015.pdf', 1, 4, 11, '2023-12-04 07:59:58', '2024-01-10 10:46:07', '2024-01-10 12:07:40'),
(25, 'uploads/FileReport/24781704890778.pdf', 'Financial Info 2016.pdf', 1, 4, 10, '2023-12-04 07:59:58', '2024-01-10 10:46:18', '2024-01-10 12:07:40'),
(26, 'uploads/FileReport/176381704890914.pdf', 'Financial Info 2017.pdf', 1, 4, 9, '2023-12-04 07:59:58', '2024-01-10 10:48:34', '2024-01-10 12:08:43'),
(27, 'uploads/FileReport/416811704891198.pdf', 'Financial Info 2020.pdf', 1, 4, 6, '2023-12-04 07:59:58', '2024-01-10 10:53:18', '2024-01-10 12:10:36'),
(28, 'uploads/FileReport/995641704891215.pdf', 'Financial Info 2022.pdf', 1, 4, 4, '2023-12-04 07:59:58', '2024-01-10 10:53:35', '2024-01-10 12:11:06'),
(29, 'uploads/FileReport/530881704893849.pdf', 'BPC Financial Info June 2023.pdf', 1, 4, 2, '2023-12-04 07:59:58', '2024-01-10 11:37:29', '2024-01-10 12:11:31'),
(30, 'uploads/FileReport/611741704894095.pdf', 'Financial Info 2018.pdf', 1, 4, 8, '2023-12-04 07:59:58', '2024-01-10 11:41:35', '2024-01-10 12:09:53'),
(31, 'uploads/FileReport/540881704894804.PDF', 'Financial Info 2021.PDF', 1, 4, 5, '2023-12-04 07:59:58', '2024-01-10 11:53:24', '2024-01-10 12:11:06'),
(32, 'uploads/FileReport/7491704894829.pdf', 'Financial Info 2019.pdf', 1, 4, 7, '2023-12-04 07:59:58', '2024-01-10 11:53:49', '2024-01-10 12:10:36'),
(33, 'uploads/FileReport/124871704894861.pdf', 'BPC Financial Info March 2023.pdf', 1, 4, 3, '2023-12-04 07:59:58', '2024-01-10 11:54:21', '2024-01-10 12:11:31'),
(34, 'uploads/FileReport/747581704895087.pdf', 'BPC Financial Info September 2023.pdf', 1, 4, 1, '2023-12-04 07:59:58', '2024-01-10 11:58:07', '2024-01-10 12:11:31'),
(35, 'uploads/FileReport/486951704895332.pdf', 'Annual Report 2019.pdf', 0, 0, NULL, '2023-12-04 07:59:58', '2024-01-10 12:02:12', '2024-01-10 12:02:12'),
(36, 'uploads/FileReport/126631704895442.pdf', 'Annual Report 2020.pdf', 0, 0, NULL, '2023-12-04 07:59:58', '2024-01-10 12:04:02', '2024-01-10 12:04:02'),
(37, 'uploads/FileReport/668511704895461.PDF', 'Annual Report 2021.PDF', 0, 0, NULL, '2023-12-04 07:59:58', '2024-01-10 12:04:21', '2024-01-10 12:04:21'),
(38, 'uploads/FileReport/587081704895476.pdf', 'Annual Report 2022.pdf', 0, 0, NULL, '2023-12-04 07:59:58', '2024-01-10 12:04:36', '2024-01-10 12:04:36');

-- --------------------------------------------------------

--
-- Table structure for table `governances`
--

CREATE TABLE `governances` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `image` varchar(255) DEFAULT NULL,
  `file` varchar(255) DEFAULT NULL,
  `file_name` varchar(255) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `governances`
--

INSERT INTO `governances` (`id`, `image`, `file`, `file_name`, `created_at`, `updated_at`) VALUES
(1, 'uploads/Governance/55241701773508.webp', NULL, NULL, '2023-12-04 08:00:04', '2023-12-05 08:51:48'),
(2, 'uploads/Governance/438421704628967.jpeg', NULL, NULL, '2023-12-04 08:00:04', '2024-01-07 10:02:47'),
(3, 'uploads/Governance/47101704620348.jpg', NULL, NULL, '2023-12-04 08:00:04', '2024-01-07 07:39:08'),
(4, 'uploads/Governance/40651704620709.jpg', NULL, NULL, '2023-12-04 08:00:04', '2024-01-07 07:45:09'),
(5, 'uploads/Governance/260661704620909.jpg', NULL, NULL, '2023-12-04 08:00:04', '2024-01-07 07:48:29'),
(6, 'uploads/Governance/126551701779597.webp', 'uploads/Governance/728921701779597.pdf', 'Code-of-Conduct.pdf', '2023-12-04 08:00:04', '2023-12-05 10:33:17'),
(7, 'uploads/Governance/721291704632760.jpg', NULL, NULL, '2023-12-04 08:00:04', '2024-01-07 11:06:00');

-- --------------------------------------------------------

--
-- Table structure for table `governance_translations`
--

CREATE TABLE `governance_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `governance_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `title` varchar(255) DEFAULT NULL,
  `title_color` varchar(255) DEFAULT NULL,
  `description_one` text DEFAULT NULL,
  `description_two` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `governance_translations`
--

INSERT INTO `governance_translations` (`id`, `governance_id`, `locale`, `title`, `title_color`, `description_one`, `description_two`, `created_at`, `updated_at`) VALUES
(1, 1, 'en', 'Board', 'Membership', '<p>The Company is managed by a Board of Directors consisting of seven to nine members elected by the General Assembly through secret vote, to represent the shareholders. The term of the Council shall not exceed two years, which is by default exterminated through the election of a new Council.</p>', '<p class=\"wow animate__ animate__fadeInUp animated\">The company\'s articles of association require a series of provisions on the issues of membership in the board of directors, and the provisions are summarized in the following:</p>\r\n<ul>\r\n<li class=\"wow  animate__ animate__fadeInUp animated\">The candidate holds at least one thousand shares of the company\'s shares throughout the term of membership</li>\r\n<li class=\"wow  animate__ animate__fadeInUp animated\">Must be older than twenty-one years of age.</li>\r\n</ul>', NULL, NULL),
(2, 2, 'en', 'Tasks of the', 'Board of Directors', '<p>The Board of Directors is the first organizing authority in the company, as it is the one that sets the company&rsquo;s policy and strategies, approves the regulations the company follows, and follows it in its internal relations, and it supervises the implementations of this policy and strategies and the application of these regulations.<br><br>Duties and Committees of the Board of Directors:</p>\r\n<p>The Chairman and members of the Board of Directors carry out their duties through periodic sessions to follow up and discuss the progress of the company\'s businesses and develop the necessary tactics to improve its performance.</p>', NULL, NULL, NULL),
(3, 1, 'ar', 'مجلس الإدارة', 'عضوية', '<p>يتولى إدارة الشركة مجلس إدارة يتكون من سبعة إلى تسعة أعضاء تنتخبهم الجمعية العامة بالتصويت السري لتمثيل المساهمين. ولا تزيد مدة المجلس على سنتين، وتنتهي افتراضياً بانتخاب مجلس جديد.</p>', '<p>يتطلب النظام الأساسي للشركة مجموعة من الأحكام المتعلقة بمسائل العضوية في مجلس الإدارة، وتتلخص الأحكام في ما يلي:</p>\r\n<ul>\r\n<li class=\"wow  animate__ animate__fadeInUp animated\" style=\"visibility: visible; animation-name: fadeInUp;\">أن يحمل المرشح ما لا يقل عن ألف سهم من أسهم الشركة طوال مدة العضوية</li>\r\n<li class=\"wow  animate__ animate__fadeInUp animated\" style=\"visibility: visible; animation-name: fadeInUp;\">أن يكون عمره أكبر من إحدى وعشرين سنة.</li>\r\n</ul>', NULL, NULL),
(4, 2, 'ar', 'مهام مجلس', 'الإدارة', 'واجبات ولجان مجلس الإدارة:\n            يقوم رئيس وأعضاء مجلس الإدارة بواجباتهم من خلال جلسات دورية لمتابعة ومناقشة سير أعمال الشركة ووضع الأساليب اللازمة لتحسين أدائها.\n\n            <br><br>\n            واجبات ولجان مجلس الإدارة:<br>\n            يقوم رئيس وأعضاء مجلس الإدارة بواجباتهم من خلال جلسات دورية لمتابعة ومناقشة سير أعمال الشركة ووضع الأساليب اللازمة لتحسين أدائها.', NULL, NULL, NULL),
(5, 3, 'en', 'Development and', 'Investment Committee', '<p>This Committee is chaired by Dr. Salem Abukhaizaran and includes in its membership Mr. Talal Nasereddin and Mr. Firas Nasereddin. This committee aims to review and analyze the company\'s investments and provide recommendations on them.</p>\r\n<p><br>Delegated Authorities: The Committee submits recommendations to the Board of Directors for approval.</p>', NULL, NULL, NULL),
(6, 4, 'en', 'Internal', 'Audit Committee', '<p>This Committee is chaired by Dr. Farhan Abu Al-Lail and includes in its membership Dr. Yahya Shawar and Mrs. Rasha Nasereddin. The objective of this committee is to audit financial and technical operations and research the risks that the company may face and offer advice on how to avoid them. Delegated Authorities: The Committee submits recommendations to the Board of Directors for approval.</p>', NULL, NULL, NULL),
(7, 5, 'en', 'Designations and', 'Promotions Committee', '<p>This Committee is chaired by Mr. Talal Nasereddin and includes Mr. Firas Nasereddin and Mr. Azzam Shawwa, a representative of the Palestine Investment Fund. The committee&rsquo;s objective is to set the minimum wage, review incentives and bonuses, and approve annual increments and salary adjustments.</p>\r\n<p><br>Delegated Authorities: The Committee submits recommendations to the Board of Directors for approval.</p>', NULL, NULL, NULL),
(8, 3, 'ar', 'التنمية والاستثمار', 'لجنة', '<p>ويرأس هذه اللجنة الدكتور سالم أبوخيزران وعضوية السيد طلال ناصر الدين والسيد فراس ناصر الدين. تهدف هذه اللجنة إلى مراجعة وتحليل استثمارات الشركة وتقديم التوصيات بشأنها.<br>الصلاحيات المفوضة: تقوم اللجنة برفع توصياتها إلى مجلس الإدارة للاعتماد.</p>', NULL, NULL, NULL),
(9, 4, 'ar', ' الداخلي ', 'لجنة التدقيق', 'ويرأس هذه اللجنة الدكتور فرحان أبو الليل وعضوية الدكتور يحيى شاور والسيدة رشا ناصر الدين. هدف هذه اللجنة هو تدقيق العمليات المالية والفنية وبحث المخاطر التي قد تواجه الشركة وتقديم المشورة بشأن كيفية تجنبها.\n            الصلاحيات المفوضة: تقوم اللجنة برفع توصياتها إلى مجلس الإدارة للاعتماد.', NULL, NULL, NULL),
(10, 5, 'ar', ' التعيينات والترقيات', 'لجنة ', 'ويرأس هذه اللجنة السيد طلال ناصر الدين وتضم في عضويتها السيد فراس ناصر الدين والسيد عزام الشوا ممثلاً عن صندوق الاستثمار الفلسطيني. هدف اللجنة هو تحديد الحد الأدنى للأجور، ومراجعة الحوافز والمكافآت، والموافقة على الزيادات السنوية وتعديلات الرواتب.\n            الصلاحيات المفوضة: تقوم اللجنة برفع توصياتها إلى مجلس الإدارة للاعتماد.', NULL, NULL, NULL),
(11, 7, 'en', NULL, NULL, '<p>The Company\'s Board of Directors holds several board meetings every year, with a minimum of six meetings per annum. All shareholders are personally invited to attend the Ordinary General Assembly Meeting, and this invitation includes the meeting schedule. The date of the general assembly is publicly announced in official newspapers at least two weeks prior to the meeting date.</p>', NULL, NULL, NULL),
(12, 7, 'ar', NULL, NULL, 'اجتماعات مجلس الإدارة: يعقد مجلس إدارة الشركة عدة اجتماعات سنوياً، بما لا يقل عن 6 اجتماعات سنوياً. اجتماع الجمعية العامة العادية: يتم إرسال دعوة شخصية لجميع المساهمين لحضور اجتماع الجمعية العامة العادية. تتضمن الدعوة جدول الاجتماع. يتم الإعلان عن موعد انعقاد الجمعية العمومية في الصحف الرسمية قبل أسبوعين على الأقل من موعد انعقاد الجمعية.', NULL, NULL, NULL),
(14, 6, 'ar', NULL, NULL, '<p>نص dssdsdsdfdfdffffffffffffffffff</p>', NULL, NULL, NULL),
(15, 6, 'en', NULL, NULL, '<p>Birzeit Pharmaceutical Company places great importance on its social responsibility, considering it both a principle and a priority. For numerous years, the company has dedicated its resources to support and enhance our community. This commitment is evident through various initiatives focused on the environment, health, and education. Additionally, Birzeit Pharmaceutical Company actively engages in sustainable projects, implementing programs that contribute to long-term development.</p>\r\n<p>The company\'s primary focus lies in supporting students at schools and universities, as well as conducting campaigns that benefit hospitals and medical centers, reflecting its deep interest in the healthcare sector. Furthermore, Birzeit Pharmaceutical Company provides annual support to multiple societies, further demonstrating its dedication to making a positive impact.</p>', NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `info_careers`
--

CREATE TABLE `info_careers` (
  `id` int(10) UNSIGNED NOT NULL,
  `file` varchar(255) DEFAULT NULL,
  `file_name` varchar(255) DEFAULT NULL,
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `info_careers`
--

INSERT INTO `info_careers` (`id`, `file`, `file_name`, `order_by`, `created_at`, `updated_at`) VALUES
(2, NULL, NULL, NULL, '2023-12-05 11:37:21', '2023-12-05 11:37:21');

-- --------------------------------------------------------

--
-- Table structure for table `info_career_translations`
--

CREATE TABLE `info_career_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `info_career_id` int(10) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `title` varchar(255) DEFAULT NULL,
  `description` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `info_career_translations`
--

INSERT INTO `info_career_translations` (`id`, `info_career_id`, `locale`, `title`, `description`, `created_at`, `updated_at`) VALUES
(3, 2, 'en', 'HR', 'HR - Test', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `investor_services`
--

CREATE TABLE `investor_services` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) DEFAULT NULL,
  `card_id` varchar(255) DEFAULT NULL,
  `mobile` varchar(255) DEFAULT NULL,
  `email` varchar(255) DEFAULT NULL,
  `address` varchar(255) DEFAULT NULL,
  `image` varchar(255) DEFAULT NULL,
  `bank_name` varchar(255) DEFAULT NULL,
  `iban` varchar(255) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `investor_services`
--

INSERT INTO `investor_services` (`id`, `name`, `card_id`, `mobile`, `email`, `address`, `image`, `bank_name`, `iban`, `created_at`, `updated_at`) VALUES
(1, 'raghad', '5434567656', '0592675429', 'raghad@fis.ps', '4455', 'uploads/InvestorService/827891701783066.jpg', 'pppp', '898898989898', '2023-12-05 11:31:06', '2023-12-05 11:31:06'),
(2, 'raghad', '123', '0592675429', 'admin@admin.com', 'رام الله البيرة', 'uploads/InvestorService/420431702116092.jpg', '123', '12222', '2023-12-09 08:01:32', '2023-12-09 08:01:32'),
(3, 'test', '0999898877', '0592675429', 'raghad@fis.ps', 'رام الله البيرة', 'uploads/InvestorService/407971704962247.png', 'test', '6787687878', '2024-01-11 06:37:27', '2024-01-11 06:37:27');

-- --------------------------------------------------------

--
-- Table structure for table `investor_services_info`
--

CREATE TABLE `investor_services_info` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `whatsapp` varchar(255) DEFAULT NULL,
  `email` varchar(255) DEFAULT NULL,
  `description_ar` text DEFAULT NULL,
  `description_en` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `investor_services_info`
--

INSERT INTO `investor_services_info` (`id`, `whatsapp`, `email`, `description_ar`, `description_en`, `created_at`, `updated_at`) VALUES
(1, '+972 594203043', 'shareholders@bpc.ps', '<p dir=\"rtl\">مع تمنياتنا للجميع بالتوفيق، نود إعلامكم أننا سنعتمد التحويل البنكي إلى حساباتكم المبينة أدناه لتوزيع الأرباح النقدية المستحقة على مساهمتكم في شركة بيرزيت للأدوية. يرجى التأكد من ملء النموذج بدقة، والتحقق من أن حسابك البنكي نشط، وإرفاق المستندات المطلوبة كما هو محدد أدناه.<br><br>ولأننا نفخر بمساهمينا، فإننا نسعى باستمرار للحفاظ على آلية اتصال واضحة وسريعة مع عملائنا المساهمين والمستثمرين.<br><br>يرجى إرسال النموذج التالي ومرفقاته إلى البريد الإلكتروني&nbsp;<a href=\"mailto:shareholders@bpc.ps\">shareholders@bpc.ps</a>. إذا كانت لديك أي استفسارات أو واجهت أي مشكلات، فيرجى الاتصال بنا على <a href=\"https://wa.me/972594203043\">+972594203043</a></p>\r\n<p dir=\"rtl\"><br>يرجى ملاحظة أنه إذا لم تتمكن من ذلك أرسل النموذج عبر البريد الإلكتروني، ويمكن إرساله إلى رقم الفاكس: <a>+972 2 2967206</a></p>', '<p>We would like to extend our warmest wishes to all of you. We would like to inform you that we will be implementing bank transfers for the disbursement of cash dividends on your shareholding in Birzeit Pharmaceutical Company. To ensure a smooth process, please make sure to accurately fill out the provided form, verify the activity of your bank account, and attach the necessary documents as specified below.</p>\r\n<p>At our company, we take great pride in our shareholders and continuously strive to maintain a transparent and efficient communication channel with both our shareholders and investors. Please send the completed form and its attachments to the email address shareholders@bpc.ps. If you have any inquiries or encounter any issues, please feel free to contact us via WhatsApp at +972 594203043. In the event that you are unable to send the form via email, you may also send it to the fax number: +972 2 2967206.</p>', '2023-12-04 08:00:04', '2024-01-10 09:05:28');

-- --------------------------------------------------------

--
-- Table structure for table `languages`
--

CREATE TABLE `languages` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) NOT NULL,
  `fullname` varchar(255) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `languages`
--

INSERT INTO `languages` (`id`, `name`, `fullname`) VALUES
(1, 'ar', 'Arabic'),
(2, 'en', 'English');

-- --------------------------------------------------------

--
-- Table structure for table `likes`
--

CREATE TABLE `likes` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `members`
--

CREATE TABLE `members` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `image` varchar(255) DEFAULT NULL,
  `type` tinyint(4) NOT NULL COMMENT '2  مجلس الإدارة 1 ,  الاإدارة التنفيذي',
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `members`
--

INSERT INTO `members` (`id`, `image`, `type`, `order_by`, `created_at`, `updated_at`) VALUES
(1, 'uploads/Member/493241701776643.jpg', 1, 1, '2023-12-04 08:00:04', '2023-12-05 09:44:03'),
(6, 'uploads/Member/911951701776685.jpg', 1, 2, '2023-12-05 08:56:13', '2023-12-05 09:44:45'),
(7, 'uploads/Member/534581701776916.jpg', 1, NULL, '2023-12-05 09:10:08', '2023-12-05 09:48:36'),
(8, 'uploads/Member/820441701778066.jpg', 1, NULL, '2023-12-05 10:07:46', '2023-12-05 10:07:46'),
(9, 'uploads/Member/930911701778205.jpg', 1, NULL, '2023-12-05 10:10:05', '2023-12-05 10:10:05'),
(10, 'uploads/Member/459331701778269.jpg', 1, NULL, '2023-12-05 10:11:09', '2023-12-05 10:11:09'),
(11, 'uploads/Member/114361701778321.jpg', 1, NULL, '2023-12-05 10:12:01', '2023-12-05 10:12:01'),
(12, 'uploads/Member/564751701778925.jpg', 2, NULL, '2023-12-05 10:22:05', '2023-12-05 10:22:05'),
(13, 'uploads/Member/211951701778971.jpg', 2, NULL, '2023-12-05 10:22:51', '2023-12-05 10:22:51'),
(14, 'uploads/Member/623211701779015.jpg', 2, NULL, '2023-12-05 10:23:35', '2023-12-05 10:23:35'),
(15, 'uploads/Member/452861701779048.jpg', 2, NULL, '2023-12-05 10:24:08', '2023-12-05 10:24:08'),
(16, 'uploads/Member/505521701779087.jpg', 2, NULL, '2023-12-05 10:24:47', '2023-12-05 10:24:47'),
(17, 'uploads/Member/301811701779124.jpg', 2, NULL, '2023-12-05 10:25:24', '2023-12-05 10:25:24'),
(18, 'uploads/Member/63391701779156.jpg', 2, NULL, '2023-12-05 10:25:56', '2023-12-05 10:25:56'),
(19, 'uploads/Member/69941701779190.jpg', 2, NULL, '2023-12-05 10:26:30', '2023-12-05 10:26:30'),
(20, 'uploads/Member/882181701779231.jpg', 2, NULL, '2023-12-05 10:27:11', '2023-12-05 10:27:11'),
(21, 'uploads/Member/299321701779271.jpg', 2, NULL, '2023-12-05 10:27:51', '2023-12-05 10:27:51'),
(22, 'uploads/Member/914371701779300.jpg', 2, NULL, '2023-12-05 10:28:20', '2023-12-05 10:28:20'),
(23, 'uploads/Member/433381701779336.jpg', 2, NULL, '2023-12-05 10:28:56', '2023-12-05 10:28:56'),
(24, 'uploads/Member/968051701779366.jpg', 2, NULL, '2023-12-05 10:29:26', '2023-12-05 10:29:26'),
(25, 'uploads/Member/872671701779395.jpg', 2, NULL, '2023-12-05 10:29:55', '2023-12-05 10:29:55'),
(26, 'uploads/Member/818421701779432.jpg', 2, NULL, '2023-12-05 10:30:32', '2023-12-05 10:30:32'),
(27, 'uploads/Member/785761701779463.jpg', 2, NULL, '2023-12-05 10:31:03', '2023-12-05 10:31:03');

-- --------------------------------------------------------

--
-- Table structure for table `member_translations`
--

CREATE TABLE `member_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `member_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `name` varchar(255) NOT NULL,
  `job_title` varchar(255) DEFAULT NULL,
  `description` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `member_translations`
--

INSERT INTO `member_translations` (`id`, `member_id`, `locale`, `name`, `job_title`, `description`, `created_at`, `updated_at`) VALUES
(1, 1, 'en', 'Talal Nasereddin', 'General Director', '<p>In his position as General Manager since 1/4/1984 and as Chairman of the Board since 1990, he holds a Master&rsquo;s degree in Industrial Chemistry from the American University of Beirut in 1974.<br>He holds the position of Vice Chairman of the Board of Directors of the Palestine Islamic Bank.<br>Vital positions, including: Chairman of the Board of Directors of Abraaj Real Estate Investments Company, Petropal Mineral Oils Company, and Lotus Financial Investments Company, in addition to being a board member in the Palestinian Telecommunications Group and the Palestinian Electricity Company, in addition to being a member of the Board of Trustees of Saint Joseph Hospital in Jerusalem 2016 -2021 and Chairman of the Board of Directors of SOS Children&rsquo;s Villages since 2019.</p>', NULL, NULL),
(6, 1, 'ar', 'طلال نصر الدين', 'المدير العام', '<p>في منصبه مديراً عاماً منذ 1/4/1984 ورئيساً لمجلس الإدارة منذ عام 1990، حاصل على درجة الماجستير في الكيمياء الصناعية من الجامعة الأمريكية في بيروت عام 1974.<br>يشغل منصب نائب رئيس مجلس إدارة البنك الإسلامي الفلسطيني.<br>مناصب حيوية منها: رئيس مجلس إدارة شركة أبراج للاستثمارات العقارية، شركة بتروبال للزيوت المعدنية، وشركة اللوتس للاستثمارات المالية، بالإضافة إلى كونه عضو مجلس إدارة في مجموعة الاتصالات الفلسطينية وشركة الكهرباء الفلسطينية، بالإضافة إلى كونه عضو مجلس أمناء مستشفى القديس يوسف في القدس 2016 -2021 ورئيس مجلس إدارة قرى الأطفال SOS منذ عام 2019.</p>', NULL, NULL),
(11, 6, 'en', 'Firas Nasereddin', 'Board of Director', '<p>Dr. Firas Kazem Abdullah Nasereddin Member of the Board of Directors.</p>\r\n<p>In his position since 9/6/2003, he holds a Bachelor&rsquo;s degree in pharmacy from the Jordan University of Science and Technology in 1992. Deputy General Manager and Marketing Director at Birzeit Pharmaceutical Company, CEO of Grand Pharm for Pharmaceutical Investments, member of the Board of Directors of APIC, and member of the Board of Directors of the General Federation of Palestinian Industries.</p>', NULL, NULL),
(12, 7, 'en', 'Salem Abukhaizaran', 'Member of the Board of Directors', '<p>Razan Medical Center specialized in infertility and IVF treatment is represented by Dr. Salem Mustafa Salem Abukhaizaran, Member of the Board of Directors</p>\r\n<p>In his position since 4/18/2011, Obstetrics and Gynecology Specialist, Obtained the British Fellowship in 1991, MRCOG Chairman and General Manager of Razan Medical Center for Infertility and IVF / Nablus / Ramallah, Chairman of the Board of Directors of the Arab Specialist Hospital Nablus and Chairman of the Board Management of the Arab Center for Heart and Hematology Surgery / Nablus and Chairman of the Board of Directors of Istishari Arab Hospital / Ramallah.</p>', NULL, NULL),
(13, 8, 'en', 'Mr. Azzam Shawwa', 'member of the Board of Directors', '<p>Aswaq Company affiliated to the Palestine Investment Fund, represented by Mr. Azzam Shawa, a member of the Board of Directors, a member representing the Palestine Investment Fund</p>\r\n<p>Mr. Azzam Al-Shawarath has a distinguished professional in the fields of government and banking. His Excellency Mr. Azzam Shawa held the position of Governor of the Palestinian Monetary Authority and Chairman of its Board of Directors for a period of five years, from 11/20/2015 to 1/3/2021. During that period, he also chaired the National Anti-Money Laundering Committee and the Board of Directors of the Palestinian Deposit Insurance Corporation and the Banking Institute. In 2003, Mr. Shawa was appointed Minister of Energy and Natural Resources in the Palestinian National Authority and joined Bank of Palestine in 1989 where he held the position of Director of International Relations. The year 2007 witnessed the peak of His Excellency Mr. Shawa&rsquo;s involvement in the midst of the banking business by assuming the position of General Manager of Quds Bank, and in 2012, His Excellency Mr. Shawa chaired the Board of Directors of the Association of Banks in Palestine, where he significantly activated its role in serving member banks and the banking sector in general. In March 2013, Mr. Shawa joined the Palestine Commercial Bank as its General Manager.</p>', NULL, NULL),
(14, 9, 'en', 'Farhan Nasser Abu Lail', 'member of the Board of Directors', '<p>Dr. Farhan Nasser Abu Lail Abu Lail Member of the Board of Directors</p>\r\n<p>In his position since 30/7/1990, he holds a Bachelor&rsquo;s degree in Medicine and General Surgery, specializing in pediatrics from the University of London in 1964. A pediatrician, he founded the pediatric department at the National Hospital in Nablus.</p>', NULL, NULL),
(15, 10, 'en', 'Yahya Mohammad Shawar', 'member of the Board of Directors', '<p>Dr. Yahya Mohammad Shawar, Member of the Board of Directors</p>\r\n<p>In his position since May 28, 1992. He holds a medical degree specializing in diagnostic imaging from the American University of Beirut in 1976. An experienced physician in a private clinic in Hebron, director of radiological and specialized clinics, assistant professor of radiology, board member and head of the Continuing Medical Education Department at the University of Beirut. Quds.</p>', NULL, NULL),
(16, 11, 'en', 'Rasha Mohamed Nasser Eddin', 'member of the Board of Directors', '<p>Mrs. Rasha Mohamed Nasser Eddin has been a Board of Directors member since December 2022, Ms. Rasha is a development expert Of Planning and monitoring, with over 15 years of experience in Project management, design, and implementation of monitoring and evaluation systems. She holds two master&rsquo;s degrees, the first in economics from Birzeit University and the second in Quality Management from the Arab American University</p>\r\n<p>Mrs. Rasha is currently working as an Enterprise Development Specialist.</p>', NULL, NULL),
(17, 12, 'en', 'Talal Nasereddin', 'member of the Board of Directors', '<p>In his position as General Manager since 1/4/1984 and as Chairman of the Board since 1990, he holds a Masters degree in Industrial Chemistry from the American University of Beirut in 1974. He holds the position of Vice Chairman of the Board of Directors of the Palestine Islamic Bank as well as the Chairman of the Board of Directors of Abraaj Real Estate Investments Company, Petropal Mineral Oils Company, and Lotus Financial Investments Company, in addition to being a board member in the Palestinian Telecommunications Group PALTEL and the Palestinian Electricity Company.</p>', NULL, NULL),
(18, 13, 'en', 'Firas Nasereddin', 'member of the Board of Directors', '<p>Dr. Firas Kazem Abdullah Nasereddin ia a member of the Board of Directors, he is the Deputy General Manager and Director of Operations.</p>\r\n<p>Nassereddin joined BPC in 9/6/2003, he holds a Bachelor degree in pharmacy from the Jordan University of Science and Technology in 1992. Deputy General Manager and Marketing Director at Birzeit Pharmaceutical Company, CEO of Grand Pharm for Pharmaceutical Investments, member of the Board of Directors of APIC, and member of the Board of Directors of the General Federation of Palestinian Industries.</p>', NULL, NULL),
(19, 14, 'en', 'Abdul Qader Badawi', 'Executive Management', '<p>Financial Department Manager.</p>\r\n<p>He has been working in the company since 15/11/1984, he holds a Bachelor Degree in Management, as well as the ACPA.</p>', NULL, NULL),
(20, 15, 'en', 'Fahim Al-Zubaidi', 'Executive Management', '<p>Technical Manager.</p>\r\n<p>He has been working in the company since 1/8/1984, he holds a Bachelor Degree in Chemistry.</p>', NULL, NULL),
(21, 16, 'en', 'Salwa Al-Jabali', 'Executive Management', '<p>Supply Chain Manager.</p>\r\n<p>She has been working in the company since 1/1/1991, she holds a Master\'s Degree in electrical engineering.</p>', NULL, NULL),
(22, 17, 'en', 'Tayseer Elayyan', 'Executive Management', '<p>Research and Development Manager</p>\r\n<p>He has been working in the company since 8/10/1986, he holds a master\'s degree in pharmaceutical technology.</p>', NULL, NULL),
(23, 18, 'en', 'Tayseer Abu Taha', 'Executive Management', '<p>Warehouse Manager.</p>\r\n<p>He has been working in the company since 2/7/1988, he holds a Bachelor of Arts.</p>', NULL, NULL),
(24, 19, 'en', 'Harb Mohsen', 'Executive Management', '<p>Quality Assurance Manager.</p>\r\n<p>He has been working in the company since 1/1/2004, he holds a Bachelor Degree in Pharmacy.</p>', NULL, NULL),
(25, 20, 'en', 'Shorouq Saleh', 'Executive Management', '<p>Internal Audit Manager.</p>\r\n<p>She has been working in the company since 09/09/1998, she holds a Bachelor Degree in Chemical Engineering.</p>', NULL, NULL),
(26, 21, 'en', 'Ahed Hussein', 'Executive Management', '<p>Projects Department Manager.</p>\r\n<p>He has been working in the company since 16/2/1992, he holds a diploma in electricity.</p>', NULL, NULL),
(27, 22, 'en', 'Alia Nassereddin', 'Executive Management', '<p>Human Resources Manager.</p>\r\n<p>She has been working in the company since 6/1/2009, she holds a Bachelor Degree in Sociology.</p>', NULL, NULL),
(28, 23, 'en', 'Fuad Tirhi', 'Executive Management', '<p>Engineering Department Manager.</p>\r\n<p>He has been working in the company since 01/10/2002, he holds a Bachelors in Mechanical Engineering.</p>', NULL, NULL),
(29, 24, 'en', 'Maher Al-Tamimi', 'Executive Management', '<p>Information Technology Manager.</p>\r\n<p>He has been working in the company since 1/2/1997, he holds a bachelor\'s degree in computer science.</p>', NULL, NULL),
(30, 25, 'en', 'Najeeb Hamad', 'Executive Management', '<p>Validation Manager.</p>\r\n<p>He has been working in the company since 8/7/1990, he holds a Bachelor Degree in Chemistry.</p>', NULL, NULL),
(31, 26, 'en', 'Wahba Zareer', 'Executive Management', '<p>Quality Control Manager</p>\r\n<p>He has been working in the company since 14/9/1987, he holds a Bachelor Degree in Chemistry.</p>', NULL, NULL),
(32, 27, 'en', 'Younis Alama', 'Executive Management', '<p>Production Manager</p>\r\n<p>He has been working at BPC since 1995. He holds a Masters degree in Chemical Engineering.&nbsp;</p>', NULL, NULL),
(33, 27, 'ar', 'يونس علامة', 'الادارة التنفيذية', '<p>مدير قسم الإنتاج يعمل في الشركة منذ 2/1/1995 حاصل على درجة الماجستير في الهندسة الكيميائية.&nbsp; &nbsp;</p>', NULL, NULL),
(34, 26, 'ar', 'وهبة زرير', 'الادارة التنفيذية', '<p>مدير إدارة مكافحة المخدرات يعمل بالشركة منذ 14/9/1987 حاصل على درجة البكالوريوس في الكيمياء.</p>', NULL, NULL),
(35, 25, 'ar', 'نجيب حمد', 'الادارة التنفيذية', '<p>مدير قسم التحقق، يعمل في الشركة منذ 8/7/1990، حاصل على درجة البكالوريوس في الكيمياء.</p>', NULL, NULL),
(36, 24, 'ar', 'ماهر التميمي', 'الادارة التنفيذية', '<p>مدير قسم تكنولوجيا المعلومات، يعمل في الشركة منذ 1/2/1997، حاصل على درجة البكالوريوس في علوم الحاسوب.</p>', NULL, NULL),
(37, 23, 'ar', 'فؤاد الطرحي', 'الادارة التنفيذية', '<p>مدير القسم الهندسي، يعمل في الشركة منذ 01/10/2002، حاصل على بكالوريوس في الهندسة الميكانيكية.</p>', NULL, NULL),
(38, 22, 'ar', 'علياء ناصر الدين', 'الادارة التنفيذية', '<p>مديرة إدارة الموارد البشرية والشؤون الإدارية تعمل في الشركة منذ 6/1/2009، حاصلة على درجة البكالوريوس في علم الاجتماع.</p>', NULL, NULL),
(39, 21, 'ar', 'عاهد حسين', 'الادارة التنفيذية', '<p>مدير دائرة المشاريع يعمل في الشركة منذ 16/2/1992 حاصل على دبلوم في الكهرباء.</p>', NULL, NULL),
(40, 20, 'ar', 'شروق صالح', 'الادارة التنفيذية', '<p>مديرة التدقيق الداخلي تعمل في الشركة منذ 1998/09/09 وهي حاصلة على درجة البكالوريوس في الهندسة الكيميائية.</p>', NULL, NULL),
(41, 19, 'ar', 'حرب محسن', 'الادارة التنفيذية', '<p>مدير قسم ضمان الجودة يعمل في الشركة منذ 1/1/2004 حاصل على درجة البكالوريوس في الصيدلة.</p>', NULL, NULL),
(42, 18, 'ar', 'تيسير أبو طه', 'الادارة التنفيذية', '<p>مدير قسم المستودعات يعمل في الشركة منذ 2/7/1988 حاصل على بكالوريوس في الآداب.</p>', NULL, NULL),
(43, 17, 'ar', 'تيسير عليان', 'الادارة التنفيذية', '<p>مدير دائرة البحث والتطوير يعمل في الشركة منذ 8/10/1986 حاصل على درجة الماجستير في التكنولوجيا الصيدلانية.</p>', NULL, NULL),
(44, 16, 'ar', 'سلوى الجبالي', 'الادارة التنفيذية', '<p>مديرة سلسلة التوريد تعمل في الشركة منذ 1/1/1991، حاصلة على درجة الماجستير في الهندسة الكهربائية.</p>', NULL, NULL),
(45, 15, 'ar', 'فهيم الزبيدي', 'الادارة التنفيذية', '<p>المدير الفني يعمل في الشركة منذ 1/8/1984 حاصل على درجة البكالوريوس في الكيمياء.</p>', NULL, NULL),
(46, 14, 'ar', 'عبد القادر بدوي', 'الادارة التنفيذية', '<p>مدير الدائرة المالية يعمل في الشركة منذ 15/11/1984 حاصل على درجة البكالوريوس في الإدارة ACPA.</p>', NULL, NULL),
(47, 13, 'ar', 'فراس نصر الدين', 'عضو مجلس الإدارة', '<p>الدكتور فراس كاظم عبد الله ناصر الدين عضو مجلس الإدارة.&lt;/p&gt; &lt;p&gt;في منصبه منذ 9/6/2003 حاصل على درجة البكالوريوس في الصيدلة من جامعة العلوم والتكنولوجيا الأردنية عام 1992. نائب المدير العام ومدير التسويق في شركة بيرزيت للأدوية، الرئيس التنفيذي لشركة جراند فارم للاستثمارات الدوائية، عضو مجلس إدارة أيبك، وعضو مجلس إدارة الاتحاد العام للصناعات الفلسطينية.</p>', NULL, NULL),
(48, 12, 'ar', 'طلال ناصر الدين', 'عضو مجلس الإدارة', '<p>في منصبه مديراً عاماً منذ 1/4/1984 ورئيساً لمجلس الإدارة منذ عام 1990، حاصل على درجة الماجستير في الكيمياء الصناعية من الجامعة الأمريكية في بيروت عام 1974.&lt;br&gt;ويشغل منصب نائب رئيس مجلس الإدارة عضو مجلس إدارة البنك الإسلامي الفلسطيني.&lt;br&gt;مواقع حيوية منها: رئيس مجلس إدارة شركة أبراج للاستثمارات العقارية، شركة بتروبال للزيوت المعدنية، وشركة اللوتس للاستثمارات المالية، بالإضافة إلى كونه عضو مجلس إدارة في مجموعة الاتصالات الفلسطينية وشركة الكهرباء الفلسطينية، بالإضافة إلى كونه عضو مجلس أمناء مستشفى القديس يوسف في القدس 2016 -2021 ورئيس مجلس إدارة قرى الأطفال SOS منذ عام 2019.</p>', NULL, NULL),
(49, 6, 'ar', 'فراس نصر الدين', 'مجلس ادارة', '<p>د. فراس كاظم عبد الله ناصر الدين عضو مجلس الإدارة.</p>\r\n<p>يشغل منصبه منذ 9/6/2003 حاصل على درجة البكالوريوس في الصيدلة من جامعة العلوم والتكنولوجيا الأردنية عام 1992. نائب المدير العام ومدير التسويق في شركة بيرزيت للأدوية، الرئيس التنفيذي لشركة جراند فارم للاستثمارات الدوائية، عضو مجلس إدارة شركة بيرزيت للأدوية. مجلس إدارة أيبك، وعضو مجلس إدارة الاتحاد العام للصناعات الفلسطينية.</p>', NULL, NULL),
(50, 7, 'ar', 'سالم ابوخيزران', 'عضو مجلس الإدارة', '<p>مركز رزان الطبي المتخصص في علاج العقم وأطفال الأنابيب يمثله الدكتور سالم مصطفى سالم أبوخيزران عضو مجلس الإدارة</p>\r\n<p>في منصبه منذ 18/4/2011، أخصائي أمراض النساء والتوليد، حاصل على الزمالة البريطانية عام 1991، رئيس مجلس إدارة ومدير عام مركز رزان الطبي للعقم وأطفال الأنابيب / نابلس / رام الله، رئيس مجلس إدارة المركز العربي التخصصي مستشفى نابلس ورئيس مجلس إدارة المركز العربي لجراحة القلب وأمراض الدم / نابلس ورئيس مجلس إدارة المستشفى الاستشاري العربي / رام الله.</p>', NULL, NULL),
(51, 8, 'ar', 'السيد عزام الشوا', 'عضو مجلس الإدارة', '<p>شركة أسواق التابعة لصندوق الاستثمار الفلسطيني ويمثلها السيد عزام الشوا عضو مجلس الإدارة عضواً ممثلاً لصندوق الاستثمار الفلسطيني</p>\r\n<p>يتمتع السيد عزام الشوارث بمهنية متميزة في المجال الحكومي والمصرفي. شغل معالي السيد عزام الشوا منصب محافظ سلطة النقد الفلسطينية ورئيس مجلس إدارتها لمدة خمس سنوات، من 20/11/2015 إلى 2021/3/1. كما ترأس خلال تلك الفترة اللجنة الوطنية لمكافحة غسل الأموال ومجلس إدارة المؤسسة الفلسطينية لضمان الودائع والمعهد المصرفي. وفي عام 2003، تم تعيين السيد الشوا وزيراً للطاقة والموارد الطبيعية في السلطة الوطنية الفلسطينية، وانضم إلى بنك فلسطين في عام 1989 حيث شغل منصب مدير العلاقات الدولية. وشهد عام 2007 ذروة انخراط سعادة السيد الشوا في خضم العمل المصرفي من خلال توليه منصب مدير عام بنك القدس، وفي عام 2012 ترأس سعادة السيد الشوا مجلس إدارة جمعية البنوك وفي فلسطين حيث تفعيل دوره بشكل كبير في خدمة البنوك الأعضاء والقطاع المصرفي بشكل عام. وفي مارس 2013، انضم السيد الشوا إلى البنك التجاري الفلسطيني كمدير عام له.</p>', NULL, NULL),
(52, 9, 'ar', 'فرحان ناصر ابو ليل', 'عضو مجلس الإدارة', '<p>د. فرحان ناصر أبو ليل أبو ليل عضو مجلس الإدارة</p>\r\n<p>في منصبه منذ 30/7/1990 حاصل على درجة البكالوريوس في الطب والجراحة العامة تخصص طب الأطفال من جامعة لندن عام 1964. طبيب أطفال أسس قسم طب الأطفال في المستشفى الوطني في نابلس.</p>', NULL, NULL),
(53, 10, 'ar', 'د. يحيى محمد شاور', 'عضو مجلس الإدارة', '<p>د. يحيى محمد شاور عضو مجلس الإدارة</p>\r\n<p>في منصبه منذ 28 مايو 1992. حاصل على شهادة الطب تخصص التصوير التشخيصي من الجامعة الأمريكية في بيروت عام 1976. طبيب ذو خبرة في عيادة خاصة في الخليل، مدير العيادات الإشعاعية والتخصصية، أستاذ مساعد في الأشعة، البورد عضو ورئيس قسم التعليم الطبي المستمر في جامعة بيروت. القدس.</p>', NULL, NULL),
(54, 11, 'ar', 'رشا محمد ناصر الدين', 'عضو مجلس الإدارة', '<p>السيدة رشا محمد ناصر الدين عضو مجلس إدارة منذ ديسمبر 2022، السيدة رشا خبيرة تطوير في التخطيط والمراقبة، تتمتع بخبرة تزيد عن 15 عامًا في إدارة المشاريع وتصميم وتنفيذ أنظمة المراقبة والتقييم. حاصلة على درجتي ماجستير الأولى في الاقتصاد من جامعة بيرزيت والثانية في إدارة الجودة من الجامعة العربية الأمريكية</p>\r\n<p>تعمل السيدة رشا حاليا كأخصائية تطوير المشاريع.</p>', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `migrations`
--

CREATE TABLE `migrations` (
  `id` int(10) UNSIGNED NOT NULL,
  `migration` varchar(255) NOT NULL,
  `batch` int(11) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `migrations`
--

INSERT INTO `migrations` (`id`, `migration`, `batch`) VALUES
(1, '2014_10_12_000000_create_users_table', 1),
(2, '2014_10_12_100000_create_password_reset_tokens_table', 1),
(3, '2019_08_19_000000_create_failed_jobs_table', 1),
(4, '2019_12_14_000001_create_personal_access_tokens_table', 1),
(5, '2023_11_12_190410_create_pages_table', 1),
(6, '2023_11_12_190423_create_page_translations_table', 1),
(7, '2023_11_12_191138_create_sliders_table', 1),
(8, '2023_11_12_191153_create_slider_translations_table', 1),
(9, '2023_11_12_192115_create_members_table', 1),
(10, '2023_11_12_192140_create_member_translations_table', 1),
(11, '2023_11_14_073944_create_product_types_table', 1),
(12, '2023_11_14_073950_create_categories_table', 1),
(13, '2023_11_14_073957_create_products_table', 1),
(14, '2023_11_14_085657_create_productivities_table', 1),
(15, '2023_11_15_090011_create_product_images_table', 1),
(16, '2023_11_15_103229_create_certificates_table', 1),
(17, '2023_11_15_151614_create_project_models_table', 1),
(18, '2023_11_16_104533_create_settings_table', 1),
(19, '2023_11_16_131423_create_languages_table', 1),
(20, '2023_11_21_151859_create_article_types_table', 1),
(21, '2023_11_21_151935_create_articles_table', 1),
(22, '2023_11_23_121922_create_page_lists_table', 1),
(23, '2023_11_25_094919_create_contacts_table', 1),
(24, '2023_11_25_122038_create_stoke_prices_table', 1),
(25, '2023_11_25_134713_create_file_reports_table', 1),
(26, '2023_11_26_090539_create_governances_table', 1),
(27, '2023_11_27_091611_create_investor_services_table', 1),
(28, '2023_11_27_102220_create_investor_services_info_table', 1),
(29, '2023_11_28_093820_create_branches_table', 1),
(30, '2023_11_29_083517_create_product_category_table', 1),
(31, '2023_12_01_074600_create_constans_table', 1),
(32, '2023_12_01_074600_create_constant_options_table', 1),
(33, '2023_12_02_203214_create_permission_tables', 1),
(34, '2023_12_03_060924_create_info_careers_table', 1),
(35, '2023_12_03_060930_create_careers_table', 1),
(36, '2023_12_04_102057_create_news_letter_table', 1);

-- --------------------------------------------------------

--
-- Table structure for table `model_has_permissions`
--

CREATE TABLE `model_has_permissions` (
  `permission_id` bigint(20) UNSIGNED NOT NULL,
  `model_type` varchar(255) NOT NULL,
  `model_id` bigint(20) UNSIGNED NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `model_has_roles`
--

CREATE TABLE `model_has_roles` (
  `role_id` bigint(20) UNSIGNED NOT NULL,
  `model_type` varchar(255) NOT NULL,
  `model_id` bigint(20) UNSIGNED NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `news_letter`
--

CREATE TABLE `news_letter` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `message_ar` varchar(255) DEFAULT NULL,
  `message_en` varchar(255) DEFAULT NULL,
  `file` varchar(255) DEFAULT NULL,
  `file_name` varchar(255) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `news_letter`
--

INSERT INTO `news_letter` (`id`, `message_ar`, `message_en`, `file`, `file_name`, `created_at`, `updated_at`) VALUES
(1, 'Our 2022 Newsletter', 'Our 2022 Newsletter', 'uploads/NewsLetter/939401701780582.pdf', 'Newsletter-2022.pdf', NULL, '2023-12-05 10:49:42');

-- --------------------------------------------------------

--
-- Table structure for table `pages`
--

CREATE TABLE `pages` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `page_key` varchar(255) NOT NULL,
  `section_key` varchar(255) NOT NULL,
  `image_one` varchar(255) DEFAULT NULL,
  `image_two` varchar(255) DEFAULT NULL,
  `info` varchar(255) DEFAULT NULL,
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `pages`
--

INSERT INTO `pages` (`id`, `page_key`, `section_key`, `image_one`, `image_two`, `info`, `order_by`, `created_at`, `updated_at`) VALUES
(1, 'home', 'sliders', NULL, NULL, NULL, 1, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(2, 'home', 'experience', 'uploads/Page/95031701759301.webp', 'uploads/Page/825171703426995.jpg', NULL, 2, '2023-12-04 08:00:02', '2023-12-24 12:09:55'),
(3, 'home', 'products', NULL, NULL, NULL, 3, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(4, 'home', 'productivity', NULL, NULL, NULL, 4, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(5, 'home', 'news', NULL, NULL, NULL, 4, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(6, 'about', 'profile', 'uploads/Page/997971701760880.webp', 'storage/img/about/about-2.webp', NULL, 1, '2023-12-04 08:00:02', '2023-12-05 05:21:20'),
(7, 'about', 'second_profile', 'uploads/Page/642751704616195.jpg', NULL, NULL, 2, '2023-12-04 08:00:02', '2024-01-07 06:29:55'),
(8, 'about', 'vision', 'uploads/Page/717561704614414.JPG', NULL, NULL, 3, '2023-12-04 08:00:02', '2024-01-07 06:00:14'),
(9, 'about', 'history', 'uploads/Page/147061701760975.webp', 'uploads/Page/728891701760975.webp', NULL, 4, '2023-12-04 08:00:02', '2023-12-05 05:22:55'),
(10, 'other', 'privacy', NULL, NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(11, 'other', 'terms', NULL, NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(12, 'responsibility', 'social_responsibility', NULL, NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(13, 'responsibility', 'environment', 'uploads/Page/327331704619096.jpg', NULL, NULL, NULL, '2023-12-04 08:00:02', '2024-01-07 07:18:16'),
(14, 'responsibility', 'community', 'uploads/Page/445371701761130.webp', NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-05 05:25:30'),
(15, 'investor-relations', 'stok-price', 'storage/img/about/about-4.webp', NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(16, 'investor-relations', 'investor-services', NULL, NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(17, 'investor-relations', 'financial-reports', 'assets/img/general/about-5.webp', NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(18, 'investor-relations', 'governance', NULL, NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(19, 'governance', 'board-of-directors', 'assets/img/board/Board-Of-Direcors-picture-1.webp', NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(20, 'governance', 'committees', 'assets/img/general/about-1.webp', NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(21, 'governance', 'executive-management', NULL, NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(22, 'governance', 'code-of-conduct', NULL, NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(23, 'governance', 'general-assembly-meeting', 'assets/img/general/about-1.webp', NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(24, 'contact', 'branch', 'assets/img/general/branch-3.webp', NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(25, 'contact', 'info', '', NULL, NULL, NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02');

-- --------------------------------------------------------

--
-- Table structure for table `page_lists`
--

CREATE TABLE `page_lists` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `page_id` bigint(20) UNSIGNED DEFAULT NULL,
  `order_by` int(11) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `page_lists`
--

INSERT INTO `page_lists` (`id`, `page_id`, `order_by`, `created_at`, `updated_at`) VALUES
(1, 13, 1, '2023-12-04 08:00:04', '2023-12-04 08:00:04'),
(2, 13, 2, '2023-12-04 08:00:04', '2023-12-04 08:00:04'),
(3, 13, 3, '2023-12-04 08:00:04', '2023-12-04 08:00:04');

-- --------------------------------------------------------

--
-- Table structure for table `page_list_translations`
--

CREATE TABLE `page_list_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `page_list_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `title` varchar(255) DEFAULT NULL,
  `title_color` varchar(255) DEFAULT NULL,
  `description` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `page_list_translations`
--

INSERT INTO `page_list_translations` (`id`, `page_list_id`, `locale`, `title`, `title_color`, `description`, `created_at`, `updated_at`) VALUES
(1, 1, 'en', 'Water', 'Drainage', '<p>We assess the amounts of water we utilize monthly and have equipped an area for the reuse of about 1000 litre /per hour&nbsp; treated water, in addition to the treatment and the reuse of steaming water.</p>', NULL, NULL),
(2, 2, 'en', 'Solid', 'waste', '<p>The waste generated from our activities is divided into two categories: contaminated waste, which is disposed of under the supervision of the Ministry of Health, and clean waste, which is collected and sorted. Depending on the type of waste, such as plastic, aluminum, glass, and wood, recycling or reusing methods are employed.</p>', NULL, NULL),
(3, 3, 'en', 'Proper gas usage and', 'air treatment system', '<p>At BPC, we recognize the significance of safeguarding the ozone layer. Therefore, we have implemented strict measures to prevent the use of harmful gases. For instance, we have replaced halon fire extinguishers with CO2 fire extinguishers and prohibited the use of Freon gas in water chillers. Furthermore, we take measures to control dust generated during the handling of raw materials and processing of certain products. To achieve this, we have installed an air treatment system that ensures the circulation of 100% clean air in our production areas. Additionally, we utilize dust collection systems to extract all the dust and maintain clean exhaust air.</p>\r\n<p>&nbsp;BPC is committed to establishing an efficient administrative environmental system and production method. As part of this commitment, we prioritize sourcing our raw materials from environmentally friendly providers. Moreover, all of our production waste undergoes proper treatment before disposal.</p>', NULL, NULL),
(4, 1, 'ar', 'صرف', 'المياه', '<p>نقوم بتقييم كميات المياه التي نستخدمها شهرياً وقمنا بتجهيز منطقة لإعادة الاستخدام تبلغ حوالي 1000 لتر/ساعة لإعادة استخدام المياه المعالجة، بالإضافة إلى معالجة وإعادة استخدام المياه البخارية.</p>', NULL, NULL),
(5, 2, 'ar', 'النفايات', 'الصلبة', '<p>يتم فصل النفايات الصلبة الناتجة عن عملياتنا إلى نفايات ملوثة؛ ويتم التخلص منها تحت إشراف وزارة الصحة. يتم جمع النفايات النظيفة وفصلها. ووفقاً لطبيعة النفايات، يتم بعد ذلك إعادة تدوير البلاستيك والألومنيوم والزجاج والخشب أو إعادة استخدامها.</p>', NULL, NULL),
(6, 3, 'ar', 'الاستخدام السليم للغاز', 'ونظام معالجة الهواء', '<p>نحن في BPC ندرك أهمية حماية طبقة الأوزون؛ نحظر استخدام الغازات الكارثية، مثل استبدال طفايات الحريق الهالون بطفايات الحريق بثاني أكسيد الكربون، كما نحظر استخدام غاز الفريون في مبردات المياه.<br>نقوم أيضًا بالتحكم في الغبار الناتج عن التعامل مع المواد الخام ومعالجة بعض المنتجات، من خلال توفير نظام معالجة الهواء الذي يفرض دوران الهواء النظيف بنسبة 100% في مناطق الإنتاج لدينا أيضًا، كما نستخدم أنظمة جمع الغبار لاستخراج جميع الغبار و ضمان هواء العادم النظيف. تسعى BPC إلى إنشاء نظام بيئي إداري فعال وطريقة إنتاج، حيث نفضل دائمًا شراء المواد الخام لدينا من مقدمي خدمات صديقين للبيئة، كما تتم معالجة جميع مخلفات الإنتاج لدينا قبل التخلص منها.</p>', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `page_translations`
--

CREATE TABLE `page_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `page_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `title` varchar(255) DEFAULT NULL,
  `subtitle` varchar(255) DEFAULT NULL,
  `description` text DEFAULT NULL,
  `list` text DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `page_translations`
--

INSERT INTO `page_translations` (`id`, `page_id`, `locale`, `title`, `subtitle`, `description`, `list`) VALUES
(1, 1, 'en', 'slider', NULL, NULL, NULL),
(2, 2, 'en', '50 Years of Experience in The Pharmaceutical Industry', 'experience', '<p><span style=\"color: rgb(149, 165, 166);\">Birzeit Pharmaceutical Company, a prominent Palestinian pharmaceutical manufacturer, specializes in producing and distributing over 270 pharmaceutical products in various dosage forms. These products cover 14 therapeutic categories distributed across 16 production lines - in 4 different locations, and are widely available throughout Palestine. With pride, the company encompasses approximately 170 brand names. In addition to supplying its products to the Palestinian Health Ministry, various local and international healthcare organizations, Birzeit Pharmaceutical Company also ensures that its products reach local consumers through pharmacies and doctors.</span></p>', NULL),
(3, 2, 'ar', '50 عامًا من الخبرة في صناعة الأدوية', 'experience', '<p>شركة بيرزيت للأدوية هي شركة فلسطينية رائدة في مجال التصنيع الدوائي. تختص شركة بيرزيت للأدوية بتصنيع وإنتاج ما يقارب المئتا وسبعون مستحضراً دوائياً موزعون على ستة عشر خط إنتاج في أربع مواقع مختلفة. حيث تغطي هذه المسحضرات مختلف المجالات العلاجية. وتستهدف الشركة جميع أنواع العملاء في السوق الفلسطيني المحلي، بما في ذلك وزارة الصحة ومؤسسات وبرامج الرعاية الصحية المحلية والدولية، بالإضافة الى الأطباء والصيادلة في السوق المحلي.&nbsp;</p>', NULL),
(4, 3, 'en', 'Our Products', NULL, '<p>As a manufacturer and marketer of generic products in virtually all therapeutic areas, BPC manufactures a wide range of dosage forms. As a result of our commitment to maintaining the highest standards of quality, we are able to ensure our products deliver the maximum benefit to our patients. Our commitment to quality plays a crucial role in our success.</p>', NULL),
(5, 3, 'ar', 'منتجاتنا', NULL, '<p>تقوم شركة BPC بتصنيع وتسويق المنتجات العامة في جميع المجالات العلاجية تقريبًا بما في ذلك مجموعة متنوعة من أشكال الجرعات التي تقوم الشركة بتصنيعها. نحن نركز باستمرار على الحفاظ على أعلى معايير الجودة، لضمان أن منتجاتنا تقدم أقصى فائدة للمرضى، والتزامنا بالجودة هو العامل الرئيسي لنجاحنا.</p>', NULL),
(6, 4, 'en', 'Our professional team works to increase productivity on the market', NULL, NULL, NULL),
(7, 5, 'en', 'Latest ', NULL, NULL, NULL),
(8, 5, 'ar', ' الاخبار', NULL, NULL, NULL),
(9, 6, 'en', 'Company', 'Profile', '<div class=\"cs-contact_card_wrap lh-lg text-dark rounded-lg p-5\">\r\n<p>An established Palestinian pharmaceutical manufacturing company, Birzeit Pharmaceutical Company produces around 270 pharmaceutical products, distributed across 16 production lines - in 4 different locations - covering a variety of therapeutical areas.<span style=\"color: rgb(0, 0, 0);\"> With pride, the company has approximately 170 brand names under its umbrella. In add</span>ition to providing services to the Ministry of Health and local and international healthcare organizations and programs, the company also provides services to consumers by way of pharmacies and doctors within the local Palestinian market.</p>\r\n<p>&nbsp;</p>\r\n</div>', NULL),
(10, 7, 'en', 'Sedonde Profile', NULL, '<p>Birzeit Pharmaceutical Company market is not confined to the Palestinian territories. BPC also exports to international markets mainly to Eastern Europe and is constantly seeking to open new markets. The company exercises its activities through three locations; one in Birzeit and the other two are located in the industrial area of Ramallah; which are the head office of the company as well as the Marketing Department.</p>\r\n<p>BPC Heardquarter includes three buildings. The first building includes the general administration and central warehouses, in addition to the quality assurance department. The second building includes the production lines for general productions of solid, liquid, semi-solid and sterile liquid preparations, the Research and Development Department and subsidiary warehouses.<br><br>The third building includes three completely separate wings. The first wing houses the production lines for penicillin preparations, the second wing houses the cephalosporin production lines, and the third wing houses the dry injection preparations production line, in addition to the Drug Control Department.</p>', NULL),
(11, 7, 'ar', 'الملف الشخصي الثاني', NULL, '<p>ولا يقتصر سوق الشركة على الأراضي الفلسطينية. وهي تصدر إلى الأسواق الدولية بشكل رئيسي في أوروبا الشرقية وتسعى باستمرار لفتح أسواق جديدة. وتمارس الشركة أنشطتها من خلال ثلاثة مواقع. يقع المركز الرئيسي للشركة في المنطقة الصناعية بمدينة رام الله. يتضمن هذا الموقع ثلاثة مباني. يضم المبنى الأول الإدارة العامة والمستودعات المركزية بالإضافة إلى قسم ضمان الجودة. أما المبنى الثاني في هذا الموقع، فيشمل بالإضافة إلى خطوط إنتاج المحضرات العامة من المحضرات السائلة الصلبة والسائلة وشبه الصلبة والمعقمة، ويضم إدارة البحث والتطوير والمستودعات التابعة.</p>\r\n<p>يضم المبنى الثالث ثلاثة أجنحة منفصلة تمامًا. ويضم الجناح الأول خطوط إنتاج مستحضرات البنسلين، والجناح الثاني يضم خطوط إنتاج السيفالوسبورينات، والجناح الثالث يضم خط إنتاج مستحضرات الحقن الجاف، بالإضافة إلى إدارة مكافحة المخدرات.</p>', NULL),
(12, 8, 'en', 'Company', 'Mission and Vision', '<p>BPC Mission&nbsp;</p>\r\n<p>Creativity in the targeted markets through providing high-quality products that keep pace with continuous development via a distinguished professional staff, in fulfillment of our responsibilities towards our employees, society, and our partners. And a commitment to keeping our environment clean and safe for us.</p>\r\n<p>BPC Vision</p>\r\n<p>The Leading Company locally and regionally in providing pharmaceutical products for a better life.</p>\r\n<p>BPC Values</p>\r\n<p>BPC is built upon a foundation of core values that define our identity and guide our actions. Each product we craft, every initiative we undertake, is imbued with a commitment to:</p>\r\n<p>&bull; Trust,&nbsp;Professionalism, Efficiency,&nbsp;Effectiveness,&nbsp;Belonging, and Cooperation.</p>', NULL),
(13, 9, 'en', 'Company', 'History', '<div class=\"cs-contact_card_wrap lh-lg text-dark rounded-lg p-5  wow  animate__ animate__fadeInUp animated\">\r\n<p>Birzeit Pharmaceuticals Company was founded in 1974 in Birzeit, a town located 10 km away from Ramallah. Initially, BPC started as a private joint stock company with a total capital investment of $150,000. However, in 1979, it transformed into a public joint stock company with a capital of 0.5 million US Dollars.</p>\r\n<p>&nbsp;In 1992, Birzeit Pharmaceuticals Company merged with the Palestine Pharmaceutical Manufacturing Company, which was the third largest pharmaceutical company in Palestine at that time. Additionally, it established the MEDIX skincare company, representing renowned international brands like Maybelline, Vichy, and Andola. In 2001, Birzeit Pharmaceuticals Company obtained the ISO 9001 certificate, further enhancing its credibility.</p>\r\n<p>The company expanded its portfolio in 2000 by acquiring 73% of the shares of the Eastern Chemical Company. It later acquired the remaining 27% in 2004. In the same year, Birzeit Pharmaceutical Company obtained the ISO 14001 certificate, demonstrating its commitment to environmental standards.</p>\r\n<p>In 2005, Birzeit Pharmaceutical Company became listed on the Palestine Stock Exchange, solidifying its position in the market. The company\'s dedication to quality investment paid off in 2008, when it obtained GMP certification according to the standards set by the World Health Organization. This achievement further established Birzeit Pharmaceuticals as a reputable key players in the industry.</p>\r\n<p>In 2010, the company experienced significant growth in its export market share, leading to increased revenues. BPC consistently evaluates its operations with the goal of becoming the most distinguished pharmaceutical company in Palestine. Its ultimate aim is to meet the healthcare needs of the people and ensure their well-being.</p>\r\n</div>', NULL),
(14, 10, 'en', 'Privacy Policy', NULL, '<h4>Welcome to the Privacy Policy for Birzeit Pharmaceutical Company’s website at bpc.ps. This Privacy Policy explains how we collect, use, and protect the personal information that you provide to us when you use our website.</h4>\n            <ol><li>Information we collect: We collect personal information that you voluntarily provide to us when you use our website, such as your name, email address, phone number, and any other information that you choose to provide.</li><li>Use of information: We use your personal information to provide you with the products and services that you request, to communicate with you about our products and services, and to improve our website and customer service.</li><li>Sharing of information: We do not sell or rent your personal information to third parties. We may share your personal information with our affiliates, service providers, or business partners to the extent necessary to provide you with the products and services that you request.</li><li>Cookies and tracking technologies: We may use cookies, web beacons, and other tracking technologies to collect information about your use of our website, such as your IP address, browser type, and operating system. This information helps us to improve our website and to provide you with a better user experience.</li><li>Data security: We take reasonable measures to protect your personal information from unauthorized access, use, or disclosure. However, no data transmission over the internet can be guaranteed to be completely secure, so we cannot guarantee the security of your information.</li><li>Children’s privacy: Our website is not directed to children under the age of 13, and we do not knowingly collect personal information from children under the age of 13. If you are under the age of 13, please do not provide us with any personal information.</li><li>Changes to Privacy Policy: We reserve the right to update or modify this Privacy Policy at any time without prior notice. Your continued use of our website following any changes to this Privacy Policy constitutes your acceptance of those changes.</li><li>Contact us: If you have any questions or concerns about this Privacy Policy or our website, please contact us at <strong>info@bpc.ps</strong> or by calling our office at <strong>+970-2-2987573.</strong></li></ol>\n            <p>Thank you for visiting our website.</p>', NULL),
(15, 11, 'en', 'Terms and Condition', NULL, '<h4>Welcome to the Terms and Conditions for Birzeit Pharmaceutical Company’s website at bpc.ps. By accessing and using our website, you agree to be bound by the following terms and conditions:</h4>\n            <ol><li>Ownership of content: All content on the website, including but not limited to text, graphics, logos, images, and software, is the property of Birzeit Pharmaceutical Company and is protected by copyright laws.</li><li>Use of website: You may use our website for personal, non-commercial purposes only. You may not copy, modify, distribute, transmit, display, perform, reproduce, publish, license, create derivative works from, transfer or sell any information or content obtained from the website without our prior written consent.</li><li>Accuracy of information: We strive to ensure that all information on our website is accurate, but we cannot guarantee the accuracy, completeness, or timeliness of the information. We reserve the right to update or modify the information on our website at any time without prior notice.</li><li>Product information: Any information or content provided on our website about our products is for informational purposes only and should not be used as a substitute for professional medical advice or treatment. Please consult your healthcare provider before using any of our products.</li><li>Links to third-party websites: Our website may contain links to third-party websites that are not under our control. We are not responsible for the content or availability of these websites and we do not endorse any products or services offered on them.</li><li>Limitation of liability: Birzeit Pharmaceutical Company shall not be liable for any damages, including but not limited to direct, indirect, incidental, consequential, or punitive damages, arising out of or in connection with the use or inability to use our website or the information or content provided on our website.</li><li>Indemnification: You agree to indemnify and hold Birzeit Pharmaceutical Company and its affiliates, officers, agents, employees, and licensors harmless from any claim or demand, including reasonable attorneys’ fees, made by any third party due to or arising out of your use of our website or your violation of these terms and conditions.</li><li>Governing law: These terms and conditions shall be governed by and construed in accordance with the laws of the State of Palestine, without giving effect to any principles of conflicts of law.</li><li>Jurisdiction: Any legal action arising out of or in connection with these terms and conditions or the use of our website shall be brought in the courts of the State of Palestine.</li><li>Changes to terms and conditions: We reserve the right to update or modify these terms and conditions at any time without prior notice. Your continued use of our website following any changes to these terms and conditions constitutes your acceptance of those changes.</li><li>Contact us: If you have any questions or concerns about these terms and conditions or our website, please contact us at <strong>info@bpc.ps</strong> or by calling our office at <strong>+970-2-2987573.</strong></li></ol>\n            <p>Thank you for visiting our website.</p>', NULL),
(16, 12, 'en', 'Social Responsibility', NULL, '<p>BPC places utmost importance on fulfilling its social responsibility as a fundamental priority. The organization directs its resources towards sustainable investments in various crucial domains, including the environment, education, health, social and cultural development, and above all, the well-being of BPC\'s internal community and its employees.&nbsp;</p>', NULL),
(17, 13, 'en', 'OUR ENVIRONMENT', NULL, '<p>Since 2004, BPC has invested in eliminating the environmental damage associated with pharmaceutical manufacturing. The Company&rsquo;s first environment-friendly building was completed in 2012, whereby solar energy had been utilized as an alternative to fuel. BPC aims to replicate this environment-friendly example in its other facilities and is still investing in applying new green energy resources.</p>', NULL),
(18, 14, 'en', 'OUR COMMUNITY', NULL, '<p>Birzeit Pharmaceutical Company places great importance on its social responsibility, considering it both a principle and a priority. For numerous years, the company has dedicated its resources to support and enhance our community. This commitment is evident through various initiatives focused on the environment, health, and education. Additionally, Birzeit Pharmaceutical Company actively engages in sustainable projects, implementing programs that contribute to long-term development. The company\'s primary focus lies in supporting students at schools and universities, as well as conducting campaigns that benefit hospitals and medical centers, reflecting its deep interest in the healthcare sector. Furthermore, Birzeit Pharmaceutical Company provides annual support to multiple societies, further demonstrating its dedication to making a positive impact.</p>', NULL),
(19, 12, 'ar', 'المسؤولية الاجتماعية', NULL, '<p>تعتبر BPC التزامها بمسؤوليتها الاجتماعية أولوية أساسية. تركز الشركة على الاستثمارات المستدامة في عدة مجالات مهمة مثل البيئة والتعليم والصحة والتنمية الاجتماعية والثقافية والتطوير الرياضي، والأهم من ذلك المجتمع الداخلي لشركة BPC وموظفيها.</p>', NULL),
(20, 13, 'ar', 'بيئتنا', NULL, '<p>منذ عام 2004، استثمرت شركة BPC في القضاء على الأضرار البيئية المرتبطة بتصنيع الأدوية. تم الانتهاء من أول مبنى صديق للبيئة للشركة في عام 2012، حيث تم استخدام الطاقة الشمسية كبديل للوقود. وتهدف شركة BPC إلى تكرار هذا المثال الصديق للبيئة في منشآتها الأخرى، ولا تزال تستثمر في تطبيق موارد الطاقة الخضراء الجديدة.</p>', NULL),
(21, 14, 'ar', 'مجتمعنا', NULL, '<p>تعتبر شركة بيرزيت للأدوية مسؤوليتها الاجتماعية مبدأ وأولوية. منذ سنوات عديدة، تستثمر الشركة في دعم وتطوير مجتمعنا، من خلال الحملات المختلفة المتعلقة بالبيئة والصحة والتعليم، بالإضافة إلى تنفيذ العديد من البرامج القائمة على المشاريع المستدامة. تركز شركة بيرزيت للأدوية اهتمامها على دعم طلاب المدارس والجامعات، بالإضافة إلى الحملات التي تستهدف المستشفيات والمراكز الطبية، انطلاقاً من اهتمامها الكبير بمجال الرعاية الصحية. كما تدعم الشركة العديد من الجمعيات على أساس سنوي.</p> ', NULL),
(22, 15, 'en', 'Stock Price', NULL, NULL, NULL),
(23, 16, 'en', 'Investor services', NULL, 'With our best wishes to all, we wish to inform you that we will be adopting bank transfers to your below-indicated accounts for disbursing the cash dividends due on your shareholding in Birzeit Pharmaceutical Company. Please ensure to fill out the form accurately, verify your bank account is active, and attach the required documents as specified below.\n\n            Priding ourselves on our shareholders, we continuously strive to maintain a clear and rapid communication mechanism with our shareholders and investors.\n\n            Kindly send the following form and its attachments to the email shareholders@bpc.ps. Should you have any inquiries or encounter any issues, please contact us at +972594203043 on WhatsApp.\n            Please note, if you are unable to send the form via email, it can be sent to the fax number: +972 2 2967206', NULL),
(24, 17, 'en', 'Financial Reports', NULL, NULL, NULL),
(25, 18, 'en', 'Governance', NULL, NULL, NULL),
(26, 15, 'ar', 'سعر السهم', NULL, NULL, NULL),
(27, 16, 'ar', 'خدمات المستثمرين', NULL, 'مع أطيب تمنياتنا للجميع، نود إعلامكم أننا سنعتمد التحويل البنكي إلى حساباتكم المبينة أدناه لتوزيع الأرباح النقدية المستحقة على مساهمتكم في شركة بيرزيت للأدوية. يرجى التأكد من ملء النموذج بدقة، والتحقق من أن حسابك البنكي نشط، وإرفاق المستندات المطلوبة كما هو محدد أدناه.\n\n            ومن منطلق فخرنا بمساهمينا، فإننا نسعى باستمرار للحفاظ على آلية اتصال واضحة وسريعة مع المساهمين والمستثمرين.\n\n            يرجى إرسال النموذج التالي ومرفقاته إلى البريد الإلكتروني المساهمين@bpc.ps. إذا كان لديك أي استفسار أو واجهت أي مشكلة، يرجى الاتصال بنا على الرقم +972594203043 عبر الواتساب.\n            يرجى ملاحظة أنه إذا لم تتمكن من إرسال النموذج عبر البريد الإلكتروني، فيمكن إرساله إلى رقم الفاكس: +972 2 2967206', NULL),
(28, 17, 'ar', 'تقارير مالية', NULL, NULL, NULL),
(29, 18, 'ar', 'الحكم', NULL, NULL, NULL),
(30, 19, 'en', 'Board of Directors', NULL, 'A seven to nine-member Board, elected by shareholders through secret vote, manages the Company. Board terms are limited to two years, ending with new elections.', NULL),
(31, 20, 'en', 'Committees', NULL, 'The Chairman and the members of the Board of Directors fulfill their responsibilities by conducting regular meetings to monitor the company\'s progress in its operations through various committees.', NULL),
(32, 21, 'en', 'Executive Management', NULL, 'The management includes a variety of leaders like Talal and Firas Nasereddin, with expertise across finance, chemistry, engineering, pharmacy, and more, driving company operations.', NULL),
(33, 22, 'en', 'Code of conduct', NULL, 'Birzeit Pharmaceuticals emphasizes transparency and integrity, mandating adherence to a Code of Ethics for all management and staff, ensuring ethical conduct in all operations.', NULL),
(34, 23, 'en', 'General Assembly Meeting', NULL, 'BPC\'s Board Of Directors hold a minimum of six meetings annually. All shareholders are personally invited to attend the Ordinary General Assembly Meeting, and this invitation includes the meeting schedule. The date of the general assembly is publicly announced in official newspapers at least two weeks prior to the meeting date.', NULL),
(35, 19, 'ar', 'مجلس إدارة', NULL, 'ويتولى إدارة الشركة مجلس إدارة يتكون من سبعة إلى تسعة أعضاء، ينتخبهم المساهمون بالاقتراع السري. وتقتصر فترة ولاية مجلس الإدارة على عامين، وتنتهي بإجراء انتخابات جديدة.', NULL),
(36, 20, 'ar', 'اللجان', NULL, 'تقوم لجنة الدكتور أبو خيزران بوضع استراتيجيات الاستثمار، ويقوم فريق الدكتور أبو الليل بإجراء عمليات التدقيق المالي، وتقوم لجنة السيد نصر الدين بصياغة أطر الأجور.', NULL),
(37, 21, 'ar', 'الادارة التنفيذية', NULL, 'تضم الإدارة قادة متمرسين مثل طلال وفراس ناصر الدين، يتمتعون بخبرة في مجالات التمويل والكيمياء والهندسة والصيدلة والمزيد، مما يؤدي إلى قيادة عمليات الشركة.', NULL),
(38, 22, 'ar', 'مدونة لقواعد السلوك', NULL, 'تؤكد شركة بيرزيت للأدوية على الشفافية والنزاهة، وتفرض الالتزام بقواعد الأخلاقيات لجميع الإدارة والموظفين، مما يضمن السلوك الأخلاقي في جميع العمليات.', NULL),
(39, 23, 'ar', 'اجتماع الجمعية العمومية', NULL, 'يجتمع مجلس إدارة الشركة لمدة ست جلسات على الأقل كل سنة. تتم دعوة المساهمين شخصياً لحضور الجمعية العامة العادية، وسيتم الإعلان عن التفاصيل في الصحافة قبل أسبوعين.', NULL),
(40, 10, 'ar', 'سياسة الحصوصية', NULL, ' <h4><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">مرحبا بكم في سياسة الخصوصية لموقع شركة بيرزيت للأدوية bpc.ps. </font><font style=\"vertical-align: inherit;\">تشرح سياسة الخصوصية هذه كيف نقوم بجمع واستخدام وحماية المعلومات الشخصية التي تقدمها لنا عند استخدام موقعنا.</font></font></h4>\n            <ol><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">المعلومات التي نجمعها: نقوم بجمع المعلومات الشخصية التي تقدمها لنا طوعًا عند استخدام موقعنا، مثل اسمك وعنوان بريدك الإلكتروني ورقم هاتفك وأي معلومات أخرى تختار تقديمها.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">استخدام المعلومات: نستخدم معلوماتك الشخصية لتزويدك بالمنتجات والخدمات التي تطلبها، وللتواصل معك بشأن منتجاتنا وخدماتنا، ولتحسين موقعنا الإلكتروني وخدمة العملاء.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">مشاركة المعلومات: نحن لا نبيع أو نؤجر معلوماتك الشخصية لأطراف ثالثة. </font><font style=\"vertical-align: inherit;\">يجوز لنا مشاركة معلوماتك الشخصية مع الشركات التابعة لنا، أو مقدمي الخدمات، أو شركاء العمل بالقدر اللازم لتزويدك بالمنتجات والخدمات التي تطلبها.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">ملفات تعريف الارتباط وتقنيات التتبع: قد نستخدم ملفات تعريف الارتباط وإشارات الويب وتقنيات التتبع الأخرى لجمع معلومات حول استخدامك لموقعنا الإلكتروني، مثل عنوان IP الخاص بك ونوع المتصفح ونظام التشغيل. </font><font style=\"vertical-align: inherit;\">تساعدنا هذه المعلومات على تحسين موقعنا الإلكتروني وتزويدك بتجربة مستخدم أفضل.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">أمن البيانات: نحن نتخذ تدابير معقولة لحماية معلوماتك الشخصية من الوصول أو الاستخدام أو الكشف غير المصرح به. </font><font style=\"vertical-align: inherit;\">ومع ذلك، لا يمكن ضمان أن يكون نقل البيانات عبر الإنترنت آمنًا تمامًا، لذلك لا يمكننا ضمان أمان معلوماتك.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">خصوصية الأطفال: موقعنا غير موجه للأطفال دون سن 13 عامًا، ولا نقوم عمدًا بجمع معلومات شخصية من الأطفال دون سن 13 عامًا. إذا كان عمرك أقل من 13 عامًا، فيرجى عدم تزويدنا بأي معلومات شخصية .</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">التغييرات في سياسة الخصوصية: نحتفظ بالحق في تحديث أو تعديل سياسة الخصوصية هذه في أي وقت دون إشعار مسبق. </font><font style=\"vertical-align: inherit;\">إن استمرارك في استخدام موقعنا الإلكتروني بعد أي تغييرات على سياسة الخصوصية هذه يشكل موافقتك على هذه التغييرات.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">اتصل بنا: إذا كان لديك أي أسئلة أو استفسارات بشأن سياسة الخصوصية هذه أو موقعنا الإلكتروني، يرجى الاتصال بنا على </font></font><strong><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">info@bpc.ps</font></font></strong><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\"> أو عن طريق الاتصال بمكتبنا على الرقم </font></font><strong><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">+970-2-2987573.</font></font></strong></li></ol>\n            <p><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">شكرا لكم لزيارة موقعنا.</font>', NULL),
(41, 11, 'ar', 'أحكام وشروط', NULL, ' <h4><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">أهلاً بكم في الشروط والأحكام الخاصة بالموقع الإلكتروني لشركة بيرزيت للأدوية bpc.ps. </font><font style=\"vertical-align: inherit;\">من خلال الدخول إلى موقعنا واستخدامه، فإنك توافق على الالتزام بالشروط والأحكام التالية:</font></font></h4>\n            <ol><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">ملكية المحتوى: جميع محتويات الموقع، بما في ذلك على سبيل المثال لا الحصر، النصوص والرسومات والشعارات والصور والبرامج، هي ملك لشركة بيرزيت للأدوية ومحمية بموجب قوانين حقوق النشر.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">استخدام الموقع: يجوز لك استخدام موقعنا لأغراض شخصية وغير تجارية فقط. </font><font style=\"vertical-align: inherit;\">لا يجوز لك نسخ أو تعديل أو توزيع أو نقل أو عرض أو تنفيذ أو إعادة إنتاج أو نشر أو ترخيص أو إنشاء أعمال مشتقة من أو نقل أو بيع أي معلومات أو محتوى تم الحصول عليه من الموقع دون موافقة كتابية مسبقة منا.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">دقة المعلومات: نحن نسعى جاهدين للتأكد من أن جميع المعلومات الموجودة على موقعنا دقيقة، ولكن لا يمكننا ضمان دقة المعلومات أو اكتمالها أو توقيتها. </font><font style=\"vertical-align: inherit;\">نحن نحتفظ بالحق في تحديث أو تعديل المعلومات الموجودة على موقعنا في أي وقت دون إشعار مسبق.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">معلومات المنتج: أي معلومات أو محتوى مقدم على موقعنا الإلكتروني حول منتجاتنا هو لأغراض إعلامية فقط ولا ينبغي استخدامه كبديل عن المشورة الطبية المتخصصة أو العلاج. </font><font style=\"vertical-align: inherit;\">يرجى استشارة مقدم الرعاية الصحية الخاص بك قبل استخدام أي من منتجاتنا.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">روابط لمواقع طرف ثالث: قد يحتوي موقعنا على روابط لمواقع طرف ثالث لا تخضع لسيطرتنا. </font><font style=\"vertical-align: inherit;\">نحن لسنا مسؤولين عن محتوى هذه المواقع أو توفرها ولا نؤيد أي منتجات أو خدمات مقدمة عليها.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">حدود المسؤولية: لن تكون شركة بيرزيت للأدوية مسؤولة عن أي أضرار، بما في ذلك على سبيل المثال لا الحصر، الأضرار المباشرة أو غير المباشرة أو العرضية أو التبعية أو التأديبية، التي تنشأ عن أو فيما يتعلق باستخدام أو عدم القدرة على استخدام موقعنا أو المعلومات. أو المحتوى المقدم على موقعنا.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">التعويض: أنت توافق على تعويض شركة بيرزيت للأدوية والشركات التابعة لها ومسؤوليها ووكلائها وموظفيها ومرخصيها وحمايتهم من أي مطالبة أو طلب، بما في ذلك أتعاب المحاماة المعقولة، التي يقدمها أي طرف ثالث بسبب أو ناشئ عن استخدامك للموقع. موقعنا أو مخالفتك لهذه الشروط والأحكام.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">القانون الحاكم: تخضع هذه الشروط والأحكام وتفسر وفقًا لقوانين دولة فلسطين، دون تفعيل أي مبادئ تتعلق بتعارض القوانين.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">الاختصاص القضائي: أي إجراء قانوني ينشأ عن أو فيما يتعلق بهذه الشروط والأحكام أو استخدام موقعنا يجب رفعه أمام محاكم دولة فلسطين.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">التغييرات على الشروط والأحكام: نحتفظ بالحق في تحديث أو تعديل هذه الشروط والأحكام في أي وقت دون إشعار مسبق. </font><font style=\"vertical-align: inherit;\">إن استمرارك في استخدام موقعنا الإلكتروني بعد أي تغييرات على هذه الشروط والأحكام يشكل موافقتك على هذه التغييرات.</font></font></li><li><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">اتصل بنا: إذا كان لديك أي أسئلة أو استفسارات بشأن هذه الشروط والأحكام أو موقعنا الإلكتروني، يرجى الاتصال بنا على </font></font><strong><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">info@bpc.ps</font></font></strong><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\"> أو عن طريق الاتصال بمكتبنا على الرقم </font></font><strong><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">+970-2-2987573.</font></font></strong></li></ol>\n            <p><font style=\"vertical-align: inherit;\"><font style=\"vertical-align: inherit;\">شكرا لكم لزيارة موقعنا.</font></font></p>', NULL),
(42, 24, 'en', 'Branches', NULL, NULL, NULL),
(43, 24, 'ar', 'الفروع', NULL, NULL, NULL),
(44, 25, 'en', 'Information Contact ', NULL, NULL, NULL),
(45, 25, 'ar', 'معولمات الإتصال', NULL, NULL, NULL),
(46, 4, 'ar', 'يعمل فريقنا المحترف على زيادة الإنتاجية في السوق', NULL, NULL, NULL),
(47, 6, 'ar', 'نبذة عن', 'الشركة', '<p>شركة بيرزيت للأدوية هي شركة فلسطينية رائدة في مجال تصنيع الأدوية. تنتج الشركة ما يقارب 300 مستحضر موزعة على عشرة خطوط إنتاج تغطي مختلف المجالات العلاجية. وتستهدف الشركة جميع أنواع العملاء في السوق الفلسطيني المحلي، بما في ذلك وزارة الصحة ومؤسسات وبرامج الرعاية الصحية المحلية والعالمية، بالإضافة إلى المستهلكين (من خلال الصيدليات والأطباء).</p>', NULL),
(48, 8, 'ar', 'الرؤية والرسالة', 'للشركة', '<p>تتمثل رؤية بيرزيت فارما في أن تكون الرائدة محلياً وإقليمياً في توفير المنتجات الصيدلانية لحياة أفضل. القيم هي الثقة والاحتراف والكفاءة والفعالية والانتماء والتعاون.</p>\r\n<p>لقد حرصنا دائمًا على الابتكار في الأسواق المستهدفة من خلال تقديم منتجات عالية الجودة تواكب التقدم المستمر الذي يشهده العالم، من خلال توظيف كادر متميز ومؤهل للوفاء بمسؤولياتنا تجاه موظفينا ومجتمعنا ومجتمعنا. . نحن ملتزمون بالحفاظ على بيئة نظيفة لمجتمعنا وشعبنا.</p>', NULL),
(49, 9, 'ar', 'تاريخ', 'الشركة', '<p>تأسست شركة بيرزيت للأدوية عام 1974 في مدينة بيرزيت التي تبعد 10 كم عن مدينة رام الله، كشركة مساهمة خاصة يبلغ رأسمالها الإجمالي 150 ألف دولار أمريكي. وفي عام 1979، أصبحت شركة بيرزيت للأدوية شركة مساهمة عامة برأسمال قدره 0.5 مليون دولار أمريكي. وفي عام 1992، اندمجت الشركة مع شركة فلسطين لصناعة الأدوية، وهي ثالث أكبر شركة أدوية في فلسطين في ذلك الوقت. كما قامت بتأسيس شركة MEDIX للعناية بالبشرة والتي تمثل عدد من الشركات العالمية مثل ميبلين، فيشي، وأندولا. حصلت شركة بيرزيت للأدوية على شهادة الأيزو 9001 عام 2001. وفي عام 2000 قامت الشركة بشراء 73% من أسهم شركة الكيماويات الشرقية وحصلت على الـ 27% المتبقية منها في عام 2004، وفي نفس العام حصلت على شهادة الأيزو 14001 . وفي عام 2005، كانت شركة بيرزيت تمتلك 51% من شركة بتروفام في الجزائر، حيث تقوم شركة بيرزيت بتصدير المنتجات شبه المصنعة إليها، والتي تقوم بتروفام بتعبئتها وبيعها في السوق الجزائرية. وفي عام 2005 أيضاً، أصبحت شركة بيرزيت للأدوية مدرجة في بورصة فلسطين. أدى الاستثمار المستمر في الجودة إلى حصول شركة بيرزيت للأدوية على شهادة GMP وفقًا لمعايير منظمة الصحة العالمية في عام 2008. وفي عام 2010، ضاعفت شركة بيرزيت للأدوية حصتها في سوق التصدير، وهو ما انعكس على إيراداتها في عام 2010. وتعيد شركة بيرزيت للأدوية باستمرار تقييم أعمالها بهدف أن تكون الشركة الأكثر تميزا في صناعة الأدوية في فلسطين، لتكون قادرة على تزويد الناس بالاحتياجات التي تضمن صحتهم.</p>', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `password_reset_tokens`
--

CREATE TABLE `password_reset_tokens` (
  `email` varchar(255) NOT NULL,
  `token` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `permissions`
--

CREATE TABLE `permissions` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) NOT NULL,
  `guard_name` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `personal_access_tokens`
--

CREATE TABLE `personal_access_tokens` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `tokenable_type` varchar(255) NOT NULL,
  `tokenable_id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) NOT NULL,
  `token` varchar(64) NOT NULL,
  `abilities` text DEFAULT NULL,
  `last_used_at` timestamp NULL DEFAULT NULL,
  `expires_at` timestamp NULL DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `productivities`
--

CREATE TABLE `productivities` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `icone` varchar(255) NOT NULL,
  `value` varchar(255) DEFAULT NULL,
  `order_by` int(11) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `productivities`
--

INSERT INTO `productivities` (`id`, `icone`, `value`, `order_by`, `created_at`, `updated_at`) VALUES
(1, 'uploads/Productivity/75201701759411.svg', '1974', 1, '2023-12-04 08:00:03', '2023-12-05 04:56:51'),
(2, 'uploads/Productivity/497261701759421.svg', '4', 2, '2023-12-04 08:00:03', '2023-12-05 04:57:01'),
(3, 'uploads/Productivity/404241701759429.svg', '370', 3, '2023-12-04 08:00:03', '2023-12-05 04:57:09'),
(4, 'uploads/Productivity/630211701759464.svg', '6', 4, '2023-12-04 08:00:03', '2023-12-05 04:57:44');

-- --------------------------------------------------------

--
-- Table structure for table `productivity_translations`
--

CREATE TABLE `productivity_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `productivity_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `name` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `productivity_translations`
--

INSERT INTO `productivity_translations` (`id`, `productivity_id`, `locale`, `name`, `created_at`, `updated_at`) VALUES
(1, 1, 'en', 'Established', NULL, NULL),
(2, 2, 'en', 'Countries', NULL, NULL),
(3, 3, 'en', 'Workers', NULL, NULL),
(4, 4, 'en', 'Sites', NULL, NULL),
(5, 1, 'ar', 'تأسست', NULL, NULL),
(6, 2, 'ar', 'الدول', NULL, NULL),
(7, 3, 'ar', 'العاملين', NULL, NULL),
(8, 4, 'ar', 'المواقع', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `products`
--

CREATE TABLE `products` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `product_type_id` bigint(20) UNSIGNED DEFAULT NULL,
  `image` varchar(255) DEFAULT NULL,
  `file` varchar(255) DEFAULT NULL,
  `file_name` varchar(255) DEFAULT NULL,
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `products`
--

INSERT INTO `products` (`id`, `product_type_id`, `image`, `file`, `file_name`, `order_by`, `created_at`, `updated_at`) VALUES
(7, 2, 'uploads/Product/205641701845322.jpg', 'uploads/Product/819731701845322.docx', 'Abecedin.docx', NULL, '2023-12-06 04:48:42', '2023-12-06 04:48:42'),
(8, 2, 'uploads/Product/106191701845430.jpg', 'uploads/Product/363161701845430.docx', 'decomb.docx', NULL, '2023-12-06 04:50:30', '2023-12-06 04:50:30'),
(9, 2, 'uploads/Product/997231701845516.jpg', 'uploads/Product/780751701845516.docx', 'Dilax.docx', NULL, '2023-12-06 04:51:56', '2023-12-06 04:51:56'),
(10, 2, 'uploads/Product/304721701845627.jpg', 'uploads/Product/998181701845627.docx', 'dimestil drops.docx', NULL, '2023-12-06 04:53:47', '2023-12-06 04:53:47'),
(11, 2, 'uploads/Product/705351701845722.jpg', 'uploads/Product/708381701845722.docx', 'Dimestil gel.docx', NULL, '2023-12-06 04:55:22', '2023-12-06 04:55:22'),
(12, 2, 'uploads/Product/897941701845819.jpg', 'uploads/Product/694621701845819.docx', 'Febramol.docx', NULL, '2023-12-06 04:56:59', '2023-12-06 04:56:59'),
(13, 2, 'uploads/Product/778131701845891.jpg', 'uploads/Product/223801701845891.docx', 'Febramol.docx', NULL, '2023-12-06 04:58:11', '2023-12-06 04:58:11'),
(14, 2, 'uploads/Product/833091701845992.jpg', 'uploads/Product/742671701845992.docx', 'fergole.docx', NULL, '2023-12-06 04:59:52', '2023-12-06 04:59:52'),
(15, 2, 'uploads/Product/800241701846064.jpg', 'uploads/Product/165121701846064.docx', 'fungitrin cream.docx', NULL, '2023-12-06 05:01:04', '2023-12-06 05:01:04'),
(16, 2, 'uploads/Product/243421701846217.jpg', 'uploads/Product/539571701846217.docx', 'Fungitrin oral gel.docx', NULL, '2023-12-06 05:03:37', '2023-12-06 05:03:37'),
(17, 2, 'uploads/Product/911261701846293.jpg', 'uploads/Product/993031701846293.docx', 'gingival.docx', NULL, '2023-12-06 05:04:53', '2023-12-06 05:04:53'),
(18, 2, 'uploads/Product/60431701846362.jpg', 'uploads/Product/802821701846362.docx', 'lamirase cream & solution.docx', NULL, '2023-12-06 05:06:02', '2023-12-06 05:06:02'),
(19, 2, 'uploads/Product/119491701846452.jpg', 'uploads/Product/390771701846452.docx', 'nirvin.docx', NULL, '2023-12-06 05:07:32', '2023-12-06 05:07:32'),
(20, 2, 'uploads/Product/149651701846532.jpg', 'uploads/Product/664991701846532.docx', 'oracal.docx', NULL, '2023-12-06 05:08:52', '2023-12-06 05:08:52'),
(21, 1, 'uploads/Product/141281701846679.jpg', 'uploads/Product/614021701846679.docx', 'Orlislim 120.docx', NULL, '2023-12-06 05:11:19', '2023-12-06 05:11:19'),
(22, 2, 'uploads/Product/422831701846777.jpg', 'uploads/Product/927921701846777.docx', 'Pantinol plus.docx', NULL, '2023-12-06 05:12:57', '2023-12-06 05:12:57'),
(23, 2, 'uploads/Product/40671701846885.jpg', 'uploads/Product/492731701846885.docx', 'Rhinofex MD.docx', NULL, '2023-12-06 05:14:45', '2023-12-06 05:14:45'),
(24, 2, 'uploads/Product/632431701846961.jpg', 'uploads/Product/448011701846961.docx', 'RUFENAL DS EMULGEL.docx', NULL, '2023-12-06 05:16:01', '2023-12-06 05:16:01'),
(25, 2, 'uploads/Product/107101701847034.jpg', 'uploads/Product/196131701847034.docx', 'sedamol.docx', NULL, '2023-12-06 05:17:14', '2023-12-06 05:17:14'),
(26, 2, 'uploads/Product/417261701847178.jpg', 'uploads/Product/144051701847178.docx', 'Sedaprin.docx', NULL, '2023-12-06 05:19:38', '2023-12-06 05:19:38'),
(27, 2, 'uploads/Product/627011701847313.jpg', 'uploads/Product/605211701847313.docx', 'Siafil.docx', NULL, '2023-12-06 05:21:53', '2023-12-06 05:21:53'),
(28, 2, 'uploads/Product/881041701847407.jpg', 'uploads/Product/945721701847407.docx', 'Simeped.docx', NULL, '2023-12-06 05:23:27', '2023-12-06 05:23:27'),
(29, 2, 'uploads/Product/900881701847477.jpg', 'uploads/Product/988411701847477.docx', 'TETRIN.docx', NULL, '2023-12-06 05:24:37', '2023-12-06 05:24:37'),
(30, 1, 'uploads/Product/617521701850289.jpg', 'uploads/Product/520821701850289.docx', 'Adol.docx', NULL, '2023-12-06 06:11:29', '2023-12-06 06:11:29'),
(31, 1, 'uploads/Product/778241701850662.jpg', 'uploads/Product/876641701850662.docx', 'Allnex 0.1_ drops.docx', NULL, '2023-12-06 06:17:42', '2023-12-06 06:17:42'),
(32, 1, 'uploads/Product/191531701851034.jpg', 'uploads/Product/800171701851034.docx', 'Amoxitid.docx', NULL, '2023-12-06 06:23:54', '2023-12-06 06:23:54'),
(33, 1, 'uploads/Product/260621701851919.jpg', 'uploads/Product/361961701851919.docx', 'Azimex caps & Powder.docx', NULL, '2023-12-06 06:38:39', '2023-12-06 06:38:39'),
(34, 1, 'uploads/Product/794381701853313.jpg', 'uploads/Product/352921701853313.docx', 'Basilox 400.docx', NULL, '2023-12-06 07:01:53', '2023-12-06 07:01:53'),
(35, 1, 'uploads/Product/215851701855124.jpg', 'uploads/Product/314011701855124.docx', 'candistan.docx', NULL, '2023-12-06 07:32:04', '2023-12-06 07:32:04'),
(36, 1, 'uploads/Product/665861702363313.jpg', 'uploads/Product/768041701855515.docx', 'Cefpo Tablet.docx', NULL, '2023-12-06 07:38:35', '2023-12-12 04:41:53'),
(37, 1, 'uploads/Product/80541701855882.jpg', 'uploads/Product/763891701855882.docx', 'chlorosone.docx', NULL, '2023-12-06 07:44:42', '2023-12-06 07:44:42'),
(38, 1, 'uploads/Product/449501701856293.jpg', 'uploads/Product/243341701856293.docx', 'clafoxim vial.docx', NULL, '2023-12-06 07:51:33', '2023-12-06 07:51:33'),
(39, 1, 'uploads/Product/236461703510624.jpg', 'uploads/Product/591851702405014.docx', 'Alfacal.docx', NULL, '2023-12-12 16:16:54', '2023-12-25 11:23:44'),
(40, 1, 'uploads/Product/122201703515749.jpg', 'uploads/Product/366341702407246.docx', 'Amicor plus.docx', NULL, '2023-12-12 16:54:06', '2023-12-25 12:49:09'),
(41, 1, 'uploads/Product/955411703516217.jpg', 'uploads/Product/523331702407530.docx', 'Amicor.docx', NULL, '2023-12-12 16:58:50', '2023-12-25 12:56:57'),
(42, 1, 'uploads/Product/958041703516293.jpg', 'uploads/Product/374041702407698.docx', 'Amiran.docx', NULL, '2023-12-12 17:01:38', '2023-12-25 12:58:13'),
(43, 1, 'uploads/Product/457361703516325.jpg', 'uploads/Product/985221702407870.docx', 'Ancozine.docx', NULL, '2023-12-12 17:04:30', '2023-12-25 12:58:45'),
(44, 1, 'uploads/Product/915421704707536.jpg', 'uploads/Product/124621702448139.docx', 'Basilox eye drops.docx', NULL, '2023-12-13 04:15:39', '2024-01-08 07:52:16'),
(45, 1, 'uploads/Product/168061704707523.jpg', 'uploads/Product/982601702448267.docx', 'Bepen VK.docx', NULL, '2023-12-13 04:17:47', '2024-01-08 07:52:03'),
(46, 2, 'uploads/Product/430471704707508.jpg', 'uploads/Product/28131702448407.docx', 'BUVIDAL.docx', NULL, '2023-12-13 04:20:07', '2024-01-08 07:51:48'),
(47, 1, 'uploads/Product/700101704707491.jpg', 'uploads/Product/747831702450814.docx', 'cefadrox.docx', NULL, '2023-12-13 05:00:14', '2024-01-08 07:51:31'),
(48, 1, 'uploads/Product/696021704707474.jpg', 'uploads/Product/950241702450954.docx', 'cefalex.docx', NULL, '2023-12-13 05:02:34', '2024-01-08 07:51:14'),
(49, 1, 'uploads/Product/415641704707458.jpg', 'uploads/Product/543151702451175.docx', 'CEFIMED CAP & SUSP.docx', NULL, '2023-12-13 05:06:15', '2024-01-08 07:50:58'),
(50, 1, 'uploads/Product/928761704707443.jpg', 'uploads/Product/496411702451281.docx', 'cefixon vial.docx', NULL, '2023-12-13 05:08:01', '2024-01-08 07:50:43'),
(51, 1, 'uploads/Product/670371704707427.jpg', 'uploads/Product/774911702451406.docx', 'ceproxx.docx', NULL, '2023-12-13 05:10:06', '2024-01-08 07:50:27'),
(52, 2, 'uploads/Product/800441704707411.jpg', 'uploads/Product/430871702451525.docx', 'chloromyxin.docx', NULL, '2023-12-13 05:12:05', '2024-01-08 07:50:11'),
(53, 1, 'uploads/Product/346151704707394.jpg', 'uploads/Product/10121702451678.docx', 'CINOLONE.docx', NULL, '2023-12-13 05:14:38', '2024-01-08 07:49:54'),
(54, 1, 'uploads/Product/933451704707372.jpg', 'uploads/Product/575141702451785.docx', 'clovix.docx', NULL, '2023-12-13 05:16:25', '2024-01-08 07:49:32'),
(55, 1, 'uploads/Product/466161704707356.jpg', 'uploads/Product/634571702451909.docx', 'collihist.docx', NULL, '2023-12-13 05:18:29', '2024-01-08 07:49:16'),
(56, 1, 'uploads/Product/797021702452035.jpg', 'uploads/Product/310681702452035.docx', 'cyprodin.docx', NULL, '2023-12-13 05:20:35', '2023-12-13 05:20:35'),
(57, 1, 'uploads/Product/764661704707342.jpg', 'uploads/Product/363861702452292.docx', 'decongex sr caps.docx', NULL, '2023-12-13 05:24:52', '2024-01-08 07:49:02'),
(58, 1, 'uploads/Product/121911704707328.jpg', 'uploads/Product/423741702452532.docx', 'decort amp.docx', NULL, '2023-12-13 05:28:52', '2024-01-08 07:48:48'),
(59, 1, 'uploads/Product/14051704707312.jpg', 'uploads/Product/524731702453276.docx', 'decort tab.docx', NULL, '2023-12-13 05:41:16', '2024-01-08 07:48:32'),
(60, 1, 'uploads/Product/442871704707296.jpg', 'uploads/Product/151391702453650.docx', 'DELECAS.docx', NULL, '2023-12-13 05:47:30', '2024-01-08 07:48:16'),
(61, 1, 'uploads/Product/917401704707277.jpg', 'uploads/Product/47201702453784.docx', 'dermasept.docx', NULL, '2023-12-13 05:49:44', '2024-01-08 07:47:57'),
(62, 1, 'uploads/Product/32661704707163.jpg', 'uploads/Product/13491702453893.docx', 'dexacol.docx', NULL, '2023-12-13 05:51:33', '2024-01-08 07:46:03'),
(63, 1, 'uploads/Product/403441704706842.jpg', 'uploads/Product/649161702454067.docx', 'DORACEPH.docx', NULL, '2023-12-13 05:54:27', '2024-01-08 07:40:42'),
(64, 1, 'uploads/Product/941591704706823.jpg', 'uploads/Product/223921702455157.docx', 'Dupisor Gel.docx', NULL, '2023-12-13 06:12:37', '2024-01-08 07:40:23'),
(65, 1, 'uploads/Product/949711704706789.jpg', 'uploads/Product/194501702455264.docx', 'Dupisor ointment.docx', NULL, '2023-12-13 06:14:24', '2024-01-08 07:39:49'),
(66, 1, 'uploads/Product/770001704706540.jpg', 'uploads/Product/815621702455479.docx', 'duvalep.docx', NULL, '2023-12-13 06:17:59', '2024-01-08 07:35:40'),
(67, 1, 'uploads/Product/216811702455640.jpg', 'uploads/Product/908491702455640.docx', 'emestop.docx', NULL, '2023-12-13 06:20:40', '2023-12-13 06:20:40'),
(68, 1, 'uploads/Product/852271702455764.jpg', 'uploads/Product/427041702455764.docx', 'extrafen.docx', NULL, '2023-12-13 06:22:44', '2023-12-13 06:22:44'),
(69, 1, 'uploads/Product/182871704706806.jpg', 'uploads/Product/309991702455944.docx', 'flucan.docx', NULL, '2023-12-13 06:25:44', '2024-01-08 07:40:06'),
(70, 1, 'uploads/Product/70061704706773.jpg', 'uploads/Product/975521702456087.docx', 'folic acid.docx', NULL, '2023-12-13 06:28:07', '2024-01-08 07:39:33'),
(71, 1, 'uploads/Product/535651704706755.jpg', 'uploads/Product/868881702456211.docx', 'Fungitrin Ovules.docx', NULL, '2023-12-13 06:30:11', '2024-01-08 07:39:15'),
(72, 1, 'uploads/Product/361031704706738.jpg', 'uploads/Product/66181702456308.docx', 'gastrex.docx', NULL, '2023-12-13 06:31:48', '2024-01-08 07:38:58'),
(73, 1, 'uploads/Product/371651704706724.jpg', 'uploads/Product/237701702456439.docx', 'gentacol.docx', NULL, '2023-12-13 06:33:59', '2024-01-08 07:38:44'),
(74, 1, 'uploads/Product/991711702456619.jpg', 'uploads/Product/438611702456560.docx', 'glucomet xr 750.docx', NULL, '2023-12-13 06:36:00', '2023-12-13 06:36:59'),
(75, 1, 'uploads/Product/190361704706709.jpg', 'uploads/Product/767211702456740.docx', 'glucomet.docx', NULL, '2023-12-13 06:39:00', '2024-01-08 07:38:29'),
(76, 1, 'uploads/Product/308701704706691.jpg', 'uploads/Product/661521702456857.docx', 'GOLINE 0.5.docx', NULL, '2023-12-13 06:40:57', '2024-01-08 07:38:11'),
(77, 1, 'uploads/Product/624281704706671.jpg', 'uploads/Product/559981702456958.docx', 'GOUTEX.docx', NULL, '2023-12-13 06:42:39', '2024-01-08 07:37:51'),
(78, 1, 'uploads/Product/151431704706654.jpg', 'uploads/Product/638731702457200.docx', 'hydrocortisone.docx', NULL, '2023-12-13 06:46:40', '2024-01-08 07:37:34'),
(79, 1, 'uploads/Product/564881704706637.jpg', 'uploads/Product/645301702457312.docx', 'hypothal.docx', NULL, '2023-12-13 06:48:32', '2024-01-08 07:37:17'),
(80, 2, 'uploads/Product/285541704706615.jpg', 'uploads/Product/246281702457470.docx', 'I.O.P plus.docx', NULL, '2023-12-13 06:51:10', '2024-01-08 07:36:55'),
(81, 2, 'uploads/Product/245811704706559.jpg', 'uploads/Product/224931702457564.docx', 'I.O.P.docx', NULL, '2023-12-13 06:52:44', '2024-01-08 07:35:59'),
(82, 1, 'uploads/Product/116571702458006.jpg', 'uploads/Product/696151702458006.docx', 'indolin.docx', NULL, '2023-12-13 07:00:06', '2023-12-13 07:00:06'),
(83, 1, 'uploads/Product/197211702458139.jpg', 'uploads/Product/979521702458139.docx', 'INFLICTA 10.docx', NULL, '2023-12-13 07:02:19', '2023-12-13 07:02:19'),
(84, 1, 'uploads/Product/758511704706228.jpg', 'uploads/Product/473671702458260.docx', 'Ipravent.docx', NULL, '2023-12-13 07:04:20', '2024-01-08 07:30:28'),
(85, 1, 'uploads/Product/331861704706209.jpg', 'uploads/Product/789431702458382.docx', 'itranox.docx', NULL, '2023-12-13 07:06:22', '2024-01-08 07:30:09'),
(86, 1, 'uploads/Product/798831704706194.jpg', 'uploads/Product/474551702458478.docx', 'IXABAN.docx', NULL, '2023-12-13 07:07:58', '2024-01-08 07:29:54'),
(88, 2, 'uploads/Product/352811704706173.jpg', 'uploads/Product/441211702458690.docx', 'Izilack eye drops.docx', NULL, '2023-12-13 07:11:30', '2024-01-08 07:29:33'),
(89, 1, 'uploads/Product/14891702458839.jpg', 'uploads/Product/340991702458839.docx', 'lamirase Tablet.docx', NULL, '2023-12-13 07:13:59', '2023-12-13 07:13:59'),
(90, 1, 'uploads/Product/751321704706408.jpg', 'uploads/Product/459841702458959.docx', 'lipidex.docx', NULL, '2023-12-13 07:15:59', '2024-01-08 07:33:28'),
(91, 1, 'uploads/Product/131411704706389.jpg', 'uploads/Product/866361702459073.docx', 'lozar.docx', NULL, '2023-12-13 07:17:53', '2024-01-08 07:33:09'),
(92, 1, 'uploads/Product/610071704706245.jpg', 'uploads/Product/5381702459180.docx', 'lucast.docx', NULL, '2023-12-13 07:19:40', '2024-01-08 07:30:45'),
(93, 1, 'uploads/Product/627811702459338.jpg', 'uploads/Product/983771702459338.docx', 'luterone.docx', NULL, '2023-12-13 07:22:18', '2023-12-13 07:22:18'),
(94, 1, 'uploads/Product/956351703516845.jpg', 'uploads/Product/34741702459823.docx', 'macrofuran.docx', NULL, '2023-12-13 07:30:23', '2023-12-25 13:07:25'),
(95, 1, 'uploads/Product/897781703516871.jpg', 'uploads/Product/436741702459939.docx', 'medihist.docx', NULL, '2023-12-13 07:32:19', '2023-12-25 13:07:51'),
(96, 1, 'uploads/Product/25101704706133.jpg', 'uploads/Product/145471702460056.docx', 'mepral.docx', NULL, '2023-12-13 07:34:16', '2024-01-08 07:28:53'),
(97, 1, 'uploads/Product/95811704706118.jpg', 'uploads/Product/188161702460195.docx', 'metrozole.docx', NULL, '2023-12-13 07:36:35', '2024-01-08 07:28:38'),
(98, 1, 'uploads/Product/520701704706072.jpg', 'uploads/Product/776251702460396.docx', 'mobicol.docx', NULL, '2023-12-13 07:39:56', '2024-01-08 07:27:52'),
(99, 1, 'uploads/Product/940421704706023.jpg', 'uploads/Product/127881702460517.docx', 'modex.docx', NULL, '2023-12-13 07:41:57', '2024-01-08 07:27:03'),
(100, 1, 'uploads/Product/426381703516465.jpg', 'uploads/Product/182571702460640.docx', 'modulon.docx', NULL, '2023-12-13 07:44:00', '2023-12-25 13:01:05'),
(101, 1, 'uploads/Product/578141703516443.jpg', 'uploads/Product/546171702460746.docx', 'naprex.docx', NULL, '2023-12-13 07:45:46', '2023-12-25 13:00:43'),
(102, 1, 'uploads/Product/32581702460856.jpg', 'uploads/Product/28971702460856.docx', 'naproxan.docx', NULL, '2023-12-13 07:47:36', '2023-12-13 07:47:36'),
(103, 1, 'uploads/Product/742651703516347.jpg', 'uploads/Product/975011702461013.docx', 'Nirvin Complete.docx', NULL, '2023-12-13 07:50:13', '2023-12-25 12:59:07'),
(104, 1, 'uploads/Product/679071703516396.jpg', 'uploads/Product/722701702461137.docx', 'Nosatrex.docx', NULL, '2023-12-13 07:52:17', '2023-12-25 12:59:56'),
(105, 1, 'uploads/Product/970291703516418.jpg', 'uploads/Product/348571702461257.docx', 'Nystazole Vaginal Ovules.docx', NULL, '2023-12-13 07:54:17', '2023-12-25 13:00:18'),
(106, 1, 'uploads/Product/440381702461387.jpg', 'uploads/Product/408931702461387.docx', 'Ocutacin eye drops.docx', NULL, '2023-12-13 07:56:27', '2023-12-13 07:56:27'),
(107, 1, 'uploads/Product/17061702461560.jpg', 'uploads/Product/325731702461560.docx', 'ogmin.docx', NULL, '2023-12-13 07:59:20', '2023-12-13 07:59:20'),
(108, 1, 'uploads/Product/340301703516698.jpg', 'uploads/Product/682641702461683.docx', 'oralute.docx', NULL, '2023-12-13 08:01:23', '2023-12-25 13:04:58'),
(109, 1, 'uploads/Product/667381704706003.jpg', 'uploads/Product/970061702461778.docx', 'otodex.docx', NULL, '2023-12-13 08:02:58', '2024-01-08 07:26:43'),
(110, 1, 'uploads/Product/375621704705983.jpg', 'uploads/Product/992201702461904.docx', 'ovaclomin.docx', NULL, '2023-12-13 08:05:04', '2024-01-08 07:26:23'),
(111, 1, 'uploads/Product/627421704705959.jpg', 'uploads/Product/41781702461993.docx', 'Oxidur.docx', NULL, '2023-12-13 08:06:33', '2024-01-08 07:25:59'),
(112, 1, 'uploads/Product/807001704705938.jpg', 'uploads/Product/17201702462091.docx', 'prednilet syrup.docx', NULL, '2023-12-13 08:08:11', '2024-01-08 07:25:38'),
(113, 1, 'uploads/Product/685321704705915.jpg', 'uploads/Product/327661702462218.docx', 'prednitab.docx', NULL, '2023-12-13 08:10:18', '2024-01-08 07:25:15'),
(114, 1, 'uploads/Product/99981704705894.jpg', 'uploads/Product/945811702473531.docx', 'premonor.docx', NULL, '2023-12-13 11:18:51', '2024-01-08 07:24:54'),
(115, 1, 'uploads/Product/417951702473657.jpg', 'uploads/Product/333671702473657.docx', 'profort vial.docx', NULL, '2023-12-13 11:20:57', '2023-12-13 11:20:57'),
(116, 1, 'uploads/Product/571921704705876.jpg', 'uploads/Product/662901702473768.docx', 'progest.docx', NULL, '2023-12-13 11:22:48', '2024-01-08 07:24:36'),
(117, 1, 'uploads/Product/24311704705856.jpg', 'uploads/Product/921191702473908.docx', 'Psoriderm Cream & Ointment.docx', NULL, '2023-12-13 11:25:08', '2024-01-08 07:24:16'),
(118, 1, 'uploads/Product/602421704705836.jpg', 'uploads/Product/19531702474018.docx', 'pulmadrin DM.docx', NULL, '2023-12-13 11:26:58', '2024-01-08 07:23:56'),
(119, 1, 'uploads/Product/38481702474151.jpg', 'uploads/Product/831451702474151.docx', 'pulmadrin exp.docx', NULL, '2023-12-13 11:29:11', '2023-12-13 11:29:11'),
(120, 1, 'uploads/Product/532331702474264.jpg', 'uploads/Product/901191702474264.docx', 'pulmadrin syrup.docx', NULL, '2023-12-13 11:31:04', '2023-12-13 11:31:04'),
(121, 1, 'uploads/Product/57311704705817.jpg', 'uploads/Product/391651702474364.docx', 'ramacetine HC.docx', NULL, '2023-12-13 11:32:44', '2024-01-08 07:23:37'),
(122, 1, 'uploads/Product/119491703516373.jpg', 'uploads/Product/974431702474508.docx', 'ramacetine.docx', NULL, '2023-12-13 11:35:08', '2023-12-25 12:59:33'),
(123, 1, 'uploads/Product/708191702474629.jpg', 'uploads/Product/973701702474629.docx', 'Rinazal.docx', NULL, '2023-12-13 11:37:09', '2023-12-13 11:37:09'),
(124, 1, 'uploads/Product/311721704705789.jpg', 'uploads/Product/716701702474801.docx', 'Rosulip.docx', NULL, '2023-12-13 11:40:01', '2024-01-08 07:23:09'),
(125, 1, 'uploads/Product/536871702474920.jpg', 'uploads/Product/545281702474920.docx', 'rufenal emulgel.docx', NULL, '2023-12-13 11:42:00', '2023-12-13 11:42:00'),
(126, 1, 'uploads/Product/789231702475029.jpg', 'uploads/Product/823881702475029.docx', 'RUFENAL EYE DROPS.docx', NULL, '2023-12-13 11:43:49', '2023-12-13 11:43:49'),
(127, 1, 'uploads/Product/20411702475287.jpg', 'uploads/Product/763301702475287.docx', 'rufenal.docx', NULL, '2023-12-13 11:48:07', '2023-12-13 11:48:07'),
(128, 1, 'uploads/Product/813461704705746.jpg', 'uploads/Product/998881702475521.docx', 'Ruvar.docx', NULL, '2023-12-13 11:52:01', '2024-01-08 07:22:26'),
(129, 1, 'uploads/Product/303261704705727.jpg', 'uploads/Product/432841702475629.docx', 'Serepam amp.docx', NULL, '2023-12-13 11:53:49', '2024-01-08 07:22:07'),
(130, 1, 'uploads/Product/330141702475814.jpg', 'uploads/Product/713571702475814.docx', 'spirone.docx', NULL, '2023-12-13 11:56:54', '2023-12-13 11:56:54'),
(131, 1, 'uploads/Product/639181704626719.jpg', 'uploads/Product/576081702475914.docx', 'Tanup eye drops.docx', NULL, '2023-12-13 11:58:34', '2024-01-07 09:25:19'),
(132, 1, 'uploads/Product/558961702476005.jpg', 'uploads/Product/896591702476005.docx', 'tempyrin.docx', NULL, '2023-12-13 12:00:05', '2023-12-13 12:00:05'),
(133, 1, 'uploads/Product/186641704626627.jpg', 'uploads/Product/18581702476114.docx', 'tericox.docx', NULL, '2023-12-13 12:01:54', '2024-01-07 09:23:47'),
(134, 1, 'uploads/Product/470721704626610.jpg', 'uploads/Product/675741702476261.docx', 'three b_s.docx', NULL, '2023-12-13 12:04:21', '2024-01-07 09:23:30'),
(135, 1, 'uploads/Product/327841704626529.jpg', 'uploads/Product/471181702476390.docx', 'Toleran.docx', NULL, '2023-12-13 12:06:30', '2024-01-07 09:22:09'),
(136, 1, 'uploads/Product/516631704626503.jpg', 'uploads/Product/326071702476521.docx', 'ultrafen plus.docx', NULL, '2023-12-13 12:08:41', '2024-01-07 09:21:43'),
(137, 1, 'uploads/Product/607951704626481.jpg', 'uploads/Product/540731702476649.docx', 'ultrafen suspension & suppositories.docx', NULL, '2023-12-13 12:10:49', '2024-01-07 09:21:21'),
(138, 1, 'uploads/Product/938191702476772.jpg', 'uploads/Product/221011702476772.docx', 'ultrafen.docx', NULL, '2023-12-13 12:12:52', '2023-12-13 12:12:52'),
(139, 1, 'uploads/Product/475151704626454.jpg', 'uploads/Product/858271702476872.docx', 'urix.docx', NULL, '2023-12-13 12:14:32', '2024-01-07 09:20:54'),
(140, 1, 'uploads/Product/287481702476961.jpg', 'uploads/Product/975541702476961.docx', 'utised.docx', NULL, '2023-12-13 12:16:01', '2023-12-13 12:16:01'),
(141, 1, 'uploads/Product/712171704626397.jpg', 'uploads/Product/391441702477061.docx', 'valecort G.docx', NULL, '2023-12-13 12:17:41', '2024-01-07 09:19:57'),
(142, 1, 'uploads/Product/114601704626378.jpg', 'uploads/Product/263201702477592.docx', 'ventol respiratory soln.docx', NULL, '2023-12-13 12:26:32', '2024-01-07 09:19:38'),
(143, 1, 'uploads/Product/394861703516247.jpg', 'uploads/Product/183081702477703.docx', 'ventol Syrup.docx', NULL, '2023-12-13 12:28:23', '2023-12-25 12:57:27'),
(144, 1, 'uploads/Product/918541703515688.jpg', 'uploads/Product/176801702477809.docx', 'viraserc.docx', NULL, '2023-12-13 12:30:09', '2023-12-25 12:48:08'),
(145, 1, 'uploads/Product/601181702477919.jpg', 'uploads/Product/38441702477919.docx', 'Virax HC.docx', NULL, '2023-12-13 12:31:59', '2023-12-13 12:31:59'),
(146, 1, 'uploads/Product/551711703515641.jpg', 'uploads/Product/221751702478155.docx', 'Voloxal 0.5_ eye drops.docx', NULL, '2023-12-13 12:35:55', '2023-12-25 12:47:21'),
(147, 1, 'uploads/Product/268861703515618.jpg', 'uploads/Product/218831702478244.docx', 'Voloxal Tablets.docx', NULL, '2023-12-13 12:37:24', '2023-12-25 12:46:58'),
(148, 1, 'uploads/Product/516841702478341.jpg', 'uploads/Product/285171702478341.docx', 'Xtram Amp.docx', NULL, '2023-12-13 12:39:01', '2023-12-13 12:39:01'),
(149, 1, 'uploads/Product/199401703515597.jpg', 'uploads/Product/261591702478440.docx', 'xylene gel.docx', NULL, '2023-12-13 12:40:40', '2023-12-25 12:46:37'),
(150, 1, 'uploads/Product/454381702478532.jpg', 'uploads/Product/580961702478532.docx', 'Zetamycin.docx', NULL, '2023-12-13 12:42:12', '2023-12-13 12:42:12'),
(151, 1, 'uploads/Product/635461702478719.jpg', 'uploads/Product/771051702478719.docx', 'zinex tab.docx', NULL, '2023-12-13 12:45:19', '2023-12-13 12:45:19'),
(152, 1, 'uploads/Product/869341702478825.jpg', NULL, NULL, NULL, '2023-12-13 12:47:05', '2023-12-13 12:47:05');

-- --------------------------------------------------------

--
-- Table structure for table `product_category`
--

CREATE TABLE `product_category` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `product_id` bigint(20) UNSIGNED NOT NULL,
  `category_id` bigint(20) UNSIGNED NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `product_category`
--

INSERT INTO `product_category` (`id`, `product_id`, `category_id`, `created_at`, `updated_at`) VALUES
(2, 7, 5, NULL, NULL),
(3, 8, 6, NULL, NULL),
(4, 9, 7, NULL, NULL),
(5, 10, 8, NULL, NULL),
(6, 11, 6, NULL, NULL),
(7, 12, 9, NULL, NULL),
(8, 13, 9, NULL, NULL),
(9, 14, 5, NULL, NULL),
(10, 15, 6, NULL, NULL),
(11, 16, 10, NULL, NULL),
(12, 17, 10, NULL, NULL),
(13, 18, 6, NULL, NULL),
(14, 19, 12, NULL, NULL),
(15, 20, 7, NULL, NULL),
(16, 20, 11, NULL, NULL),
(17, 21, 5, NULL, NULL),
(18, 22, 6, NULL, NULL),
(19, 23, 12, NULL, NULL),
(20, 24, 6, NULL, NULL),
(21, 25, 9, NULL, NULL),
(22, 26, 9, NULL, NULL),
(23, 27, 5, NULL, NULL),
(24, 28, 7, NULL, NULL),
(25, 29, 13, NULL, NULL),
(26, 30, 11, NULL, NULL),
(27, 30, 5, NULL, NULL),
(28, 31, 13, NULL, NULL),
(29, 32, 14, NULL, NULL),
(30, 33, 14, NULL, NULL),
(31, 34, 14, NULL, NULL),
(32, 35, 15, NULL, NULL),
(33, 36, 14, NULL, NULL),
(34, 36, 15, NULL, NULL),
(35, 37, 15, NULL, NULL),
(36, 37, 13, NULL, NULL),
(37, 38, 15, NULL, NULL),
(38, 38, 14, NULL, NULL),
(39, 39, 24, NULL, NULL),
(40, 40, 19, NULL, NULL),
(41, 41, 19, NULL, NULL),
(42, 42, 25, NULL, NULL),
(43, 43, 17, NULL, NULL),
(44, 44, 27, NULL, NULL),
(45, 45, 15, NULL, NULL),
(46, 45, 14, NULL, NULL),
(47, 46, 5, NULL, NULL),
(48, 47, 15, NULL, NULL),
(49, 47, 14, NULL, NULL),
(50, 48, 15, NULL, NULL),
(51, 48, 14, NULL, NULL),
(52, 49, 15, NULL, NULL),
(53, 49, 14, NULL, NULL),
(54, 50, 15, NULL, NULL),
(55, 50, 14, NULL, NULL),
(56, 51, 15, NULL, NULL),
(57, 51, 14, NULL, NULL),
(58, 52, 13, NULL, NULL),
(59, 53, 22, NULL, NULL),
(60, 54, 19, NULL, NULL),
(61, 55, 27, NULL, NULL),
(62, 56, 16, NULL, NULL),
(63, 57, 16, NULL, NULL),
(64, 58, 22, NULL, NULL),
(65, 59, 22, NULL, NULL),
(66, 60, 22, NULL, NULL),
(67, 61, 28, NULL, NULL),
(68, 62, 27, NULL, NULL),
(69, 63, 15, NULL, NULL),
(70, 63, 14, NULL, NULL),
(71, 64, 28, NULL, NULL),
(72, 65, 28, NULL, NULL),
(73, 66, 17, NULL, NULL),
(74, 67, 18, NULL, NULL),
(75, 67, 17, NULL, NULL),
(76, 68, 17, NULL, NULL),
(77, 69, 21, NULL, NULL),
(78, 70, 15, NULL, NULL),
(79, 70, 21, NULL, NULL),
(80, 71, 23, NULL, NULL),
(81, 72, 18, NULL, NULL),
(82, 73, 27, NULL, NULL),
(83, 74, 25, NULL, NULL),
(84, 75, 25, NULL, NULL),
(85, 76, 24, NULL, NULL),
(86, 77, 17, NULL, NULL),
(87, 78, 22, NULL, NULL),
(88, 79, 18, NULL, NULL),
(89, 80, 13, NULL, NULL),
(90, 81, 13, NULL, NULL),
(91, 82, 20, NULL, NULL),
(92, 83, 25, NULL, NULL),
(93, 84, 26, NULL, NULL),
(94, 85, 21, NULL, NULL),
(95, 85, 15, NULL, NULL),
(96, 86, 19, NULL, NULL),
(97, 88, 13, NULL, NULL),
(98, 89, 15, NULL, NULL),
(99, 89, 28, NULL, NULL),
(100, 90, 19, NULL, NULL),
(101, 91, 19, NULL, NULL),
(102, 92, 26, NULL, NULL),
(103, 93, 22, NULL, NULL),
(104, 93, 24, NULL, NULL),
(105, 94, 15, NULL, NULL),
(106, 95, 28, NULL, NULL),
(107, 96, 18, NULL, NULL),
(108, 97, 15, NULL, NULL),
(109, 97, 21, NULL, NULL),
(110, 98, 20, NULL, NULL),
(111, 99, 18, NULL, NULL),
(112, 100, 18, NULL, NULL),
(113, 101, 20, NULL, NULL),
(114, 102, 17, NULL, NULL),
(115, 103, 21, NULL, NULL),
(116, 104, 26, NULL, NULL),
(117, 105, 23, NULL, NULL),
(118, 106, 27, NULL, NULL),
(119, 107, 15, NULL, NULL),
(120, 108, 24, NULL, NULL),
(121, 109, 21, NULL, NULL),
(122, 110, 22, NULL, NULL),
(123, 111, 20, NULL, NULL),
(124, 112, 22, NULL, NULL),
(125, 113, 22, NULL, NULL),
(126, 114, 24, NULL, NULL),
(127, 115, 15, NULL, NULL),
(128, 115, 14, NULL, NULL),
(129, 116, 24, NULL, NULL),
(130, 117, 28, NULL, NULL),
(131, 118, 26, NULL, NULL),
(132, 119, 26, NULL, NULL),
(133, 120, 17, NULL, NULL),
(134, 121, 27, NULL, NULL),
(135, 122, 27, NULL, NULL),
(136, 123, 17, NULL, NULL),
(137, 124, 19, NULL, NULL),
(138, 125, 20, NULL, NULL),
(139, 126, 27, NULL, NULL),
(140, 127, 20, NULL, NULL),
(141, 128, 28, NULL, NULL),
(142, 129, 17, NULL, NULL),
(143, 130, 23, NULL, NULL),
(144, 131, 27, NULL, NULL),
(145, 132, 21, NULL, NULL),
(146, 133, 20, NULL, NULL),
(147, 134, 19, NULL, NULL),
(148, 135, 20, NULL, NULL),
(149, 136, 17, NULL, NULL),
(150, 137, 17, NULL, NULL),
(151, 138, 20, NULL, NULL),
(152, 139, 23, NULL, NULL),
(153, 140, 23, NULL, NULL),
(154, 141, 28, NULL, NULL),
(155, 142, 26, NULL, NULL),
(156, 143, 26, NULL, NULL),
(157, 144, 17, NULL, NULL),
(158, 145, 28, NULL, NULL),
(159, 146, 27, NULL, NULL),
(160, 147, 15, NULL, NULL),
(161, 148, 17, NULL, NULL),
(162, 149, 23, NULL, NULL),
(163, 150, 15, NULL, NULL),
(164, 151, 15, NULL, NULL),
(165, 152, 15, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `product_images`
--

CREATE TABLE `product_images` (
  `id` int(10) UNSIGNED NOT NULL,
  `product_id` bigint(20) UNSIGNED DEFAULT NULL,
  `image_sm` varchar(255) DEFAULT NULL,
  `image_lg` varchar(255) DEFAULT NULL,
  `order_by` int(11) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `product_images`
--

INSERT INTO `product_images` (`id`, `product_id`, `image_sm`, `image_lg`, `order_by`, `created_at`, `updated_at`) VALUES
(6, 7, 'uploads/Product/330811701845322.jpg', 'uploads/Product/33451701845322.jpg', NULL, '2023-12-06 04:48:42', '2023-12-06 04:48:42'),
(7, 8, 'uploads/Product/8811701845430.jpg', 'uploads/Product/566591701845430.jpg', NULL, '2023-12-06 04:50:32', '2023-12-06 04:50:32'),
(8, 9, 'uploads/Product/465211701845516.jpg', 'uploads/Product/227951701845516.jpg', NULL, '2023-12-06 04:51:56', '2023-12-06 04:51:56'),
(9, 10, 'uploads/Product/220061701845627.jpg', 'uploads/Product/399691701845627.jpg', NULL, '2023-12-06 04:53:47', '2023-12-06 04:53:47'),
(10, 11, 'uploads/Product/332551701845722.jpg', 'uploads/Product/119681701845722.jpg', NULL, '2023-12-06 04:55:22', '2023-12-06 04:55:22'),
(11, 12, 'uploads/Product/295581701845819.jpg', 'uploads/Product/537201701845819.jpg', NULL, '2023-12-06 04:56:59', '2023-12-06 04:56:59'),
(12, 13, 'uploads/Product/678001701845891.jpg', 'uploads/Product/860391701845891.jpg', NULL, '2023-12-06 04:58:13', '2023-12-06 04:58:13'),
(13, 14, 'uploads/Product/24061701845992.jpg', 'uploads/Product/390861701845992.jpg', NULL, '2023-12-06 04:59:52', '2023-12-06 04:59:52'),
(14, 15, 'uploads/Product/288521701846064.jpg', 'uploads/Product/855161701846064.jpg', NULL, '2023-12-06 05:01:05', '2023-12-06 05:01:05'),
(15, 16, 'uploads/Product/968121701846217.jpg', 'uploads/Product/193531701846217.jpg', NULL, '2023-12-06 05:03:37', '2023-12-06 05:03:37'),
(16, 17, 'uploads/Product/142831701846293.jpg', 'uploads/Product/25751701846293.jpg', NULL, '2023-12-06 05:04:53', '2023-12-06 05:04:53'),
(17, 18, 'uploads/Product/860551701846362.jpg', 'uploads/Product/479421701846362.jpg', NULL, '2023-12-06 05:06:02', '2023-12-06 05:06:02'),
(18, 19, 'uploads/Product/609421701846452.jpg', 'uploads/Product/68561701846452.jpg', NULL, '2023-12-06 05:07:33', '2023-12-06 05:07:33'),
(19, 20, 'uploads/Product/168261701846532.jpg', 'uploads/Product/333851701846532.jpg', NULL, '2023-12-06 05:08:52', '2023-12-06 05:08:52'),
(20, 21, 'uploads/Product/865461701846679.jpg', 'uploads/Product/469171701846679.jpg', NULL, '2023-12-06 05:11:19', '2023-12-06 05:11:19'),
(21, 21, 'uploads/Product/400481701846679.jpg', 'uploads/Product/642481701846679.jpg', NULL, '2023-12-06 05:11:19', '2023-12-06 05:11:19'),
(22, 22, 'uploads/Product/267951701846777.jpg', 'uploads/Product/343691701846777.jpg', NULL, '2023-12-06 05:12:57', '2023-12-06 05:12:57'),
(23, 23, 'uploads/Product/791471701846885.jpg', 'uploads/Product/566081701846885.jpg', NULL, '2023-12-06 05:14:45', '2023-12-06 05:14:45'),
(24, 24, 'uploads/Product/693591701846961.jpg', 'uploads/Product/551731701846961.jpg', NULL, '2023-12-06 05:16:01', '2023-12-06 05:16:01'),
(25, 25, 'uploads/Product/612271701847034.jpg', 'uploads/Product/466581701847034.jpg', NULL, '2023-12-06 05:17:14', '2023-12-06 05:17:14'),
(26, 26, 'uploads/Product/760371701847178.jpg', 'uploads/Product/377291701847178.jpg', NULL, '2023-12-06 05:19:38', '2023-12-06 05:19:38'),
(27, 27, 'uploads/Product/700211701847313.jpg', 'uploads/Product/429481701847313.jpg', NULL, '2023-12-06 05:21:57', '2023-12-06 05:21:57'),
(28, 27, 'uploads/Product/255771701847313.jpg', 'uploads/Product/275871701847313.jpg', NULL, '2023-12-06 05:21:57', '2023-12-06 05:21:57'),
(29, 27, 'uploads/Product/938191701847313.jpg', 'uploads/Product/195431701847313.jpg', NULL, '2023-12-06 05:21:57', '2023-12-06 05:21:57'),
(30, 28, 'uploads/Product/835511701847407.jpg', 'uploads/Product/62921701847407.jpg', NULL, '2023-12-06 05:23:27', '2023-12-06 05:23:27'),
(31, 29, 'uploads/Product/828551701847477.jpg', 'uploads/Product/239421701847477.jpg', NULL, '2023-12-06 05:24:38', '2023-12-06 05:24:38'),
(32, 30, 'uploads/Product/745581701850289.jpg', 'uploads/Product/530271701850289.jpg', NULL, '2023-12-06 06:11:37', '2023-12-06 06:11:37'),
(33, 31, 'uploads/Product/233401701850662.jpg', 'uploads/Product/831551701850662.jpg', NULL, '2023-12-06 06:17:48', '2023-12-06 06:17:48'),
(34, 32, 'uploads/Product/113961701851034.jpg', 'uploads/Product/718481701851034.jpg', NULL, '2023-12-06 06:23:54', '2023-12-06 06:23:54'),
(35, 32, 'uploads/Product/240141701851034.jpg', 'uploads/Product/759301701851034.jpg', NULL, '2023-12-06 06:23:54', '2023-12-06 06:23:54'),
(36, 32, 'uploads/Product/921571701851034.jpg', 'uploads/Product/659591701851034.jpg', NULL, '2023-12-06 06:23:54', '2023-12-06 06:23:54'),
(37, 33, 'uploads/Product/146681701851919.jpg', 'uploads/Product/523261701851919.jpg', NULL, '2023-12-06 06:38:44', '2023-12-06 06:38:44'),
(38, 34, 'uploads/Product/636931701853313.jpg', 'uploads/Product/996341701853313.jpg', NULL, '2023-12-06 07:01:53', '2023-12-06 07:01:53'),
(39, 34, 'uploads/Product/890251701853313.jpg', 'uploads/Product/866201701853313.jpg', NULL, '2023-12-06 07:01:53', '2023-12-06 07:01:53'),
(40, 35, 'uploads/Product/363601701855124.jpg', 'uploads/Product/882411701855124.jpg', NULL, '2023-12-06 07:32:04', '2023-12-06 07:32:04'),
(41, 35, 'uploads/Product/365551701855124.jpg', 'uploads/Product/296941701855124.jpg', NULL, '2023-12-06 07:32:04', '2023-12-06 07:32:04'),
(42, 36, 'uploads/Product/449721702363313.jpg', 'uploads/Product/29851702363313.jpg', NULL, '2023-12-06 07:38:35', '2023-12-12 04:41:53'),
(43, 37, 'uploads/Product/482661701855882.jpg', 'uploads/Product/382341701855882.jpg', NULL, '2023-12-06 07:44:42', '2023-12-06 07:44:42'),
(44, 38, 'uploads/Product/737191701856293.jpg', 'uploads/Product/695491701856293.jpg', NULL, '2023-12-06 07:51:34', '2023-12-06 07:51:34'),
(45, 38, 'uploads/Product/621051701856293.jpg', 'uploads/Product/530471701856293.jpg', NULL, '2023-12-06 07:51:34', '2023-12-06 07:51:34'),
(46, 36, 'uploads/Product/80401702363313.jpg', 'uploads/Product/795651702363313.jpg', NULL, '2023-12-12 04:41:53', '2023-12-12 04:41:53'),
(47, 39, 'uploads/Product/811451703510624.jpg', 'uploads/Product/370871703510624.jpg', NULL, '2023-12-12 16:16:54', '2023-12-25 11:23:44'),
(48, 40, 'uploads/Product/6261703515749.jpg', 'uploads/Product/933771703515749.jpg', NULL, '2023-12-12 16:54:06', '2023-12-25 12:49:09'),
(49, 41, 'uploads/Product/114871703516217.jpg', 'uploads/Product/533791703516217.jpg', NULL, '2023-12-12 16:58:50', '2023-12-25 12:56:57'),
(50, 42, 'uploads/Product/415391703516293.jpg', 'uploads/Product/849521703516293.jpg', NULL, '2023-12-12 17:01:38', '2023-12-25 12:58:13'),
(51, 43, 'uploads/Product/368871703516325.jpg', 'uploads/Product/102211703516325.jpg', NULL, '2023-12-12 17:04:30', '2023-12-25 12:58:45'),
(52, 44, 'uploads/Product/108481702448139.webp', 'uploads/Product/711491702448139.webp', NULL, '2023-12-13 04:15:39', '2023-12-13 04:15:39'),
(53, 45, 'uploads/Product/151541702448267.webp', 'uploads/Product/123271702448267.webp', NULL, '2023-12-13 04:17:47', '2023-12-13 04:17:47'),
(54, 46, 'uploads/Product/301441702448407.webp', 'uploads/Product/252201702448407.webp', NULL, '2023-12-13 04:20:07', '2023-12-13 04:20:07'),
(55, 47, 'uploads/Product/428591702450814.webp', 'uploads/Product/645331702450814.webp', NULL, '2023-12-13 05:00:14', '2023-12-13 05:00:14'),
(56, 48, 'uploads/Product/603371702450954.webp', 'uploads/Product/779781702450954.webp', NULL, '2023-12-13 05:02:34', '2023-12-13 05:02:34'),
(57, 49, 'uploads/Product/539941702451175.webp', 'uploads/Product/146761702451175.webp', NULL, '2023-12-13 05:06:15', '2023-12-13 05:06:15'),
(58, 50, 'uploads/Product/960791702451281.webp', 'uploads/Product/725351702451281.webp', NULL, '2023-12-13 05:08:02', '2023-12-13 05:08:02'),
(59, 51, 'uploads/Product/228801702451406.webp', 'uploads/Product/106541702451406.webp', NULL, '2023-12-13 05:10:07', '2023-12-13 05:10:07'),
(60, 52, 'uploads/Product/309771702451525.webp', 'uploads/Product/787071702451525.webp', NULL, '2023-12-13 05:12:06', '2023-12-13 05:12:06'),
(61, 53, 'uploads/Product/589391702451678.webp', 'uploads/Product/544341702451678.webp', NULL, '2023-12-13 05:14:40', '2023-12-13 05:14:40'),
(62, 54, 'uploads/Product/573881702451785.webp', 'uploads/Product/254921702451785.webp', NULL, '2023-12-13 05:16:26', '2023-12-13 05:16:26'),
(63, 55, 'uploads/Product/78191702451909.webp', 'uploads/Product/298641702451909.webp', NULL, '2023-12-13 05:18:29', '2023-12-13 05:18:29'),
(64, 56, 'uploads/Product/419261702452035.jpg', 'uploads/Product/29091702452035.jpg', NULL, '2023-12-13 05:20:35', '2023-12-13 05:20:35'),
(65, 57, 'uploads/Product/546401702452292.webp', 'uploads/Product/225661702452292.webp', NULL, '2023-12-13 05:24:53', '2023-12-13 05:24:53'),
(66, 58, 'uploads/Product/392991702452532.webp', 'uploads/Product/927201702452532.webp', NULL, '2023-12-13 05:28:52', '2023-12-13 05:28:52'),
(67, 59, 'uploads/Product/846331702453276.webp', 'uploads/Product/261381702453276.webp', NULL, '2023-12-13 05:41:16', '2023-12-13 05:41:16'),
(68, 60, 'uploads/Product/902751702453650.webp', 'uploads/Product/836721702453650.webp', NULL, '2023-12-13 05:47:30', '2023-12-13 05:47:30'),
(69, 61, 'uploads/Product/83331702453784.webp', 'uploads/Product/59151702453784.webp', NULL, '2023-12-13 05:49:47', '2023-12-13 05:49:47'),
(70, 62, 'uploads/Product/489711702453893.webp', 'uploads/Product/276711702453893.webp', NULL, '2023-12-13 05:51:34', '2023-12-13 05:51:34'),
(71, 63, 'uploads/Product/865541702454067.webp', 'uploads/Product/152671702454067.webp', NULL, '2023-12-13 05:54:27', '2023-12-13 05:54:27'),
(72, 64, 'uploads/Product/170481702455157.webp', 'uploads/Product/333021702455157.webp', NULL, '2023-12-13 06:12:37', '2023-12-13 06:12:37'),
(73, 65, 'uploads/Product/458471702455264.webp', 'uploads/Product/857121702455264.webp', NULL, '2023-12-13 06:14:26', '2023-12-13 06:14:26'),
(74, 66, 'uploads/Product/422731702455479.webp', 'uploads/Product/115611702455479.webp', NULL, '2023-12-13 06:17:59', '2023-12-13 06:17:59'),
(75, 67, 'uploads/Product/47821702455640.jpg', 'uploads/Product/219411702455640.jpg', NULL, '2023-12-13 06:20:40', '2023-12-13 06:20:40'),
(76, 68, 'uploads/Product/446981702455764.jpg', 'uploads/Product/291861702455764.jpg', NULL, '2023-12-13 06:22:46', '2023-12-13 06:22:46'),
(77, 69, 'uploads/Product/697811702455944.webp', 'uploads/Product/822111702455944.webp', NULL, '2023-12-13 06:25:44', '2023-12-13 06:25:44'),
(78, 70, 'uploads/Product/515671702456087.webp', 'uploads/Product/929531702456087.webp', NULL, '2023-12-13 06:28:07', '2023-12-13 06:28:07'),
(79, 71, 'uploads/Product/723741702456211.webp', 'uploads/Product/920851702456211.webp', NULL, '2023-12-13 06:30:11', '2023-12-13 06:30:11'),
(80, 72, 'uploads/Product/202161702456308.webp', 'uploads/Product/891231702456308.webp', NULL, '2023-12-13 06:31:48', '2023-12-13 06:31:48'),
(81, 73, 'uploads/Product/897091702456439.webp', 'uploads/Product/944471702456439.webp', NULL, '2023-12-13 06:33:59', '2023-12-13 06:33:59'),
(82, 74, 'uploads/Product/212501702456619.jpg', 'uploads/Product/402741702456619.jpg', NULL, '2023-12-13 06:36:00', '2023-12-13 06:36:59'),
(83, 75, 'uploads/Product/954931702456740.webp', 'uploads/Product/728061702456740.webp', NULL, '2023-12-13 06:39:00', '2023-12-13 06:39:00'),
(84, 76, 'uploads/Product/456041702456857.webp', 'uploads/Product/664841702456857.webp', NULL, '2023-12-13 06:40:57', '2023-12-13 06:40:57'),
(85, 77, 'uploads/Product/843241702456958.webp', 'uploads/Product/255221702456958.webp', NULL, '2023-12-13 06:42:39', '2023-12-13 06:42:39'),
(86, 78, 'uploads/Product/86111702457200.webp', 'uploads/Product/702361702457200.webp', NULL, '2023-12-13 06:46:40', '2023-12-13 06:46:40'),
(87, 79, 'uploads/Product/634191702457312.webp', 'uploads/Product/815811702457312.webp', NULL, '2023-12-13 06:48:32', '2023-12-13 06:48:32'),
(88, 80, 'uploads/Product/474891702457470.webp', 'uploads/Product/240071702457470.webp', NULL, '2023-12-13 06:51:14', '2023-12-13 06:51:14'),
(89, 81, 'uploads/Product/581051702457564.webp', 'uploads/Product/178811702457564.webp', NULL, '2023-12-13 06:52:50', '2023-12-13 06:52:50'),
(90, 82, 'uploads/Product/921451702458006.jpg', 'uploads/Product/863411702458006.jpg', NULL, '2023-12-13 07:00:09', '2023-12-13 07:00:09'),
(91, 83, 'uploads/Product/947631702458139.jpg', 'uploads/Product/843431702458139.jpg', NULL, '2023-12-13 07:02:20', '2023-12-13 07:02:20'),
(92, 84, 'uploads/Product/841561702458260.webp', 'uploads/Product/924961702458260.webp', NULL, '2023-12-13 07:04:20', '2023-12-13 07:04:20'),
(93, 85, 'uploads/Product/491851702458382.webp', 'uploads/Product/836271702458382.webp', NULL, '2023-12-13 07:06:23', '2023-12-13 07:06:23'),
(94, 86, 'uploads/Product/838521702458478.webp', 'uploads/Product/23711702458478.webp', NULL, '2023-12-13 07:07:58', '2023-12-13 07:07:58'),
(96, 88, 'uploads/Product/255041702458690.webp', 'uploads/Product/988951702458690.webp', NULL, '2023-12-13 07:11:30', '2023-12-13 07:11:30'),
(97, 89, 'uploads/Product/665961702458839.jpg', 'uploads/Product/683931702458839.jpg', NULL, '2023-12-13 07:13:59', '2023-12-13 07:13:59'),
(98, 90, 'uploads/Product/567621702458959.webp', 'uploads/Product/801681702458959.webp', NULL, '2023-12-13 07:15:59', '2023-12-13 07:15:59'),
(99, 91, 'uploads/Product/296971702459073.webp', 'uploads/Product/480571702459073.webp', NULL, '2023-12-13 07:17:55', '2023-12-13 07:17:55'),
(100, 92, 'uploads/Product/333171702459180.webp', 'uploads/Product/790111702459180.webp', NULL, '2023-12-13 07:19:41', '2023-12-13 07:19:41'),
(101, 93, 'uploads/Product/374501702459338.jpg', 'uploads/Product/346421702459338.jpg', NULL, '2023-12-13 07:22:18', '2023-12-13 07:22:18'),
(102, 93, 'uploads/Product/504181702459338.jpg', 'uploads/Product/799391702459338.jpg', NULL, '2023-12-13 07:22:18', '2023-12-13 07:22:18'),
(103, 94, 'uploads/Product/843091703516845.jpg', 'uploads/Product/854261703516845.jpg', NULL, '2023-12-13 07:30:23', '2023-12-25 13:07:25'),
(104, 95, 'uploads/Product/893941703516871.jpg', 'uploads/Product/469041703516871.jpg', NULL, '2023-12-13 07:32:19', '2023-12-25 13:07:51'),
(105, 96, 'uploads/Product/525421702460056.webp', 'uploads/Product/524321702460056.webp', NULL, '2023-12-13 07:34:16', '2023-12-13 07:34:16'),
(106, 97, 'uploads/Product/241271702460195.webp', 'uploads/Product/978671702460195.webp', NULL, '2023-12-13 07:36:35', '2023-12-13 07:36:35'),
(107, 98, 'uploads/Product/77081702460396.webp', 'uploads/Product/882321702460396.webp', NULL, '2023-12-13 07:39:56', '2023-12-13 07:39:56'),
(108, 99, 'uploads/Product/861381702460517.webp', 'uploads/Product/899331702460517.webp', NULL, '2023-12-13 07:41:57', '2023-12-13 07:41:57'),
(109, 100, 'uploads/Product/806181703516465.jpg', 'uploads/Product/869701703516465.jpg', NULL, '2023-12-13 07:44:01', '2023-12-25 13:01:05'),
(110, 101, 'uploads/Product/909171703516443.jpg', 'uploads/Product/343211703516443.jpg', NULL, '2023-12-13 07:45:46', '2023-12-25 13:00:43'),
(111, 102, 'uploads/Product/800011702460856.jpg', 'uploads/Product/869131702460856.jpg', NULL, '2023-12-13 07:47:36', '2023-12-13 07:47:36'),
(112, 103, 'uploads/Product/961171703516347.jpg', 'uploads/Product/937321703516347.jpg', NULL, '2023-12-13 07:50:13', '2023-12-25 12:59:07'),
(113, 104, 'uploads/Product/798291703516396.jpg', 'uploads/Product/393371703516396.jpg', NULL, '2023-12-13 07:52:18', '2023-12-25 12:59:56'),
(114, 105, 'uploads/Product/987721703516418.jpg', 'uploads/Product/101381703516418.jpg', NULL, '2023-12-13 07:54:17', '2023-12-25 13:00:18'),
(115, 106, 'uploads/Product/464971702461387.jpg', 'uploads/Product/774041702461387.jpg', NULL, '2023-12-13 07:56:28', '2023-12-13 07:56:28'),
(116, 107, 'uploads/Product/922941702461560.jpg', 'uploads/Product/129551702461560.jpg', NULL, '2023-12-13 07:59:21', '2023-12-13 07:59:21'),
(117, 107, 'uploads/Product/979911702461560.jpg', 'uploads/Product/662851702461560.jpg', NULL, '2023-12-13 07:59:21', '2023-12-13 07:59:21'),
(118, 108, 'uploads/Product/945151703516698.jpg', 'uploads/Product/347661703516698.jpg', NULL, '2023-12-13 08:01:23', '2023-12-25 13:04:58'),
(119, 109, 'uploads/Product/87901702461778.webp', 'uploads/Product/507421702461778.webp', NULL, '2023-12-13 08:02:58', '2023-12-13 08:02:58'),
(120, 110, 'uploads/Product/814411702461904.webp', 'uploads/Product/873851702461904.webp', NULL, '2023-12-13 08:05:05', '2023-12-13 08:05:05'),
(121, 111, 'uploads/Product/602861702461993.webp', 'uploads/Product/178841702461993.webp', NULL, '2023-12-13 08:06:33', '2023-12-13 08:06:33'),
(122, 112, 'uploads/Product/105551702462091.webp', 'uploads/Product/699231702462091.webp', NULL, '2023-12-13 08:08:12', '2023-12-13 08:08:12'),
(123, 113, 'uploads/Product/120331702462218.webp', 'uploads/Product/892241702462218.webp', NULL, '2023-12-13 08:10:19', '2023-12-13 08:10:19'),
(124, 114, 'uploads/Product/398161702473531.webp', 'uploads/Product/637351702473531.webp', NULL, '2023-12-13 11:18:51', '2023-12-13 11:18:51'),
(125, 115, 'uploads/Product/958371702473657.jpg', 'uploads/Product/447061702473657.jpg', NULL, '2023-12-13 11:20:58', '2023-12-13 11:20:58'),
(126, 116, 'uploads/Product/819401702473768.webp', 'uploads/Product/768071702473768.webp', NULL, '2023-12-13 11:22:48', '2023-12-13 11:22:48'),
(127, 117, 'uploads/Product/855611702473908.webp', 'uploads/Product/218051702473908.webp', NULL, '2023-12-13 11:25:10', '2023-12-13 11:25:10'),
(128, 118, 'uploads/Product/266311702474018.webp', 'uploads/Product/454651702474018.webp', NULL, '2023-12-13 11:26:58', '2023-12-13 11:26:58'),
(129, 119, 'uploads/Product/735861702474151.jpg', 'uploads/Product/873641702474151.jpg', NULL, '2023-12-13 11:29:11', '2023-12-13 11:29:11'),
(130, 120, 'uploads/Product/455171702474264.jpg', 'uploads/Product/525071702474264.jpg', NULL, '2023-12-13 11:31:04', '2023-12-13 11:31:04'),
(131, 121, 'uploads/Product/747861702474364.webp', 'uploads/Product/925131702474364.webp', NULL, '2023-12-13 11:32:45', '2023-12-13 11:32:45'),
(132, 122, 'uploads/Product/330721703516373.jpg', 'uploads/Product/819491703516373.jpg', NULL, '2023-12-13 11:35:08', '2023-12-25 12:59:33'),
(133, 123, 'uploads/Product/566171702474629.jpg', 'uploads/Product/422961702474629.jpg', NULL, '2023-12-13 11:37:09', '2023-12-13 11:37:09'),
(134, 124, 'uploads/Product/47581702474801.webp', 'uploads/Product/571431702474801.webp', NULL, '2023-12-13 11:40:01', '2023-12-13 11:40:01'),
(135, 125, 'uploads/Product/423061702474920.jpg', 'uploads/Product/861761702474920.jpg', NULL, '2023-12-13 11:42:00', '2023-12-13 11:42:00'),
(136, 126, 'uploads/Product/955471702475029.jpg', 'uploads/Product/29741702475029.jpg', NULL, '2023-12-13 11:43:49', '2023-12-13 11:43:49'),
(137, 127, 'uploads/Product/43341702475287.jpg', 'uploads/Product/102051702475287.jpg', NULL, '2023-12-13 11:48:07', '2023-12-13 11:48:07'),
(138, 127, 'uploads/Product/870431702475287.jpg', 'uploads/Product/286921702475287.jpg', NULL, '2023-12-13 11:48:07', '2023-12-13 11:48:07'),
(139, 127, 'uploads/Product/410311702475287.jpg', 'uploads/Product/728941702475287.jpg', NULL, '2023-12-13 11:48:07', '2023-12-13 11:48:07'),
(140, 128, 'uploads/Product/495411702475521.webp', 'uploads/Product/162001702475521.webp', NULL, '2023-12-13 11:52:01', '2023-12-13 11:52:01'),
(141, 129, 'uploads/Product/310181702475629.webp', 'uploads/Product/873711702475629.webp', NULL, '2023-12-13 11:53:49', '2023-12-13 11:53:49'),
(142, 130, 'uploads/Product/658981702475814.jpg', 'uploads/Product/595401702475814.jpg', NULL, '2023-12-13 11:56:54', '2023-12-13 11:56:54'),
(143, 131, 'uploads/Product/174901702475914.webp', 'uploads/Product/250241702475914.webp', NULL, '2023-12-13 11:58:35', '2023-12-13 11:58:35'),
(144, 132, 'uploads/Product/111121702476005.jpg', 'uploads/Product/562131702476005.jpg', NULL, '2023-12-13 12:00:06', '2023-12-13 12:00:06'),
(145, 133, 'uploads/Product/209941702476114.webp', 'uploads/Product/496931702476114.webp', NULL, '2023-12-13 12:01:54', '2023-12-13 12:01:54'),
(146, 134, 'uploads/Product/602391702476261.webp', 'uploads/Product/764111702476261.webp', NULL, '2023-12-13 12:04:22', '2023-12-13 12:04:22'),
(147, 135, 'uploads/Product/77731702476390.webp', 'uploads/Product/492131702476390.webp', NULL, '2023-12-13 12:06:30', '2023-12-13 12:06:30'),
(148, 136, 'uploads/Product/787131702476521.webp', 'uploads/Product/303001702476521.webp', NULL, '2023-12-13 12:08:42', '2023-12-13 12:08:42'),
(149, 137, 'uploads/Product/268301702476649.webp', 'uploads/Product/524921702476649.webp', NULL, '2023-12-13 12:10:49', '2023-12-13 12:10:49'),
(150, 138, 'uploads/Product/24741702476772.jpg', 'uploads/Product/420411702476772.jpg', NULL, '2023-12-13 12:12:52', '2023-12-13 12:12:52'),
(151, 139, 'uploads/Product/206111702476872.webp', 'uploads/Product/503571702476872.webp', NULL, '2023-12-13 12:14:32', '2023-12-13 12:14:32'),
(152, 140, 'uploads/Product/365021702476961.jpg', 'uploads/Product/859181702476961.jpg', NULL, '2023-12-13 12:16:01', '2023-12-13 12:16:01'),
(153, 141, 'uploads/Product/576441702477061.webp', 'uploads/Product/394551702477061.webp', NULL, '2023-12-13 12:17:44', '2023-12-13 12:17:44'),
(154, 142, 'uploads/Product/857891702477592.webp', 'uploads/Product/672401702477592.webp', NULL, '2023-12-13 12:26:34', '2023-12-13 12:26:34'),
(155, 143, 'uploads/Product/522681703516247.jpg', 'uploads/Product/767201703516247.jpg', NULL, '2023-12-13 12:28:23', '2023-12-25 12:57:27'),
(156, 144, 'uploads/Product/744741703515688.jpg', 'uploads/Product/290181703515688.jpg', NULL, '2023-12-13 12:30:09', '2023-12-25 12:48:08'),
(157, 145, 'uploads/Product/870051702477919.jpg', 'uploads/Product/317361702477919.jpg', NULL, '2023-12-13 12:31:59', '2023-12-13 12:31:59'),
(158, 146, 'uploads/Product/277601703515641.jpg', 'uploads/Product/111441703515641.jpg', NULL, '2023-12-13 12:35:57', '2023-12-25 12:47:21'),
(159, 147, 'uploads/Product/521271703515618.jpg', 'uploads/Product/499951703515618.jpg', NULL, '2023-12-13 12:37:24', '2023-12-25 12:46:58'),
(160, 148, 'uploads/Product/350011702478341.jpg', 'uploads/Product/51431702478341.jpg', NULL, '2023-12-13 12:39:06', '2023-12-13 12:39:06'),
(161, 149, 'uploads/Product/735301703515597.jpg', 'uploads/Product/593011703515597.jpg', NULL, '2023-12-13 12:40:40', '2023-12-25 12:46:37'),
(162, 150, 'uploads/Product/817591702478532.jpg', 'uploads/Product/953591702478532.jpg', NULL, '2023-12-13 12:42:12', '2023-12-13 12:42:12'),
(163, 151, 'uploads/Product/313201702478719.jpg', 'uploads/Product/25471702478719.jpg', NULL, '2023-12-13 12:45:19', '2023-12-13 12:45:19'),
(164, 152, 'uploads/Product/25891702478825.jpg', 'uploads/Product/284511702478825.jpg', NULL, '2023-12-13 12:47:05', '2023-12-13 12:47:05');

-- --------------------------------------------------------

--
-- Table structure for table `product_translations`
--

CREATE TABLE `product_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `product_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `use` text DEFAULT NULL,
  `how_to_use` text DEFAULT NULL,
  `name` varchar(255) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `product_translations`
--

INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(7, 7, 'en', '<div class=\"elementor-element elementor-element-45ce600 elementor-widget elementor-widget-heading\" data-id=\"45ce600\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">&nbsp;</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-fe646cd elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"fe646cd\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Increase requirements because of acute and/or chronic diseases, convalescence, post surgical state, during and after treatment with antibiotics or chemotherapeutic agents. Prevention of anaemia caused by iron and/or folic acid deficiency.</p>\r\n<div class=\"elementor-element elementor-element-45ce600 elementor-widget elementor-widget-heading\" data-id=\"45ce600\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-fe646cd elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"fe646cd\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each Tablet contains Vitamins &amp; Minirals.</p>\r\n</div>\r\n</div>\r\n</div>\r\n</div>\r\n</div>\r\n</div>', '<p>One tablet daily, taken at breakfast. &nbsp;In cases of morning sickness, it is recommended that the tablets be taken at noon or if necessary, in the evening.</p>', 'Abecedin', NULL, NULL),
(8, 8, 'en', '<p>Decomb is indicated for use in corticosteroid responsive dermatoses complicated or threatened by secondary monilial and/or bacterial infections, such as:</p>\r\n<p>&bull; Atopic dermatitis<br>&bull; Seborrheic dermatitis<br>&bull; Lichen simplex chronicus<br>&bull; Psoriasis (particularly of the face and body folds)<br>&bull; Allergic contact dermatitis</p>\r\n<p>Decomb cream permits use in moist intertrigenous areas.</p>\r\n<div class=\"elementor-element elementor-element-5f55044 elementor-widget elementor-widget-heading\" data-id=\"5f55044\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-71ff4a8 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"71ff4a8\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>-Each gram contains:<br>-Gramicidin 0.25 mg<br>-Neomycin (as sulphate) 2.50 mg<br>-Nystatin 100,000 I.U.<br>Triamcinolone acetonide 1.00 mg</p>\r\n</div>\r\n</div>\r\n</div>', '<p>The cream should be applied 2-3 times daily, with or without occlusive dressing.</p>', 'DECOMB CREAM', NULL, NULL),
(9, 9, 'en', '<p>Dilax is indicated for the treatment of occasional constipation, for use as bowel cleansing regimen, for preparing the patient for surgery or for preparing the colon for x-ray or endoscopic examination.</p>\r\n<div class=\"elementor-element elementor-element-9b56cad elementor-widget elementor-widget-heading\" data-id=\"9b56cad\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-c72a08b elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"c72a08b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each tablet contains Bisacodyl 5 mg</p>\r\n</div>\r\n</div>\r\n</div>', '<p>&mdash; Adults and children 12 years and over<br>One to three tablets in a single daily dose.</p>\r\n<p>&mdash; Children 6 to fewer than 12 years<br>One tablet in a single daily dose.</p>\r\n<p>&mdash; Dosage for bowel cleansing (Adults)<br>2 &ndash; 4 tablets the previous night.<br>Not recommended for use in children under the age of 6 years</p>', 'DILAX TAB', NULL, NULL),
(10, 10, 'en', '<p>Dimestil drops are used for the treatment of allergic reactions such as nettle rash, upper respiratory allergies (e.g. hay fever and vasomotoric rhinitis), as well as drug and food allergies. Dimestil drops are suitable for the treatment of itching caused by skin diseases connected to various rashes (e.g. varicella), and for insect bites. They can also be used as an additional treatment for eczema and other non-inflammatory skin diseases of allergic origin.</p>\r\n<div class=\"elementor-element elementor-element-b59e12e elementor-widget elementor-widget-heading\" data-id=\"b59e12e\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-832d190 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"832d190\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each 1 ml contains Dimethindene Maleate 1 mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>*Adults and children above the age of 12 years: the usual daily dose is 3 to 6 mg of Dimestil, divided over 3 intakes, this is corresponds to: Drops 1 mg/ml: 20 to 40 drops, 3 times a day. *Children: the usual dose is approximately 0.1 mg/kg body weight per day.</p>', 'DIMESTIL DROPS', NULL, NULL),
(11, 11, 'en', '<p>Dimestil gel is most frequently used to treat sunburns, itching, nettle rash, insect bites, and mild burns. It can be used after contact with toxic plants, jellyfish, etc. It is also useful in treating allergic reactions to metal (cheap jewels, metal buttons) or exotic foods (tropic fruits).</p>\r\n<p>Dimestil not only protects against allergic reaction but also reduces the urge to scratch the affected area excessively. This is important because scratching can cause secondary infection, and if continued could turn a simple insect bite into a much more serious problem.</p>\r\n<p>Adults can usually control the urge to scratch, but this is not always the case when dealing with small children. Thus it it&rsquo;s important to note that Dimestil gel helps not only adults, but also small children aged 6 months and older.</p>\r\n<div class=\"elementor-element elementor-element-9fd7745 elementor-widget elementor-widget-heading\" data-id=\"9fd7745\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-1c356a0 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"1c356a0\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each gram contains Dimethindene Maleate 1 mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>Apply to the affected area 2 &ndash; 4 times daily.</p>', 'DIMESTIL GEL', NULL, NULL),
(12, 12, 'en', '<p>For fast effective temporary relief of pain and discomfort associated with immunisation, earache, cold and flu symptoms, teething and headache. Reduces fever.</p>\r\n<div class=\"elementor-element elementor-element-30824ea elementor-widget elementor-widget-heading\" data-id=\"30824ea\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-5b00778 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"5b00778\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each suppository contains Paracetamol 150 or 300 mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>*Infant 150 Suppositories<br>Up to 3 years one suppository up to 5 times daily</p>\r\n<p>*Children&rsquo;s 300 Suppositories<br>3-6 years 1 suppository 4-5 times daily<br>6-11 years 2 suppositories 4-5 times daily</p>', 'FEBRAMOL SUPPOSITORIES', NULL, NULL),
(13, 13, 'en', '<p>For fast effective temporary relief of pain and discomfort associated with immunisation, earache, cold and flu symptoms, teething and headache. Reduces fever.</p>\r\n<div class=\"elementor-element elementor-element-a1d4ec7 elementor-widget elementor-widget-heading\" data-id=\"a1d4ec7\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-0fb8e5b elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"0fb8e5b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each teaspoonful (5 ml) contains Paracetamol 125 mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>*Children</p>\r\n<p>Age Dosage<br>0-4 months 2 ml up to 4-5 times daily<br>4-12 months 3ml up to 4-5 times daily<br>1-2 years 5 ml 4-5 times daily<br>2-4 years 6 ml 4-5 times daily<br>4-6 years 10 ml 4-5 times daily<br>6-9 years 13 ml 4-5 times daily<br>9-10 years 15 ml 4-5 times daily</p>\r\n<p>*Adults<br>20 ml every 4-5 hours.</p>\r\n<p><br><strong>&ldquo;Note: Do not exceed 4 grams of Paracetamol (166 ml) in any 24-hour period.&rdquo;</strong></p>', 'FEBRAMOL SYRUP', NULL, NULL),
(14, 14, 'en', '<p>Prevention of anemia caused by iron and folic acid deficiency, especially that associated with pregnancy.</p>\r\n<div class=\"elementor-element elementor-element-16a6268 elementor-widget elementor-widget-heading\" data-id=\"16a6268\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-45bba70 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"45bba70\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each coated tablet contains:<br>Elemental iron (as ferrous fumarate) 106 mg &amp; Folic acid 1 mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>One tablet daily.</p>', 'Fergole', NULL, NULL),
(15, 15, 'en', '<p>Skin, nail and hair infections caused by dermatophytes or Candida species.</p>\r\n<div class=\"elementor-element elementor-element-0c2d475 elementor-widget elementor-widget-heading\" data-id=\"0c2d475\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-7b144a4 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"7b144a4\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each gram contains Miconazole nitrate 2%.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>&ndash;Skin Infections<br>Apply a small quantity of the cream to the lesion, once or twice a day. Continue the treatment until all signs of the skin lesion have disappeared (usually 2-5 weeks). To prevent a relapse, prolong treatment for a further 10 days.</p>\r\n<p>&ndash;Nail Infections<br>Clip infected nails as closely as possible. Once a day, apply some cream to the infected nail and rub in. Cover the nail with non-perforated plaster. Continue this procedure even after the infected nail has loosened from the nail bed, until a new nail begins to grow and a definite cure is established (usually after 2 months of treatment, sometimes later).</p>', 'FUNGITRIN CREAM', NULL, NULL),
(16, 16, 'en', '<p>&bull; Oral mycosis (thrush) and fungal infections of the upper gastrointestinal tract.<br>&bull; Fungitrin oral gel can be used for the prevention of oral thrush in patients receiving long-term treatment with antibiotics, steroids, cytotoxic and radiation therapy.</p>\r\n<div class=\"elementor-element elementor-element-e61c1f3 elementor-widget elementor-widget-heading\" data-id=\"e61c1f3\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-c8ce652 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"c8ce652\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each gram contains Miconazole base 2%.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>*Infants: For infants 6-24 months, one quarter (1/4) of a measuring spoon* of gel four times daily, or 20 mg/kg/day is recommended.</p>\r\n<p>*Children (2 years of age and older) and Adults: Half (1/2) a measuring spoon* of gel four times daily.<br>* measuring spoon (5 mL). One spoonful contains approximately 124 mg of miconazole. All spoonful dose volumes should be administered with this spoon.</p>', 'FUNGITRIN ORAL GEL', NULL, NULL),
(17, 17, 'en', '<p>Gingival is indicated for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing.</p>\r\n<div class=\"elementor-element elementor-element-7625f24 elementor-widget elementor-widget-heading\" data-id=\"7625f24\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-9bf119a elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"9bf119a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each ml contains Chlorhexidine gluconate &nbsp;0.2% w/v.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>Therapy is initiated directly following dental prophylaxis.<br>Rinse the mouth thoroughly for 30 seconds with the solution twice daily, morning and evening, after brushing the teeth.</p>\r\n<p>The usual dose is 10 ml of undiluted solution. The solution is not intended for ingestion, and should be expectorated after rinsing.</p>', 'GINGIVAL', NULL, NULL),
(18, 18, 'en', '<p>Prescription Lamirase solution 1% is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (formerly Pityrosporum ovale).&nbsp;</p>\r\n<div class=\"elementor-element elementor-element-7744d3a elementor-widget elementor-widget-heading\" data-id=\"7744d3a\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-d6b29dd elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6b29dd\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Terbinafine HCL 1%.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>Lamirase solution 1%, is applied twice daily for 1 week. The affected areas should be cleansed and dried thoroughly before applying Lamirase solution 1%. Sufficient solution should be applied to wet the treatment area(s) thoroughly, and to cover the affected skin and surrounding area. If successful outcome is not achieved during the post treatment period, the diagnosis should be reviewed.</p>', 'LAMIRASE SPRAY', NULL, NULL),
(19, 19, 'en', '<p>Reduces swelling &amp; congestion. Effect begins within 0 min of application &amp; lasts for up to 10 hrs. It is a useful nasal decongestant &amp;, in lower strength a good conjunctival decongestant.</p>\r\n<div class=\"elementor-element elementor-element-7587e6d elementor-widget elementor-widget-heading\" data-id=\"7587e6d\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-0e46590 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"0e46590\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each ml contains Xylometazoline HCl &nbsp;0.5 or 1.0 mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>The dose of nasal Nirvin will be different for different patients. Follow the directions on the label.&nbsp;</p>', 'NIRIVIN', NULL, NULL),
(20, 20, 'en', '<p>Anatcid &amp; Calcium Supplement.</p>\r\n<div class=\"elementor-element elementor-element-1370b0b elementor-widget elementor-widget-heading\" data-id=\"1370b0b\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-b605fbf elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"b605fbf\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each tablet contains Calcium carbonate 600 mg, equivalent to 240 mg calcium.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>&mdash; Antacid<br>1-2 tablets, to be taken after every meal or when required.<br>Antacids should be administered frequently, due to the rapid emptying of the gastric contents.</p>\r\n<p>&mdash; Calcium Supplement<br>Children 1-10 years of age<br>The recommended dosage is 800 mg of calcium daily (3 tablets daily).<br>Adolescents<br>The recommended dosage is 1,200 mg of calcium daily (5 tablets daily).<br>Over 18 years of age<br>The recommended dosage is 800 mg of calcium daily (3 tablets daily).<br>Pregnant and nursing women<br>The recommended dosage is 1,200 mg of calcium daily (5 tablets daily).</p>', 'ORACAL TAB', NULL, NULL),
(21, 21, 'en', '<div class=\"elementor-element elementor-element-e7d1523 elementor-widget elementor-widget-heading\" data-id=\"e7d1523\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Action:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-0ad617c elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"0ad617c\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p><strong>Mechanism of Action</strong><br><strong>Orlislim</strong>&nbsp;is a potent, specific, and reversible long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the serine residue of the active site of gastric and pancreatic lipases. The inactivated enzyme is thus unable to hydrolyze dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides. As undigested triglycerides are not absorbed, the resulting caloric deficit has a positive effect on the weight control.</p>\r\n<p><strong>Pharmacokinetics</strong><br>Based on fecal fat measurements, the effect of Orlistat is seen as soon as 24 to 48 hours after dosing. Upon discontinuation of therapy, fecal fat content usually returns to pre-treatment levels, within 48 to 72 hours.</p>\r\n<p><em>Absorption</em><br>In normal weight and obese volunteers, the systemic exposure to orlistat was minimal. Plasma concentrations of intact orlistat were nearly non-measurable (&lt; 5 ng/mL) following a single oral administration of 360 mg orlistat.</p>\r\n<p>In general, after long-term treatment at therapeutic doses, detection of intact orlistat in plasma was sporadic and concentrations were extremely low (&lt;10 ng/mL or 0.02 &micro;M), without evidence of accumulation showing consistency with negligible absorption.</p>\r\n<p><em>Distribution</em><br>The volume of distribution cannot be determined because orlistat is minimally absorbed. In vitro orlistat is &gt; 99% bound to plasma proteins (lipoproteins and albumin were the major binding proteins). Orlistat minimally partitions into erythrocytes.</p>\r\n<p><em>Metabolism</em><br>Based on animal data, it is likely that the metabolism of orlistat occurs mainly presystemically. Two major metabolites (M1 and M3) accounted for approximately 42% of the total radioactivity in plasma resulting from the minute fraction of the dose that was absorbed systemically in obese patients.<br>These two major metabolites have very weak lipase inhibitory activity (1000- and 2500-fold less than orlistat respectively). In view of this low inhibitory activity and the low plasma levels at therapeutic doses (average of 26 ng/mL and 108 ng/mL respectively), these metabolites are pharmacologically inconsequential.</p>\r\n<p><em>Elimination</em><br>Studies in normal weight and obese subjects have shown that fecal excretion of the unabsorbed orlistat was the major route of elimination. Approximately 97% of the administered dose was excreted in faeces and 83% of that as unchanged orlistat.</p>\r\n<p>The cumulative renal excretion of total orlistat-related materials was &lt; 2% of the given dose. The time to reach complete excretion (fecal plus urinary) was 3-5 days. The disposition of orlistat appeared to be similar between normal weight and obese volunteers. Orlistat, M1 and M3 are all subject to biliary excretion.</p>\r\n<p><em>Pharmacokinetics in special populations</em><br>Plasma concentrations of orlistat and its metabolites M1 and M3 were similar in paediatric patients compared to those found in adults at the same dose level. Daily fecal fat excretions were 27% and 7% of dietary intake in orlistat and placebo treatment groups, respectively.</p>\r\n<p><em>Hepatic and/or renal impairment</em><br>Clinical investigations in patients with hepatic and/or renal impairment have not been undertaken.</p>\r\n</div>\r\n</div>\r\n</div>', '<div class=\"elementor-element elementor-element-f244752 elementor-widget elementor-widget-heading\" data-id=\"f244752\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Composition:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-fa0dd0d elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"fa0dd0d\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each Capsule contains Orlistat 120 mg.</p>\r\n</div>\r\n</div>\r\n</div>', 'Orlislim 120', NULL, NULL),
(22, 22, 'en', '<p>&bull; In case of minor injuries of any kind, that could become infected: scrapes, cuts, scratches, cracks, burns.<br>&bull; Light, intertrigo (inflammation of the skin at the folds).<br>&bull; In case of inflammation of the skin accompanied by an infection;<br>&bull; In case of inflammation of the nipple during lactation;<br>&bull; On prescription only in cases of chronic wounds such as leg ulceration (ulcus cruris), decubitus ulcer and surgical wounds.</p>\r\n<div class=\"elementor-element elementor-element-49c4633 elementor-widget elementor-widget-heading\" data-id=\"49c4633\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-832763a elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"832763a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each 1 gram contains 50 mg Dexpanthenol and 5 mg Chlorhexidine HCl.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>Gently rub the medicine in until it is evenly distributed to the affected area.</p>\r\n<p>&bull; Wound and burns: 1 time daily or if necessary more times.<br>&bull; Nipple cracked in nursing mothers: After every breastfeed applied to nipples. Before nursing, nipples must be cleaned with water.<br>&bull; Nappy rash: Pantinol plus cream is used every nappy change.</p>', 'PANTINOL PLUS CREAM', NULL, NULL),
(23, 23, 'en', '<p>Rhinofex MD Spray is used as a symptomatic agent in the following conditions:<br>&bull; Colds;<br>&bull; Nasal congestion;<br>&bull; Acute and chronic rhinitis;<br>&bull; Allergic rhinitis;<br>&bull; Acute otitis media (as an adjuvant therapy);<br>&bull; Preoperative preparation and postoperative elimination of edema of the nasal mucosa and accessory sinuses.</p>\r\n<div class=\"elementor-element elementor-element-abea2c7 elementor-widget elementor-widget-heading\" data-id=\"abea2c7\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-0df931c elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"0df931c\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each 1 ml contains Dimetindene maleate 0.25mg &amp; Phenylephrine (HCL) 2.5mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>Before irrigation of the nasal cavity, it is recommended to thoroughly clean the nasal passages. Adults and children who reached the age of 6, it is recommended to use the drug 3-4 times a day, 1-2 injections. The bottle should be kept strictly vertical when injecting the nebulizer into the nasal cavity. After injecting the spray, you need to inhale slightly through the nose. The course of treatment should not exceed 7 days.&nbsp;</p>', 'RHINOFEX MD SPRAY', NULL, NULL),
(24, 24, 'en', '<p>For the local symptomatic relief of pain and inflammation in:</p>\r\n<ul>\r\n<li>Trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises.</li>\r\n<li>Localized forms of soft tissue rheumatism.</li>\r\n</ul>\r\n<div class=\"elementor-element elementor-element-1fbd88b elementor-widget elementor-widget-heading\" data-id=\"1fbd88b\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-70318d6 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"70318d6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each gram contains Diclofenac diethyl ammonium equivalent to 2% Diclofenac sodium.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>Adults and children 12 years and over: The gel should be rubbed gently into the skin. Depending on</p>\r\n<p>the size of the affected site to be treated, 2-4g (a circular shaped mass approximately 2.0-2.5cm in</p>\r\n<p>diameter) should be applied 2 Times a day (preferably morning and evening). The maximum daily dose</p>\r\n<p>is 8g. Therefore, the maximum weekly dose is 56g.</p>', 'RUFENAL DS EMULGEL', NULL, NULL),
(25, 25, 'en', '<p>For fast effective temporary relief of pain and discomfort associated with headache, muscular aches, period pain, arthritis/osteoarthritis, toothache, migraine, cold &amp; flu symptoms, tension headache, sinus pain/headache and backache. Reduces fever.</p>\r\n<div class=\"elementor-element elementor-element-906880d elementor-widget elementor-widget-heading\" data-id=\"906880d\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-e61643b elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e61643b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each caplet contains Paracetamol 500 mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>*Adults and children aged 12 years and over: 1 to 2 tablets every four to six hours as required. Maximum of 8 tablets in 24 hours. Do not use for more than a few days at a time in adults without medical advice.</p>\r\n<p>*Children 7 to 12 years: &frac12; to 1 tablet every four to six hours as required. Maximum of 4 tablets in 24 hours. Should not be used for more than 48 hours for children 7 &ndash; 17 except on medical advice.</p>', 'SEDAMOL', NULL, NULL),
(26, 26, 'en', '<p>For the treatment of mild to moderate pain including headache, migraine, neuralgia, toothache, sore throat, period pains, symptomatic relief of sprains, strains, rheumatic pain, sciatica, lumbago, fibrositis, muscular aches and pains, joint swelling and stiffness, influenza, feverishness and feverish colds.</p>\r\n<div class=\"elementor-element elementor-element-5181902 elementor-widget elementor-widget-heading\" data-id=\"5181902\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-054e810 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"054e810\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each caplet contains Paracetamol 250mg, Aspirin 250mg, Caffeine 65mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p><em>Adults, the elderly and young persons aged 16 and over:</em></p>\r\n<p>2 tablets every 4 hours to a maximum of 8 tablets in 24 hours.</p>\r\n<p><strong>Do not give to children aged under 16 years, unless specifically indicated (e.g. for Kawasaki&rsquo;s disease).</strong></p>', 'SEDAPRIN CAPLET', NULL, NULL),
(27, 27, 'en', '<div class=\"elementor-element elementor-element-08f3192 elementor-widget elementor-widget-heading\" data-id=\"08f3192\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Action:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-5c3785d elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"5c3785d\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p><strong>Tadalafil</strong>&nbsp;is a potent, selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by Tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Tadalafil has no effect in the absence of sexual stimulation.</p>\r\n<p>Tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal muscle, platelets, kidney, lung, and cerebellum. The effect of Tadalafil is more potent on PDE5 than on other phosphodiesterase. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1, PDE2, PDE4, and PDE7 enzymes which are found in the heart, brain, blood vessels, liver, leukocytes, skeletal muscle and other organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels.</p>\r\n<p>This selectivity for PDE5 over PDE3 is important because PDE3 is an enzyme involved in cardiac contractility. Additionally, Tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an enzyme which is found in the retina and is responsible for phototransduction. Tadalafil is also &gt;9,000-fold more potent for PDE5 than for PDE8, 9 and 10 and 14-fold more potent for PDE5 than for PDE11. The tissue distribution and physiological effects of the inhibition of PDE8 through PDE11 have not been elucidated.</p>\r\n<p>Tadalafil produced no significant difference in supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8 mm Hg, respectively), in standing systolic and diastolic blood pressure (mean maximal decrease of 0.2/4.6 mm Hg, respectively), and no significant change in heart rate. Larger effects were recorded among subjects receiving concomitant nitrates.</p>\r\n<p>No impairment of colour discrimination (blue/green) was detected. This finding is consistent with the low affinity of Tadalafil for PDE6 compared to PDE5. In addition, no effects were observed on visual acuity, electroretinograms, intraocular pressure, or pupillometry. There were no clinically relevant effects on sperm concentration, sperm count, and motility.</p>\r\n<p><strong>Pharmacokinetics</strong><br><em>Absorption</em><br>Tadalafil is rapidly absorbed after oral administration and the mean maximum observed plasma concentration (Cmax) is achieved at a median time of 2 hours after dosing. The rate and extent of absorption of Tadalafil are not influenced by food, thus Siafil may be taken with or without food. The time of dosing (morning versus evening) had no clinically relevant effects on the rate and extent of absorption.</p>\r\n<p><em>Distribution</em><br>The mean volume of distribution is approximately 63 liters, indicating that Tadalafil is distributed into tissues. At therapeutic concentrations, 94% of Tadalafil in plasma is bound to proteins. Protein binding is not affected by impaired renal function.</p>\r\n<p><em>Biotransformation</em><br>Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major circulating metabolite is the methylcatechol glucuronide. This metabolite is at least 13,000-fold less potent than Tadalafil for PDE5. Consequently, it is not expected to be clinically active at observed metabolite concentrations.</p>\r\n<p><em>Elimination</em><br>The mean oral clearance for Tadalafil is 2.5 l/hour and the mean half-life is 17.5 hours in healthy subjects. Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).</p>\r\n<p><em>Elderly</em><br>Healthy elderly subjects (65 years or over), had a lower oral clearance of Tadalafil, resulting in 25% higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is not clinically significant and does not warrant a dose adjustment.</p>\r\n<p><em>Renal Impairment</em><br>In subjects with renal insufficiency, including those on haemodialysis, Tadalafil exposure (AUC) was higher than in healthy subjects. Therefore, the recommended starting dose of Tadalafil in patients with mild or moderate renal impairment is 10 mg. For patients with severe renal impairment, 10 mg is the maximum recommended dose.</p>\r\n<p><em>Hepatic Impairment</em><br>Tadalafil exposure (AUC) in subjects with mild or moderate hepatic impairment (Child-Pugh Class A and B) is comparable to exposure in healthy subjects. No controlled data are available in patients with severe hepatic impairment (Child-Pugh Class C).</p>\r\n<p><em>Patients with Diabetes</em><br>Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC value for healthy subjects. This difference in exposure does not warrant a dose adjustment.</p>\r\n</div>\r\n</div>\r\n</div>', '<div class=\"elementor-element elementor-element-22ddec3 elementor-widget elementor-widget-heading\" data-id=\"22ddec3\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Composition:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-bea43bf elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"bea43bf\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each tablet contains Tadalafil 5or20 mg.</p>\r\n</div>\r\n</div>\r\n</div>', 'Siafil 5 or 20 mg', NULL, NULL),
(28, 28, 'en', '<p>Simeped is used to relieve abdominal pain which is due to excessive gas in the digestive tract.</p>\r\n<div class=\"elementor-element elementor-element-8022ea2 elementor-widget elementor-widget-heading\" data-id=\"8022ea2\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-5b0fbd4 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"5b0fbd4\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each 0.6 ml contains simethicone 40 mg.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>0.3 ml (20 mg) before each meal. Dosage may be increased to 0.6 ml (40 mg) if required. Do not exceed 12 doses of 0.3 ml or 6 doses of 0.6 ml (240 mg) a day.</p>', 'SIMEPED DROPS', NULL, NULL),
(29, 29, 'en', '<p>For the relief of burning, itching, irritation and redness of eyes.</p>\r\n<div class=\"elementor-element elementor-element-f8edc37 elementor-widget elementor-widget-heading\" data-id=\"f8edc37\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\r\n<div class=\"elementor-widget-container\">\r\n<h2 class=\"elementor-heading-title elementor-size-default\">Generic Name:</h2>\r\n</div>\r\n</div>\r\n<div class=\"elementor-element elementor-element-94fb216 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"94fb216\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\r\n<div class=\"elementor-widget-container\">\r\n<div class=\"elementor-text-editor elementor-clearfix\">\r\n<p>Each ml contains Tetrahydrozoline HCl 0.05%.</p>\r\n</div>\r\n</div>\r\n</div>', '<p>Instil one or two drops of Tetrin Eye Drops in each eye two or three times a day.<br>Tetrin Eye Drops should be used sparingly in children. Its use in children under 2 years of age is not recommended.</p>', 'TETRIN EYE DROPS', NULL, NULL),
(30, 30, 'en', '<p><strong>Action</strong></p>\r\n<p>Vitamin&nbsp;A is essential for normal vision, in dim light and for the integrity of epithelial cells. Deficiency may give rise to night-blindness and skin changes with a lowered resistance to minor skin infections, inflammation of the gums and pyorrhea.<br>Vitamin&nbsp;D is necessary for the absorption of calcium and phosphorus from the gastro-intestinal tract and for their transport. Deficiency of Vitamin&nbsp;D is associated with the occurrence of rickets in children and osteomalacia in adults.</p>', '<p><strong>Indications</strong></p>\r\n<p>Vitamin A and D supplement in infants.</p>\r\n<p><strong>Dosage and Administration</strong></p>\r\n<p>The recommended dosage in infants less than 1 year of age is 2 drops daily, diluted with water, milk, or fruit juice.</p>', 'Adol', NULL, NULL),
(31, 31, 'en', '<p><strong>Composition</strong></p>\r\n<p><span lang=\"EN\">Olopatadine hydrochloride 0.1</span>% (1 mg/mL)</p>\r\n<p><strong>Action</strong></p>\r\n<p>Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H1-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.</p>\r\n<p><strong>Indications</strong></p>\r\n<p>Allnex &nbsp;0.1 % is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.</p>', '<p><span style=\"font-size: 14pt;\"><strong>Geriatric Use</strong></span></p>\r\n<p>No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>', 'Allnex 0.1_ drops', NULL, NULL),
(32, 32, 'en', '<p><strong><span lang=\"EN-GB\">Action</span></strong></p>\r\n<p>Amoxycillin is a semisynthetic aminopenicillin of the beta-lactam group of antibiotics. It has a broad spectrum of antibacterial activity against many Gram-positive and Gram-negative microorganisms, acting through the inhibition of biosynthesis of cell wall mucopeptide. Amoxycillin is, however, susceptible to degradation by beta-lactamases and therefore the spectrum of activity does not include organisms that produce these enzymes including resistant staphylococci, and all strains of Pseudomonas, Klebsiella, and Enterobacter.</p>', '<p><strong><span lang=\"EN-GB\">Indications</span></strong></p>\r\n<ul>\r\n<li><span lang=\"EN-GB\">Infections caused by amoxicillin-susceptible organisms including upper respiratory tract infections, chest infections, urinary tract infections, skin and soft tissue infections, and gonorrhoea.</span></li>\r\n<li><span lang=\"EN-GB\">Amoxitid may be used for the prevention of bacteraemia associated with procedures such as dental extraction in patients at risk of developing bacterial endocarditis.</span></li>\r\n</ul>', 'Amoxitid', NULL, NULL),
(33, 33, 'en', '<p><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\">Action</span></strong></span></p>\r\n<p><span lang=\"EN-GB\">Azithromycin acts by binding to the 50S ribosomal subunit of susceptible organisms and thus interfering with microbial protein synthesis. Nucleic acid synthesis is not affected.</span></p>\r\n<p><span lang=\"EN-GB\">Azithromycin concentrates in phagocytes and fibroblasts as demonstrated by in vitro incubation techniques. Using such methodology, the ratio of intracellular to extra cellular concentration was &gt; 30 after one-hour incubation. In vivo studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues. Azithromycin has been shown to be active against most strains of the following organisms &ndash; both in vitro and in clinical infections.</span></p>', '<p><strong><span lang=\"EN-GB\" style=\"font-size: 14pt;\">Composition</span></strong></p>\r\n<p><strong><span lang=\"EN-GB\">Azimex 250 Capsules</span></strong></p>\r\n<p>Each capsule contains Azithromycin (as dihydrate) 250 mg</p>\r\n<p><strong><span lang=\"EN-GB\">Azimex 500 mg Capsules</span></strong></p>\r\n<p>Each capsule contains Azithromycin (as dihydrate) 500 mg</p>\r\n<p><strong><span lang=\"EN-GB\">Azimex Powder</span></strong></p>\r\n<p>Each 5 ml contains Azithromycin (as dihydrate) 200 mg</p>', 'Azimex caps & Powder', NULL, NULL),
(34, 34, 'en', '<p><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\">Action</span></strong></span></p>\r\n<p><span lang=\"EN\">Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens.</span></p>\r\n<p><span lang=\"EN\">The bactericidal action of moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the norA or pmrA genes seen in certain Gram-positive bacteria.</span></p>\r\n<p><span lang=\"EN\">Pharmacodynamic investigations have demonstrated that moxifloxacin exhibits a concentration dependent killing rate. Minimum bactericidal concentrations (MBC) were found to be in the range of the minimum inhibitory concentrations (MIC).</span></p>', '<p><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\">Indications</span></strong></span></p>\r\n<p><span lang=\"EN\">Basilox 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to moxifloxacin.</span></p>\r\n<p><span lang=\"EN\">In the following indications, Moxifloxacin should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections:</span></p>\r\n<p><span lang=\"EN\">Acute bacterial sinusitis </span></p>\r\n<p><span lang=\"EN\">Acute exacerbation of chronic obstructive pulmonary disease including bronchitis</span></p>\r\n<p><span lang=\"EN\">In the following indications, Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed:</span></p>\r\n<p><span lang=\"EN\">Community acquired pneumonia, except severe cases</span></p>\r\n<p><span lang=\"EN\">Mild to moderate pelvic inflammatory disease</span><span lang=\"EN\"> (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess.</span></p>\r\n<p><span lang=\"EN\">Basilox 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing moxifloxacin resistance of Neisseria gonorrhoeae unless moxifloxacin-resistant Neisseria gonorrhoeae can be excluded.</span></p>\r\n<p><span lang=\"EN\">Basilox 400 mg film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous moxifloxacin for the following indications:</span></p>\r\n<p><span lang=\"EN\">Community-acquired pneumonia</span></p>\r\n<p><span lang=\"EN\">Complicated skin and skin structure infections</span></p>\r\n<p><span lang=\"EN\">Basilox 400 mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection or in severe community-acquired pneumonia.</span></p>', 'Basilox 400', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(35, 35, 'en', '<p>Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. Nystatin is an antibiotic with antifungal activity against a wide variety of yeasts and yeast-like fungi. The antifungal activity of nystatin is at least in part dependent on its binding to a sterol moiety, primarily ergosterol, present in the membrane of sensitive fungi, which results in an increase in the permeability of the membrane and leakage of intra-cellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.</p>\r\n<p><strong><span lang=\"EN-GB\">Composition</span></strong></p>\r\n<p><span lang=\"EN-GB\">Each ml contains Nystatin 100,000 I.U.</span></p>\r\n<p>&nbsp;</p>', '<ul>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\">Treatment of infections caused by sensitive strains of Candida albicans (Monilia), and specifically for the treatment of monilial infections of the oral cavity and in intestinal moniliasis.</span></li>\r\n<li><span lang=\"EN-GB\">Candistan Ready Mix suspension is particularly useful for the treatment of thrush in the newborn and monilial infections of the oral cavity and esophagus in infants, children and adults.</span></li>\r\n</ul>', 'Candistan', NULL, NULL),
(36, 36, 'en', '<p><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\">Action</span></strong></span></p>\r\n<p><span lang=\"EN\">Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases.</span></p>\r\n<p><span lang=\"EN\">The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis.</span></p>', '<p><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\">Composition</span></strong></span><span lang=\"EN-GB\"><br></span><span lang=\"EN-GB\">each tablet contains </span><span lang=\"EN\">Cefpodoxime </span><span lang=\"EN-GB\">100 &amp; 200 mg.</span></p>', 'Cefpo Tablet', NULL, NULL),
(37, 37, 'en', '<p><span lang=\"EN-GB\">Chloramphenicol is a broad spectrum antibiotic, highly effective against a wide range of Gram-positive and Gram-negative organisms.</span></p>\r\n<p><span lang=\"EN-GB\">Polymyxin B has a narrower field of activity, mainly against Gram-negative organisms such as Pseudomonas aeruginosa.</span></p>\r\n<p><span lang=\"EN-GB\">Together, these two antibiotics possess an antibacterial spectrum of activity covering most organisms implicated in blepharitis and conjunctivitis.</span></p>\r\n<p>Dexamethasone is one of the most potent corticosteroids; it is 5 -14&nbsp;times more potent than prednisolone and 25 - 75&nbsp;times more potent than cortisone and hydrocortisone. Of paramount importance with regard to local therapy is the fact that dexamethasone is over 2000&nbsp;times more soluble than hydrocortisone or prednisolone. Thanks to the addition of chloramphenicol, a broad-spectrum antibiotic, this combination yields excellent results in inflammation of the anterior uvea (iritis, iridocyclitis).</p>', '<p><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\">Composition</span></strong></span></p>\r\n<p><strong><span lang=\"EN-GB\">Each ml contains:</span></strong></p>\r\n<p><span lang=\"EN-GB\">Chloramphenicol&nbsp; &nbsp;2.00 mg</span></p>\r\n<p><span lang=\"EN-GB\">Polymyxin B sulphate&nbsp; &nbsp; 2500 I.U.</span></p>\r\n<p><span lang=\"EN-GB\">Dexamethasone sodium phosphate&nbsp; 0.25 mg</span></p>\r\n<p><span lang=\"EN-GB\">In a stable, buffered, sterile solution.</span></p>\r\n<p><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\">Indications</span></strong></span></p>\r\n<p><span lang=\"EN-GB\">Chlorosone is indicated for the treatment of corticosteroid-responsive allergic and inflammatory ocular conditions in which bacterial infection or a risk of such infection caused by susceptible microorganisms exists, such as blepharitis and conjunctivitis.</span></p>\r\n<p>&nbsp;</p>', 'Chlorosone', NULL, NULL),
(38, 38, 'en', '<p>Clafoxim is a semi-synthetic cephalosporin antibiotic with a broad spectrum of activity against both Gram positive and Gram-negative bacteria. Clafoxim is bactericidal in its mode of action and has a high degree of stability in the presence of &szlig;-lactamases.</p>\r\n<p><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\">Composition</span></strong></span></p>\r\n<p><span lang=\"EN-GB\">Each vial contains </span>Cefotaxime (as sodium) equivalent to 1 gm Cefotaxime base.</p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong>Indications</strong></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"><br></span>Clafoxim is indicated for use primarily in the treatment of infections of the Genito urinary, gastrointestinal and respiratory tracts, in the skin and soft tissues and meningitis in children caused by susceptible strains of the following organisms:</p>\r\n<ul>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Staphylococcal infections: (including infections caused by both penicillinase-producing and non-penicillinase-producing strains): abscess, furunculosis, bronchitis and impetigo.</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Streptococcal infections: (both &szlig;-haemolytic and group D streptococci), cellulitis, pneumonia, follicular tonsillitis, otitis media, pharyngitis, sinusitis, scarlet fever, septic sore throat, urinary tract infections (Enterococci) and meningitis in children.</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Pneumococcal infections: Lobar pneumonia, bronchitis, cellulitis and otitis media.</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Haemophilus influenzae infections: Otitis media, laryngotracheobronchitis and meningitis in children.</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">E coli infections: Lobar pneumonia, urinary tract infections and meningitis in children.</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Shigella infections: Bacillary dysentery</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Salmonella infections: Enteritis</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Sensitive strains of Pseudomonas aeruginosa: Sepsis</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Gonococcus: Gonorrhoea</li>\r\n<li class=\"MsoNormal\" style=\"text-align: left; text-indent: 0in; direction: ltr; unicode-bidi: embed;\">Neisseria Meningitidis: Meningitis in children.</li>\r\n</ul>\r\n<p><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: \'Times New Roman\'; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"><br></span>Bacteriological studies to determine the causative organisms and their sensitivity to Clafoxim should be performed.<span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: \'Times New Roman\'; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"><br><br></span><strong><span style=\"font-size: 14pt;\">Prophylactic uses</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: \'Times New Roman\'; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"><strong><br></strong></span>the administration of Clafoxim preoperatively may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as potentially contaminated.<br>The minimum effective dose has been found to be 1 g Clafoxim 30-90 minutes prior to surgery.</p>', 'Clafoxim vial', NULL, NULL),
(39, 39, 'en', '<p><span style=\"font-size: 14pt;\"><strong>Indications</strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Renal Bone Disease<br></span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">most patients with osteitis fibrosa and osteomalacia show a symptomatic and gradual biochemical, radiographic and histological improvement.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hypoparathyroidism<br></span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Low plasma calcium levels restored to normal relatively quickly with 1alpha-OHD3. Severe hypocalcaemia (e.g. after extensive neck surgery) may decline with higher doses of 1alpha-OHD3, (e.g. 3&nbsp;-5&nbsp;micrograms) and calcium supplements. Maintain Normocalcemia with smaller doses within a relatively narrow dose range.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Secondary Hyperparathyroidism<br></span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Following parathyroidectomy, patients with primary or tertiary hyperparathyroidism and bone disease often require large doses of vitamin&nbsp;D and intravenous calcium to avoid severe hypocalcemia. Preliminary studies suggest that pre-operative treatment with 1alpha-OHD3 for two to three weeks alleviates bone pain and myopathy when present without aggravating pre-operative hypercalcemia. Continued post-operative treatment decreases post-operative hypocalcaemia and be continued until the plasma alkaline phosphatase level falls to normal or hypercalcemia occurs.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hypophosphataemic Vitamin&nbsp;D resistant rickets and osteomalacia<br></span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">this is characterized by hypophosphataemia due to defective renal tubular re-absorption and intestinal absorption of phosphorus. Neither large doses of vitamin&nbsp;D nor phosphate supplements are entirely satisfactory, the latter tending to produce hypocalcaemia and hypoparathyroidism. 1alpha-OHD3 relieves myopathy when present, increases calcium and phosphorus retention and promotes bone healing. Phosphate supplements may also be required in some patients.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pseudo-deficiency (D-dependent) rickets<br></span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">This requires large doses of vitamin&nbsp;D probably because of an inherited defect in the production of 1,25-(OH)2D3. 1alpha-OHD3 reverses this condition.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Nutritional and malabsorptive rickets and osteomalacia<br></span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Nutritional rickets and osteomalacia can be cured with physiological doses of 1alpha-OHD3. Patients with malabsorptive osteomalacia responding to large doses of vitamin&nbsp;D will respond to small doses of 1alpha-OHD3.<br style=\"mso-special-character: line-break;\"><!-- [if !supportLineBreakNewLine]--><br style=\"mso-special-character: line-break;\"><!--[endif]--></span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition </span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each soft gelatin capsules contains<span style=\"color: black;\"> 1&nbsp;microgram or 0,25&nbsp;micrograms of </span>Alphacalcidol<span style=\"color: black;\">.</span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Alfacalcidol (1alpha-OHD<sub>3</sub>) is rapidly converted in the liver to 1, 25-dihydroxyvitamin D<sub>3</sub> (1,25-(OH)<sub>2</sub>D<sub>3</sub>), the metabolite of vitamin D which acts as a regulator of calcium and phosphate homeostasis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Impaired endogenous production of 1, 25-dihydroxyvitamin D<sub>3</sub> by the kidneys appears to contribute to the disturbances in mineral metabolism found in several disorders, including renal bone disease, hypoparathyroidism, and vitamin D-dependent rickets. These disorders, which require high doses of vitamin D for their correction, will respond to small doses of Alfacal.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">As compared to vitamin D, the main advantage of Alfacal is more rapid onset and offset of action. This allows a more accurate titration of dosage and decreases the risk of prolonged hypercalcemia.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: Calibri, sans-serif;\">Pharmacokinetics</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Serum levels of 1,25-(OH)<sub>2</sub> D<sub>3</sub> peak approximately 12 hours after a single dose of Alfacalcidol and remain at measurable levels for at least 48 hours. The effect of 1 mcg of Alfacalcidol on calcium absorption has been observed within 6 hours and was maximal at 24 hours. The biological half-life is approximately 35 hours.</span></p>', 'Alfacal', NULL, NULL),
(40, 40, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications </span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 12pt;\"><strong><span lang=\"EN\" style=\"font-family: Calibri, sans-serif;\">Hypertension</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Amicor plus (Amlodipine and Valsartan) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including Amlodipine and the ARB class to which Valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Amicor plus.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program\'s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amicor plus (Amlodipine and Valsartan) is indicated for the treatment of hypertension.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Amicor plus may be used in patients whose blood pressure is not adequately controlled on either monotherapy.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Amicor plus may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">The choice of Amicor plus as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the lowest dose of Amicor plus.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Patients with stage 2 hypertension (moderate or severe) are at a relatively higher risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient\'s risk.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amicor plus 5/80 </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Amlodipine 5mg &amp; Valsartan 80 mg </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amicor plus 5/160</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Amlodipine 5mg &amp; Valsartan 160 mg </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amicor plus 10/160 </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Amlodipine 10mg &amp; Valsartan 160 mg </span></p>', 'Amicor plus', NULL, NULL),
(41, 41, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications </span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hypertension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amicor is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Chronic Stable Angina</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amicor is indicated for the treatment of chronic stable angina. Amicor may be used alone or in combination with other antianginal agents. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Vasospastic Angina (Prinzmetal\'s or Variant Angina)</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; tab-stops: list 21.3pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amicor is indicated for the treatment of confirmed or suspected vasospastic angina. Amicor may be used as a monotherapy or in combination with other antianginal drugs. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Amlodipine besylate equivalent to 5 Amlodipine.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action </span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amlodipine is a calcium ion influx inhibitor (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and smooth muscle.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The mechanism of the antihypertensive action of Amlodipine is due to a direct relaxant effect on vascular smooth muscle.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The precise mechanism by which Amlodipine relieves angina has not been fully determined but Amlodipine reduces total ischemic burden by the following two actions:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amlodipine dilates peripheral arterioles and thus reduces the total peripheral resistance (after load) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The mechanism of action of Amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal\'s or variant angina) and blunts smoking induced coronary vasoconstriction.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24-hour interval.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Due to the slow onset of action, acute hypotension is not a feature of Amlodipine administration.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In patients with angina, once daily administration of Amlodipine increases total exercise time, time to angina onset and time to 1 mm ST segment depression, and decreases both angina attack frequency and nitroglycerine tablet consumption.</span></p>', 'Amicor', NULL, NULL),
(42, 42, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amiran is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with non-insulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled by diet and exercise alone. Amiran may be used concomitantly with Glucomet (metformin) when diet, exercise, and Amiran or Glucomet alone do not result in adequate glycemic control.&nbsp;</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: \'Times New Roman\'; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Amiran is not suitable for the treatment of insulin-dependent (type I) diabetes mellitus (e.g. for the treatment of diabetics with a history of ketoacidosis, of diabetic ketoacidosis, or of diabetic precoma or coma).</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Glimepiride 4 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Glimepiride is a sulfonylurea anti-diabetic agent, which decreases blood glucose concentrations. The primary mechanism of action of glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion in the rhythm of meals. In addition, extrapancreatic effects (eg. reduction of basal hepatic glucose production and increased peripheral tissue sensitivity to insulin and glucose uptake) may also play a limited role in the activity of glimepiride.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In non-fasting diabetic patients, the hypoglycemic action of a single dose of glimepiride persists for 24 hours.</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The efficacy of Glimepiride is not affected by age, gender, or<strong> </strong>weight. Amiran therapy is effective in controlling blood glucose without deleterious changes in the plasma lipoprotein profile of patients. The physiological response to acute exercise (i.e. reduction of insulin secretion) is still present during glimepiride therapy.</span></p>', 'Amiran', NULL, NULL),
(43, 43, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Ancozine is an anti-emetic, effective in the management of nausea, vomiting, and dizziness during pregnancy or dizziness associated with motion sickness.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Ancozine has been found useful in the management of vertigo associated with diseases affecting the vestibular system.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 12pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: Calibri, sans-serif;\">Ancozine Tablets</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Meclozine HCl<span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>25 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pyridoxine HCl <span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>50 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"><span style=\"mso-tab-count: 1;\"> </span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Meclozine HCl is an H<sub>1</sub> histamine receptor blocker of the piperazine side chain group; it acts on CNS by its ability to block muscarinic receptors in the brain.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pyridoxine HCl is a water-soluble vitamin involved in amino acid, carbohydrate, and fat metabolism. It is also required for the formation of haemoglobin. It is used to prevent uncontrolled excitation of CNS, and eventually uncontrolled muscle seizures.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">This combination provides a synergistic anti-emetic effect.</span></p>', 'Ancozine', NULL, NULL),
(44, 44, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Topical treatment of purulent bacterial conjunctivitis, caused by Moxifloxacin susceptible strains Consideration should be given to official guidance on the appropriate use of antibacterial agents.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Moxifloxacin 0.5% (5 mg/ml)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">BASILOX 0.5 Eye Drops contains the fourth-generation fluoroquinolone, Moxifloxacin. Moxifloxacin has <em>in vitro </em>activity against a wide range of Gram-positive and Gram-negative micro-organisms. Moxifloxacin inhibits the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription repair, and<span style=\"mso-spacerun: yes;\">&nbsp; </span>recombination. The C8-methoxy moiety of moxifloxacin also lessens the selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety found in older<span style=\"mso-spacerun: yes;\">&nbsp; </span>fluoroquinolones. Moxifloxacin&rsquo;s bulky C-7 substituent group interferes with the quinolone efflux pump mechanism of bacteria. Moxifloxacin is often bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The mechanism of action for quinolones, including Moxifloxacin, is different from that of macrolides, aminoglycosides, or tetracyclines. Therefore, Moxifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to Moxifloxacin. There is no cross-resistance between Moxifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic Moxifloxacin and some other quinolones.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In vitro</span></em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> resistance to Moxifloxacin develops via multiple-step mutations. Resistance to Moxifloxacin occurs <em>in vitro</em> at a general frequency of between 1.8 x 10<sup>-9</sup> to &lt; 1 x 10<sup>-11</sup> for Gram-positive bacteria.</span></p>', 'Basilox eye drops', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(45, 45, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Bepen V.K is indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms that are sensitive to the low serum levels of this particular form of penicillin.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Bepen V.K 250 mg Syrup</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each teaspoonful (5 ml) contains phenoxymethyl penicillin (as potassium) 250 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Bepen V.K 500 mg Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains phenoxymethyl penicillin (as potassium) 500 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Penicillin V exerts a bactericidal action against penicillin sensitive microorganisms during the stage of active multiplication. It is not active against the penicillinase-producing bacteria, which include many strains of staphylococci.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Sensitive organisms include the following:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l3 level1 lfo1; tab-stops: list .5in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gram-positive cocci, e.g. Streptococci (groups A,C,G,H,L and M), and non-penicillinase producing <em>Staphylococcus pyogenes</em>. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l1 level1 lfo2; tab-stops: list .5in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gram-positive bacilli, e.g. Clostridium tetani, Cl. Perfrigens, Corynebacterium diphtheriae and Bacillus anthracis. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l2 level1 lfo3; tab-stops: list .5in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gram-negative bacteria, both <em>Neisseria meningitidis </em>and <em>N. gonorrhoeae </em>are sensitive to a degree but <em>Haemophilus influenzae </em>is moderately resistant and other aerobic Gram-negative bacilli are highly resistant. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo4; tab-stops: list .5in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treponema pallidum </span></em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">is sensitive, but treatment of syphilis with oral penicillins is not recommended. </span></p>', 'Bepen VK', NULL, NULL),
(46, 46, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The treatment of vitamin D deficiency.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Vitamin D<sub>3</sub> 50000 IU (Cholecalciferol)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Cholecalciferol is a vitamin D compound which possesses the property of preventing<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>or treating rickets.<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp;&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Vitamin D is essential for promoting absorption and utilization of calcium and phosphate and for normal calcification of bone.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Along with parathyroid hormone and calcitonin, it regulates serum calcium concentrations by increasing serum calcium and phosphate concentrations as needed.<span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Vitamin D stimulates calcium and phosphate absorption from the small intestine and mobilizes calcium from bone.<span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Cholecalciferol is transferred to the liver where it is converted to calcifediol (25-hydroxycolecalciferol), which is then transferred to the kidneys and converted to calcitriol (1,25-dihyroxycolecalciferol, thought to be the most active form) and 24,25-dihydroxycolecalciferol (physiologic role not determined).<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Calcitriol appears to act by binding to a specific receptor in the cytoplasm of the intestinal mucosa and subsequently being incorporated into the nucleus, probably leading to formation of the calcium-binding protein which results in increased absorption of calcium from the intestine.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Also, calcitriol may regulate the transfer of calcium ion from bone and stimulate reabsorption of calcium in the distal renal tubule, thereby effecting calcium homeostasis in the extracellular fluid.<span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Onset of action &ndash; Hypercalcaemic: 12 to 24 hours; therapeutic effect may take 10 to 14 days.<span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Duration of action &ndash; Following oral administration: up to 6 months; repeated doses have a cumulative action.</span></p>', 'BUVIDAL', NULL, NULL),
(47, 47, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefadrox is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Urinary tract infections caused by E. coli,<em> </em>P. mirabilis, and Klebsiella species.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Skin and skin structure infections caused by staphylococci and/or streptococci.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pharyngitis and tonsillitis caused by group A beta-hemolytic streptococci. (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefadrox is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Cefadrox in the subsequent prevention of rheumatic fever are not available at present.)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">&ldquo;<em>Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated</em>.&rdquo;</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefadrox<em> </em>250 Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each teaspoonful (5 ml) contains Cefadroxil (as monohydrate) 250 mg<strong>&nbsp;</strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefadrox Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Cefadroxil (as monohydrate) 500 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefadroxil is a semi synthetic cephalosporin antibiotic intended for oral administration.<span style=\"mso-spacerun: yes;\"> &nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefadroxil is rapidly absorbed after oral administration. Following single doses of 500 and 1000 mg, average peak serum concentrations were approximately 16 and 28 mg/ml, respectively.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Measurable levels were present 12 hours after administration.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Over 90% of the drug is excreted unchanged in the urine within 24 hours.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Peak urine concentrations are approximately 1800 mg/ml during the period following a single 500-mg oral dose.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Increases in dosage generally produce a proportionate increase in Cefadroxil urinary concentration.<span style=\"mso-spacerun: yes;\">&nbsp; </span>The urine antibiotic concentration, following a<strong> </strong>1-gram dose, was maintained well<strong> </strong>above the MIC of susceptible urinary pathogens for 20 to 22 hours.</span></p>', 'cefadrox', NULL, NULL),
(48, 48, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefalex is indicated for the treatment of the following infections, when caused by susceptible organisms:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Upper and lower respiratory tract infections</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Otitis media</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Genitourinary tract infections and acute prostatitis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Skin and soft tissue infections</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Bone infections.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefalex 500 Capsules</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each capsule contains Cephalexin (as monohydrate)<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>500 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefalex 250 mg suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each 5 ml of the reconstituted suspension contains 250 mg Cephalexin (as monohydrate)<span style=\"mso-spacerun: yes;\">&nbsp; </span>.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cephalexin is a semisynthetic cephalosporin antibiotic drug.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is bactericidal, acting by inhibition of bacterial cell wall synthesis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefalex is intended for oral administration.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is stable in gastric acid, and may be administered without regard to meals.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Cefalex is rapidly and almost completely absorbed from the upper gastrointestinal tract.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Its use is therefore associated with a relatively low incidence of gastrointestinal side effects.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Peak blood levels are reached within 1 hour of administration.<span style=\"mso-spacerun: yes;\">&nbsp; </span>They are comparable to those attained with equivalent doses of intramuscular cephaloridine, and exceed those obtained with equivalent doses of intramuscular cephalothin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefalex is widely distributed in the tissues and high concentrations are achieved in all organs, especially the kidneys and liver.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Cefalex is excreted unchanged in urine.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cephalexin enjoys a wide margin of safety, and may be administered to the majority of penicillin-sensitive patients.</span></p>', 'cefalex', NULL, NULL),
(49, 49, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: \'Times New Roman\'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Prescribing CEFDINIR in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: \'Times New Roman\'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">As with other broad-spectrum antibiotics, prolonged treatment may result in the possible emergence and overgrowth of resistant organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate alternative therapy should be administered.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: \'Times New Roman\'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Cefdinir, as with other broad-spectrum antimicrobials (antibiotics), should be prescribed with caution in individuals with a history of colitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: \'Times New Roman\'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">In patients with transient or persistent renal insufficiency (creatinine clearance &lt; 30 mL/min), the total daily dose of CEFDINIR should be reduced because high and prolonged plasma concentrations of cefdinir can result following recommended doses.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"><br></span></strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefimed 300</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each capsule contains </span><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">cefdinir 3</span><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">00 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefimed 250 Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each teaspoonful (5 ml) contains Cefdinir 250 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cefimed 125 Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each teaspoonful (5 ml) contains Cefdinir 125 mg<strong>&nbsp;</strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, &beta;-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.</span></p>', 'CEFIMED CAP &amp; SUSP', NULL, NULL),
(50, 50, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cefixon is indicated for the treatment of the following infections when caused by susceptible organisms.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each vial contains 1 g Ceftriaxone (as sodium).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The bactericidal activity of Ceftriaxone results from inhibition of cell wall Synthesis. Ceftriaxone has a high degree of stability in the presence of beta-lactamases, both penicillinase and cephalosporinases, of gram-negative and gram-positive bacteria. Ceftriaxone is usually active against the following microorganisms in vitro and in clinical infections.</span></p>', 'cefixon vial', NULL, NULL),
(51, 51, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Urinary tract infections lower respiratory tract infections, gastro-intestinal infections, bone, and joint, skin, and soft tissue infections (caused by Ciprofloxacin sensitive bacteria).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gonorrhea (Ciprofloxacin is not effective against Treponema pallidum)</span></p>\r\n<p><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: \'Times New Roman\'; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">An aminoglycoside must be administered with Ciprofloxacin in the treatment of infections caused by Pseudomonas aeruginosa.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Ciprofloxacin (as Hcl) equivalent to 250 or 500 mg Ciprofloxacin</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ciprofloxacin is a synthetic, fluorinated 4-quinolone antimicrobial agent.<br>It has broad antimicrobial activity and is effective, after oral administration, for the treatment of a wide variety of infectious diseases. The bactericidal action of Ciprofloxacin results from interference with the enzyme DNA gyrase, needed for the synthesis of bacterial DNA. </span></p>', 'ceproxx', NULL, NULL),
(52, 52, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Treatment of eye infections associated with inflammation, such as blepharitis and conjunctivitis, caused by susceptible microorganisms.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol<span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>2.00 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Polymyxin B Sulphate<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>2500 I.U.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong><strong><span lang=\"EN-GB\" style=\"font-family: Calibri, sans-serif;\"><span style=\"mso-tab-count: 1;\">&nbsp; </span></span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol is a broad spectrum antibiotic, highly effective against a wide range of Gram-positive and Gram-negative organisms.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Polymyxin B has a narrower field of activity, mainly against Gram-negative organisms such as Pseudomonas aeruginosa.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Together, these two antibiotics possess an antibacterial spectrum of activity covering most organisms implicated in blepharitis and conjunctivitis.</span></p>', 'chloromyxin', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(53, 53, 'en', '<div class=\"WordSection1\">\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoBodyText\" style=\"margin-left: 0in; text-align: justify;\"><span style=\"font-size: 14pt;\"><u><span style=\"font-family: Calibri, sans-serif;\">Rheumatology</span></u></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -21.3pt; line-height: 13.8pt; mso-line-height-rule: exactly; mso-list: l3 level1 lfo1; tab-stops: 21.3pt 20.1pt; margin: .05pt 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Active<span style=\"letter-spacing: -.15pt;\"> </span>phases<span style=\"letter-spacing: -.05pt;\"> </span>of<span style=\"letter-spacing: -.15pt;\"> </span>systemic<span style=\"letter-spacing: -.1pt;\"> </span>vasculitis:</span></p>\r\n<p class=\"MsoBodyText\" style=\"text-align: justify; text-indent: -21.3pt; mso-list: l3 level1 lfo1; tab-stops: 21.3pt; margin: 0in 5.4pt .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Polyarteritis<span style=\"letter-spacing: .05pt;\"> </span>nodosa<span style=\"letter-spacing: .05pt;\"> </span>(in<span style=\"letter-spacing: .05pt;\"> </span>patients<span style=\"letter-spacing: .05pt;\"> </span>with<span style=\"letter-spacing: .05pt;\"> </span>concomitant<span style=\"letter-spacing: .05pt;\"> </span>positive<span style=\"letter-spacing: .05pt;\"> </span>hepatitis<span style=\"letter-spacing: .05pt;\"> </span>B<span style=\"letter-spacing: .05pt;\"> </span>serology,<span style=\"letter-spacing: 3.0pt;\"> </span>the<span style=\"letter-spacing: .05pt;\"> </span>duration of treatment should be restricted to two weeks), polymyalgia rheumatica (PMR),<span style=\"letter-spacing: .05pt;\"> </span>PMR<span style=\"letter-spacing: -.05pt;\"> </span>with giant<span style=\"letter-spacing: -.05pt;\"> </span>cell arteritis, temporal<span style=\"letter-spacing: -.05pt;\"> </span>arteritis with<span style=\"letter-spacing: -.05pt;\"> </span>acute<span style=\"letter-spacing: -.1pt;\"> </span>vision loss;</span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -21.3pt; mso-list: l3 level1 lfo1; tab-stops: 21.3pt 20.1pt; margin: 0in 5.3pt .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Active<span style=\"letter-spacing: 1.3pt;\"> </span>phases<span style=\"letter-spacing: 1.5pt;\"> </span>of<span style=\"letter-spacing: 1.35pt;\"> </span>systemic<span style=\"letter-spacing: 1.3pt;\"> </span>rheumatic<span style=\"letter-spacing: 1.3pt;\"> </span>disease:<span style=\"letter-spacing: 1.5pt;\"> </span>systemic<span style=\"letter-spacing: 1.3pt;\"> </span>lupus<span style=\"letter-spacing: 1.5pt;\"> </span>erythematosus,<span style=\"letter-spacing: 1.35pt;\"> </span>mixed<span style=\"letter-spacing: -2.85pt;\"> </span>connective<span style=\"letter-spacing: -.1pt;\"> </span>tissue<span style=\"letter-spacing: -.05pt;\"> </span>disease;</span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -21.3pt; line-height: 98%; mso-list: l3 level1 lfo1; tab-stops: 21.3pt 20.1pt; margin: .2pt 5.45pt .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; line-height: 98%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; line-height: 98%; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Severe<span style=\"letter-spacing: 2.6pt;\"> </span>progressive<span style=\"letter-spacing: 2.7pt;\"> </span>forms<span style=\"letter-spacing: 2.7pt;\"> </span>of<span style=\"letter-spacing: 2.6pt;\"> </span>active<span style=\"letter-spacing: 2.75pt;\"> </span>rheumatoid<span style=\"letter-spacing: 2.65pt;\"> </span>arthritis,<span style=\"letter-spacing: 2.7pt;\"> </span>e.g.<span style=\"letter-spacing: 2.65pt;\"> </span>rapidly<span style=\"letter-spacing: 2.7pt;\"> </span>destructive<span style=\"letter-spacing: 2.6pt;\"> </span>forms<span style=\"letter-spacing: -2.85pt;\"> </span>and/or<span style=\"letter-spacing: -.1pt;\"> </span>with extra-articular<span style=\"letter-spacing: -.05pt;\"> </span>manifestations;</span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -21.3pt; mso-list: l3 level1 lfo1; tab-stops: 21.3pt 20.1pt; margin: .1pt 5.25pt .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Other<span style=\"letter-spacing: 1.2pt;\"> </span>forms<span style=\"letter-spacing: 1.25pt;\"> </span>of<span style=\"letter-spacing: 1.2pt;\"> </span>inflammatory<span style=\"letter-spacing: 1.15pt;\"> </span>rheumatic<span style=\"letter-spacing: 1.2pt;\"> </span>arthritis,<span style=\"letter-spacing: 1.25pt;\"> </span>provided<span style=\"letter-spacing: 1.25pt;\"> </span>that<span style=\"letter-spacing: 1.3pt;\"> </span>the<span style=\"letter-spacing: 1.3pt;\"> </span>severity<span style=\"letter-spacing: 1.0pt;\"> </span>of<span style=\"letter-spacing: 1.35pt;\"> </span>symptoms<span style=\"letter-spacing: -2.85pt;\"> </span>requires it and non-steroidal anti-inflammatory drugs (NSAIDs) cannot be used:<span style=\"letter-spacing: .05pt;\"> </span>Spondylarthritis<span style=\"letter-spacing: 2.05pt;\"> </span>(ankylosing<span style=\"letter-spacing: 2.0pt;\"> </span>spondylitis<span style=\"letter-spacing: 2.1pt;\"> </span>with<span style=\"letter-spacing: 2.1pt;\"> </span>involvement<span style=\"letter-spacing: 2.15pt;\"> </span>of<span style=\"letter-spacing: 2.05pt;\"> </span>peripheral<span style=\"letter-spacing: 2.25pt;\"> </span>joints,<span style=\"letter-spacing: 2.1pt;\"> </span>psoriatic<span style=\"letter-spacing: -2.85pt;\"> </span>arthritis,<span style=\"letter-spacing: -.05pt;\"> </span>enteropathic<span style=\"letter-spacing: .05pt;\"> </span>arthropathy<span style=\"letter-spacing: -.15pt;\"> </span>with<span style=\"letter-spacing: -.05pt;\"> </span>high inflammatory<span style=\"letter-spacing: -.25pt;\"> </span>activity);</span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -21.3pt; line-height: 13.8pt; mso-line-height-rule: exactly; mso-list: l3 level1 lfo1; tab-stops: 21.3pt 20.1pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Reactive<span style=\"letter-spacing: -.15pt;\"> </span>forms<span style=\"letter-spacing: -.05pt;\"> </span>of<span style=\"letter-spacing: -.05pt;\"> </span>arthritis;</span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -21.3pt; line-height: 13.85pt; mso-line-height-rule: exactly; mso-list: l3 level1 lfo1; tab-stops: 21.3pt 20.1pt; margin: .1pt 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Arthritis<span style=\"letter-spacing: -.1pt;\"> </span>in<span style=\"letter-spacing: -.1pt;\"> </span>sarcoidosis;</span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -21.3pt; mso-list: l3 level1 lfo1; tab-stops: 21.3pt 20.1pt; margin: 0in 5.4pt .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Severe<span style=\"letter-spacing: 1.15pt;\"> </span>systemic<span style=\"letter-spacing: 1.15pt;\"> </span>form<span style=\"letter-spacing: 1.25pt;\"> </span>of<span style=\"letter-spacing: 1.3pt;\"> </span>juvenile<span style=\"letter-spacing: 1.15pt;\"> </span>idiopathic<span style=\"letter-spacing: 1.2pt;\"> </span>arthritis<span style=\"letter-spacing: 1.2pt;\"> </span>(Still&rsquo;s<span style=\"letter-spacing: 1.2pt;\"> </span>disease)<span style=\"letter-spacing: 1.2pt;\"> </span>or<span style=\"letter-spacing: 1.15pt;\"> </span>with<span style=\"letter-spacing: 1.2pt;\"> </span>iridocyclitis<span style=\"letter-spacing: -2.85pt;\"> </span>refractory<span style=\"letter-spacing: -.3pt;\"> </span>to topical treatment.</span></p>\r\n<p class=\"MsoBodyText\" style=\"margin-left: 0in; text-align: justify;\"><span style=\"font-size: 14pt;\"><u><span style=\"font-family: Calibri, sans-serif;\">Pulmonary<span style=\"letter-spacing: -.35pt;\"> </span>and<span style=\"letter-spacing: .05pt;\"> </span>respiratory<span style=\"letter-spacing: -.25pt;\"> </span>tract<span style=\"letter-spacing: -.05pt;\"> </span>disorders</span></u></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -.25in; line-height: 13.8pt; mso-line-height-rule: exactly; mso-list: l0 level1 lfo2; tab-stops: 20.05pt; margin: .05pt 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Bronchial<span style=\"letter-spacing: -.15pt;\"> </span>asthma:</span></p>\r\n<p class=\"MsoBodyText\" style=\"text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo2; tab-stops: 20.05pt; margin: 0in 28.95pt .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">For the long-term treatment of severe chronic asthma (category 4) and for treatment of<span style=\"letter-spacing: -2.85pt;\"> </span>exacerbations<span style=\"letter-spacing: -.05pt;\"> </span>in adults and children.</span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo2; tab-stops: 20.05pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Chronic<span style=\"letter-spacing: -.15pt;\"> </span>obstructive<span style=\"letter-spacing: -.1pt;\"> </span>pulmonary<span style=\"letter-spacing: -.3pt;\"> </span>disease<span style=\"letter-spacing: -.05pt;\"> </span>(COPD):</span></p>\r\n<p class=\"MsoBodyText\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo2; tab-stops: 20.05pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">For<span style=\"letter-spacing: -.15pt;\"> </span>short-term<span style=\"letter-spacing: -.1pt;\"> </span>treatment (max.<span style=\"letter-spacing: -.05pt;\"> </span>14<span style=\"letter-spacing: -.1pt;\"> </span>days)<span style=\"letter-spacing: -.15pt;\"> </span>of exacerbations;</span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo2; tab-stops: 20.05pt; margin: .1pt 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Upper<span style=\"letter-spacing: -.1pt;\"> </span>respiratory<span style=\"letter-spacing: -.25pt;\"> </span>tract<span style=\"letter-spacing: -.05pt;\"> </span>disorders:</span></p>\r\n</div>\r\n<p class=\"MsoBodyText\" style=\"text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo2; tab-stops: 20.05pt; margin: 4.0pt 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">For<span style=\"letter-spacing: 1.5pt;\"> </span>short-term<span style=\"letter-spacing: 1.6pt;\"> </span>treatment<span style=\"letter-spacing: 1.75pt;\"> </span>of<span style=\"letter-spacing: 1.5pt;\"> </span>severe<span style=\"letter-spacing: 1.55pt;\"> </span>forms<span style=\"letter-spacing: 1.55pt;\"> </span>of<span style=\"letter-spacing: 1.7pt;\"> </span>allergic<span style=\"letter-spacing: 1.65pt;\"> </span>rhinitis<span style=\"letter-spacing: 1.6pt;\"> </span>in<span style=\"letter-spacing: 1.55pt;\"> </span>adults<span style=\"letter-spacing: 1.6pt;\"> </span>after<span style=\"letter-spacing: 1.5pt;\"> </span>failure<span style=\"letter-spacing: 1.55pt;\"> </span>of<span style=\"letter-spacing: 1.5pt;\"> </span>all<span style=\"letter-spacing: -2.85pt;\"> </span>other<span style=\"letter-spacing: -.1pt;\"> </span>treatment alternatives, including<span style=\"letter-spacing: -.2pt;\"> </span>topical<span style=\"letter-spacing: .1pt;\"> </span>glucocorticoids.</span></p>\r\n<p class=\"MsoBodyText\" style=\"margin-left: 0in; text-align: justify;\"><span style=\"font-size: 14pt;\"><u><span style=\"font-family: Calibri, sans-serif;\">Dermatology</span></u></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -.25in; line-height: 98%; mso-list: l1 level1 lfo3; tab-stops: 20.05pt; margin: .2pt 5.45pt .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; line-height: 98%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; line-height: 98%; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Oral<span style=\"letter-spacing: .65pt;\"> </span>initial<span style=\"letter-spacing: .65pt;\"> </span>treatment<span style=\"letter-spacing: .65pt;\"> </span>of<span style=\"letter-spacing: .6pt;\"> </span>extensive,<span style=\"letter-spacing: .65pt;\"> </span>severe,<span style=\"letter-spacing: .65pt;\"> </span>acute<span style=\"letter-spacing: .6pt;\"> </span>skin<span style=\"letter-spacing: .65pt;\"> </span>conditions<span style=\"letter-spacing: .65pt;\"> </span>responsive<span style=\"letter-spacing: .6pt;\"> </span>to<span style=\"letter-spacing: -2.85pt;\"> </span>glucocorticoids,<span style=\"letter-spacing: -.05pt;\"> </span>such as:</span></p>\r\n<p class=\"MsoBodyText\" style=\"text-align: justify; text-indent: -.25in; mso-list: l1 level1 lfo3; margin: .05pt 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Allergic<span style=\"letter-spacing: .05pt;\"> </span>skin<span style=\"letter-spacing: .15pt;\"> </span>disease<span style=\"letter-spacing: .1pt;\"> </span>(e.g.<span style=\"letter-spacing: .15pt;\"> </span>acute<span style=\"letter-spacing: .1pt;\"> </span>urticaria,<span style=\"letter-spacing: .1pt;\"> </span>contact<span style=\"letter-spacing: .3pt;\"> </span>dermatitis,<span style=\"letter-spacing: .15pt;\"> </span>drug<span style=\"letter-spacing: .15pt;\"> </span>eruption),<span style=\"letter-spacing: .1pt;\"> </span>atopic<span style=\"letter-spacing: .1pt;\"> </span>eczema<span style=\"letter-spacing: -2.85pt;\"> </span>(acute exacerbations or<span style=\"letter-spacing: -.05pt;\"> </span>extensive<span style=\"letter-spacing: -.1pt;\"> </span>weeping<span style=\"letter-spacing: -.15pt;\"> </span>eczema), pemphigus<span style=\"letter-spacing: -.05pt;\"> </span>vulgaris.</span></p>\r\n<p class=\"MsoBodyText\" style=\"margin-left: 0in; text-align: justify;\"><span style=\"font-size: 14pt;\"><u><span style=\"font-family: Calibri, sans-serif;\">Nephrology</span></u></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -.25in; line-height: 13.85pt; mso-line-height-rule: exactly; mso-list: l2 level1 lfo4; tab-stops: 20.1pt; margin: .1pt 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Minimal<span style=\"letter-spacing: -.15pt;\"> </span>change<span style=\"letter-spacing: -.05pt;\"> </span>glomerulonephritis;</span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-align: justify; text-indent: -.25in; mso-list: l2 level1 lfo4; tab-stops: 20.1pt; margin: 0in 5.45pt .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis),<span style=\"letter-spacing: .05pt;\"> </span>generally in combination with cytostatics, tapering and ending treatment in Goodpasture&rsquo;s<span style=\"letter-spacing: .05pt;\"> </span>syndrome;<span style=\"letter-spacing: .05pt;\"> </span>for<span style=\"letter-spacing: -.05pt;\"> </span>all<span style=\"letter-spacing: -.05pt;\"> </span>other<span style=\"letter-spacing: .05pt;\"> </span>forms, long-term<span style=\"letter-spacing: -.05pt;\"> </span>continuation of<span style=\"letter-spacing: -.05pt;\"> </span>treatment;</span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l2 level1 lfo4; tab-stops: 20.1pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Idiopathic<span style=\"letter-spacing: -.15pt;\"> </span>retroperitoneal<span style=\"letter-spacing: -.1pt;\"> </span>fibrosis.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains 4 mg triamcinolone.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Triamcinolone is a synthetic glucocorticoid with marked anti-allergic, anti-inflammatory and membrane-stabilizing properties, as well as effects on carbohydrate, protein and lipid metabolism.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Triamcinolone has less mineralocorticoid activity than prednisolone.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Glucocorticoids exert their biological effect by activating transcription of corticosteroid- sensitive genes. The anti-inflammatory, immunosuppressive and antiproliferative effects are induced by various factors, including reduced formation, release and activity of inflammatory mediators and inhibition of specific functions and migration of inflammatory cells. In addition, the effect of sensitized T-lymphocytes and macrophages on target cells may be prevented by corticosteroids.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">If long-term corticosteroid medication is necessary, possible induction of transient adrenocortical insufficiency must be taken into consideration. Suppressibility of the hypothalamic-pituitary-adrenocortical axis depends, amongst other things, on individual factors.</span></p>', 'CINOLONE', NULL, NULL),
(54, 54, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prevention of vascular ischemia associated with atherothrombotic events (MI, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Each tablet contains:<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clopidogrel Bisulfate 75 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pharmacodynamics</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clopidogrel is a specific and potent inhibitor of platelet aggregation. Platelets have an established role in the pathophysiology of atherosclerotic disease and thrombotic events. Long term use of anti-platelet drugs has shown consistent benefit in the prevention of ischemic stroke, myocardial infarction and vascular death in patients at increased risk of such outcomes, including those with established atherosclerosis or a history of atherothrombosis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, and the subsequent ADP-mediated activation of the GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Biotransformation of clopidogrel is necessary to produce inhibition of platelet aggregation. However, an active metabolite responsible for the activity of the drug has not been isolated. Clopidogrel also inhibits platelet aggregation induced by other agonists by blocking the amplification of platelet activation by released ADP.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clopidogrel acts by irreversibly modifying the platelet ADP receptor. Consequently, platelets exposed to clopidogrel are affected for the remainder of their lifespan and recovery of normal platelet function occurs at a rate consistent with platelet turnover (approximately 7 days).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Statistically significant and dose-dependent inhibition of platelet aggregation was noted 2 hours after single oral doses of clopidogrel. Repeated doses of 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%. Platelet aggregation and bleeding time gradually returned to baseline values, generally within 7 days after treatment was discontinued.</span></p>', 'clovix', NULL, NULL),
(55, 55, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">For relief of ocular irritation and/or congestion or for the treatment of allergic of inflammatory ocular conditions.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Pheniramine Maleate <span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>3 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Naphazoline Nitrate<span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>0.25 mg.</span></p>', 'Collihist', NULL, NULL),
(56, 56, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Perennial and seasonal allergic rhinitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Vasomotor rhinitis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Allergic conjunctivitis due to inhalant allergens and foods.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Amelioration of allergic reactions to blood or plasma.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cold urticaria</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Dermatographism</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cyprodin Syrup</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each 5 ml contains Cyproheptadine HCl (as anhydrous) 2 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cyprodin Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Cyproheptadine HCl (as anhydrous) 4 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cyproheptadine hydrochloride is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Animal studies have shown Cyproheptadine hydrochloride to be an effective serotonin and histamine antagonist, comparable, in general, to the most active known substances.</span></p>', 'Cyprodin', NULL, NULL),
(57, 57, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Decongex SR is indicated for the relief of nasal and eustachian tube congestion, which is associated with common cold, sinusitis and acute upper respiratory infections.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is also indicated for the symptomatic relief of perenial and seasonal allergic rhinitis and in vasomotor rhinitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Decongestants, in combination with antihistamines, have been used to relieve eustachian tube congestion that is associated with acute eustachian salpingitis, acrotitis and serious otitis media.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each capsule contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine hydrochloride<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>120 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chlorpheniramine maleate <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>8 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">In a slow-release formulation designed for oral bid dosage.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine hydrochloride is a nasal decongestant, Chlorpheniramine maleate is an antihistamine. Pseudoephedrine HCl produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than amphetamines.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It has the potential for excitatory side effects.<span style=\"mso-spacerun: yes;\">&nbsp; </span>At the recommended doses, it has little or no pressor effect in normotensive adults.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chlorpheniramine possesses anticholinergic and sedative effects.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is considered one of the most effective and least toxic of the histamine antagonists.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is also an H1 receptor antagonist.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It antagonizes many of the pharmacologic actions of histamine and prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa.</span></p>', 'Decongex sr caps', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(58, 58, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Decort 4 mg ampoule</span></strong><em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">(<strong>I.V. or I.M. Injection)</strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Endocrine Disorders</span></em></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Primary or secondary adrenocortical insufficiency (the drug of choice is hydrocortisone or cortisone - synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Acute adrenocortical insufficiency (the drug of choice is hydrocortisone or cortisone - mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Preoperatively, and in the event of serious trauma or illness in patients with known adrenal insufficiency, or when adrenocortical reserve is doubtful.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.<span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Congenital adrenal hyperplasia.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Nonsuppurative thyroiditis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Hypercalcemia associated with cancer.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Decort 4 mg Injection</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 1 ml contains Dexamethasone phosphate (as sodium) 4 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Decort 20 mg Injection</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 1 ml contains Dexamethasone phosphate (as sodium) 20 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dexamethasone is a synthetic corticosteroid (glucocorticoid). As such, its main actions may be grouped as follows:&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Anti-inflammatory and Immunological Actions: Glucocorticoids prevent the development of the inflammatory response, i.e. Redness, swelling, tenderness. They also inhibit capillary dilation and phagocytosis and appear to prevent the hypersensitivity responses that occur after antigen-antibody reactions.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pharmacological Actions: The principal action of dexamethasone is on gluconeogenesis, glycogen deposition, and protein and calcium metabolism, together with inhibition of corticotrophin secretion. Glucocorticoids also influence the mobilization, oxidation, synthesis, and storage of fats. Except for its use in the treatment of adrenal insufficiency it does not cure disease but it is used rather to treat disease symptoms because of its pharmacological properties, i.e. Anti-inflammatory and anti-allergic actions. </span></p>', 'Decort amp', NULL, NULL),
(59, 59, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Endocrine</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Congenital adrenal hyperplasia, non-suppurative thyroiditis, hypercalcemia associated with cancer.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Rheumatic Disorders</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in psoriatic arthritis, rheumatoid arthritis including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute non-specific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Collagen Diseases</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">In exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus, acute rheumatic carditis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Dermatological</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme, exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic dermatitis.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Decort 0.5 mg Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Dexamethasone 0.5 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Decort 0.75 mg Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Dexamethasone 0.75 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Decort 2 mg Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Dexamethasone 2 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dexamethasone is a synthetic corticosteroid (glucocorticoid). As such, its main actions may be grouped as follows:&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Anti-inflammatory and Immunological Actions: Glucocorticoids prevent the development of the inflammatory response, i.e. Redness, swelling, tenderness. They also inhibit capillary dilation and phagocytosis and appear to prevent the hypersensitivity responses that occur after antigen-antibody reactions.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pharmacological Actions: The principal action of dexamethasone is on gluconeogenesis, glycogen deposition, and protein and calcium metabolism, together with inhibition of corticotrophin secretion. Glucocorticoids also influence the mobilization, oxidation, synthesis, and storage of fats. Except for its use in the treatment of adrenal insufficiency it does not cure disease but it is used rather to treat disease symptoms because of its pharmacological properties, i.e. Anti-inflammatory and anti-allergic actions. </span></p>', 'Decort tab', NULL, NULL),
(60, 60, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">DELECAS is indicated for the treatment of acute and chronic corticosteroid-responsive disorders such as the following conditions:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Musculoskeletal and Soft Tissue Conditions:</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, radiculitis, coccydynia, torticollis, sciatica, lumbago, ganglion cyst, exostosis, fasciitis.</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Allergic Conditions:</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Chronic bronchial asthma (including adjunctive therapy for status asthmaticus), hay fever, angioneurotic edema, allergic bronchitis, seasonal or perennial allergic rhinitis, drug reactions, serum sickness, insect bites.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Dermatologic Conditions:</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Atopic dermatitis (nummular eczema), neurodermatitis (circumscribed lichen simplex), necrobiosis lipoidica diabeticorum, alopecia areata, discoid lupus erythematosus, psoriasis, keloids, pemphigus, dermatitis herpetiformis, urticaria, hypertrophic lichen planus, contact dermatitis, severe solar dermatitis, cystic acne.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Collagen Diseases:</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Disseminated lupus erythematosus, scleroderma, dermatomyositis, polyarteritis nodosa.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">Neoplastic Diseases:</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;\">For palliative management of leukemias and lymphomas in adults; acute leukemia of childhood.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each 1 ml contains 5 mg of Betamethasone as dipropionate and 2 mg of Betamethasone as sodium phosphate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betamethasone is a synthetic glucocorticoid (9 alpha-fluoro-16 beta-methylprednisolone).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betamethasone has strong anti-inflammatory, immunosuppressive and anti-allergic activity.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betamethasone has no clinically significant mineralocorticoid effect. Glucocorticoids diffuse across cell membranes and form complexes with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin) and stimulate the transcription of messenger RNA and the protein synthesis of various enzymes. These are finally responsible for the effects observed in systemic glucocorticoid use. In addition to their significant effect on the inflammatory and immune processes, glucocorticoids also influence the metabolism of carbohydrates, proteins and lipids. Finally, they also have an effect on the cardiovascular system, skeletal muscles and the central nervous system.</span></p>', 'DELECAS', NULL, NULL),
(61, 61, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Dermasept is effective against certain protozoa, Rickettsia and virus-like infections, as well as against many Gram-positive and Gram-negative bacteria.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is useful in the treatment of superficial pyodermas, impetigo, acute folliculitis, seborrhea-like streptodermatitis, and infectious eczematoid dermatitis.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol 3%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol possesses a wide range of antibacterial activity and is effective against virtually all bacterial pathogens known to cause diseases of the eye, and the skin. Resistance to it is slow to develop, moderate in degree and not necessarily permanent.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Preparations of chloramphenicol for local treatment are well tolerated. Chloramphenicol is bacteriostatic.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Since it is lipid-soluble, it diffuses through the bacterial cell membrane and reversibly binds to the 50 S subunit of bacterial ribosomes, where transfer of amino acids to growing peptide chains is prevented, possibly by suppression of peptidyl transferase activity.<span style=\"mso-spacerun: yes;\">&nbsp; </span>This inhibits peptide bond formation and subsequent protein synthesis.</span></p>', 'Dermasept', NULL, NULL),
(62, 62, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Steroid responsive inflammatory conditions or the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation, corneal injury from chemical or thermal burns, or penetration of foreign bodies.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Chloramphenicol is used for the treatment of infections susceptible to the antibiotic.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol<span style=\"mso-tab-count: 1;\"> </span> <span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>2 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Dexamethasone Sodium Phosphate<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dexamethasone is one of the most potent corticosteroids; it is 5 -14&nbsp;times more potent than prednisolone and 25 - 75&nbsp;times more potent than cortisone and hydrocortisone. Of paramount importance with regard to local therapy is the fact that dexamethasone is over 2000&nbsp;times more soluble than hydrocortisone or prednisolone. Thanks to the addition of chloramphenicol, a broad-spectrum antibiotic, this combination yields excellent results in inflammation of the anterior uvea (iritis, iridocyclitis).</span></p>', 'Dexacol', NULL, NULL),
(63, 63, 'en', '<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">DORACEPH</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> (Cefixime) is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Upper Respiratory Tract:</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pharyngitis and tonsillitis caused by <em style=\"mso-bidi-font-style: normal;\">S. pyogenes</em>.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Middle Ear:</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Otitis media caused by <em style=\"mso-bidi-font-style: normal;\">S. pneumoniae</em>, <em style=\"mso-bidi-font-style: normal;\">H. influenzae </em>(beta-lactamase positive and negative strains), <em style=\"mso-bidi-font-style: normal;\">M. catarrhalis </em>(former <em style=\"mso-bidi-font-style: normal;\">B. catarrhalis</em>) (beta-lactamase positive and negative strains) and</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><em style=\"mso-bidi-font-style: normal;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">S. pyogenes</span></em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Paranasal sinuses:</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Sinusitis caused by <em style=\"mso-bidi-font-style: normal;\">S. pneumoniae</em>, <em style=\"mso-bidi-font-style: normal;\">H. influenzae </em>(beta-lactamase positive and negative strains), and <em style=\"mso-bidi-font-style: normal;\">M. catarrhalis </em>(former <em style=\"mso-bidi-font-style: normal;\">B. catarrhalis</em>) (beta-lactamase positive and negative strains).</span></p>', '<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"><br></span></strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">each tablet contains </span><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Cefixime </span><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">400 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 4.2pt; text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">As with other cephalosporin, the bactericidal action of Cefixime results from inhibition of cell wall synthesis. Cefixime is stable in the presence of certain beta-lactamase enzymes. As a result, certain organism&rsquo;s resistant to penicillin and some cephalosporin due to the presence of beta-lactamases may be susceptible to Cefixime.</span></p>', 'DORACEPH', NULL, NULL),
(64, 64, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<ul>\r\n<li><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dupisor gel is indicated for the topical treatment of scalp psoriasis. </span></li>\r\n<li><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dupisor gel is indicated for the topical treatment of mild to moderate &ldquo;non scalp&rdquo; plaque psoriasis vulgaris. </span></li>\r\n</ul>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"><span style=\"mso-spacerun: yes;\">&nbsp;</span>50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\"><span style=\"mso-spacerun: yes;\">&nbsp;</span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol exhibits a vitamin D-like effect by competing for the 1,25(OH)2D3 receptor. Calcipotriol is as potent as 1,25(OH)2D3, the naturally occurring active form of vitamin D, in regulating cell proliferation and cell differentiation, but much less active than 1,25(OH)2D3 in its effect on calcium metabolism. Calcipotriol induces differentiation and suppresses proliferation (without any evidence of a cytotoxic effect) of keratinocytes, thus reversing the abnormal keratinocyte changes in psoriasis. The therapeutic goal envisaged with Calcipotriol is thus a normalization of epidermal growth.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betamethasone dipropionate is a potent topically-active corticosteroid producing prompt, marked and prolonged anti-inflammatory, antipruritic, vasoconstrictive and immunosuppressive properties, without curing the underlying condition. These effects can be enhanced under occlusive conditions due to increased penetration of stratum corneum (by approximately a factor of 10). The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear.</span></p>', 'Dupisor Gel', NULL, NULL),
(65, 65, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dupisor ointment is indicated for the once daily topical treatment of plaque-type psoriasis vulgaris amenable to topical therapy in adult patients 18 years and older.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"><span style=\"mso-spacerun: yes;\">&nbsp;</span>50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\"><span style=\"mso-spacerun: yes;\">&nbsp;</span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol exhibits a vitamin D-like effect by competing for the 1,25(OH)2D3 receptor. Calcipotriol is as potent as 1,25(OH)2D3, the naturally occurring active form of vitamin D, in regulating cell proliferation and cell differentiation, but much less active than 1,25(OH)2D3 in its effect on calcium metabolism. Calcipotriol induces differentiation and suppresses proliferation (without any evidence of a cytotoxic effect) of keratinocytes, thus reversing the abnormal keratinocyte changes in psoriasis. The therapeutic goal envisaged with Calcipotriol is thus a normalization of epidermal growth.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betamethasone dipropionate is a potent topically-active corticosteroid producing prompt, marked and prolonged anti-inflammatory, antipruritic, vasoconstrictive and immunosuppressive properties, without curing the underlying condition. These effects can be enhanced under occlusive conditions due to increased penetration of stratum corneum (by approximately a factor of 10). The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear.</span></p>', 'Dupisor ointment', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(66, 66, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Generalized or Partial Epilepsy</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Primary generalized epilepsy (including photosensitive forms), preferably as single-drug therapy, in particular: grand mal (with or without myoclonia), petit mal (in this type of epilepsy, valproates also provide protection against the possible occurrence of tonicclonic seizures), juvenile myoclonic epilepsy, grand mal petit mal combination.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Secondary generalized epilepsy, in particular: West syndrome, Lennox-Gestaut syndrome.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Partial epilepsy with elementary symptomatology or with complex symptomatology (such as psychosensory, psychomotor forms), in particular: partial epilepsy with partial seizures secondarily generalized, benign partial epilepsy (with Rolandic or occipital spikes) &ndash;elective indication for single-drug therapy.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Duvalep Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each enteric-coated tablet contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Sodium valproate <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>200 mg&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Duvalep Syrup/Duvalep Sugar-Free syrup</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each teaspoonful (5 ml) contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Sodium valproate <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>200 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">&nbsp;</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Duvalep is an anticonvulsant agent, chemically unrelated to other drugs indicated for the treatment of seizure disorders.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">The mechanism by which Duvalep exerts its anticonvulsant effects has not yet been established, but it probably increases brain levels of y-aminobutyric acid (GABA).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Duvalep is rapidly absorbed and distributed after oral administration. The peak blood levels for the liquid form are achieved 1-1.5 hours after intake. For the enteric-coated form, peak blood levels are achieved generally within 2-8 hours, depending on the time of the day, particularly in relation to ingestion of food. The average half-life of sodium valproate at steady state is 12 hours in children and adults. The drug is highly bound (90%) to human plasma proteins. Elimination occurs mainly via the kidney</span></p>', 'Duvalep', NULL, NULL),
(67, 67, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Digestive Disorders</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Relief of symptoms such as gastrointestinal pain, heartburn, dyspepsia, flatulence, regurgitation in peptic ulcer, reflux esophagitis, gastritis, duodenitis, hiatus hernia, cholelithiasis post-cholecystectomy dyspepsia, post-anaesthetic vomiting, vomiting due to anti-migraine therapy and intolerance to drugs.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Emestop Injection </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each ampoule of 2 ml contains Metoclopramide hydrochloride 10 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&nbsp;</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Emestop Syrup</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each teaspoonful (5 ml) contains Metoclopramide hydrochloride 5 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&nbsp;</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: Calibri, sans-serif;\">Emestop Tablets</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Metoclopramide hydrochloride 10 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metoclopramide, a dopamine receptor antagonist, acts both centrally and peripherally.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Its antiemetic action is due to a central effect on the chemoreceptor trigger zone-vomiting centre).<span style=\"mso-spacerun: yes;\">&nbsp; </span>Peripherally, Emestop stimulates motility of the upper gastrointestinal tract without affecting gastric, biliary or pancreatic secretions. Experimental evidence has suggested that the effect on motility may be associated with enhanced cholinergic excitatory processes at the postganglionic neuromuscular junction, antagonism of non-adrenergic, non-cholinergic (i.e. dopaminergic) inhibitory nerves and/or a direct effect on smooth muscle.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The post-synaptic activity of Metoclopramide appears to result from its ability to enhance acetylcholine release from post-ganglionic neurons in the gastrointestinal tract, and from its ability to sensitize muscarinic receptors of gastrointestinal smooth muscle to the actions of acetylcholine.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Although the major effects of Metoclopramide appear to be cholinergically based, antagonism of gastrointestinal dopaminergic activity might enhance the cholinergic like activity of the drug.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The effect of Emestop is not dependent on intact vagal innervations, but anticholinergic drugs can abolish it.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metoclopramide increases the tone and amplitude of gastric and especially antral contractions.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It relaxes the pyloric sphincter and the duodenal bulb and increases peristalsis of the duodenum and jejunum, resulting in accelerated gastric emptying and intestinal transit.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Like phenothiazines and related drugs that are dopamine antagonists, Metoclopramide produces sedation and may produce extrapyramidal reactions.<span style=\"mso-spacerun: yes;\">&nbsp; </span>The drug inhibits the central and peripheral effects of apomorphine, induces release of prolactin and causes a transient increase in circulating aldosterone levels.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Emestop also increases the resting tone of the lower esophageal sphincter but has little, if any, effect on the colon or the gall bladder.</span></p>', 'Emestop', NULL, NULL),
(68, 68, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Extrafen is indicated for the reduction of fever in patients\' ages 1 year and older and discomfort due to cold and \"flu</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">,\"</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> and of simple pain and discomfort due to teething, immunizations, and tonsillectomy.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each 5 ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ibuprofen<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>100 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Paracetamol<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>125 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: \'Times New Roman\'; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Paracetamol has analgesic and antipyretic effects. Ibuprofen has analgesic, antipyretic, and anti-inflammatory activities. Ibuprofen inhibits platelet aggregation. </span></p>', 'Extrafen', NULL, NULL),
(69, 69, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Flucan is indicated in the following fungal infections.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><u><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Flucan is indicated in adults for the treatment of:</span></u></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Cryptococcal meningitis</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Coccidioidomycosis</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Invasive candidiasis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Candidal balanitis when local therapy is not appropriate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Dermatomycosis including&nbsp;<em>tinea pedis, tinea corporis, tinea cruris, tinea versicolor</em>&nbsp;and dermal&nbsp;<em>candida</em>&nbsp;infections when systemic therapy is indicated.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull;&nbsp;<em>Tinea unguinium (onychomycosis)</em>&nbsp;when other agents are not considered appropriate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><u><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Flucan is indicated in adults for the prophylaxis of:</span></u></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Relapse of cryptococcal meningitis in patients with high risk of recurrence.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><u><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Flucan is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:</span></u></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Flucan is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Flucan can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Consideration should be given to official guidance on the appropriate use of antifungals.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each capsule contains Fluconazole 150 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Fluconazole 50 mg daily given up to 28 days has been shown not to effect testosterone plasma concentrations in males or steroid concentration in females of child-bearing age. Fluconazole 200 mg to 400 mg daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50 mg do not affect its metabolism.</span></p>', 'Flucan', NULL, NULL),
(70, 70, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Folic Acid 5 mg tablets are indicated for the treatment of megaloblastic anaemia when foliate deficiency is identified as the exclusive cause. Foliate deficiency is a consequence of inadequate dietary intake, malabsorption, or increased utilization in conditions such as pregnancy, lactation, haemolytic anaemia, hyperthyroidism, exfoliative dermatitis, and chronic infection.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Folic Acid 5 mg tablets are also indicated for prophylaxis of foliate deficiency resulting from renal dialysis, pregnancy and lactation when the mother is malnourished, and chronic haemolytic states such as thalassemia major or sickle-cell anaemia. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains folic acid 5 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Folic acid is a member of the vitamin B group and is the substrate for the production of tetrahydrofolate by enzymatic reduction <em>in vivo</em>. Tetrahydrofolate is a coenzyme for various metabolic pathways including purine and pyrimidine nucleotide synthesis, and ultimately DNA synthesis. It is also involved in some amino acid conversions, and in the formation and utilization of formate. It is involved in the maturation of all rapidly proliferating tissues particularly those of bone marrow and gastrointestinal tract. Folic acid deficiency develops from inadequate dietary intake through malnutrition or malabsorption, or may result from increased utilization in pregnancy or conditions such as haemolytic anaemia. Foliate deficiency is also an adverse side effect of chemotherapeutic agents that function as foliate antagonists by interfering with foliate metabolism.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Conclusive evidence that folic acid therapy when taken as a supplement by women during the periconceptional period significantly reduces the incidence of fetal neural tube defects was established by a multinational, multicentre, controlled clinical study organized by the Medical Research Council in the United Kingdom. In the final report of this study published in 1991, investigators concluded that a daily supplement of folic acid would be beneficial to all women planning a pregnancy. </span></p>', 'Folic acid', NULL, NULL),
(71, 71, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Fungitrin ovules are indicated for the local treatment of vulvovaginal candidiasis (moniliasis).<span style=\"mso-spacerun: yes;\">&nbsp; </span>In such cases, the diagnosis should be confirmed by KOH smear and/or cultures.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Other pathogens commonly associated with vulvovaginitis should be ruled out by appropriate laboratory methods.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each Ovules contains Miconazole nitrate 400 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Miconazole combines a potent antifungal activity against common dermatophytes and yeasts with an antibacterial activity against certain Gram-positive bacilli and cocci. Miconazole inhibits the biosynthesis of ergosterol in fungi and changes the composition of other lipid components in the membrane, resulting in fungal cell necrosis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In general, miconazole exerts a very rapid effect on pruritus, a symptom that frequently accompanies dermatophyte and yeast infections.</span></p>', 'Fungitrin Ovules', NULL, NULL),
(72, 72, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gastrex is indicated in:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Short </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">term</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">treatment</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> of active </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">duodenal</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> ulcer. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Maintenance </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">therapy</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> for </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">duodenal</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">ulcer</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> patients at reduced </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">dosage</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> after </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">healing</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> of an active ulcer.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Short </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">term</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">treatment</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> of active </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">benign</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">gastric</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> ulcer. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Short </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">term</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">treatment</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> of </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">gastroesophageal</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">reflux</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">disease</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> (GERD).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">multiple</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">endocrine</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> adenomas).</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains 40 mg of Famotidine.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Famotidine<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>is a competitive </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">inhibitor</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> of </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">histamine</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> H<sub>2</sub>-receptors. The </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">primary</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> clinically important pharmacologic </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">activity</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> of Famotidine is </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">inhibition</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> of </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">gastric</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> secretion. Both the </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">acid</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">concentration</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> and </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">volume</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> of </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">gastric</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">secretion</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> are suppressed by Famotidine , while changes in </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">pepsin</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">secretion</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> are proportional to </span><a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: windowtext; text-decoration: none; text-underline: none;\">volume</span></a><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> output.</span></p>', 'Gastrex', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(73, 73, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Gentacol is indicated for the topical treatment of infections of the external eye and its surroundings caused by Gentamicin-susceptible bacteria, such as conjunctivitis, keratitis and keratoconjunctivitis, corneal ulcers, blepharitis and blepharoconjunctivitis, acute meibomianitis and dacryocystitis.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ml contains: </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Gentamicin (as sulphate)<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>3 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gentacol contains Gentamicin sulfate, a water-soluble antibiotic of the aminoglycoside group, active against a wide variety of pathogenic Gram-negative and Gram-positive bacteria.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Sensitive Gram-positive bacteria include coagulase-positive and coagulase-negative staphylococci (including certain strains that are resistant to penicillin), Group-A </span><span lang=\"EL\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EL;\">&beta;</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">-hemolytic and non-hemolytic streptococci and <em>Diplococcus pneumoniae</em>.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Sensitive Gram-negative bacteria include certain strains of <em>Pseudomonas aeruginosa</em>, indole-positive and indole-negative Proteus species<em>, Escherichia coli, Klebsiella Pneumoniae</em> (Friedlander&rsquo;s bacillus), <em>Haemophilus influenzae and Haemophilus aegyptius</em> (Koch-Weeks bacillus), <em>Aerobacter aerogenes, Moraxella lacunata</em> (Morax-Axenfeld bacillus) and Neisseria species, including <em>Neisseria gonorrhoeae</em>.</span></p>', 'Gentacol', NULL, NULL),
(74, 74, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: justify; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: decimal 9.0pt 30.6pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 8.0pt; mso-bidi-font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black; letter-spacing: -.05pt;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG* who are:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; tab-stops: decimal 9.0pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">-<span style=\"mso-tab-count: 1;\"> </span>at high risk for developing overt type 2 diabetes mellitus and,</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; tab-stops: decimal 9.0pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">-<span style=\"mso-tab-count: 1;\"> </span>not suitable for intensive lifestyle modifications.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; tab-stops: decimal 9.0pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">Treatment with Glucomet XR must be based on a risk score incorporating appropriate measures of glycemic control and including evidence of high cardiovascular risk.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; tab-stops: decimal 9.0pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 9.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: justify; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: decimal 9.0pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 8.0pt; mso-bidi-font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black; letter-spacing: -.05pt;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; tab-stops: decimal 9.0pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">Glucomet XR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 18pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each extended release tablet contains 750 mg metformin hydrochloride.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metformin may act via 3 mechanisms</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">(1)<span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">,</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">(2)<span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">,</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">(3)<span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">and delay of intestinal glucose absorption</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase. Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT)</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In clinical studies use of metformin was associated with either a stable body weight or modest weight loss</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In humans, independently of its action on glycaemia, immediate release metformin has favorable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: immediate release metformin reduces total cholesterol, LDL cholesterol and triglyceride levels</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri;\">.</span><span lang=\"AR-SA\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">A similar action has not been demonstrated with the extended release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.</span></p>', 'Glucomet xr 750', NULL, NULL),
(75, 75, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Glucomet is indicated in diet-failed, noninsulin dependent diabetic patients, especially if overweight, either alone as initial therapy or in combination with a sulfonylurea.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Occasionally, as adjuvant therapy in insulin-dependent diabetic patients who are usually obese and not well controlled with insulin.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each coated tablet contains Metformin hydrochloride 850 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metformin is an oral biguanide hypoglycemic agent. It causes an increased peripheral uptake of glucose by increasing the biological efficiency of available exogenous or endogenous insulin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The mode of action of metformin may be linked to an increase of insulin sensitivity. It does not stimulate insulin release but does require the presence of insulin to exert its hypoglycemic effect. Possible mechanisms of action include inhibition of gluconeogenesis in the liver, delay in glucose absorption from the gastrointestinal tract and an increase in peripheral uptake of glucose.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metformin has an antiketogenic activity that is comparable, though inferior, to insulin itself.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metformin lowers both basal and post-prandial blood glucose in diabetic patients but does not cause hypoglycemia in either diabetics or normal individuals.</span></p>', 'Glucomet', NULL, NULL),
(76, 76, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prevention of the onset of lactation in the puerperium only for clearly defined medical reasons</span></em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Goline is indicated for the inhibition of physiological lactation soon after delivery.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">After parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">After stillbirth or abortion. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cabergoline 0.5 mg tablet</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Mechanism of Action</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Goline is a dopaminergic ergoline derivative with potent and long-lasting Prolactin-lowering activity. It acts by direct stimulation of the D2-dopamine receptors on pituitary lactotrophs, thus inhibiting Prolactin secretion. In addition Goline exerts a central dopaminergic effect via D2 receptor stimulation at oral doses higher than those effective in lowering serum Prolactin levels. The long-lasting Prolactin-lowering effect of Cabergoline is probably due to its long persistence in the target organ (t&frac12; of approximately 60 hours).</span></p>', 'GOLINE 0.5', NULL, NULL),
(77, 77, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Treatment of acute gout</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&bull; Prophylaxis of gout attack during initiation of therapy with allopurinol and uricosuric drugs </span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Colchicine 0.5mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Colchicine&rsquo;s effectiveness as a treatment for gout has been postulated to be due to its ability to block neutrophil-mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of &beta;-tubulin into microtubules, thereby preventing the activation, degranulation, and migration of neutrophils to sites of inflammation. Colchicine also interferes with the inflammasome complex found in neutrophils and monocytes that mediates interleukin-1&beta; (IL-1&beta;) activation.</span></p>', 'GOUTEX', NULL, NULL),
(78, 78, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hydrocortisone tablets are indicated in the following conditions:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Endocrine Disorders</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Congenital adrenal hyperplasia.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Nonsuppurative thyroiditis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hypercalcemia associated with cancer.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains 10 mg hydrocortisone.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. It exhibits anti-inflammatory and immunosuppressant properties inhibiting the clinical manifestations of disease in a wide range of disorders.</span></p>', 'Hydrocortisone', NULL, NULL),
(79, 79, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Psychiatry</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Psychoses of schizophrenia, of both organic and confusional origin.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Pre-psychotic states. Schizophrenic states with symptoms of apathy and apragmatism.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">In cases of delusional and hallucinatory states and in cases of non-acute agitation, Hypothal should be combined with a sedative neuroleptic (e.g. levopromazine).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Acute confusional states, phobias.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Depressive states of various origins, including geriatric cases.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Neurosis with psychomotor inhibition.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Childhood psychoses and pre-psychotic states.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Autistic behavioural disturbances.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each capsule contains Sulpride 50 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Sulpride is a substituted benzamide, unrelated chemically to other dopamine receptor antagonists of the phenothiazine, butyrophenone or thioxanthene groups.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Sulpride demonstrates pronounced antipsychotic activity as well as peripheral activity on the gastrointestinal system.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">An antipsychotic agent, it shares some common properties with the \"classical\" neuroleptics (e.g. haloperidol, chlorpromazine).<span style=\"mso-spacerun: yes;\">&nbsp; </span>However, as shown in biochemical and behavioural laboratory studies, it also differs from them in several fundamental respects, especially based on its selectivity for dopamine receptors and relatively limited interference with other neuronal pathways.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Sulpride is effective clinically in most forms of depression, especially in the true psychoses.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It also has an important thymo-analeptic component.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is of value in the treatment of autism, phobic conditions and vertigo of various types.<span style=\"mso-spacerun: yes;\">&nbsp; </span>The effect on vertigo is due to its selective tropism in the central nervous system, and its involvement in the vestibular area.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Sulpride stimulates gastrointestinal motility, but this effect is less pronounced than that of metoclopramide.<span style=\"mso-spacerun: yes;\">&nbsp; </span>There is no clear indication that peripheral or central dopamine receptors, or both, are involved in the gastrointestinal effects of Sulpride.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Anti-ulcer activity has been observed in a variety of experimental models.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Sulpride is used successfully clinically in the treatment of stress ulcers and produces favourable effects in the healing of peptic ulcers, mainly by improving functional disturbances of the gastrointestinal tract and, hence, relieving pain.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It also has antiemetic properties and inhibits gastric secretion.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">The average serum half-life of Sulpride is 8 hours.<span style=\"mso-spacerun: yes;\">&nbsp; </span>About 70% of the dose is recovered in the urine within 36 hours.</span></p>', 'Hypothal', NULL, NULL),
(80, 80, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">I.O.P plus is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"FR\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Composition</span></strong></span><strong><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Dorzolamide (As Hydrochloride) <span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp; </span><span style=\"mso-spacerun: yes;\">&nbsp;</span>2%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Timolol maleate<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-spacerun: yes;\">&nbsp;</span>0.5%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">I.O.P plus is comprised of two components: Dorzolamide hydrochloride and Timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Timolol maleate is a beta 2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. The combined effect of these two agents administered as I.O.P plus b.i.d. results in additional intraocular pressure reduction compared to either component administered alone, but the reduction is not as much as when Dorzolamide t.i.d. and Timolol b.i.d. are administered concomitantly</span></p>', 'I.O.P PLUS', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(81, 81, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"FR\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Composition</span></strong></span><strong><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Dorzolamide (As Hydrochloride) <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>2%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II) found primarily in red blood cells (RBCs) but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion. The result is a reduction in intraocular pressure (IOP).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">I.O.P Ophthalmic Solution contains dorzolamide hydrochloride, a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, I.O.P reduces elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Unlike miotics, I.O.P reduces intraocular pressure without the common adverse effects of miotics such as night blindness, accommodative spasm, and pupillary constriction. Unlike topical beta-blockers, I.O.P has minimal or no effect on pulse rate or blood pressure.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Topically applied beta-adrenergic blocking agents also reduce IOP by decreasing aqueous humor secretion but by a different mechanism of action. Studies have shown that when </span><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Dorzolamide</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> added to a topical beta-blocker, additional reduction in IOP observed; this finding is consistent with the reported additive effects of beta-blockers and oral carbonic anhydrase inhibitors.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">I.O.P is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.</span></p>', 'I.O.P', NULL, NULL),
(82, 82, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indolin has been found to be effective in active stages of the following:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">moderate to severe rheumatoid arthritis, including acute flares of chronic disease</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">moderate to severe ankylosing spondylitis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">moderate to severe osteoarthritis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">acute musculoskeletal disorders such as bursitis, tendinitis, synovitis, tenosynovitis, and in low back pain</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">acute gouty arthritis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">pain and associated symptoms of primary dysmenorrhea.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indolin Suppositories</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each suppository contains Indomethacin 100 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indomethacin has anti-inflammatory and analgesic-antipyretic properties. The anti-inflammatory effects of indomethacin are evident in patients with rheumatoid and other types of arthritis and in acute gout. Although indomethacin is more potent than aspirin, the anti-inflammatory effects of tolerated doses of indomethacin in rheumatoid arthritis are not superior to those of salicylate. Whether indomethacin has analgesic properties distinct from its anti-inflammatory effects remains uncertain. However, in patients with acute post-operative and post-traumatic pain of mild to moderate intensity, single doses of indomethacin provide relief approximately equivalent to that of 600 mg of aspirin. The antipyretic effect of indomethacin has also been readily demonstrated in patients with fever. Single doses of indomethacin are usually adequately tolerated; however, because of its potential toxicity, indomethacin is not recommended as a general analgesic-antipyretic.<br style=\"mso-special-character: line-break;\"><!-- [if !supportLineBreakNewLine]--><!--[endif]--></span></p>\r\n<p><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: \'Times New Roman\'; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Like the salicylates and related anti-inflammatory agents, indomethacin inhibits the biosynthesis of prostaglandins; this action may be the basis of its anti-inflammatory and antipyretic properties and certain of its other effects. Like colchicine, it inhibits motility of polymorphonuclear leucocytes; like salicylate, it uncouples oxidative phosphorylation in cartilaginous and hepatic mitochondria.</span></p>', 'Indolin', NULL, NULL),
(83, 83, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">INFLICTA (Dapagliflozin) is indicated:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes</span></p>\r\n<p class=\"MsoListParagraph\" style=\"mso-add-space: auto; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 14pt; font-family: Calibri, sans-serif; color: black;\">Limitations of Use</span></strong></p>\r\n<p class=\"MsoListParagraphCxSpFirst\" style=\"mso-add-space: auto; text-align: justify; text-indent: -.25in; mso-list: l1 level1 lfo2; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">INFLICTA is not recommended for patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: justify; text-indent: -.25in; mso-list: l1 level1 lfo2; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">INFLICTA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m2. INFLICTA is likely to be ineffective in this setting based upon its mechanism of action.</span></p>\r\n<p class=\"MsoListParagraphCxSpLast\" style=\"mso-add-space: auto; text-align: justify; text-indent: -.25in; mso-list: l1 level1 lfo2; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt 21.3pt;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black;\">INFLICTA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. INFLICTA is not expected to be effective in these populations.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each extended release tablet contains 10 mg Dapagliflozin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, Dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity, and decreased intraglomerular pressure which is believed to be mediated by increased tubuloglomerular feedback.</span></p>', 'INFLICTA 10', NULL, NULL),
(84, 84, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></p>\r\n<p style=\"margin: 0in;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Ipravent is indicated for the treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD). </span></p>\r\n<p style=\"margin: 0in;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">&nbsp;</span></p>\r\n<p style=\"margin: 0in;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Ipravent is indicated, when used concomitantly with inhaled beta<sub>2</sub>-agonists, for treatment of reversible airways obstruction as in acute and chronic asthma.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each ml of Ipravent Solution for inhalation contains </span><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Ipratropium Bromide 250 micrograms.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Ipratropium bromide is a quaternary ammonium compound with anticholinergic (parasympatholytic) properties. In nonclinical studies, it appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve.&nbsp;</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Anticholinergics prevent the increase in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. Ca++ release is mediated by the second messenger system consisting of IP3 (inositol triphosphate) and DAG (diacylglycerol).</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">The bronchodilation following inhalation of ipratropium bromide is induced by local drug concentrations sufficient for anticholinergic efficacy at the bronchial smooth muscle and not by systemic drug concentrations.</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">In clinical trials using metered dose inhalers in patients with reversible bronchospasm associated with chronic obstructive pulmonary disease significant improvements in pulmonary function (FEV1 increases of 15% or more) occurred within 15 minutes, reached a peak in 1-2 hours, and persisted for approximately 4 hours.</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Preclinical and clinical evidence suggest no deleterious effect of ipratropium bromide on airway mucous secretion, mucociliary clearance or gas exchange.</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">The bronchodilator effect of ipratropium bromide in the treatment of acute bronchospasm associated with asthma has been shown in studies in adults and children &ge; 6 years of age. In most of these studies&rsquo; ipratropium bromide was administered in combination with an inhaled beta2-agonist.</span></p>', 'Ipravent', NULL, NULL),
(85, 85, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Itranox capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l1 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Blastomycosis, pulmonary and extrapulmonary;</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l1 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis; and</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l1 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Itranox capsules are also indicated for the treatment of the following fungal infections in non- immunocompromised patients:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo2; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Onychomycosis of the toenail with or without fingernail involvement due to dermatophytes (tinea unguium).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo2; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Onychomycosis of the fingernail due to dermatophytes (tinea unguium)</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo2; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"FR\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Each capsule contains&nbsp;:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Itraconazole<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>100 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"FR\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Itraconazole is a synthetic triazole derivative. When administered orally, it has shown fungistatic activity against superficial dermatophytes and <em>Candida</em> species including <em>C. albicans and C. glabrata.</em></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Itraconazole has shown antifungal activity against a variety of fungi and yeasts. This spectrum includes superficial dermatophytes (<em>Trichophyton </em>spp., <em>Microsporum</em>spp., <em>Epidermophyton floccosum</em>), yeasts (<em>Cryptococcus neoformans, Pityrosporum</em>spp., <em>Candida</em> spp. including <em>C. albicans</em>, <em>C. glabrata</em> and <em>C. krusei</em>), <em>Aspergillus</em> spp., <em>Histoplasma</em> spp., <em>Paracoccidioides brasiliensis, Sporothrix schenckii</em>, <em>Fonsecaea</em> spp., <em>Cladosporium</em> spp., <em>Blastomyces dermatitidis</em>.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In vitro</span></em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.</span></p>', 'Itranox', NULL, NULL),
(86, 86, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">IXABAN is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">IXABAN is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with at least one additional risk factor for stroke.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">IXABAN is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">IXABAN is indicated for the prevention of recurrent DVT and PE in adult patients.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Each tablet contains :<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Apixaban 2.5 or 5 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pharmacodynamics</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The pharmacodynamic effects of APIXABAN are reflective of the mechanism of action (FXa inhibition). As a result of FXa inhibition, APIXABAN prolongs clotting tests such as prothrombin time (PT), INR and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability. They are not recommended to assess the pharmacodynamic effects of APIXABAN. In the thrombin generation assay, APIXABAN reduced endogenous thrombin potential, a measure of thrombin generation in human plasma.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">APIXABAN also demonstrates anti-FXa activity as evident by reduction in FXa enzyme activity in the Rotachrom<sup>&reg;</sup> Heparin chromogenic assay data from clinical studies. Anti-FXa activity exhibits a close direct linear relationship with APIXABAN plasma concentration, reaching maximum values at the time of APIXABAN peak plasma concentrations. The relationship between APIXABAN plasma concentration and anti-FXa activity is linear over a wide dose range of APIXABAN. The dose- and concentration-related changes observed following APIXABAN administration are more pronounced, and less variable, with anti-FXa activity compared with clotting tests.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The table<span style=\"mso-spacerun: yes;\">&nbsp; </span>below shows the predicted steady state exposure and anti-Factor Xa activity for each indication. In patients taking APIXABAN for the prevention of VTE following hip or knee replacement surgery, the results demonstrate a less than 1.6-fold fluctuation in peak-to-trough levels. In nonvalvular atrial fibrillation patients taking APIXABAN for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels. In patients taking APIXABAN for the treatment of VTE or prevention of recurrence of VTE, the results demonstrate a less than 2.2-fold fluctuation in peak-to-trough levels.</span></p>', 'IXABAN', NULL, NULL),
(88, 88, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: Arial;\">As a lubricant and artificial tear in dry eye and other ocular irritation syndromes associated with deficient tear or mucous secretion.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each ml contains<span style=\"mso-tab-count: 1;\"> </span></span><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Hypromellose</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> 0.3%.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: Arial;\">Hypromellose in an aqueous presentation provides a soothing lubricant preparation for the relief of dry eye syndrome associated with deficient tear secretion or deficient mucous.</span></p>', 'Izilack eye drops', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(89, 89, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Onychomycosis (fungal infection of the nail) caused by dermatophyte fungi.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Tinea capitis </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Fungal infections of the skin for the treatment of tinea corporis, tinea cruris, tinea pedis and yeast infections of the skin caused by the genus candida (e.g. <em>Candida albicans</em>) where oral therapy is generally considered appropriate owing to the site, severity or extent of the infection</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablets contains Terbinafine (as hydrochloride) <a name=\"17|0212ca|0000\"></a>250 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Terbinafine hydrochloride is a synthetic allylamine derivative. Terbinafine hydrochloride exerts its antifungal effect by inhibiting squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This action results in a deficiency in ergosterol and a corresponding accumulation of sterol within the fungal cell. Depending on the concentration of the drug and the fungal species tested <em>in vitro</em>, Terbinafine hydrochloride may be fungicidal; however, the clinical significance of these data is unknown. <em>In vitro</em>, mammalian squalene epoxidase is only inhibited at higher (4,000 fold) concentrations.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Terbinafine has been shown to be active against most strains of the following organisms both <em>in vitro</em> and in clinical infections of the nail. <em>Trichophyton rubrum, Trichophyton mentagrophytes</em></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Blood and tissue levels of Terbinafine following oral dosing with Terbinafine hydrochloride 250 mg QD exceed <em>in vitro</em> MICs against most strains of the following organisms that can infect the nail; however, the efficacy of Terbinafine in treating nail infections due to these organisms has not been studied in controlled clinical trials.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Epidermophyton floccosum, Microsporum gypseum, Microsporum nanum, </span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Trichophyton verrucosum, Candida albicans, Scopulariopsis brevicaulis</span></em></p>', 'lamirase Tablet', NULL, NULL),
(90, 90, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lipidex is indicated as an adjunct to diet for reduction of elevated total-cholesterol, LDL-cholesterol, apolipoprotein-B, and triglyceride levels in patients with primary hypercholesterolaemia; mixed dyslipidaemia; and heterozygous familial hypercholesterolaemia.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lipidex is also indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Therapy with lipid-lowering agents should be a component of multiple-risk-factor intervention in individuals at increased risk of atherosclerotic vascular disease due to hypercholesterolaemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other non-pharmacological measures has been inadequate.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prior to initiating therapy with Lipidex, secondary causes for hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be excluded, and a lipid profile performed to measure total-C, LDL-C, HDL-C, and TG.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lipidex 20 mg</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains 20 mg Atorvastatin (as calcium).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lipidex 40 mg</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains 40 mg Atorvastatin (as calcium).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.<br>The liver is its primary site of action and the principal site of cholesterol synthesis and low-density lipoprotein cholesterol (LDL-C) clearance.&nbsp;</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In animal models, Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of LDL-C receptors on the cell-surface of liver cells, providing for enhanced uptake and catabolism of LDL-C. Atorvastatin reduces LDL-C production and the number of LDL-C particles. Depending on dose, Atorvastatin reduces the number of apolipoprotein-B-containing particles in patients with hypercholesterolaemia. Atorvastatin produces a profound and sustained increase in LDL-C receptor activity coupled with a change in the quality of circulating LDL-C particles.&nbsp;</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: \'Times New Roman\'; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Atorvastatin reduces total cholesterol (total-C), LDL-C, apolipoprotein-B in normal volunteers, and in patients with heterozygous familial hypercholesterolaemia, non-familial hypercholesterolaemia, mixed dyslipidaemia, and in some patients with homozygous familial hypercholesterolaemia. It also reduces serum triglycerides (TG) and produces variable increases in high-density lipoprotein cholesterol (HDL-C) and apolipoprotein-A-1 in non-familial hypercholesterolaemia and mixed dyslipidaemias.</span></p>', 'lipidex', NULL, NULL),
(91, 91, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hypertension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lozar is indicated for the treatment of hypertension.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Reduction in the Risk of Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lozar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Heart Failure</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lozar is indicated for the treatment of heart failure in patients who cannot tolerate an ACE inhibitor. Switching patients with heart failure who are stable on an ACE inhibitor to Lozar is not recommended.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Renal Protection in Type 2 Diabetic Patients with Proteinuria</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lozar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Losartan potassium 50 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor. The primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<sub>1</sub> receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT<sub>2</sub> receptor found in many tissues but it unknown to be associated with cardiovascular homeostatis. Both Losartan and its principal active metabolite do not exhibit any partial agonist activity at the AT<sub>1</sub> receptor and have much greater affinity (about 1000-fold) for the AT<sub>1</sub> receptor than for the AT 2 receptor.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In vitro binding studies indicate that Losartan is a reversible, competitive inhibitor of the AT 1 receptor. The active metabolite is 10 to 40 times more potent by weight than Losartan and appears to be a reversible, non-competitive inhibitor of the AT<sub>1</sub> receptor. Neither Losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin); nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. </span></p>', 'lozar', NULL, NULL),
(92, 92, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lucast is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short acting &beta;-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Lucast is indicated in asthma, Lucast can also provide symptomatic relief of seasonal allergic rhinitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lucast is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lucast 10 mg Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Montelukast (as sodium salt) 10 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The cysteinyl leukotrienes (LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>), are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT<sub>1</sub>) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include a number of airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis. Intranasal challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of nasal obstruction.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Montelukast is a potent, orally active compound that significantly improves parameters of asthmatic inflammation. Based on biochemical and pharmacological bioassays, it binds with high affinity and selectivity to the CysLT<sub>1</sub> receptor (in preference to other pharmacologically important airway receptors such as the prostanoid, cholinergic, or &beta;-adrenergic receptor). Montelukast potently inhibits physiologic actions of LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4 </sub>at the CysLT<sub>1</sub> receptor without any agonist activity. </span></p>', 'lucast', NULL, NULL),
(93, 93, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Amenorrhea (primary and secondary).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Functional uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Production of secretory endometrium and desquamation. Adenocarcinoma of uterine corpus in advanced stage (stage III or IV).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Test for endogenous estrogen production.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Luterone 250 Depot</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 1 ml contains Hydroxyprogesterone caproate 250 mg in a sterile oily solution.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Luterone 500 Depot</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 2 ml contains Hydroxyprogesterone caproate 500 mg in a sterile oily solution.<span style=\"mso-tab-count: 1;\"> &nbsp;&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">A long-acting progestin, Luterone Depot has duration of action lasting 9-17 days. Luterone Depot prevents follicular maturation and ovulation by inhibiting the secretion of pituitary gonadotropins. Luterone Depot transforms proliferative endometrium into secretory endometrium. Luterone Depot inhibits spontaneous uterine contraction.</span></p>', 'luterone', NULL, NULL),
(94, 94, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Treatment of urinary tract infections such as pyelonephritis, pyelitis and cystitis, when due to susceptible organisms: <em>Escherichia coli</em>, enterococci, Streptococcus pyogenes, <em>Staphylococcus aureus</em> and certain strains of <em>Klebsiella</em>, <em>Aerobacter </em>and <em>Proteus</em>.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each capsule contains Nitrofurantoin 100 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Nitrofurantoin is bactericidal in urine at therapeutic doses. The mechanism of the antimicrobial action of Nitrofurantoin is unusual among antibacterials. Nitrofurantoin reduced by bacterial flavoproteins to reactive intermediates that inactivate or alter bacterial ribosomal proteins and other macromolecules. Because of such inactivation, the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited. The broad-based nature of this mode of action may explain the lack of acquired bacterial resistance to Nitrofurantoin, as the necessary multiple and simultaneous mutations of the target macromolecules would likely be lethal to the bacteria. Development of resistance to Nitrofurantoin has not been a significant problem since its introduction. Cross-resistance with antibiotics and sulfonamides not been observed, and transferable resistance is, at most, a very rare phenomenon.</span></p>', 'MACROFURAN', NULL, NULL),
(95, 95, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Medihist indicated for the treatment of mycotic infections of the skin complicated by inflammation and/or secondary infection. After the inflammation stage has subsided, treatment may be continued with a preparation containing an antimycotic agent alone, such as plain Clotrimazole (Candizone), without the added corticosteroid or antibiotic component.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each 100 gm contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Clotrimazole <span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1 gm</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Dexamethasone acetate <span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>44 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Neomycin sulphate<span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>645 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Medihist combines the antimycotic/antibacterial activity of Clotrimazole with the anti-inflammatory, anti-allergic and antipruritic effect of Dexamethasone, and the antibacterial activity of neomycin in a well-tolerated cream base.</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> Clotrimazole is a broad-spectrum antimycotic agent exerting fungicidal activity against dermatophytes such as Trichophyton, Microsporum and Epidermophyton species, against yeasts such as Candida species, against molds and other fungi, as well as against some Gram-positive bacteria such as streptococci and staphylococci.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Neomycin acts against both Gram-positive and a broad spectrum of Gram-negative bacteria such <em>as Escherichia coli, Proteus, Pseudomonas</em> and others, and is considered a classic anti-infective component in dermatological preparations.</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Medihist is particularly useful when a mixed fungal and/ or bacterial skin infection accompanied by local <strong>inflammation.</strong></span></p>', 'Medihist', NULL, NULL),
(96, 96, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Mepral indicated for the treatment of:</span></p>\r\n<p class=\"MsoListParagraphCxSpFirst\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of duodenal ulcers</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prevention of relapse of duodenal ulcers</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of gastric ulcers</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prevention of relapse of gastric ulcers</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In combination with appropriate antibiotics,&nbsp;<em>Helicobacter pylori (H. pylori)</em>&nbsp;eradication in peptic ulcer disease</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of NSAID-associated gastric and duodenal ulcers</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of reflux oesophagitis</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Long-term management of patients with healed reflux oesophagitis</span></p>\r\n<p class=\"MsoListParagraphCxSpMiddle\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of symptomatic gastro-oesophageal reflux disease</span></p>\r\n<p class=\"MsoListParagraphCxSpLast\" style=\"mso-add-space: auto; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed; margin: 0in 0in .0001pt .25in;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-fareast-font-family: Calibri;\"><span style=\"mso-list: Ignore;\">&bull;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of Zollinger-Ellison syndrome</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each capsule<strong> </strong>contains Omeprazole 20 mg in enteric coated granule form.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Omeprazole reduces gastric acid secretion through a highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapid acting and provides control through reversible inhibition of gastric acid secretion with once daily dosing.</span></p>', 'Mepral', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(97, 97, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Trichomoniasis</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Symptomatic Trichomoniasis</span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metrozole is indicated for the treatment of symptomatic trichomoniasis in women and men, when the presence of the trichomonad has been confirmed by appropriate laboratory procedures.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Asymptomatic Trichomoniasis</span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metrozole is indicated in the treatment of asymptomatic women, when the organism is associated with endocervicitis, cervicitis or cervical erosion.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Asymptomatic Consorts</span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Trichomoniasis vaginalis infection is a venereal disease.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner.<span style=\"mso-spacerun: yes;\">&nbsp; </span>During the treatment, it is recommended that the patient refrain from sexual intercourse, or the male partner use a condom to avoid reinfection.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amebiasis</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metrozole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong><span style=\"font-family: Calibri, sans-serif;\">&nbsp;</span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metrozole Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each teaspoonful (5 ml) contains Metronidazole (as benzoyl) 125 mg&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metrozole 250 Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Metronidazole 250 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metrozole 500 Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Metronidazole 500 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metronidaole is an antiprotozoal agent; anaerobic antibacterial agent.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metrozole is active against a wide range of pathogenic microorganisms notably species of <em>Bacteroides, Fusobacteria, Clostridia, Eubacteria, anaerobic cocci</em> and <em>Gardnerella vaginalis. </em>It is also active against <em>Trichomonas, Entamoeba histolytica, Giardia lamblia</em> and <em>Balantidium coli</em>.<br>It is suggested that unchanged metronidazole penetrates the protozoan cell, where the nitro group is reduced to a hydroxyl or amine group that reacts with DNA and stops nucleic acid synthesis.</span></p>', 'Metrozole', NULL, NULL),
(98, 98, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Sulindac is a non-steroidal anti-inflammatory drug with analgesic and antipyretic activity and is indicated in rheumatoid arthritis, osteoarthritis, acute gouty arthritis, ankylosing spondylitis and musculoskeletal and periarticular disorders such as tendinitis, tenosynovitis and bursitis.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Sulindac 200 mg.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong><strong><span lang=\"EN-GB\" style=\"font-family: Calibri, sans-serif;\"><span style=\"mso-tab-count: 1;\">&nbsp; </span></span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Sulindac is a non-steroidal, antirheumatic agent possessing anti-inflammatory, analgesic, and anti-pyretic properties.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prostaglandin synthetase inhibition has been hypothesized to be the basis of the mechanism of action of non-steroidal anti-inflammatory agents. Following absorption, sulindac undergoes two major biotransformation: reversible reduction to the sulfide metabolite, and irreversible oxidation to the inactive sulfone metabolite. The sulfide metabolite is a potent inhibitor of prostaglandin synthesis, and available evidence indicates that the biological activity of sulindac resides with the sulfide metabolite. Thus, the sulfoxide form (sulindac) is a prodrug.</span></p>', 'Mobicol', NULL, NULL),
(99, 99, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Control of hypersecretion, hypermotility and emotional factors associated with gastrointestinal disorders due to anxiety and tension states.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Clinidium bromide<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>2.5 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chlordiazepoxide<span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>5 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Modex combines the anticholinergic action of Clinidium bromide with the anxiolytic effect of Chlordiazepoxide.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Chlordiazepoxide has anxiolytic and central muscle relaxant properties. It has little autonomic activity.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Chlordiazepoxide acts as depressant of the central nervous system producing all levels of CNS depression, from mild sedation to hypnosis, to coma depending on the dose. The precise sites and mechanisms of action have not been fully established but various mechanisms have been proposed. It is believed that chlordiazepoxide enhances or facilitates the inhibitory neurotransmitter action of gama-aminobutyric acid (GABA) which mediates both pre- and post synaptic inhibition in all regions of the CNS following interaction between chlordiazepoxide and a specific neuronal membrane receptor. Anti-anxiety action of chlordiazepoxide is believed to result from stimulation of GABA receptors in the ascending reticular activating system, since GABA in inhibitory receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brainstem reticular formation.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The exact mechanism of action of chlordiazepoxide is not fully established. Skeletal muscle relaxation primarily occurs by inhibiting spinal polysynaptic afferent pathways but it may also inhibit monosynaptic afferent pathways.</span></p>', 'Modex', NULL, NULL),
(100, 100, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">For the symptomatic treatment of irritable bowel syndrome and other conditions usually included in this grouping, such as: chronic irritable colon, spastic constipation, mucous colitis, spastic colitis.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Modulon is effectively used to treat the symptoms of these conditions, such as: colicky abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each coated tablet contains Mebeverine hydrochloride 135 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Mebeverine is a musculotropic antispasmodic that acts directly on the smooth muscle of the gastrointestinal tract, relieving spasm without affecting normal gut motility.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Since this action is not mediated by the autonomic nervous system, anticholinergic side effects are absent.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Modulon is suitable for patients with prostatic hypertrophy and glaucoma.</span></p>', 'Modulon', NULL, NULL),
(101, 101, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Naprex is indicated for the treatment of:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rheumatoid arthritis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Osteoarthritis (degenerative arthritis).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ankylosing spondylitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Juvenile rheumatoid arthritis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Acute gout.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Acute musculoskeletal disorders.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -.25in; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dysmenorrhoea.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Naprex 250 Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Naproxen 250 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Naprex 500 Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Naproxen 500 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Naproxen is a phenylpropionic acid derivative having analgesic, anti-inflammatory, and antipyretic activity. Such activity is thought to be mediated via inhibition of the enzyme complex prostaglandin synthetase with consequent reduction in the synthesis of prostaglandins from arachidonic acid.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Naproxen also inhibits platelet aggregation by inhibition of platelet thromboxane A2. The onset of action of naproxen may be 2 or more hours after oral administration with therapeutic effects persisting for up to 7-8 hours.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Naproxen is capable of providing benefit to patients suffering from: rheumatoid arthritis, osteoarthritis, juvenile arthritis, ankylosing spondylitis, tendonitis and bursitis and acute gout. It is comparable to aspirin and indomethacin in controlling disease activity with less frequent and milder side effects. Clinical improvement induced by naproxen is not dependent on age, sex, severity, or duration of disease.</span></p>', 'Naprex', NULL, NULL),
(102, 102, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Relief of mild to moderate pain, and for the treatment of primary dysmenorrhea.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Treatment of the signs and symptoms of mild to moderately severe acute musculoskeletal and soft tissue inflammation, such as bursitis, tendinitis, synovitis, tenosynovitis and lumbago.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Naproxen sodium 275 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Naproxen sodium, the active principle of Naproxan, has been developed as an analgesic because it is more rapidly absorbed than Naproxen.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Naproxen is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties.<span style=\"mso-spacerun: yes;\">&nbsp; </span>The Naproxen anion inhibits prostaglandin synthesis, but beyond this, its mode of action is unknown.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">By virtue of its prostaglandin synthetase inhibitory activity, Naproxen has proved valuable in markedly decreasing uterine contractility in primary dysmenorrhea, thus offering relief from the associated pain and discomfort.</span></p>', 'Naproxan', NULL, NULL),
(103, 103, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indication</span></strong></span></p>\r\n<p style=\"margin: 0in;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Symptomatic treatment of nasal congestion and rhinorrhea in connection with common colds.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p style=\"margin: 0in;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Each 1ml contains 0.5mg Xylometazoline hydrochloride and 0.6mg ipratropium bromide.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action </span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Mechanism of Action</span></strong></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Xylometazoline hydrochloride is a sympathomimetic which act on &alpha;-adrenergic receptors. </span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Xylometazoline has a vasoconstrictive effect. An effect is obtained after 5-10 minutes and lasts for 6-8 hours. Ipratropium bromide is a quaternary ammonium combination with anticholinergic effect. Nasal administration reduces the nasal secretion through competitive inhibition of cholinergic receptors situated around the nasal epithelium. An effect is usually obtained within 15 minutes and lasts for 6 hours on an average.</span></p>', 'Nirvin Complete', NULL, NULL),
(104, 104, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indication</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment Of Allergic Rhinitis</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">NOSATREX<sup>&reg;</sup> Nasal Spray indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment Of Nasal Congestion Associated With Seasonal Allergic Rhinitis</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">NOSATREX Nasal Spray is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prophylaxis Of Seasonal Allergic Rhinitis</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">NOSATREX Nasal Spray is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment Of Nasal Polyps</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">NOSATREX Nasal Spray is indicated for the treatment of nasal polyps in patients 18 years of age and older.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Mometasone Furoate 0.05% w/w&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action </span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Mechanism of Action</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Mometasone Nasal Spray 50 mcg is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In two clinical studies utilizing nasal antigen challenge, Mometasone Nasal Spray, 50 mcg decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The effect of Mometasone Nasal Spray, 50 mcg on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).</span></p>', 'Nosatrex', NULL, NULL),
(105, 105, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Mixed vaginal infection due to <em style=\"mso-bidi-font-style: normal;\">Trichomonas vaginalis </em>and <em style=\"mso-bidi-font-style: normal;\">Candida albicans.</em></span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each Ovules contains </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">500 mg Metronidazole and 100,000 IU Nystatin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metronidazole is bactericidal against anaerobic bacteria; it exerts trichomonacidal activity and is also active against <em style=\"mso-bidi-font-style: normal;\">Giardia lamblia </em>and <em style=\"mso-bidi-font-style: normal;\">Entamoeba histolytica</em>. Its exact mechanism of action has not been entirely determined as yet. It has been proposed that an intermediate in the reduction of Metronidazole, produced only in anaerobic bacteria and protozoa is bound to deoxyribonucleic acid and electron-transport proteins, inhibits subsequent nucleic acid synthesis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">At present, the mechanism by which topical Metronidazole reduces the lesions and erythema associated with acne rosacea is not precisely known. Despite the established antimicrobial effects of Metronidazole, there is no evidence that the suppression of bacteria or parasitic mites harbored in the skin is directly responsible for its beneficial effects in rosacea. <em style=\"mso-bidi-font-style: normal;\">In vitro </em>and <em style=\"mso-bidi-font-style: normal;\">in vivo </em>studies indicate that Metronidazole has direct antiinflammatory activity and affects neutrophil</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">chemotaxis and cell-mediated immunity. An antioxidant action via inhibition of</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">neutrophil-generated reactive oxygen species has also been demonstrated; this action is believed to underlie its antiinflammatory effect. It has been proposed that the reduction in rosacea lesions and erythema is the result of antiinflammatory or immunosuppressive actions of Metronidazole.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Nystatin is an antifungal antibiotic, produced by a strain of <em style=\"mso-bidi-font-style: normal;\">Streptomyces noursei</em>, active against yeasts and yeast like fungi, including Candida albicans. The antifungal activity is probably due to the binding of sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin has no appreciable activity against bacteria.</span></p>', 'Nystazole Vaginal Ovules', NULL, NULL),
(106, 106, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ocutacin (Tobramycin) Eye Drops is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of Tobramycin.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Tobramycin 0.3% (3 mg)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Tobramycin is a potent, broad-spectrum, rapidly bactericidal aminoglycoside antibiotic. It exerts its primary effect on bacterial cells by inhibiting polypeptide assembly and synthesis on the ribosome. Tobramycin in this combination provides antibacterial protection against susceptible bacteria.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The following MIC breakpoints, separating susceptible from intermediate susceptible organisms, and intermediate susceptible from resistant organisms, are suggested: S (<u>&lt;</u> 4 &mu;g/ml, R (<u>&gt;</u> 8 &mu;g/ml). The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. The following information gives only an approximate guidance on probabilities whether bacteria will be susceptible to Tobramycin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The breakpoint definitions classifying isolates as susceptible or resistant are useful in predicting clinical efficacy of antibiotics that are administered systemically. However, when the antibiotic is administered in very high concentrations topically directly on the site of infection, these breakpoint definitions may not be applicable. Most isolates that would be classified as resistant by systemic breakpoints are indeed successfully treated topically.</span></p>', 'Ocutacin eye drops', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(107, 107, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Ogmin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: justify; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Lower Respiratory</span></em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> Infections-caused by B-lactamase producing strains of <em>Homophiles influenza </em>and <em>Branhamella catarrhalis</em>.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: justify; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB; mso-bidi-font-style: italic;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Otitis Media</span></em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">-caused by &szlig;-lactamase-producing strains of <em>Homophiles influenza</em> and <em>Branhamella catarrhalis.</em></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: justify; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Sinusitis-</span></em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">caused by </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">B-</span><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">lactamase-producing strains of <em>Homophiles influenza</em> and <em>Branhamella catarrhalis.</em></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: justify; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Skin and Skin Structure Infections-</span></em><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> caused by &szlig; -lactamase producing strains of <em>Staphylococcus aureus,<span style=\"mso-spacerun: yes;\">&nbsp; </span>Escherichia coli</em> and Klebsiella spp.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"FR\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Composition</span></strong><span lang=\"FR\" style=\"font-family: Calibri, sans-serif;\"><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp; </span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ogmin 500 Tablets</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amoxicillin<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>(as trihydrate) <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>500 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clavulanic acid (as potassium salt)<span style=\"mso-tab-count: 1;\">&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>125 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ogmin 875 Caplets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each Caplet contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amoxicillin<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>(as trihydrate) <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>875 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clavulanic acid (as potassium salt)<span style=\"mso-tab-count: 1;\">&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>125 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Ogmin<span style=\"mso-spacerun: yes;\">&nbsp; </span>125 mg Suspension<span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each 5 ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amoxicillin<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>(as trihydrate)<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span> 125 mg </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clavulanic acid (as potassium salt)<span style=\"mso-tab-count: 1;\">&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>31.25 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Ogmin<span style=\"mso-spacerun: yes;\">&nbsp; </span>250 mg Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each 5 ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amoxicillin<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>(as trihydrate)<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span> 250 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clavulanic acid (as potassium salt)<span style=\"mso-tab-count: 1;\">&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>62.5 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ogmin 400 mg Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each 5 ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amoxicillin<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>(as trihydrate)<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span> 400 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clavulanic acid (as potassium salt)<span style=\"mso-tab-count: 1;\">&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>57.1 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ogmin 600 mg Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each 5 ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Amoxicillin<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp; </span>(as trihydrate)<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span> 600 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clavulanic acid (as potassium salt)<span style=\"mso-tab-count: 1;\">&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>42.9 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ogmin (beta-lactam antibacterial penicillin co-formulated with a beta-lactamase inhibitor) is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. The beta-lactamase inhibitory action of clavulanate extends the spectrum of amoxycillin to embrace a wider range of organisms, including many resistant to other beta-lactam antibiotics.</span></p>', 'Ogmin', NULL, NULL),
(108, 108, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Secondary amenorrhea.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-right: 0in; text-align: left; text-indent: 0in; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Endometriosis.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Medroxyprogesterone acetate 5 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Medroxyprogesterone acetate administered orally or parenterally in the recommended doses to women with adequate endogenous oestrogen, transforms proliferative into secretory endometrium. Androgenic and anabolic effects have been noted, but medroxyprogesterone acetate is apparently devoid of significant oestrogenic activity.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">While parenterally administered medroxyprogesterone acetate inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation, available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses.</span></p>', 'Oralute', NULL, NULL),
(109, 109, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Inflammatory conditions and superficial bacterial infections of the external auditory canal, caused by staphylococci, Pseudomonas, Proteus and other Gram-positive and Gram-negative bacteria susceptible to these antibiotics.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Dexamethasone Sodium Phosphate<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Neomycin Sulphate<span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>5 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Polymyxin B Sulphate<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>10.000 I.U</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticoids may inhibit the body\'s defence mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered clinically significant in a particular case.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">The anti-infective component in the combination is included to provide action against specific organisms susceptible to it. Neomycin Sulfate considered active against the following microorganisms: Staphylococcus aureus, Corynebacterium diphteriae, Streptococcus viridans, Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, Aerobacter aerogenes, and Haemophilus influenzae.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Polymyxin B Sulfate is considered active against the following microorganisms: Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Koch-Weeks bacillus.</span></p>', 'Otodex', NULL, NULL),
(110, 110, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 12pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: Calibri, sans-serif;\">Females</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Ovaclomin is indicated for the treatment of ovulatory failure in women desiring pregnancy, whose partners are fertile and potent.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Impediments to this goal must be excluded or adequately treated before initiating therapy.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Administration of Ovaclomin is indicated only in patients with demonstrated ovulatory dysfunction, and in whom the following conditions apply:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">- Normal liver function</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">- Physiological indications of normal endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen or bleeding in response to progesterone).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Reduced estrogen levels, while less favourable, do not prevent successful therapy.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Ovaclomin therapy is not effective in patients with primary pituitary or ovarian failure.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It cannot substitute for appropriate therapy of other disturbances leading to ovulatory dysfunction, e.g. diseases of the thyroid or adrenals.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 12pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: Calibri, sans-serif;\">Males</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">To improve fertility in idiopathic oligospermia and varicocele-associated oligospermia.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">As a useful adjunct to varicocelectomy, and as first line therapy for sperm counts under 10 million/ml, when surgical therapy has not been successful.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Reported to be effective in men with long-standing infertility that has been refractory to previous treatments, such as exogenous injections of human chorionic gonadotropin and varicocelectomy.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Patients with pregerminal hypofertility respond to treatment with improved ejaculate and an increased rate of conception, and considered eligible candidates for long-term, low dose treatment with Ovaclomin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Note that Ovaclomin has not been found effective in patients with primary hypofertility, germinal hypofertility and post-germinal hypofertility.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Clomiphene citrate 50 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clomiphene citrate, an orally administered, non-steroidal agent, may induce ovulation in selected anovulatory women.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clomiphene citrate is a drug of considerable pharmacological potency. Careful evaluation and selection of the patient and close attention to the timing of the dose is mandatory prior to treatment with clomiphene citrate. Conservative selection and management of the patient contribute to successful therapy of anovulation.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clomiphene citrate induces ovulation in most selected anovulatory patients.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The various criteria for ovulation include an ovulation peak of oestrogen excretion followed by a biphasic basal body temperature curve; urinary excretion of pregnanediol at post-ovulatory levels and, endometrial histologic findings characteristic of the luteal phase.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Clomiphene citrate therapy appears to mediate ovulation through increased output of pituitary gonadotropins. These stimulate the maturation and endocrine activity of the ovarian follicle that is followed by the development and function of the corpus luteum. Increased urinary excretion of gonadotropins and oestrogen suggest involvement of the pituitary.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">In males, when Clomiphene citrate is administered in appropriate amounts, spermatogenesis is stimulated by an increase in the gonadotropins and testicular steroids.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Augmentation of sperm output is thus due to stimulation of spermatogonia by increased testosterone.</span></p>', 'Ovaclomin', NULL, NULL),
(111, 111, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Oxidur is indicated for:</span></p>\r\n<ul style=\"margin-top: 0in;\" type=\"disc\">\r\n<li class=\"MsoNormal\" style=\"margin-right: 0in; margin-left: .5in; text-align: justify; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Short term treatment of moderate pain such as pain after dental surgery</span></li>\r\n<li class=\"MsoNormal\" style=\"margin-right: 0in; margin-left: .5in; text-align: justify; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of pain associated with acute lumbo-sciatica</span></li>\r\n<li class=\"MsoNormal\" style=\"margin-right: 0in; margin-left: .5in; text-align: justify; mso-list: l0 level1 lfo1; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Symptomatic treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis</span></li>\r\n</ul>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each film-coated tablet contains 8 mg lornoxicam.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lornoxicam is a non steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. Lornoxicam\'s mode of action is mainly related to the inhibition of the prostaglandin synthesis (inhibition of<span style=\"mso-spacerun: yes;\">&nbsp; </span>the<span style=\"mso-spacerun: yes;\">&nbsp; </span>cyclooxygenase enzyme), leading<span style=\"mso-spacerun: yes;\">&nbsp; </span>to<span style=\"mso-spacerun: yes;\">&nbsp; </span>desensitization of<span style=\"mso-spacerun: yes;\">&nbsp; </span>peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception which seems to be independent of anti- inflammatory effects has also been suggested.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lornoxicam has no effect on vital signs (e.g. body temperature, respiratory rate, heart rate, blood pressure, ECG, spirometry).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The analgesic properties of lornoxicam have been demonstrated successfully in several clinical trials during development of the drug.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Due to a local gastrointestinal irritation and a systemic ulcerogenic effect related to the inhibition of prostaglandin (PG)-synthesis, gastrointestinal sequela are common undesirable effects after treatment with lornoxicam as seen with other NSAIDs.</span></p>', 'Oxidur', NULL, NULL),
(112, 112, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prednilet is indicated in the following conditions:&nbsp; </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Endocrine Disorders</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance): Congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypocalcaemia associated with cancer.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rheumatic Disorders</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, rheumatoid arthritis&mdash;including juvenile rheumatoid arthritis-(selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute gouty arthritis, acute and subacute bursitis, post-traumatic osteoarthritis, acute nonspecific tenosynovitis, synovitis of osteoarthritis, epicondylitis.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Collagen Diseases</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, acute rheumatic carditis and systemic dermatomyositis (polymyositis). </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; color: black;\">Each 5&nbsp;ml contains Prednisolone</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> <span style=\"color: black;\">15 mg</span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prednisolone is a synthetic glucocorticoid with the general properties of the corticosteroids. Prednisolone exceeds hydrocortisone in glucocorticoid and anti-inflammatory activity, being about three times more potent on a weight basis than the parent hormone, but is considerably less active than hydrocortisone in mineralocorticoid activity.<br>Prednisolone, like hydrocortisone, is a potent therapeutic agent influencing the biochemical behavior of most tissues of the body. The mechanism of action of corticosteroids is thought to be by control of protein synthesis. Corticosteroids react with receptor proteins in the cytoplasm of sensitive cells in many tissues to form a steroid-receptor complex.<br>Corticosteroids are palliative symptomatic treatment of virtue of their anti-inflammatory effects; they are never curative.</span></p>', 'Prednilet syrup', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(113, 113, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Allergy and anaphylaxis</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: bronchial asthma, drug hypersensitivity reactions, serum sickness, angioneurotic oedema, anaphylaxis, incapacitating allergies unresponsive to conventional treatment.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Arteritis/collagenosis</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: giant cell arteritis/polymyalgia rheumatica, mixed connective tissue disease, polyarteritis nodosa, polymyositis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Blood disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: haemolytic anaemia (auto-immune), leukaemia (acute and chronic lymphocytic), lymphoma, multiple myeloma, idiopathic thrombocytopenic purpura.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cardiovascular disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: post-myocardial infarction syndrome, rheumatic fever with severe carditis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Endocrine disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: primary and secondary adrenal insufficiency, congenital adrenal hyperplasia.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gastro-intestinal disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: regional ileitis (Crohn\'s disease), ulcerative colitis, persistent coeliac syndrome (coeliac disease unresponsive to gluten withdrawal), auto-immune chronic active hepatitis, multisystem disease affecting liver, biliary peritonitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hypercalcaemia</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: sarcoidosis, vitamin D excess.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Infections (with appropriate chemotherapy)</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: helminthic infestations, Herxheimer reaction, infectious mononucleosis, miliary tuberculosis, mumps orchitis (adult), tuberculous meningitis, rickettsial disease.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Muscular disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: polymyositis, dermatomyositis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Neurological disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: infantile spasms, Shy-Drager syndrome, sub-acute demyelinating polyneuropathy.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ocular disease</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: scleritis, posterior uveitis, retinal vasculitis, pseudo-tumours of the orbit, giant cell arteritis, malignant ophthalmic Graves disease.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Renal disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: lupus nephritis, acute interstitial nephritis, minimal change glomerulonephritis, nephrotic syndrome.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Respiratory disease</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: allergic pneumonitis, asthma, occupational asthma, pulmonary aspergillosis, pulmonary fibrosis, pulmonary alveolitis, aspiration of foreign body, aspiration of stomach contents, pulmonary sarcoid, drug induced lung disease, adult respiratory distress syndrome, spasmodic croup, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rheumatic disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: rheumatoid arthritis, polymyalgia rheumatica, juvenile chronic arthritis, psoriatic arthritis, systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Skin disorders</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: pemphigus vulgaris, exfoliative dermatitis, bullous pemphigoid, systemic lupus erythematosus, pyoderma gangrenosum.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Miscellaneous</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">: sarcoidosis, hyperpyrexia, Beh&ccedil;ets disease, immunosuppression in organ transplantation.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Prednitab 5 Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Prednisolone 5 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Prednitab 20 Tablets</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Prednisolone 20 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prednisolone is a synthetic glucocorticoid with the general properties of the corticosteroids. Prednisolone exceeds hydrocortisone in glucocorticoid and anti-inflammatory activity, being about three times more potent on a weight basis than the parent hormone, but is considerably less active than hydrocortisone in mineralocorticoid activity.<br>Prednisolone, like hydrocortisone, is a potent therapeutic agent influencing the biochemical behavior of most tissues of the body. The mechanism of action of corticosteroids is thought to be by control of protein synthesis. Corticosteroids react with receptor proteins in the cytoplasm of sensitive cells in many tissues to form a steroid-receptor complex.<br>Corticosteroids are palliative symptomatic treatment of virtue of their anti-inflammatory effects; they are never curative.</span></p>', 'Prednitab', NULL, NULL),
(114, 114, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Premonor is indicated: </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">At low dose:</span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dysfuntional uterine bleeding</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Polymenorrhoea</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Menorrhagia</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Metropathia</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Haemorrhagia</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pre-menstrual syndrome</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Postponement of menstruation</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Norethisterone Acetate 5 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Norethisterone is a strong progestogen with negligible androgenic effects. Complete transformation of the endometrium from a proliferative to a secretory state can be achieved in estrogen-primed women with orally administered doses of 100 -150 mg norethisterone per cycle.</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The progestogenic effect of norethisterone on the endometrium is the basis of the treatment of dysfunctional bleeding, primary and secondary amenorrhea, and endometriosis with Premonor.</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gonadotropin secretion inhibition and an ovulation can be achieved with daily intake of 0.5 mg of norethisterone. Positive effects of Premonor on premenstrual symptoms can be traced back to suppression of ovarian function.<br>Due to the stabilizing effects of norethisterone on the endometrium, administration of Premonor can be used to shift the timing of menstruation.<br>Like progesterone, the thermogenic action of norethisterone alters the basal body temperature.</span></p>', 'Premonor', NULL, NULL),
(115, 115, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Profort is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lower Respiratory Tract Infections</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenza, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; <em>Proteus mirabilis</em>; <em>Escherichia coli</em>; Serratia spp.; Citrobacter spp.;Streptococcus pneumoniae; and <em>Staphylococcus aureus</em> (methicillin-susceptible strains).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Skin and Skin-Structure Infections</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Caused by Pseudomonas aeruginosa; Klebsiella spp.; <em>Escherichia coli</em>; Proteus spp., including <em>Proteus mirabilis</em> and indole-positive Proteus; Enterobacter spp.; Serratia spp.; <em>Staphylococcus aureus </em>(methicillin-susceptible strains); and Streptococcus Pyogenes (group A beta-hemolytic streptococci).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Urinary Tract Infections</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.;Proteus spp., including <em>Proteus mirabilis</em> and indole-positive Proteus; Klebsiella spp.; and <em>Escherichia coli.</em></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Bacterial Septicemia</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Caused by <em>Pseudomonas aeruginosa</em>; Klebsiella spp., <em>Haemophilus influenza</em>, <em>Escherichia coli</em>, Serratia spp., <em>Streptococcus pneumoniae</em>, and <em>Staphylococcus aureus</em> (methicillin-susceptible strains).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Bone and Joint Infections</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Caused by <em>Pseudomonas aeruginosa</em>; Klebsiella spp.; Enterobacter spp.; and <em>Staphylococcus aureus</em> (methicillin-susceptible strains).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gynecologic Infections</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Intra-abdominal Infections</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Including peritonitis caused by <em>Escherichia coli</em>, Klebsiella spp., and <em>Staphylococcus aureus</em> (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Central Nervous System Infections</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Including meningitis caused by <em>Haemophilus influenza</em> and <em>Neisseria meningitidis</em>. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to <em>Pseudomonas aeruginosa </em>and <em>Streptococcus pneumoniae.</em></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Profort may be used alone in cases of confirmed or suspected sepsis. Profort has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each vial contains Ceftazidime <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1000 mg<span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Profort is bactericidal in action, exerting its effect by inhibition of enzymes responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to Ceftazidime in<em> vitro</em>, including strains resistant to Gentamicin and other aminoglycosides. In addition, Profort has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins.</span></p>', 'Profort vial', NULL, NULL),
(116, 116, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Threatened and habitual abortion.<span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Failure of nidation.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Allyloestrenol 5 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Progestogens are often used in combination with oestrogens in the management of postmenopausal disorders.<span style=\"mso-spacerun: yes;\">&nbsp; </span>The progestogenic component is added to reduce the increased risk of endometrial hyperplasia, or carcinoma which occurs when unopposed long term oestrogen therapy is employed.</span></p>', 'Progest', NULL, NULL),
(117, 117, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cream and Ointment</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Psoriderm is indicated for short-term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid responsive dermatoses. The product is not recommended for use in children under 12 years of age.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Psoriderm cream and Ointment</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Contains Clobetasol propionate 0.5 mg/g&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cream, Ointment</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Like other topical corticosteroids, Clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.</span></p>', 'Psoriderm Cream &amp; Ointment', NULL, NULL),
(118, 118, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Provides simultaneous antitussive, expectorant, decongestant, bronchodilator, and antihistaminic effects.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pulmadrin is indicated for the symptomatic relief of cough in conditions such as; the common cold, acute bronchitis, allergic asthma, bronchiolitis, croup, emphysema, tracheobronchitis.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each teaspoon (5 ml) contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pseudoephedrine Hydrochloride<span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>30 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Triprolidine Hydrochloride<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1.25 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Dextromethorphan Hydrobromide<span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>10 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Triprolidine is a powerful antihistamine for the control of allergic manifestations associated with upper respiratory tract infections. Pseudoephedrine produces vasoconstriction, acting on (alpha-adrenergic receptors in the mucosa of the respiratory tract.<span style=\"mso-spacerun: yes;\">&nbsp; </span>This action shrinks swollen nasal mucous membranes, thus reducing nasal congestion and thereby improving passage through the nasal airways.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Sinus secretion is increased and the opening of obstructed eustachian tubes is facilitated. Dextromethorphan is an </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">antitussive action of the non-narcotic, centrally acting cough suppressant.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine and Triprolidine are complementary. The mild stimulating effect Pseudoephedrine reduces the drowsiness associated with the antihistamine component. </span></p>', 'Pulmadrin DM', NULL, NULL),
(119, 119, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pulmadrin Expectorant provides symptomatic relief of cough, where expectorant and upper respiratory tract decongestants are required.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each teaspoonful (5 ml) contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Guaifenesin<span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>100 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine hydrochloride<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>30 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Triprolidine hydrochloride<span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1.25 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pulmadrin Expectorant facilitates the removal of mucus from the respiratory tract to provide symptomatic relief of cough, which becomes more productive.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It contains three active components- an expectorant, a decongestant and an antihistamine.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Guaifenesin is a clinically established expectorant in bronchitic conditions. By increasing respiratory tract fluid, Guaifenesin reduces the viscosity of tenacious, clinging secretions.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Cough frequency and intensity are thereby diminished in patients with non-productive cough.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine produces vasoconstriction, acting on alpha-adrenergic receptors in the mucosa of the respiratory tract.<span style=\"mso-spacerun: yes;\">&nbsp; </span>This action shrinks swollen nasal mucous membranes, thus reducing nasal congestion and thereby improving passage through the nasal airways.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Sinus secretion is increased and the opening of obstructed eustachian tubes is facilitated.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Triprolidine is a powerful antihistamine for the control of allergic manifestations associated with upper respiratory tract infections.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine and Triprolidine are complementary. The mild, stimulating effect of pseudo- ephedrine reduces the drowsiness associated with the antihistamine component.</span></p>', 'Pulmadrin exp', NULL, NULL),
(120, 120, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pulmadrin is indicated for the relief of nasal congestion associated with allergic conditions, and the symptomatic treatment of seasonal and perennial allergic rhinitis, vasomotor rhinitis and the common cold.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each teaspoonful (5 ml) contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine hydrochloride<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>30 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Triprolidine hydrochloride<span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1.25 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pulmadrin contains Pseudoephedrine, a nasal decongestant and Triprolidine, an antihistamine.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">The combination provides symptomatic relief of congestion and allergic conditions associated with rhinitis and the common cold.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine produces vasoconstriction, acting on alpha-adrenergic receptors in the mucosa of the respiratory tract.<span style=\"mso-spacerun: yes;\">&nbsp; </span>This action shrinks swollen nasal mucous membranes, thus reducing nasal congestion and thereby improving passage through the nasal airways.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Sinus secretion is increased and the opening of obstructed eustachian tubes is facilitated.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Triprolidine is a powerful antihistamine for the control of allergic manifestations associated with upper respiratory tract infections.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine and Triprolidine are complementary. The mild stimulating effect of pseudo- ephedrine reduces the drowsiness associated with the antihistamine component.</span></p>', 'Pulmadrin syrup', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(121, 121, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol is used to treat superficial infections of the conjunctiva and/or cornea when caused by susceptible organisms including Gram-positive and Gram-negative bacteria, as well as certain Rickettsia. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Steroid-responsive allergic and inflammatory ocular conditions for which corticosteroids are indicated, and where bacterial infection or a risk of bacterial ocular infection exists.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Ocular corticosteroids-containing preparations are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">It is also effective in certain virus-like infections.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol<span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>5%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Hydrocortisone acetate<span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Chloramphenicol possesses a wide range of antibacterial activity and is effective against virtually all bacterial pathogens known to cause diseases of the eye. It penetrates the non-inflamed eye better than any other antibiotic, irrespective of the mode of administration, and resistance to it is slow to develop, moderate in degree and not necessarily permanent. Preparations of chloramphenicol for local treatment are well tolerated.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol is bacteriostatic.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Since it is lipid soluble, it diffuses through the bacterial cell membrane and reversibly binds to the 50 S subunit of bacterial ribosomes, where transfer of amino acids to growing peptide chains is prevented, possibly by suppression of peptidyl transferase activity.<span style=\"mso-spacerun: yes;\">&nbsp; </span>This inhibits peptide bond formation and subsequent protein synthesis.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Hydrocortisone acetate has both the anti-inflammatory and antiallergic activity. </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">this combination yields excellent results in inflammation of the anterior uvea (iritis, iridocyclitis).</span></p>', 'Ramacetine HC', NULL, NULL),
(122, 122, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">For the treatment of bacterial conjunctivitis and other superficial ocular infections caused by chloramphenicol-sensitive organisms.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol<span style=\"mso-tab-count: 3;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>5%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol possesses a wide range of antibacterial activity and is effective against virtually all bacterial pathogens known to cause diseases of the eye.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It penetrates the non-inflamed eye better than any other antibiotic, irrespective of the mode of administration, and resistance to it is slow to develop, moderate in degree and not necessarily permanent.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Preparations of chloramphenicol for local treatment are well tolerated.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chloramphenicol is bacteriostatic. Since it is lipid soluble, it diffuses through the bacterial cell membrane and reversibly binds to the 50 S subunit of bacterial ribosomes, where transfer of amino acids to growing peptide chains is prevented, possibly by suppression of peptidyl transferase activity.<span style=\"mso-spacerun: yes;\">&nbsp; </span>This inhibits peptide bond formation and subsequent protein synthesis.</span></p>', 'Ramacetine', NULL, NULL),
(123, 123, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -19.8pt; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rinazal is indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis, such as sneezing, nasal discharge and itching, congestion/stuffiness, as well as ocular itching, tearing and redness, itching of palate and coughing.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: .25in; text-align: left; text-indent: -19.8pt; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rinazal is also indicated for the relief of symptoms associated with chronic idiopathic urticaria such as the relief of itching and the size and number of hives.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Rinazal Syrup</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Each 5 ml contains <span style=\"mso-spacerun: yes;\">&nbsp;</span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Desloratadine 2.5 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Desloratadine is a non-sedating long-acting histamine antagonist with potent, selective peripheral H<sub>1</sub>-receptor antagonist activity. Desloratadine has demonstrated antiallergic, antihistaminic and anti-inflammatory activities.</span></p>', 'Rinazal', NULL, NULL),
(124, 124, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of hypercholesterolaemia</span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prevention of Cardiovascular Events</span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Rosulip 10 mg</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains 10 mg Rosuvastatin (as calcium).&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rosulip 20 mg</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains 20 mg Rosuvastatin (as calcium).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</span></p>', 'Rosulip', NULL, NULL),
(125, 125, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">For the local treatment of </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Traumatic inflammation of the tendons, ligaments, muscles, and joints, e.g. due to sprains, strains and bruises.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Localised form soft-tissue rheumatism, e.g. tendovaginitis, shoulder-hand syndrome and bursitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Localised rheumatic diseases, e.g. osteoarthosis of peripheral joints and of the vertebral column. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each gram contains Diclofenac diethyl ammonium equivalent to 1% Diclofenac sodium.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Rufenal Emulgel is an anti-inflammatory and analgesic preparation designed for external application. It contains a quantity of active substance equivalent to 1% Diclofenac sodium. The white, creamy, non-greasy preparation can easily be rubbed into the skin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Experimental studies on animals have shown that, when applied locally, the active substance penetrates the skin, accumulates in the underlying tissue, and combats both acute and chronic inflammatory reactions.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">In the presence of inflammation of traumatic or rheumatic origin, the anti-inflammatory and analgesic properties of Rufenal Emulgel elicit a clinical response characterised by a marked decrease in inflammatory swelling. Rufenal Emulgel also affords effective relief from tenderness and pain on movement.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">When Rufenal Emulgel is applied locally, the active substance is absorbed through the skin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Determined by reference to the urinary excretion of Diclofenac and its hydroxylated metabolites, the amount of Diclofenac absorbed following local application of Rufenal<span style=\"mso-spacerun: yes;\">&nbsp; </span>Emulgel to the skin in healthy subjects - as compared with oral administration of Rufenal<span style=\"mso-spacerun: yes;\">&nbsp; </span>coated tablets - is equivalent to approx. 6% of the dose applied. In patients with rheumatoid arthritis who had received repeated treatment with Rufenal Emulgel the concentrations measure in the region of the inflamed wrist - both in the synovial fluid and in synovial tissue removed during surgery - proved higher than the plasma concentrations. This finding confirms that Diclofenac penetrates into the inflamed zone following local application.</span></p>', 'Rufenal emulgel', NULL, NULL),
(126, 126, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rufenal ophthalmic is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction and for the treatment of photophobia in patients undergoing incisional refractive surgery.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Diclofenac sodium is one of a series of phenylacetic acids that have demonstrated anti-inflammatory and analgesic properties in pharmacological studies. It is thought to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. Prostaglandins also appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. In clinical studies, Diclofenac sodium ophthalmic has been shown to decrease the signs and symptoms of inflammation resulting from cataract surgery.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Results from clinical studies indicate that Rufenal ophthalmic has no significant effect upon intraocular pressure; however, elevations in intraocular pressure may occur following cataract surgery.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Rufenal ophthalmic has been safely administered in conjunction with other ophthalmic medications such as antibiotics, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.</span></p>', 'RUFENAL EYE DROPS', NULL, NULL),
(127, 127, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Inflammatory and degenerative forms of rheumatism: rheumatoid arthritis; juvenile rheumatoid arthritis; ankylosing spondylitis; osteoarthrosis; and spondylarthritis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Painful syndromes of the vertebral column.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Non-articular rheumatism.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Acute attacks of gout.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Painful post-traumatic and post-operative inflammation and swelling, e.g. following dental or orthopaedic surgery.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">As an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. In keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Fever alone is not an indication.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 28.35pt; text-align: left; text-indent: -28.35pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Renal colic and biliary colic.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Rufenal Injection</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 3 ml contains Diclofenac sodium 75 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Rufenal 12.5 Suppositories</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each suppository contains Diclofenac sodium 12.5 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Rufenal 100 Suppositories</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each suppository contains Diclofenac sodium 100 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Rufenal 100 Tablets (S.R.)</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each sustained-release tablet contains Diclofenac sodium 100 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Rufenal contains a non - steroidal compound with pronounced antirheumatic, anti-inflammatory, analgesic and antipyretic properties.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Inhibition of prostaglandin biosynthesis, which has been demonstrated experimentally, is regarded as having an important bearing on its mechanism of action. Prostaglandins play a major role in the causation of inflammation, pain, and fever.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">In rheumatic diseases, the anti-inflammatory and analgesic properties of Diclofenac elicit a clinical response characterised by marked relief from signs and symptoms such as pain at rest, pain on movement, morning stiffness, and swelling of joints, as well as by an improvement in function. In post-traumatic and post-operative inflammatory conditions, Diclofenac rapidly relieves both spontaneous pain and pain on movement and diminishes inflammatory swelling and wound edema.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">In clinical trials, Diclofenac was found to exert a pronounced analgesic effect in moderately and severely painful states of non-rheumatic origin. In <strong>a</strong>ddition, clinical studies have revealed that in primary dysmenorrhoea Diclofenac is capable of relieving the pain and reducing the extent of bleeding.</span></p>', 'Rufenal', NULL, NULL),
(128, 128, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Leflunomide is indicated for the treatment of adult patients with:</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">&bull; active rheumatoid arthritis as a \"disease-modifying antirheumatic drug\" (DMARD),</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">&bull; active psoriatic arthritis.</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit/risk aspects.</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Each tablet contains 20 mg of leflunomide.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><strong><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Human pharmacology</span></strong></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Leflunomide is a disease-modifying anti-rheumatic agent with antiproliferative properties.</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><strong><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Animal pharmacology </span></strong></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Leflunomide is effective in animal models of arthritis and of other autoimmune diseases and transplantation, mainly if administered during the sensitization phase. It has immunomodulating/ immunosuppressive characteristics, acts as an antiproliferative agent, and displays anti-inflammatory properties. Leflunomide exhibits the best protective effects on animal models of autoimmune diseases when administered in the early phase of the disease progression.</span></p>\r\n<p style=\"margin: 0in; text-align: justify;\"><em><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">In vivo</span></em><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">, it is rapidly and almost completely metabolized to A771726 which is active <em>in vitro</em>, and is presumed to be responsible for the therapeutic effect.</span></p>', 'Ruvar', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(129, 129, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Symptomatic relief of tension and anxiety, either alone or when associated with stressful situations.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Psychoneurotic states manifested by tension, anxiety, apprehension, fatigue and depressive symptoms. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">In acute alcohol withdrawal, Serepam may be useful in the symptomatic relief of tremor, impending or acute delirium tremens and hallucinosis. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Serepam is a useful adjunct in the relief of skeletal muscle spasm, spasticity, stiff-man syndrome and tetanus.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">When used intravenously, Serepam injection is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Premedication in patients undergoing surgical procedures (the intramuscular route is preferred), or in patients undergoing cardioversion (the intravenous route is preferred).</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 2 ml contains Diazepam 10 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Diazepam is a benzodiazepine tranquillizer that is believed to act by facilitating the synaptic actions of gamma aminobutyric acid (GABA). GABA is one of the major inhibitory neurotransmitters of the CNS. Diazepam does not act at the same site as GABA, but at a presumably allosterically linked site, called the benzodiazepine receptor. It is through this site that the anticonvulsant, sedative, skeletal muscle relaxant, and amnestic properties of diazepam are mediated.</span></p>', 'Serepam amp', NULL, NULL),
(130, 130, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Congestive Heart Failure</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">For the management of edema and sodium retention when the patient is only partially responsive to, or intolerant of, other therapeutic measures. Spirone is also indicated for patients with congestive heart failure taking digitals, when other therapies are considered inappropriate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Hepatic Cirrhosis with Ascites and Oedema</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cirrhosis of the liver accompanied by Edema and / or Ascites Aldosterone levels may be exceptionally high in this condition, Spironolactone is indicated for maintenance therapy, together with bed rest and the restriction of fluid and sodium.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Nephrotic syndrome</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics fail to provide an adequate response.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Essential hypertension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Usually in combination with other drugs, Spirone is indicated for patients who cannot be treated adequately with other agents, or for whom other agents are considered inappropriate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Primary Hyperaldosteronism</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Short-term preoperative treatment of patients with primary hyperaldosteronism.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks, or who decline surgery.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism).</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Spironolactone 25 mg or 100 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium and magnesium is retained.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Spironolactone acts both as a diuretic and as an antihypertensive agent. It may be given alone or with other diuretic agents, which act more proximally in the renal tubule. Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism, Oedematous states in which secondary aldosteronism is usually involved include congestive cardiac failure, hepatic cirrhosis, and the nephrotic syndrome. By competing with aldosterone for receptor sites, spironolactone provides effective therapy for the oedema and ascites in those conditions.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Spironolactone is effective in lowering the systolic and diastolic blood pressure in patients with primary hyperaldosteronism. It is also effective in most cases of essential hypertension despite the fact that aldosterone secretion may be within normal limits in benign essential hypertension.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Through its action in antagonizing the effect of aldosterone, spironolactone inhibits the exchange of sodium for potassium in the distal renal tubule and helps to prevent potassium loss.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Spironolactone has not been demonstrated to elevate serum uric acid, to precipitate gout or to alter carbohydrate metabolism.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Spironolactone has moderate anti-androgenic activity in humans by inhibition of the interaction between dihydrotestosterone and the intracellular androgen receptor. It also inhibits several steps in ovarian steroidogenesis resulting in lowered plasma levels of testosterone and some other weak androgenic steroids. Through this activity, spironolactone is effective in the treatment of female hirsutism.</span></p>', 'Spirone', NULL, NULL),
(131, 131, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications </span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">TANUP (latanoprost) is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.<span style=\"mso-spacerun: yes;\">&nbsp; </span>TANUP may be used for the reduction of intraocular pressure in patients with chronic angle-closure glaucoma who underwent peripheral iridotomy or laser iridoplasty.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Latanoprost 0.05mg/ml <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action </span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-font-weight: bold;\">Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-font-weight: bold;\">Pharmacodynamics</span><strong style=\"mso-ansi-font-weight: normal;\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-ansi-language: EN;\">&nbsp;</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-font-weight: bold;\">Reduction of the IOP in man starts about 3-4 hours after administration and maximum effect is reached after 8-12 hours. IOP reduction is present for at least 24 hours.</span></p>', 'Tanup eye drops', NULL, NULL),
(132, 132, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Tempyrin is indicated for relief of pain and reduction of inflammation in the congestive, serious stages of acute otitis media.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is an effective adjuvant therapy when antibiotics or sulphonamides are administered systemically.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB; mso-bidi-font-weight: bold;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Tempyrin facilitates the removal of excessive or impacted cerumen.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Antipyrine<span style=\"mso-tab-count: 5;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>55 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Benzocaine<span style=\"mso-tab-count: 5;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>14 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Chlorbutanol<span style=\"mso-tab-count: 5;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>10 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Potassium hydroxyquinoline sulphate<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Glycerin anhydrous q.s.<span style=\"mso-tab-count: 4;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1 ml</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Tempyrin is an effective adjuvant to systemic antibiotic treatment.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It promptly relieves the pain and reduces the inflammation of acute otitis media, while the antibiotic of choice fights the infection.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Tempyrin contains the analgesic action of benzocaine and antipyrine plus glycerin dehydrated, a decongestant, which is so hygroscopic that it \"blots up\" the excess moisture through the tympanic membrane, for relief of pressure and pain in the middle ear.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Chlorbutanol has mild sedative, antibacterial and antifungal properties.</span></p>', 'Tempyrin', NULL, NULL),
(133, 133, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Tericox is indicated for:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 14.2pt; text-align: left; text-indent: -14.2pt; mso-list: l0 level1 lfo1; tab-stops: list 14.2pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Acute and chronic treatment of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 14.2pt; text-align: left; text-indent: -14.2pt; mso-list: l0 level1 lfo1; tab-stops: list 14.2pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The management of ankylosing spondylitis (AS) </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 14.2pt; text-align: left; text-indent: -14.2pt; mso-list: l0 level1 lfo1; tab-stops: list 14.2pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Treatment of acute gouty arthritis </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 14.2pt; text-align: left; text-indent: -14.2pt; mso-list: l0 level1 lfo1; tab-stops: list 14.2pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Relief of acute pain </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 14.2pt; text-align: left; text-indent: -14.2pt; mso-list: l0 level1 lfo1; tab-stops: list 14.2pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Relief of chronic musculoskeletal pain </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each film-coated tablet contains 60, 90, or 120 mg of Etoricoxib.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. Tericox is a potent, orally active, highly selective cyclooxygenase-2 (COX-2) inhibitor within and<strong> </strong>above the clinical dose range. Two isoforms of cyclooxygenase have been identified: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is responsible for prostaglandin-mediated normal physiologic functions such as gastric cytoprotection and platelet aggregation. Inhibition of COX-1 by nonselective NSAID\'s has been associated with gastric damage and platelet inhibition. COX-2 has been shown to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. Selective inhibition of COX-2 by Etoricoxib decreases these clinical signs and symptoms with decreased GI toxicity and without effects on platelet function.<em>&nbsp;</em></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Across clinical pharmacology studies, Etoricoxib produced dose-dependent inhibition of COX-2 without inhibition of COX-1 at doses up to 150 mg daily.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The influence on gastro-protective COX-1 activity was also assessed in a clinical study where prostaglandin synthesis was measured in gastric biopsy samples from subjects administered either Etoricoxib<span style=\"mso-spacerun: yes;\">&nbsp; </span>120 mg daily, naproxen 500 mg twice daily, or placebo. Etoricoxib did not inhibit gastric prostaglandin synthesis as compared to placebo. In contrast, naproxen inhibited gastric prostaglandin synthesis by approximately 80% compared with placebo. These data further support the COX-2 selectivity of Etoricoxib.</span></p>', 'Tericox', NULL, NULL),
(134, 134, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong><strong><span lang=\"EN-GB\" style=\"font-family: Calibri, sans-serif;\"><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Neurological pain; neuritis, polyneuritis, neuralgia, trigeminal neuralgia, sciatica, myalgia, lumbago, cramps and paraesthesias.<span style=\"mso-spacerun: yes;\">&nbsp; </span>In rheumatic painful conditions; lumbosciatica, arthritis and arthrosis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Metabolic disorders; asthenias, growth and tone disorders, severe anemias, cerebral metabolism disorders, fatigue, convalescence and senescence.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Three B\'S (1)</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 2 ml contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Thiamine HCl (vitamin B1)<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>100 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pyridoxine HCl (vitamin B6)<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>200 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Three B\'S (2) </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 1 ml contains </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Cyanocobalamine (vitamin B12) <span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>1000 mcg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Three B\'S is formulated in high and adequate pharmacodynamic doses of three essential vitamins of B complex group (B<sub>1</sub>, B<sub>6</sub> and B<sub>12</sub>) in their most active form.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">The complementary properties and the interrelated action of the three vitamins in Three B\'S ensure beneficial therapeutic effects; this is especially remarkable in causal therapy of pain, within the limits of hematological indications, and in cases of metabolic disturbances.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">For this reason, Three B\'S can be successfully used, not only within the scope of the hematological indications but in metabolic disturbances and nervous disorders as well.</span></p>', 'THREE B&#039;S', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(135, 135, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Short-term treatment in the following acute conditions:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">post-traumatic pain, inflammation and swelling, e.g. due to sprains; </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">post-operative pain, inflammation and swelling, e.g. following dental or orthopedic surgery; </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">painful and/or inflammatory conditions in gynecology, e.g. primary dysmenorrhea or adnexitis; </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">migraine attacks; </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">painful syndromes of the vertebral column; </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">non-articular rheumatism; </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-justify: kashida; text-kashida: 0%; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">As an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. In keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. Fever alone is not an indication. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains 50 mg of diclofenac potassium</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Non-steroidal anti-inflammatory drug (NSAID)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN;\">Mechanism of Action</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Toleran tablets contain the potassium salt of diclofenac, a non-steroidal compound with pronounced analgesic, anti-inflammatory, and antipyretic properties.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Toleran tablets have a rapid onset of action which makes them particularly suitable for the treatment of acute painful and inflammatory conditions. Inhibition of prostaglandin biosynthesis, which has been demonstrated in experiments, is considered to be fundamental to its mechanism of action. Prostaglandins play a major role in causing inflammation, pain, and fever.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Diclofenac potassium <em>in vitro</em> does not suppress proteoglycan biosynthesis in cartilage at concentrations equivalent to the concentrations reached in humans.</span></p>', 'Toleran', NULL, NULL),
(136, 136, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Temporarily relieves these cold, sinus, and flu symptoms:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: Symbol; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-char-type: symbol; mso-symbol-font-family: Symbol;\"><span style=\"mso-char-type: symbol; mso-symbol-font-family: Symbol;\">&middot;</span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> Nasal and sinus congestion<span style=\"mso-spacerun: yes;\">&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-spacerun: yes;\">&nbsp;&nbsp;&nbsp;</span></span><span style=\"font-size: 10.0pt; font-family: Symbol; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-char-type: symbol; mso-symbol-font-family: Symbol;\"><span style=\"mso-char-type: symbol; mso-symbol-font-family: Symbol;\">&middot;</span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> Stuffy nose </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: Symbol; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-char-type: symbol; mso-symbol-font-family: Symbol;\"><span style=\"mso-char-type: symbol; mso-symbol-font-family: Symbol;\">&middot;</span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> Minor body aches and pains <span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-spacerun: yes;\">&nbsp;&nbsp;&nbsp;</span></span><span style=\"font-size: 10.0pt; font-family: Symbol; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-char-type: symbol; mso-symbol-font-family: Symbol;\"><span style=\"mso-char-type: symbol; mso-symbol-font-family: Symbol;\">&middot;</span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> Headache</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: Symbol; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-char-type: symbol; mso-symbol-font-family: Symbol;\"><span style=\"mso-char-type: symbol; mso-symbol-font-family: Symbol;\">&middot;</span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> Fever<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-spacerun: yes;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=\"mso-spacerun: yes;\">&nbsp;&nbsp;&nbsp;</span></span><span style=\"font-size: 10.0pt; font-family: Symbol; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-char-type: symbol; mso-symbol-font-family: Symbol;\"><span style=\"mso-char-type: symbol; mso-symbol-font-family: Symbol;\">&middot;</span></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> Sore throat</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ultrafen plus Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Each 5 ml contains</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"><span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ibuprofen 100 mg </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pseudoephedrine Hcl 15 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ultrafen plus Tablet</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Each tablet contains</span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"><span style=\"mso-spacerun: yes;\">&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ibuprofen 200 mg </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pseudoephedrine Hcl 30 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ibuprofen is a nonsteroidal anti-inflammatory compound used to relieve mild to moderate pain, fever, and inflammation. Ibuprofen is rapidly absorbed after oral administration and peak plasma concentrations occur about one to two hours after ingestion. Ibuprofen is 90 to 99% bound to plasma proteins and has a plasma half-life of about 2 hours. It is rapidly excreted in the urine mainly as metabolites and their conjugates. About 1% is excreted in urine as unchanged Ibuprofen and about 14% as conjugated Ibuprofen.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Pseudoephedrine produces vasoconstriction, acting on (alpha-adrenergic receptors in the mucosa of the respiratory tract.<span style=\"mso-spacerun: yes;\">&nbsp; </span>This action shrinks swollen nasal mucous membranes, thus reducing nasal congestion and thereby improving passage through the nasal airways.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Sinus secretion is increased and the opening of obstructed eustachian tubes is facilitated.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The combination of ibuprofen and pseudoephedrine used to treat fever, body aches, and nasal congestion caused by the common cold, flu, or sinusitis.</span></p>', 'Ultrafen plus', NULL, NULL),
(137, 137, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In Juvenile Rheumatoid Arthritis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indicated for its analgesic effect in the relief of mild to moderate pain such as dental.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Used in soft-tissue injuries such as sprains and strains</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list .25in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Used as an antipyretic</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Suspension</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each 5 ml contains ibuprofen 100 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Suppositories</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each suppository contains Ibuprofen 125 mg<span style=\"mso-tab-count: 3;\"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ibuprofen is a nonsteroidal anti-inflammatory compound used to relieve mild to moderate pain, fever, and inflammation. Ibuprofen is rapidly absorbed after oral administration and peak plasma concentrations occur about one to two hours after ingestion. Ibuprofen is 90 to 99% bound to plasma proteins and has a plasma half-life of about 2 hours. It is rapidly excreted in the urine mainly as metabolites and their conjugates. About 1% is excreted in urine as unchanged Ibuprofen and about 14% as conjugated Ibuprofen. </span></p>', 'Ultrafen suspension &amp; suppositories', NULL, NULL),
(138, 138, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 14.2pt; text-align: left; text-indent: -14.2pt; mso-list: l0 level1 lfo1; tab-stops: list 14.2pt right 45.0pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ultrafen is indicated for the treatment of rheumatoid arthritis and osteoarthritis. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 14.2pt; text-align: left; text-indent: -14.2pt; mso-list: l0 level1 lfo1; tab-stops: list 14.2pt right 45.0pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">It is indicated both in the treatment of acute flares and in the long-term management of these diseases.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 14.2pt; text-align: left; text-indent: -14.2pt; mso-list: l0 level1 lfo1; tab-stops: list 14.2pt right 45.0pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ultrafen is indicated for the relief of mild to moderate pain, and for the treatment of primary dysmenorrhea.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each caplet contains</span><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\"> Ibuprofen 600 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each liquid capsule (LC) contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"FR\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: FR;\">Ibuprofen 400 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ibuprofen is a nonsteroidal anti-inflammatory agent that possesses analgesic and antipyretic activities. Its mode of action, like that of other nonsteroidal anti-inflammatory agents is not completely understood, but may be related to prostaglandin synthetase inhibition.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ibuprofen has shown anti-inflammatory, analgesic, and antipyretic activity in both animal and human studies. These properties provide symptomatic relief of inflammation and pain in rheumatoid arthritis, osteoarthritis, and allied conditions.</span></p>', 'Ultrafen', NULL, NULL),
(139, 139, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Adjunctive therapy in acute pulmonary edema.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Treatment of hypertension.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Urix Tablet</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Furosemide 40 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Urix Injection</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule contains Furosemide 20 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Frusemide, an anthranilic acid derivative, is a loop diuretic having a rapid effect. Investigations into its mode of action have utilized micropuncture studies in both human and experimental animals and stop flow experiments in dogs. It is reported to exert inhibiting effects on electrolyte reabsorption in the proximal and distal renal tubules and especially in the ascending loop of Henle. The net effect is to enhance excretion of sodium, potassium and chloride ions, and water. Frusemide has no effect on carbonic anhydrase. Frusemide has a steep dose-response curve and wide therapeutic range.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In addition to its diuretic actions, frusemide has been shown to increase peripheral venous capacitance and reduce forearm blood flow. It also reduces renal vascular resistance with a resultant increase in renal blood flow the degree of which is proportional to the initial resistance.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Frusemide may be effective in patients with moderate renal insufficiency.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Onset of diuresis following oral administration is within one hour, with peak effect occurring between 1-2 hours. Duration of effect is 6-8 hours. After intravenous administration, the onset of diuresis is within 5 minutes and somewhat later after intramuscular injection. Duration of effect is approximately 2 hours.</span></p>', 'Urix', NULL, NULL),
(140, 140, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Utised is indicated for the symptomatic relief of pain, burning, urgency, frequency and other discomfort arising from irritation of the mucosa of the lower urinary tract.<span style=\"mso-spacerun: yes;\">&nbsp; </span>These symptoms may result from infection, trauma, surgery, endoscopic procedures or catheters.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Phenazopyridine hydrochloride 100 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Phenazopyridine </span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">is known to have a direct topical analgesic effect on the mucosa lining of the urinary tract. The kidneys directly into the urine rapidly excrete it. 65% of an oral dose will be secreted directly into the urine chemically unchanged.</span></p>', 'Utised', NULL, NULL),
(141, 141, 'en', '<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Valecort -G is indicated for the topical treatment of corticosteroid-responsive inflammatory, pruritic and allergic dermatoses where secondary bacterial infection is present or is likely to be present including eczema (e.g. atopic, infantile, discoid and stasis eczemas), prurigo, psoriasis, neurodermatoses (including lichen simplex chronicus), lichen planus, seborrheic dermatitis, intertrigo, contact sensitivity reactions, discoid lupus erythematosus and generalized erythroderma.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Valecort -G used in the management of anal and vulval pruritus and otitis externa.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Valecort -G Cream/Ointment</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each gram contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Betamethasone (as valerate)<span style=\"mso-tab-count: 1;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>0.1%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Gentamicin (as sulfate)<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>0.1%</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Valecort -G contains the highly effective topical corticosteroid, Betamethasone 17-valerate.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Valecort -G exerts rapid anti-inflammatory as well as potent antipruritic and vasoconstrictive effects.<span style=\"mso-spacerun: yes;\">&nbsp; </span>It is effective in the treatment of difficult inflammatory and allergic dermatoses such as resistant psoriasis, lichen planus, lichen simplex chronicus and eczema of the hands.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Valecort -G also contains Gentamicin, a broad-spectrum aminoglycoside antibiotic that makes it particularly effective in dermatoses complicated by secondary bacterial skin infection.<span style=\"mso-spacerun: yes;\">&nbsp; </span>Compared to other antibiotics used to treat topical infections, Gentamicin is associated with a low incidence of sensitization.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Valecort -G is available as a water miscible cream or as an ointment.</span></p>', 'Valecort G', NULL, NULL),
(142, 142, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ventol solution for inhalation is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Salbutamol is a short-acting, relatively selective beta<sub>2</sub>-adrenoceptor agonist. Administration by inhalation results in direct stimulation of beta<sub>2</sub>-adrenoceptors in bronchial smooth muscle and hence bronchodilation. This is thought to be due to stimulation of adenyl cyclase by salbutamol, resulting in increased levels of cyclic AMP within cells. These are thought to inhibit the entry of calcium ions into the cells, thus inhibiting smooth muscle contraction. High levels of cyclic AMP in mast cells may also inhibit the release of histamine and slow reacting substance-A (SRS-A).&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">After administration of salbutamol, stimulation of both beta<sub>1</sub>- and beta<sub>2</sub>-adrenoceptors occurs because beta<sub>2</sub> selectivity is not absolute. This results in the beta<sub>1</sub> effect of cardiac stimulation, though not so much as with isoprenaline, and beta<sub>2</sub> effects of peripheral vasodilation and hypotension, skeletal muscle tremor and uterine muscle relaxation. Stimulation of beta<sub>2</sub>-adrenoceptors can result in changes in serum levels of glucose, insulin, and potassium.</span></p>', 'Ventol respiratory soln', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(143, 143, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ventol syrup is indicated in adults, adolescents and children aged 2 to 12 years.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Salbutamol is a selective beta-2 adrenoceptor agonist providing short-acting (4-6 hour) bronchodilation in reversible airways obstruction. Ventol syrup can be used in the management of asthma, bronchospasm and/or reversible airways obstruction.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Relief of bronchospasm in bronchial asthma of all types.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ventol syrup is suitable oral therapy for children and adults who are unable to use an inhaler device.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each Teaspoon (5 ml) contains:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Salbutamol Sulfate equivalent to Salbutamol<span style=\"mso-tab-count: 2;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>2 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Salbutamol is a selective &beta;<sub>2</sub> adrenoceptor agonist. At therapeutic doses, it acts on the &beta;<sub>2</sub> receptors of bronchial muscle, with little or no action on the &beta;-1 adrenoceptors of cardiac muscle.</span></p>', 'Ventol Syrup', NULL, NULL),
(144, 144, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Meniere\'s disease. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Meniere-Like syndromes characterized by attacks of vertigo, tinnitus and/or progressive hearing loss. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Symptomatic treatment of peripheral vertigo. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each tablet contains Betahistine hydrochloride<span style=\"mso-spacerun: yes;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>16 mg&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The mechanism of action of betahistine is only partly understood. There are several plausible hypotheses that are supported by animal studies and human data:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betahistine affects the histaminergic system</span></em></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betahistine acts both as a partial histamine H<sub>1</sub>-receptor agonist and histamine H<sub>3</sub>-receptor antagonist also in neuronal tissue, and has negligible H<sub>2</sub>-receptor activity. Betahistine increases histamine turnover and release by blocking presynaptic H<sub>3</sub>-receptors and inducing H<sub>3</sub>-receptor downregulation.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betahistine may increase blood flow to the cochlear region as well as to the whole brain:</span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pharmacological testing in animals has shown that the blood circulation in the striae vascularis of the inner ear improves, probably by means of a relaxation of the precapillary sphincters of the microcirculation of the inner ear. Betahistine was also shown to increase cerebral blood flow in humans.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betahistine facilitates vestibular compensation</span></em></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betahistine accelerates the vestibular recovery after unilateral neurectomy in animals, by promoting and facilitating central vestibular compensation; this effect characterized by an up-regulation of histamine turnover and release, is mediated via the H<sub>3</sub> Receptor antagonism. In human subjects, recovery time after vestibular neurectomy was also reduced when treated with betahistine.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betahistine alters neuronal firing in the vestibular nuclei</span></em></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Betahistine was also found to have a dose dependent inhibiting effect on spike generation of neurons in lateral and medial vestibular nuclei.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The pharmacodynamic properties as demonstrated in animals may contribute to the therapeutic benefit of betahistine in the vestibular system.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The efficacy of betahistine was shown in studies in patients with vestibular vertigo and with M&eacute;ni&egrave;re\'s disease as was demonstrated by improvements in severity and frequency of vertigo attacks.</span></p>', 'Viraserc', NULL, NULL),
(145, 145, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p style=\"margin: 0in;\"><span lang=\"EN\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;\">Indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older).</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each Gram contains 50 mg (equivalent to 5%, w/w) acyclovir and 10 mg (equivalent to 1%, w/w) hydrocortisone.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Acyclovir</span></strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> is a synthetic purine deoxynucleoside analogue with inhibitory activity against herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) DNA polymerases. It inhibits HSV-1 and HSV-2 replication in cell culture and in vivo</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The inhibitory activity of acyclovir is selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV. This viral enzyme converts acyclovir into acyclovir monophosphate, a deoxynucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In biochemical assays, acyclovir triphosphate inhibits replication of &alpha;-herpes viral DNA. This inhibition is accomplished in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase.</span></p>', 'Virax HC', NULL, NULL),
(146, 146, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Voloxal 0.5% solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Aerobic gram-positive microorganisms</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Corynebacterium species* </span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Staphylococcus aureus </span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Staphylococcus epidermidis </span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><em><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Streptococcus pneumoniae </span></em></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Streptococcus (Groups C/F)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Streptococcus (Group G)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Viridans group streptococci</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Levofloxacin 0.5% (5 mg/mL)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves the inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair, and recombination.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Levofloxacin has in vitro activity against a wide range of Gram-negative and Gram-positive microorganisms and is often bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from &beta;-lactam antibiotics and aminoglycosides, and therefore may be active against bacteria resistant to &beta;-lactam antibiotics and aminoglycosides. Additionally, &beta;-lactam antibiotics and aminoglycosides may be active against bacteria resistant to levofloxacin.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Resistance to levofloxacin due to spontaneous mutation in vitro is a rare occurrence (range: 10-9 to 10-10).</span></p>', 'Voloxal 0.5_ eye drops', NULL, NULL),
(147, 147, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In adults with infections of mild or moderate severity, Voloxal tablets are indicated for the treatment of the following infections when due to levofloxacin-susceptible microorganisms:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: 4.5pt; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Acute sinusitis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Acute exacerbations of chronic bronchitis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Community-acquired pneumonia</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Complicated urinary tract infections including pyelonephritis</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Chronic bacterial Prostatitis.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: justify; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Skin and soft tissue infections.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Before prescribing Voloxal, consideration should be given to national and/or local guidance on the appropriate use of fluoroquinolones.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"><br></span></strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">each tablet contains levofloxacin 500 &amp; 750 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Bactericidal; as a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-gyrase complex and topoisomerase IV needed for the synthesis of bacterial DNA</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-ansi-language: EN-GB;\">. </span><span lang=\"AR-SA\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\"><span style=\"mso-spacerun: yes;\">&nbsp;</span></span><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-ansi-language: EN-GB;\">. </span></p>', 'Voloxal Tablets', NULL, NULL),
(148, 148, 'en', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Xtram Ampoule is indicated for the treatment and prevention of moderate to severe pain.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Xtram Ampoules</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each 2ml Ampoule contains Tramadol HCl 100 mg (50mg/ml)</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Tramadol is a centrally acting analgesic. It is a non-selective pure agonist at mu, delta and kappa opioid receptors with a higher affinity for the mu receptor. Other mechanisms, which may contribute to its analgesic effect, are inhibition of neuronal reuptake of noradrenalin and enhancement of serotonin release.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify; text-justify: kashida; text-kashida: 0%; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Tramadol has an antitussive effect. In contrast to morphine, analgesic doses of Tramadol over a wide range have no respiratory depressant effect. Also gastrointestinal motility is less affected. Effects on the cardiovascular system tend to be slight. The potency of Tramadol is reported to be 1/10 (one tenth) to 1/6 (one sixth) that of morphine.</span></p>', 'Xtram Amp', NULL, NULL),
(149, 149, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Xylene 2% jelly are indicated as a surface anesthetic and lubricant for:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">The male and female urethra during cystoscopy, catheterisation, exploration by sound and other endourethral procedures. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Nasal and pharyngeal cavities in endoscopic procedures such as gastroscopy and bronchoscopy. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">During proctoscopy and rectoscopy. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Tracheal intubation. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">To relieve pain after circumcision in children. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each gram contains Lidocaine hydrochloride 2%.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Xylene 2% provides prompt and profound anaesthesia of mucous membranes and lubrication that reduces friction. Its water-miscible base, characterised by high viscosity and low surface tension, brings the anaesthetic into intimate and prolonged contact with the tissue, giving effective anaesthesia of long duration (approx. 20-30 min). Anaesthesia usually occurs rapidly (within 5 min, depending upon the area of application).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Lidocaine like other local anaesthetics causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide type are thought to act within the sodium channels of the nerve membrane.</span><span dir=\"RTL\" lang=\"AR-SA\" style=\"font-size: 10.0pt; mso-ascii-font-family: Calibri; mso-hansi-font-family: Calibri; mso-ansi-language: EN-GB;\">&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Local anaesthetic drugs may also have similar effects on excitable membranes in the brain and myocardium. If excessive amounts of drug reach the systemic circulation rapidly, symptoms and signs of toxicity will appear, emanating from the central nervous and cardiovascular systems.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Central nervous system toxicity usually precedes the cardiovascular effects as it occurs at lower plasma concentrations. Direct effects of local anaesthetics on the heart include slow conduction, negative inotropism and possibly cardiac arrest.</span></p>', 'Xylene gel', NULL, NULL),
(150, 150, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">For the treatment of infections due to one or more susceptible strains of bacteria, including <em>Pseudomonas</em> <em>aeruginosa</em>, <em>Proteus</em> species (indole positive and indole negative), <em>Escherichia</em> <em>coli</em>, <em>Klebsiella</em>, <em>Enterobacter</em>, <em>Serratia</em> species and <em>Staphylococcus</em> (including strains resistant to other antibiotics). </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Zetamycin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. Aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In suspected or documented Gram-negative sepsis, gentamicin should be considered for initial microbial therapy. Therapy may be instituted before obtaining results of susceptibility tests. The decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk of toxicity. If anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered. </span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><strong><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Zetamycin 80 Injection</span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span lang=\"EN-GB\" style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Each ampoule of 2 ml contains Gentamicin (as sulphate) 80 mg.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span lang=\"EN-GB\" style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\'; mso-ansi-language: EN-GB;\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gentamicin is usually bactericidal in action. Although the exact mechanism of action has not been fully elucidated, the drug appears to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In general, gentamicin is active against many aerobic gram-negative bacteria and some aerobic gram-positive bacteria. Gentamicin is inactive against fungi, viruses, and most anaerobic bacteria.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">In vitro, gentamicin concentrations of 1-8 &micro;g/ml inhibit most susceptible strains of Escherichia coli, Haemophilus influenzae, Moraxella lacunata, Neisseria, indole positive and indole negative Proteus, Pseudomonas (including most strains of Ps. aeruginosa), Staphylococcus aureus, S. epidermidis, and Serratia. However, different species and different strains of the same species may exhibit wide variations in susceptibility in vitro. In addition, in vitro susceptibility does not always correlate with in vivo activity. Gentamicin is only minimally active against Streptococci.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Natural and acquired resistance to gentamicin has been demonstrated in both gram-negative and gram-positive bacteria. Gentamicin resistance may be due to decreased permeability of the bacterial cell wall, alteration in the ribosomal binding site, or the presence of a plasmid-mediated resistance factor which is acquired by conjugation. Plasmid-mediated resistance enables the resistant bacteria to enzymatically modify the drug by acetylation, phosphorylation, or adenylation and can be transferred between organisms of the same or different species. Resistance to other aminoglycosides and several other anti-infectives (e.g. chloramphenicol, sulphonamides, tetracycline) may be transferred on the same plasmid.&nbsp;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">There is partial cross-resistance between gentamicin and other aminoglycosides.</span></p>', 'Zetamycin', NULL, NULL);
INSERT INTO `product_translations` (`id`, `product_id`, `locale`, `use`, `how_to_use`, `name`, `created_at`, `updated_at`) VALUES
(151, 151, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Zinex is indicated for the treatment of infections caused by susceptible strains of the following organisms in the following infections:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Pharyngitis and tonsillitis caused by <em>Streptococcus pyogenes</em>.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Otitis media caused by <em>Streptococcus pneumoniae, Haemophilus influenza</em> (ampicillin- sensitive and resistant strains), <em>Moraxella (Branhamella) catarrhalis</em> and <em>Streptococcus pyogenes.</em></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Sinusitis caused by <em>Streptococcus pneumoniae </em>and<em> Haemophilus influenza</em>.</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Acute and chronic bronchitis caused by <em>Streptococcus pneumoniae</em>, <em>Haemophilus influenza </em>(ampicillin-sensitive strains) and <em>Haemophilus parainfluenzae</em> (ampicillin-sensitive strains).</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Acute uncomplicated cystitis caused by <em>Escherichia coli</em> and <em>Klebsiella pneumoniae.</em></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Lyme disease caused by <em>Borrelia burgdorferi</em>.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each tablet contains Cefuroxime (as axetil) 250 or 500 mg</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized and effective antibacterial agent that has bactericidal activity against a wide range of common pathogens, including &beta;-lactamase producing strains.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cefuroxime has good stability to bacterial &beta;-lactamase, and consequently is active against many ampicillin-resistant or amoxycillin-resistant strains. The bactericidal action of cefuroxime results from inhibition of cell wall synthesis by binding to essential target proteins.</span></p>', 'Zinex Tab', NULL, NULL),
(152, 152, 'en', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Indications</span></strong></span><strong><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\"> </span></strong></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Zinex is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: </span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Respiratory tract infections</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Ear, nose and throat infections</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Urinary tract infections</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Bone and joint infections</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Soft tissue infections</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Obstetrics and gynecological infections</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Gonorrhea</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 21.3pt; text-align: left; text-indent: -21.3pt; mso-list: l0 level1 lfo1; tab-stops: list 0in; direction: ltr; unicode-bidi: embed;\"><!-- [if !supportLists]--><span style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"><span style=\"mso-list: Ignore;\">&middot;<span style=\"font: 7.0pt \'Times New Roman\';\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><!--[endif]--><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Prophylaxis against infection in abdominal, cardiac, and pulmonary surgery where there is an increased risk of infection.</span></p>', '<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Composition</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Each vial contains 750 mg of Cefuroxime (as Sodium).</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 14pt;\"><strong><span style=\"mso-bidi-font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Action</span></strong></span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cefuroxime is a well-characterized and effective antibacterial agent that has bactericidal activity against a wide range of common pathogens, including &beta;-lactamase producing strains.</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align: left; direction: ltr; unicode-bidi: embed;\"><span style=\"font-size: 10.0pt; font-family: \'Calibri\',sans-serif; mso-bidi-font-family: \'Times New Roman\';\">Cefuroxime has good stability to bacterial &beta;-lactamase, and consequently is active against many ampicillin-resistant or amoxycillin-resistant strains. The bactericidal action of cefuroxime results from inhibition of cell wall synthesis by binding to essential target proteins.</span></p>', 'Zinex vial', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `product_types`
--

CREATE TABLE `product_types` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `icone` varchar(255) NOT NULL,
  `title` varchar(255) DEFAULT NULL,
  `order_by` int(11) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `product_types`
--

INSERT INTO `product_types` (`id`, `icone`, `title`, `order_by`, `created_at`, `updated_at`) VALUES
(1, 'uploads/ProductType/441941701759493.svg', 'therapeutic', 2, '2023-12-04 08:00:03', '2023-12-05 04:58:13'),
(2, 'uploads/ProductType/311171701759539.svg', 'otc', 1, '2023-12-04 08:00:03', '2023-12-05 04:58:59'),
(3, 'uploads/ProductType/135711701759555.svg', 'brand', 3, '2023-12-04 08:00:03', '2023-12-05 04:59:15');

-- --------------------------------------------------------

--
-- Table structure for table `product_type_translations`
--

CREATE TABLE `product_type_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `product_type_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `name` varchar(255) NOT NULL,
  `description` text DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `product_type_translations`
--

INSERT INTO `product_type_translations` (`id`, `product_type_id`, `locale`, `name`, `description`, `created_at`, `updated_at`) VALUES
(1, 1, 'en', 'Products By Therapeutical Index', NULL, NULL, NULL),
(2, 2, 'en', 'OTC Products', NULL, NULL, NULL),
(3, 3, 'en', 'Products By Brand Index', NULL, NULL, NULL),
(4, 1, 'ar', 'المنتجات حسب الفهرس العلاجي', NULL, NULL, NULL),
(5, 2, 'ar', 'المنتجات دون وصفة طبية', NULL, NULL, NULL),
(6, 3, 'ar', 'المنتجات حسب العلامة التجارية', NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `project_models`
--

CREATE TABLE `project_models` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `parent_id` tinyint(4) NOT NULL,
  `route_key` varchar(255) DEFAULT NULL,
  `title_ar` varchar(255) NOT NULL,
  `title_en` varchar(255) NOT NULL,
  `is_menu` tinyint(4) NOT NULL,
  `icon` varchar(255) NOT NULL,
  `order_by` int(11) DEFAULT NULL,
  `model` varchar(255) DEFAULT NULL,
  `model_name` varchar(255) DEFAULT NULL,
  `multi_language` tinyint(4) NOT NULL DEFAULT 0 COMMENT '0 dont have seconde lang and 1 it hava',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `project_models`
--

INSERT INTO `project_models` (`id`, `parent_id`, `route_key`, `title_ar`, `title_en`, `is_menu`, `icon`, `order_by`, `model`, `model_name`, `multi_language`, `created_at`, `updated_at`) VALUES
(1, 3, 'users', 'المستخدمين', 'Users', 1, 'fas fa-users', 1, NULL, NULL, 0, NULL, NULL),
(2, 3, 'settings', 'الإعدادات', 'settings', 1, 'fas fa-cogs', 3, NULL, NULL, 0, NULL, NULL),
(3, 0, NULL, 'النظام', 'System', 1, 'fas fa-users-cog', 1, NULL, NULL, 0, NULL, NULL),
(4, 0, NULL, 'الصفحات', 'Pages', 1, 'fas fa-file-alt', 2, NULL, NULL, 0, NULL, NULL),
(5, 4, 'pageHome', 'أقسام الرئيسية', 'Home Sections', 1, 'fas fa-file-alt', 1, 'Page', '\\App\\Models\\Page', 1, NULL, NULL),
(6, 4, 'pageAbout', 'أقسام من نحن', 'About us Sections', 1, 'fas fa-file-alt', 2, 'Page', '\\App\\Models\\Page', 1, NULL, NULL),
(7, 4, 'pageOther', 'صفحات أخرى', 'Other Pages', 0, 'fas fa-file-alt', 3, 'Page', '\\App\\Models\\Page', 0, NULL, NULL),
(8, 1, 'sliders', 'السلايدر', 'Slider', 0, 'fas fa-file-alt', 3, 'Slider', '\\App\\Models\\Slider', 0, NULL, NULL),
(9, 1, 'articles', 'الاخبار', 'News', 0, 'fas fa-file-alt', 4, 'Article', '\\App\\Models\\Article', 1, NULL, NULL),
(10, 4, 'products', 'صفحة الادوية', 'Products Page', 1, 'fas fa-file-alt', 3, 'Product', '\\App\\Models\\Product', 1, NULL, NULL),
(11, 0, 'products', 'الأدوية', 'Products', 1, 'fa fa-medkit', 4, 'Product', '\\App\\Models\\Product', 1, NULL, NULL),
(12, 11, 'product-types', 'انواع الادوية', 'Type Product', 1, 'fa-brands fa-product-hunt', 1, 'ProductType', '\\App\\Models\\ProductType', 1, NULL, NULL),
(13, 11, 'categories', 'التصنيفات', 'Categories', 1, 'fa-brands fa-product-hunt', 2, 'Category', '\\App\\Models\\Category', 1, NULL, NULL),
(14, 4, 'social-responsibility', 'المسؤولية الاجتماعية', 'Social Responsibility', 1, 'fa-brands fa-product-hunt', 4, 'Page', '\\App\\Models\\Page', 1, NULL, NULL),
(15, 4, 'community', 'مجتمعنا', 'Our community', 0, 'fa-brands fa-product-hunt', 6, 'Page', '\\App\\Models\\Page', 1, NULL, NULL),
(16, 4, 'environment', 'بيئتنا', 'Our Environment', 0, 'fa-brands fa-product-hunt', 5, 'Page', '\\App\\Models\\Page', 1, NULL, NULL),
(17, 0, 'productivity', 'الإنتاجية', 'Productivity', 1, 'fa fa-briefcase', 6, 'Productivity', '\\App\\Models\\Productivity', 1, NULL, NULL),
(18, 0, 'members', 'الأعضاء', 'Members', 1, 'fas fa-user-tie', 6, '', '', 1, NULL, NULL),
(19, 18, 'board-of-directors', 'مجلس الإدارة', 'Members', 1, 'fas fa-user-tie', 0, 'Member', '\\App\\Models\\Member', 1, NULL, NULL),
(20, 18, 'executive-management', 'الإدارة التنفيذية', 'Executive Management', 1, 'fas fa-user-tie', 0, 'Member', '\\App\\Models\\Member', 1, NULL, NULL),
(21, 0, 'contacts', 'الإتصال', 'Contacts', 1, 'fa fa-phone', 8, 'contact', '\\App\\Models\\contact', 0, NULL, NULL),
(22, 4, 'investor-relations', 'علاقات المستثمرين', 'Investor Relations', 1, '', 5, 'Page', '\\App\\Models\\Page', 1, NULL, NULL),
(23, 22, 'stock-price', 'سعر السهم', 'Stock Price', 0, '', 1, 'StokePrice', '\\App\\Models\\StokePrice', 1, NULL, NULL),
(24, 22, 'financial-reports', ' التقارير المالية', 'Financial Reports', 0, '', 3, 'FileReport', '\\App\\Models\\FileReport', 0, NULL, NULL),
(25, 24, 'financial-reports-annual', ' التقارير السنوية', 'Annual  Reports', 0, '', 1, 'FileReport', '\\App\\Models\\FileReport', 0, NULL, NULL),
(26, 24, 'financial-reports-quarter', ' التقارير ربع سنوي', 'quarter Reports', 0, '', 2, 'FileReport', '\\App\\Models\\FileReport', 0, NULL, NULL),
(27, 22, 'governance', 'الحكم', 'Governance', 0, '', 2, '', '', 1, NULL, NULL),
(28, 27, 'page-board-of-directors', 'صفحة مجلس الإدارة', 'Board Of Directors', 0, '', 2, 'Governance', '\\App\\Models\\Governance', 1, NULL, NULL),
(29, 27, 'page-committees', 'اللجان', 'Committees', 0, '', NULL, 'Governance', '\\App\\Models\\Governance', 1, NULL, NULL),
(30, 27, 'page-code-of-conduct', 'مدونة لقواعد السلوك', 'Code of conduct', 0, '', NULL, 'Governance', '\\App\\Models\\Governance', 1, NULL, NULL),
(31, 27, 'page-general-assembly-meeting', 'إجتماع الجمعية العمومية', 'General Assembly Meeting', 0, '', NULL, 'Governance', '\\App\\Models\\Governance', 1, NULL, NULL),
(32, 27, 'page-general-assembly-meeting', 'إجتماع الجمعية العمومية', 'General Assembly Meeting', 0, '', NULL, 'Governance', '\\App\\Models\\Governance', 1, NULL, NULL),
(33, 4, 'page-contact', 'صفحة إتصل بنا', 'Page Contact Us', 1, '', 9, '', '', 1, NULL, NULL),
(34, 4, 'other-page', ' صقحات اخرى', 'Other Pages', 1, '', 10, 'Page', '\\App\\Models\\Page', 1, NULL, NULL),
(35, 0, 'certificates', ' الشهادات', 'Certificates', 1, 'fa fa-trophy', 22, 'Certificate', '\\App\\Models\\Certificate', 0, NULL, NULL),
(36, 0, 'investor-services', ' خدمات المستثمرين', 'Investor services', 1, 'fa fa-cubes', 7, 'InvestorService', '\\App\\Models\\InvestorService', 0, NULL, NULL),
(37, 22, 'page-investor-services', 'صفحة خدمات المستثمرين', 'Page Investor Relations', 0, '', 1, 'InvestorServicesInfo', '\\App\\Models\\InvestorServicesInfo', 0, NULL, NULL),
(38, 33, 'page-contact', 'صفحة إتصل بنا', 'Page Contact Us', 0, '', 1, '', '', 0, NULL, NULL),
(39, 38, 'branches', 'الفروع', 'Branches', 0, '', 1, 'Branch', '\\App\\Models\\Branch', 1, NULL, NULL),
(40, 0, 'article-type', 'أنواع الخبر', 'Type Of News', 1, 'fa fa-hashtag', 5, 'ArticleType', '\\App\\Models\\ArticleType', 1, NULL, NULL),
(41, 0, 'constants', 'الثوابت', 'Constants', 1, 'fa fa-code', 30, 'Constant', '\\App\\Models\\Constant', 1, NULL, NULL),
(42, 0, 'constant-options', 'خصائص الثوابت', 'Constant Options', 0, '', 30, 'ConstantOption', '\\App\\Models\\ConstantOption', 1, NULL, NULL),
(43, 0, 'careers', 'الوضائف', 'Careers', 1, 'fa fa-building', 99, '', '', 0, NULL, NULL),
(44, 43, 'career-information', 'الوضائف', 'Careers', 1, 'fa fa-building', 1, 'InfoCareer', '\\App\\Models\\InfoCareer', 1, NULL, NULL),
(45, 43, 'career-form', 'إستمارة الوضائف', 'Form Of Careers', 1, 'fa fa-building', 1, 'Career', '\\App\\Models\\Career', 1, NULL, NULL),
(46, 0, 'news-letter', 'رسالة إخبارية', 'News Letter ', 1, 'fa fa-comment', 100, 'NewsLetter', '\\App\\Models\\NewsLetter', 0, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `roles`
--

CREATE TABLE `roles` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `name` varchar(255) NOT NULL,
  `guard_name` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `roles`
--

INSERT INTO `roles` (`id`, `name`, `guard_name`, `created_at`, `updated_at`) VALUES
(1, 'Admin', 'admin', '2023-12-04 08:00:01', '2023-12-04 08:00:01');

-- --------------------------------------------------------

--
-- Table structure for table `role_has_permissions`
--

CREATE TABLE `role_has_permissions` (
  `permission_id` bigint(20) UNSIGNED NOT NULL,
  `role_id` bigint(20) UNSIGNED NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `settings`
--

CREATE TABLE `settings` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `setting_key` varchar(255) NOT NULL,
  `setting_value` text DEFAULT NULL,
  `title_ar` varchar(255) NOT NULL,
  `title_en` varchar(255) NOT NULL,
  `type_id` varchar(255) NOT NULL DEFAULT '1' COMMENT '1 input, 2 image , 3 textarea, 4 manual',
  `category` varchar(255) NOT NULL DEFAULT '1' COMMENT '1 basic, 2 contact info, 3 social media, 4 other, 5 services',
  `order_by` int(11) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `settings`
--

INSERT INTO `settings` (`id`, `setting_key`, `setting_value`, `title_ar`, `title_en`, `type_id`, `category`, `order_by`, `created_at`, `updated_at`) VALUES
(1, 'website_name_ar', 'شركة بيرزيت للأدوية', 'اسم الموقع', 'Website name', '1', '1', 1, NULL, NULL),
(2, 'website_name_en', 'Birzeit Pharmaceutical Company', 'اسم الموقع', 'Website name', '1', '1', 1, NULL, NULL),
(3, 'Headquarters_one', '+970 (2) 298-75-73', 'المقر', 'Headquarters', '1', '2', 2, NULL, NULL),
(4, 'Headquarters_two', '+972 (2) 296-72-06', 'المقر', 'Headquarters', '1', '2', 2, NULL, NULL),
(5, 'branch_one', '+970 (2) 281-03-74', 'فرع بيرزيت ', 'Birzeit Branch', '1', '2', 2, NULL, NULL),
(6, 'branch_two', '+972 (2) 2953253', 'فرع بيرزيت ', 'Birzeit Branch', '1', '2', 2, NULL, NULL),
(7, 'address_ar', '.ب 79، رام الله، فلسطين', 'صندوق البريد', 'Post Office Box', '1', '2', 3, NULL, NULL),
(8, 'address_en', 'P.O Box 79, Ramallah, Palestine', 'صندوق البريد', 'Post Office Box', '1', '2', 3, NULL, NULL),
(9, 'email', 'info@bpc.ps', 'الإيميل', 'Email', '1', '2', 4, NULL, NULL),
(10, 'description_ar', 'Birzeit Pharmaceutical Company is a leading Palestinian company in the field of pharmaceutical manufacturing.', ' وصف الموقع ', 'Website Description ', '3', '1', 1, NULL, NULL),
(11, 'description_en', 'Birzeit Pharmaceutical Company is a leading Palestinian company in the field of pharmaceutical manufacturing.', ' وصف الموقع ', 'Website Description ', '3', '1', 1, NULL, NULL),
(12, 'keywords', 'BPC', 'الكلمات الدلالية', 'Keywords ', '3', '1', 1, NULL, NULL),
(13, 'footer_description_ar', 'Birzeit Pharmaceutical Company is a leading Palestinian company in the field of pharmaceutical manufacturing.', 'وصف الفوتر ', 'Footer Description', '3', '1', 1, NULL, NULL),
(14, 'footer_description_en', 'Birzeit Pharmaceutical Company is a leading Palestinian company in the field of pharmaceutical manufacturing.', 'وصف الفوتر ', 'Footer Description', '3', '1', 1, NULL, NULL),
(15, 'favicon', 'assets/img/ps-logo.png', 'الأيقونة المفظلة', 'favicon', '2', '1', 1, NULL, NULL),
(16, 'logo', 'assets/img/logo-white.webp', 'شعار الموقع', 'logo', '2', '1', 1, NULL, NULL),
(17, 'facebook', 'https://www.facebook.com/bpcpharm', 'فيس بوك', 'Facebook', '1', '3', 1, NULL, NULL),
(18, 'twitter', NULL, 'تويتر', 'Twitter ', '1', '3', 1, NULL, NULL),
(19, 'instagram', 'https://www.instagram.com/bpc.ps/?fbclid=IwAR2-Ckqz0GOnl-IjnzHvjvB1efUvgy-8x6gfCNN4RmrZmd9_u95XnfrXopw', 'تويتر', 'Instagram  ', '1', '3', 1, NULL, NULL),
(20, 'linkedin', 'https://www.linkedin.com/company/birzeit-pharmaceutical/', 'لنكد ان', 'Linkedin', '1', '3', 1, NULL, NULL),
(21, 'youtube', NULL, 'يوتيوب', 'Youtube', '1', '3', 1, NULL, NULL),
(22, 'facebook_id', '824449542770201', 'معرف للتطبيق', 'App ID', '1', '4', 1, NULL, NULL),
(24, 'facebook_secert', '39e1db8e08be461a696def2e3d349d97', 'المفتاح السري لتطبيق', 'App secret', '1', '4', 2, NULL, NULL),
(29, 'facebook_token_long', 'EAACVgumOz10BOZC7bUr0gRLEwdNnDcT4sxjUZBk19KJEdVdO9FNpkN6ga24164oITjx0H3qy5ZCZBsZApcSfXXGfayPV8vlKp4NlABwupkVowifJZBkp6M85h03zXlZCRKZAMWSyTGgJNRQKEljvPDakdDJKs1jZAREE4GyEMyb3XsX49obZB7CZCzciBrd', 'any', 'any', '0', '1', 1, NULL, NULL),
(30, 'facebook_token', 'EAALt1R4hzhkBOwo8fcLemLnxmNNkXRIJJiZBkQ6TistAdFuHlKZCtZAmT6nyKmrjqvjk8v20QnH3HF5Ra9kjSsSmBsDti1fUS8Jo5qr2QpNX1P9FmvynwHLMibZBpgEFbJlcxgjsZCmlDcBWrzLZCCpgMcZCHdkXyuFdhYwp6c3GYbyinw7SoyOaRYRCPCbEFdcyk8ZB1daNRjwbM92VTDhYfk4ZD', 'معرف الوصول', 'Access Token', '3', '4', 3, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `sliders`
--

CREATE TABLE `sliders` (
  `id` int(10) UNSIGNED NOT NULL,
  `image` varchar(255) DEFAULT NULL,
  `order_by` int(11) DEFAULT NULL,
  `file_one` varchar(255) DEFAULT NULL,
  `file_two` varchar(255) DEFAULT NULL,
  `file_one_name` varchar(255) DEFAULT NULL,
  `file_two_name` varchar(255) DEFAULT NULL,
  `info` varchar(255) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `sliders`
--

INSERT INTO `sliders` (`id`, `image`, `order_by`, `file_one`, `file_two`, `file_one_name`, `file_two_name`, `info`, `created_at`, `updated_at`) VALUES
(2, 'uploads/Slider/732441704618217.jpg', 1, NULL, NULL, NULL, NULL, NULL, '2023-12-04 08:00:00', '2024-01-11 07:12:50'),
(6, 'uploads/Slider/310651704966146.jpg', 2, NULL, NULL, NULL, NULL, NULL, '2024-01-11 06:29:08', '2024-01-11 07:42:26'),
(8, 'uploads/Slider/927921704964548.jpg', 3, NULL, NULL, NULL, NULL, NULL, '2024-01-11 07:07:33', '2024-01-11 07:15:48');

-- --------------------------------------------------------

--
-- Table structure for table `slider_translations`
--

CREATE TABLE `slider_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `slider_id` int(10) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `title` varchar(255) DEFAULT NULL,
  `description` text DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `slider_translations`
--

INSERT INTO `slider_translations` (`id`, `slider_id`, `locale`, `title`, `description`) VALUES
(2, 2, 'en', '<p style=\"line-height: 1;\"><span style=\"font-size: 36pt;\"><strong>BPC</strong></span></p>\r\n<p style=\"line-height: 1;\"><span style=\"font-size: 36pt;\"><strong>For A Better Life</strong></span></p>', '<p><span style=\"color: rgb(0, 0, 0);\">Birzeit Pharmaceutical Company is a truly national enterprise, firmly rooted in Ramallah, Palestine, and stands as one of the leading companies in the region. BPC proudly maintains a diverse portfolio of 270 pharmaceutical products,&nbsp;distributed across 16 production lines - in 4 different locations - covering a variety of therapeutical areas.&nbsp;With pride, the company has approximately 170 brand names under its umbrella. In addition to providing services to the Ministry of Health and local and international healthcare organizations and programs, the company also provides services to consumers by way of pharmacies and doctors within the local Palestinian market.</span></p>\r\n<p><span style=\"color: rgb(0, 0, 0);\">Our Vision</span></p>\r\n<p><span style=\"color: rgb(0, 0, 0);\">The Leading Company locally and regionally in providing pharmaceutical products for a better life.</span></p>\r\n<p><span style=\"color: rgb(0, 0, 0);\">Our Mission</span></p>\r\n<p><span style=\"color: rgb(0, 0, 0);\">Creativity in the targeted markets through providing high-quality products that keep pace with continuous development via a distinguished professional staff, in fulfillment of our responsibilities towards our employees, society, and our partners. And a commitment to keeping our environment clean and safe for us.</span></p>\r\n<p><span style=\"color: rgb(0, 0, 0);\">Our Values</span></p>\r\n<p><span style=\"color: rgb(0, 0, 0);\">BPC is built upon a foundation of core values that define our identity and guide our actions. Each product we craft, every initiative we undertake, is imbued with a commitment to:</span></p>\r\n<p><span style=\"color: rgb(0, 0, 0);\">- Trust, Professionalism, Efficiency, Belonging and Cooperation.&nbsp;</span></p>'),
(4, 2, 'ar', '<p>بيرزيت للأدوية&nbsp;</p>\r\n<p>لحياة أفضل</p>', '<p style=\"text-align: right;\" align=\"right\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"mso-ascii-font-family: \'Times New Roman\'; mso-ascii-theme-font: major-bidi; mso-hansi-font-family: \'Times New Roman\'; mso-hansi-theme-font: major-bidi; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-theme-font: major-bidi;\">شركة بيرزيت للأدوية هي شركة وطنية بإمتياز، متجذرة في مدينة رام الله، فلسطين. بيرزيت للأدوية، وبكل فخر، تعتير من الشركات الفلسطينية الرائدة في مجال المنتجات الدوائية، فهي توفر أكثر من 270 منتجاً دوائياً وتغطي أربعة عشر مجالاً علاجياً لمختلف الأعمار.&nbsp;</span></p>\r\n<p style=\"text-align: right;\" align=\"right\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"mso-ascii-font-family: \'Times New Roman\'; mso-ascii-theme-font: major-bidi; mso-hansi-font-family: \'Times New Roman\'; mso-hansi-theme-font: major-bidi; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-theme-font: major-bidi;\">رؤيتنا</span></p>\r\n<p style=\"text-align: right;\" align=\"right\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"mso-ascii-font-family: \'Times New Roman\'; mso-ascii-theme-font: major-bidi; mso-hansi-font-family: \'Times New Roman\'; mso-hansi-theme-font: major-bidi; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-theme-font: major-bidi;\">الشركة الرائدة محلياً وإقليمياً في توفير منتجات دوائية لحياة أفضل</span></p>\r\n<p style=\"text-align: right;\" align=\"right\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"mso-ascii-font-family: \'Times New Roman\'; mso-ascii-theme-font: major-bidi; mso-hansi-font-family: \'Times New Roman\'; mso-hansi-theme-font: major-bidi; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-theme-font: major-bidi;\">رسالتنا</span></p>\r\n<p style=\"text-align: right;\" align=\"right\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"mso-ascii-font-family: \'Times New Roman\'; mso-ascii-theme-font: major-bidi; mso-hansi-font-family: \'Times New Roman\'; mso-hansi-theme-font: major-bidi; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-theme-font: major-bidi;\">الإبداع قي الأسواق المستهدفة من خلال تقديم مستحضرات عالية الجودة مواكبة للتطور المستمر بتشغيل كوادر مهنية متميزة، إيفاءً بسؤولياتنا إتجاه موظفينا ومجتمعنا وشركائنا، وإلتزاماً بالمحافظة على بيئتنا بيئة نظيفة وآمنة لنا ولأبنائنا</span><span style=\"mso-ascii-font-family: \'Times New Roman\'; mso-ascii-theme-font: major-bidi; mso-hansi-font-family: \'Times New Roman\'; mso-hansi-theme-font: major-bidi; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-theme-font: major-bidi;\">.</span></p>\r\n<p style=\"text-align: right;\" align=\"right\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"mso-ascii-font-family: \'Times New Roman\'; mso-ascii-theme-font: major-bidi; mso-hansi-font-family: \'Times New Roman\'; mso-hansi-theme-font: major-bidi; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-theme-font: major-bidi;\">قيمنا </span></p>\r\n<p style=\"text-align: right;\" align=\"right\"><span dir=\"RTL\" lang=\"AR-SA\" style=\"mso-ascii-font-family: \'Times New Roman\'; mso-ascii-theme-font: major-bidi; mso-hansi-font-family: \'Times New Roman\'; mso-hansi-theme-font: major-bidi; mso-bidi-font-family: \'Times New Roman\'; mso-bidi-theme-font: major-bidi;\">الثقة، المهنية، الكفاءة والفعالية، الإنتماء والتعاون.</span></p>'),
(8, 6, 'en', '<p style=\"line-height: 2;\"><strong><span style=\"font-size: 24pt;\">Birzeit Pharmaceuticals launches </span></strong><strong><span style=\"font-size: 24pt;\">its 2024 Golden Jubilee</span></strong></p>', '<p>Birzeit Pharmaceuticals launches its 2024 Golden Jubilee.</p>\r\n<p>Since 1974, A number of men and women took the first step towards establishing Birzeit Pharmaceutical Company, A year after another have culminated to reach BPC\'s Golden Jubilee. All this would not have been possible without the wisdom of its hardworking leadership, the capabilities of its founders, the strength of its investors and the dedication and sincerity of its employees.</p>\r\n<p>We truly thank everyone who have made this milestone possible.&nbsp;</p>'),
(10, 8, 'en', '<p style=\"line-height: 2;\"><span style=\"font-size: 24pt;\"><strong>BPC and Higher Council for Youth and Sports Sign Sponsorship Agreement</strong></span></p>', '<p>Birzeit Pharmaceutical Company and Higher Council for Youth&nbsp;and Sports Sign Sponsorship Agreement for the 10th Palestine International Marathon.</p>\r\n<p>BPC represented by its chairman and CEO Talal Nassereddin and the Higher Council for Youth and Sports, represented by the General Director of the Palestine Marathon Etidal Abdel Ghani have signed an agreement to sponsor the Palestine International Marathon in its tenth edition, scheduled to be held on May 10th 2024. This will be in parallel to BPC\'s celebration of its 50 years anniversary.</p>');

-- --------------------------------------------------------

--
-- Table structure for table `stoke_prices`
--

CREATE TABLE `stoke_prices` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `price` decimal(8,2) NOT NULL,
  `percent` decimal(8,2) NOT NULL,
  `link` varchar(255) NOT NULL,
  `image` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `stoke_prices`
--

INSERT INTO `stoke_prices` (`id`, `price`, `percent`, `link`, `image`, `created_at`, `updated_at`) VALUES
(1, 4.14, -0.05, 'https://www.barrons.com/market-data/stocks/bpc?countrycode=ps', 'uploads/StokePrice/772351701774394.webp', '2023-12-04 08:00:04', '2023-12-05 09:06:34');

-- --------------------------------------------------------

--
-- Table structure for table `stoke_price_translations`
--

CREATE TABLE `stoke_price_translations` (
  `id` int(10) UNSIGNED NOT NULL,
  `stoke_price_id` bigint(20) UNSIGNED NOT NULL,
  `locale` varchar(255) NOT NULL,
  `subtitle` varchar(255) NOT NULL,
  `info` varchar(255) NOT NULL,
  `description` text NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `stoke_price_translations`
--

INSERT INTO `stoke_price_translations` (`id`, `stoke_price_id`, `locale`, `subtitle`, `info`, `description`, `created_at`, `updated_at`) VALUES
(1, 1, 'en', 'Pricing delayed by 30 minutes', '4.15K (46.10% of Avg)', '<p>The stock information provided is for informational purposes only and is not intended for trading purposes. The stock information and charts are provided by Barrons &amp; PEX, a third-party service, and BPC does not provide information on this service.</p>', NULL, NULL),
(2, 1, 'ar', 'تأخر التسعير لمدة 30 دقيقة', '4.15 ألف (46.10% من المتوسط)', '<p>معلومات الأسهم المقدمة هي لأغراض إعلامية فقط وليست مخصصة لأغراض التداول. يتم توفير معلومات الأسهم والرسوم البيانية من قبل Barrons &amp; PEX، وهي خدمة تابعة لجهة خارجية، ولا توفر BPC معلومات حول هذه الخدمة.</p>', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `users`
--

CREATE TABLE `users` (
  `id` int(10) UNSIGNED NOT NULL,
  `role_id` int(11) DEFAULT NULL,
  `name` varchar(255) NOT NULL,
  `email` varchar(255) NOT NULL,
  `email_verified_at` timestamp NULL DEFAULT NULL,
  `image` varchar(255) DEFAULT NULL,
  `password` varchar(255) NOT NULL,
  `remember_token` varchar(100) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `users`
--

INSERT INTO `users` (`id`, `role_id`, `name`, `email`, `email_verified_at`, `image`, `password`, `remember_token`, `created_at`, `updated_at`) VALUES
(1, 1, 'admin', 'admin@admin.com', NULL, 'uploads/User/241171699870858.jpg', '$2y$12$.muqnHrlZ4pL2aWxACkd0einyw.wPhNkzyTRQBPL6Ugs0IpdwT9bC', NULL, '2023-12-04 08:00:02', '2023-12-04 08:00:02'),
(2, 1, 'raghad', 'raghad@fis.ps', NULL, 'uploads/User/903591701759017.jpg', '$2y$12$iJL3rXFn7ZeXDBuh4ES1pepjCuUdVlKw9k4ofYS60WA93BmY99FY2', NULL, '2023-12-05 04:50:17', '2023-12-05 04:50:17'),
(3, 1, 'ahmad', 'ahmad.anati@bpc.ps', NULL, 'uploads/User/60031703418380.png', '$2y$12$rHOemYLE/lKGn3W5QE9jSehRnEaL2liLdx.LHnB4M8N2siXyWVyoW', NULL, '2023-12-24 09:46:20', '2023-12-24 09:46:20'),
(4, 1, 'Yara', 'Y.shehada@bpc.ps', NULL, 'uploads/User/953711704360407.png', '$2y$12$3UL4RI.UbRvT8UcLYowNyOcvrQ1wPT4QIeLBQIdhpOlvqhnnNSp2K', NULL, '2024-01-04 07:26:47', '2024-01-04 08:01:50');

--
-- Indexes for dumped tables
--

--
-- Indexes for table `articles`
--
ALTER TABLE `articles`
  ADD PRIMARY KEY (`id`),
  ADD KEY `articles_article_type_id_foreign` (`article_type_id`),
  ADD KEY `articles_member_id_foreign` (`member_id`);

--
-- Indexes for table `article_translations`
--
ALTER TABLE `article_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `article_translations_article_id_locale_unique` (`article_id`,`locale`),
  ADD KEY `article_translations_locale_index` (`locale`);

--
-- Indexes for table `article_types`
--
ALTER TABLE `article_types`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `article_type_translations`
--
ALTER TABLE `article_type_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `article_type_translations_article_type_id_locale_unique` (`article_type_id`,`locale`),
  ADD KEY `article_type_translations_locale_index` (`locale`);

--
-- Indexes for table `branches`
--
ALTER TABLE `branches`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `branch_translations`
--
ALTER TABLE `branch_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `branch_translations_branch_id_locale_unique` (`branch_id`,`locale`),
  ADD KEY `branch_translations_locale_index` (`locale`);

--
-- Indexes for table `careers`
--
ALTER TABLE `careers`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `career_computer_skills`
--
ALTER TABLE `career_computer_skills`
  ADD PRIMARY KEY (`id`),
  ADD KEY `career_computer_skills_career_id_foreign` (`career_id`);

--
-- Indexes for table `career_educational`
--
ALTER TABLE `career_educational`
  ADD PRIMARY KEY (`id`),
  ADD KEY `career_educational_career_id_foreign` (`career_id`);

--
-- Indexes for table `career_languages`
--
ALTER TABLE `career_languages`
  ADD PRIMARY KEY (`id`),
  ADD KEY `career_languages_career_id_foreign` (`career_id`);

--
-- Indexes for table `career_training_courses`
--
ALTER TABLE `career_training_courses`
  ADD PRIMARY KEY (`id`),
  ADD KEY `career_training_courses_career_id_foreign` (`career_id`);

--
-- Indexes for table `career_work_experience`
--
ALTER TABLE `career_work_experience`
  ADD PRIMARY KEY (`id`),
  ADD KEY `career_work_experience_career_id_foreign` (`career_id`);

--
-- Indexes for table `categories`
--
ALTER TABLE `categories`
  ADD PRIMARY KEY (`id`),
  ADD KEY `categories_product_type_id_foreign` (`product_type_id`);

--
-- Indexes for table `category_translations`
--
ALTER TABLE `category_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `category_translations_category_id_locale_unique` (`category_id`,`locale`),
  ADD KEY `category_translations_locale_index` (`locale`);

--
-- Indexes for table `certificates`
--
ALTER TABLE `certificates`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `constants`
--
ALTER TABLE `constants`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `constant_options`
--
ALTER TABLE `constant_options`
  ADD PRIMARY KEY (`id`),
  ADD KEY `constant_options_constant_id_foreign` (`constant_id`);

--
-- Indexes for table `contacts`
--
ALTER TABLE `contacts`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `failed_jobs`
--
ALTER TABLE `failed_jobs`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `failed_jobs_uuid_unique` (`uuid`);

--
-- Indexes for table `file_reports`
--
ALTER TABLE `file_reports`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `governances`
--
ALTER TABLE `governances`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `governance_translations`
--
ALTER TABLE `governance_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `governance_translations_governance_id_locale_unique` (`governance_id`,`locale`),
  ADD KEY `governance_translations_locale_index` (`locale`);

--
-- Indexes for table `info_careers`
--
ALTER TABLE `info_careers`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `info_career_translations`
--
ALTER TABLE `info_career_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `info_career_translations_info_career_id_locale_unique` (`info_career_id`,`locale`),
  ADD KEY `info_career_translations_locale_index` (`locale`);

--
-- Indexes for table `investor_services`
--
ALTER TABLE `investor_services`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `investor_services_info`
--
ALTER TABLE `investor_services_info`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `languages`
--
ALTER TABLE `languages`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `likes`
--
ALTER TABLE `likes`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `members`
--
ALTER TABLE `members`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `member_translations`
--
ALTER TABLE `member_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `member_translations_member_id_locale_unique` (`member_id`,`locale`),
  ADD KEY `member_translations_locale_index` (`locale`);

--
-- Indexes for table `migrations`
--
ALTER TABLE `migrations`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `model_has_permissions`
--
ALTER TABLE `model_has_permissions`
  ADD PRIMARY KEY (`permission_id`,`model_id`,`model_type`),
  ADD KEY `model_has_permissions_model_id_model_type_index` (`model_id`,`model_type`);

--
-- Indexes for table `model_has_roles`
--
ALTER TABLE `model_has_roles`
  ADD PRIMARY KEY (`role_id`,`model_id`,`model_type`),
  ADD KEY `model_has_roles_model_id_model_type_index` (`model_id`,`model_type`);

--
-- Indexes for table `news_letter`
--
ALTER TABLE `news_letter`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `pages`
--
ALTER TABLE `pages`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `page_lists`
--
ALTER TABLE `page_lists`
  ADD PRIMARY KEY (`id`),
  ADD KEY `page_lists_page_id_foreign` (`page_id`);

--
-- Indexes for table `page_list_translations`
--
ALTER TABLE `page_list_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `page_list_translations_page_list_id_locale_unique` (`page_list_id`,`locale`),
  ADD KEY `page_list_translations_locale_index` (`locale`);

--
-- Indexes for table `page_translations`
--
ALTER TABLE `page_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `page_translations_page_id_locale_unique` (`page_id`,`locale`),
  ADD KEY `page_translations_locale_index` (`locale`);

--
-- Indexes for table `password_reset_tokens`
--
ALTER TABLE `password_reset_tokens`
  ADD PRIMARY KEY (`email`);

--
-- Indexes for table `permissions`
--
ALTER TABLE `permissions`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `permissions_name_guard_name_unique` (`name`,`guard_name`);

--
-- Indexes for table `personal_access_tokens`
--
ALTER TABLE `personal_access_tokens`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `personal_access_tokens_token_unique` (`token`),
  ADD KEY `personal_access_tokens_tokenable_type_tokenable_id_index` (`tokenable_type`,`tokenable_id`);

--
-- Indexes for table `productivities`
--
ALTER TABLE `productivities`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `productivity_translations`
--
ALTER TABLE `productivity_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `productivity_translations_productivity_id_locale_unique` (`productivity_id`,`locale`),
  ADD KEY `productivity_translations_locale_index` (`locale`);

--
-- Indexes for table `products`
--
ALTER TABLE `products`
  ADD PRIMARY KEY (`id`),
  ADD KEY `products_product_type_id_foreign` (`product_type_id`);

--
-- Indexes for table `product_category`
--
ALTER TABLE `product_category`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `product_category_product_id_category_id_unique` (`product_id`,`category_id`),
  ADD KEY `product_category_category_id_foreign` (`category_id`);

--
-- Indexes for table `product_images`
--
ALTER TABLE `product_images`
  ADD PRIMARY KEY (`id`),
  ADD KEY `product_images_product_id_foreign` (`product_id`);

--
-- Indexes for table `product_translations`
--
ALTER TABLE `product_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `product_translations_product_id_locale_unique` (`product_id`,`locale`),
  ADD KEY `product_translations_locale_index` (`locale`);

--
-- Indexes for table `product_types`
--
ALTER TABLE `product_types`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `product_type_translations`
--
ALTER TABLE `product_type_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `product_type_translations_product_type_id_locale_unique` (`product_type_id`,`locale`),
  ADD KEY `product_type_translations_locale_index` (`locale`);

--
-- Indexes for table `project_models`
--
ALTER TABLE `project_models`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `roles`
--
ALTER TABLE `roles`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `roles_name_guard_name_unique` (`name`,`guard_name`);

--
-- Indexes for table `role_has_permissions`
--
ALTER TABLE `role_has_permissions`
  ADD PRIMARY KEY (`permission_id`,`role_id`),
  ADD KEY `role_has_permissions_role_id_foreign` (`role_id`);

--
-- Indexes for table `settings`
--
ALTER TABLE `settings`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `sliders`
--
ALTER TABLE `sliders`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `slider_translations`
--
ALTER TABLE `slider_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `slider_translations_slider_id_locale_unique` (`slider_id`,`locale`),
  ADD KEY `slider_translations_locale_index` (`locale`);

--
-- Indexes for table `stoke_prices`
--
ALTER TABLE `stoke_prices`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `stoke_price_translations`
--
ALTER TABLE `stoke_price_translations`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `stoke_price_translations_stoke_price_id_locale_unique` (`stoke_price_id`,`locale`),
  ADD KEY `stoke_price_translations_locale_index` (`locale`);

--
-- Indexes for table `users`
--
ALTER TABLE `users`
  ADD PRIMARY KEY (`id`),
  ADD UNIQUE KEY `users_email_unique` (`email`);

--
-- AUTO_INCREMENT for dumped tables
--

--
-- AUTO_INCREMENT for table `articles`
--
ALTER TABLE `articles`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=10;

--
-- AUTO_INCREMENT for table `article_translations`
--
ALTER TABLE `article_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=14;

--
-- AUTO_INCREMENT for table `article_types`
--
ALTER TABLE `article_types`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=6;

--
-- AUTO_INCREMENT for table `article_type_translations`
--
ALTER TABLE `article_type_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=10;

--
-- AUTO_INCREMENT for table `branches`
--
ALTER TABLE `branches`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `branch_translations`
--
ALTER TABLE `branch_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=7;

--
-- AUTO_INCREMENT for table `careers`
--
ALTER TABLE `careers`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `career_computer_skills`
--
ALTER TABLE `career_computer_skills`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `career_educational`
--
ALTER TABLE `career_educational`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `career_languages`
--
ALTER TABLE `career_languages`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `career_training_courses`
--
ALTER TABLE `career_training_courses`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `career_work_experience`
--
ALTER TABLE `career_work_experience`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `categories`
--
ALTER TABLE `categories`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=29;

--
-- AUTO_INCREMENT for table `category_translations`
--
ALTER TABLE `category_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=57;

--
-- AUTO_INCREMENT for table `certificates`
--
ALTER TABLE `certificates`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `constants`
--
ALTER TABLE `constants`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=6;

--
-- AUTO_INCREMENT for table `constant_options`
--
ALTER TABLE `constant_options`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=12;

--
-- AUTO_INCREMENT for table `contacts`
--
ALTER TABLE `contacts`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=6;

--
-- AUTO_INCREMENT for table `failed_jobs`
--
ALTER TABLE `failed_jobs`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `file_reports`
--
ALTER TABLE `file_reports`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=39;

--
-- AUTO_INCREMENT for table `governances`
--
ALTER TABLE `governances`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=8;

--
-- AUTO_INCREMENT for table `governance_translations`
--
ALTER TABLE `governance_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=16;

--
-- AUTO_INCREMENT for table `info_careers`
--
ALTER TABLE `info_careers`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=3;

--
-- AUTO_INCREMENT for table `info_career_translations`
--
ALTER TABLE `info_career_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `investor_services`
--
ALTER TABLE `investor_services`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `investor_services_info`
--
ALTER TABLE `investor_services_info`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `languages`
--
ALTER TABLE `languages`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=3;

--
-- AUTO_INCREMENT for table `likes`
--
ALTER TABLE `likes`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `members`
--
ALTER TABLE `members`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=28;

--
-- AUTO_INCREMENT for table `member_translations`
--
ALTER TABLE `member_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=55;

--
-- AUTO_INCREMENT for table `migrations`
--
ALTER TABLE `migrations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=37;

--
-- AUTO_INCREMENT for table `news_letter`
--
ALTER TABLE `news_letter`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `pages`
--
ALTER TABLE `pages`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=26;

--
-- AUTO_INCREMENT for table `page_lists`
--
ALTER TABLE `page_lists`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `page_list_translations`
--
ALTER TABLE `page_list_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=7;

--
-- AUTO_INCREMENT for table `page_translations`
--
ALTER TABLE `page_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=50;

--
-- AUTO_INCREMENT for table `permissions`
--
ALTER TABLE `permissions`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `personal_access_tokens`
--
ALTER TABLE `personal_access_tokens`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `productivities`
--
ALTER TABLE `productivities`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=5;

--
-- AUTO_INCREMENT for table `productivity_translations`
--
ALTER TABLE `productivity_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=9;

--
-- AUTO_INCREMENT for table `products`
--
ALTER TABLE `products`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=154;

--
-- AUTO_INCREMENT for table `product_category`
--
ALTER TABLE `product_category`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=168;

--
-- AUTO_INCREMENT for table `product_images`
--
ALTER TABLE `product_images`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=166;

--
-- AUTO_INCREMENT for table `product_translations`
--
ALTER TABLE `product_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=154;

--
-- AUTO_INCREMENT for table `product_types`
--
ALTER TABLE `product_types`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `product_type_translations`
--
ALTER TABLE `product_type_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=7;

--
-- AUTO_INCREMENT for table `project_models`
--
ALTER TABLE `project_models`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=47;

--
-- AUTO_INCREMENT for table `roles`
--
ALTER TABLE `roles`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `settings`
--
ALTER TABLE `settings`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=32;

--
-- AUTO_INCREMENT for table `sliders`
--
ALTER TABLE `sliders`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=9;

--
-- AUTO_INCREMENT for table `slider_translations`
--
ALTER TABLE `slider_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=11;

--
-- AUTO_INCREMENT for table `stoke_prices`
--
ALTER TABLE `stoke_prices`
  MODIFY `id` bigint(20) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=2;

--
-- AUTO_INCREMENT for table `stoke_price_translations`
--
ALTER TABLE `stoke_price_translations`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=3;

--
-- AUTO_INCREMENT for table `users`
--
ALTER TABLE `users`
  MODIFY `id` int(10) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=5;

--
-- Constraints for dumped tables
--

--
-- Constraints for table `articles`
--
ALTER TABLE `articles`
  ADD CONSTRAINT `articles_article_type_id_foreign` FOREIGN KEY (`article_type_id`) REFERENCES `article_types` (`id`) ON DELETE CASCADE,
  ADD CONSTRAINT `articles_member_id_foreign` FOREIGN KEY (`member_id`) REFERENCES `members` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `article_translations`
--
ALTER TABLE `article_translations`
  ADD CONSTRAINT `article_translations_article_id_foreign` FOREIGN KEY (`article_id`) REFERENCES `articles` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `article_type_translations`
--
ALTER TABLE `article_type_translations`
  ADD CONSTRAINT `article_type_translations_article_type_id_foreign` FOREIGN KEY (`article_type_id`) REFERENCES `article_types` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `branch_translations`
--
ALTER TABLE `branch_translations`
  ADD CONSTRAINT `branch_translations_branch_id_foreign` FOREIGN KEY (`branch_id`) REFERENCES `branches` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `career_computer_skills`
--
ALTER TABLE `career_computer_skills`
  ADD CONSTRAINT `career_computer_skills_career_id_foreign` FOREIGN KEY (`career_id`) REFERENCES `careers` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `career_educational`
--
ALTER TABLE `career_educational`
  ADD CONSTRAINT `career_educational_career_id_foreign` FOREIGN KEY (`career_id`) REFERENCES `careers` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `career_languages`
--
ALTER TABLE `career_languages`
  ADD CONSTRAINT `career_languages_career_id_foreign` FOREIGN KEY (`career_id`) REFERENCES `careers` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `career_training_courses`
--
ALTER TABLE `career_training_courses`
  ADD CONSTRAINT `career_training_courses_career_id_foreign` FOREIGN KEY (`career_id`) REFERENCES `careers` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `career_work_experience`
--
ALTER TABLE `career_work_experience`
  ADD CONSTRAINT `career_work_experience_career_id_foreign` FOREIGN KEY (`career_id`) REFERENCES `careers` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `categories`
--
ALTER TABLE `categories`
  ADD CONSTRAINT `categories_product_type_id_foreign` FOREIGN KEY (`product_type_id`) REFERENCES `product_types` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `category_translations`
--
ALTER TABLE `category_translations`
  ADD CONSTRAINT `category_translations_category_id_foreign` FOREIGN KEY (`category_id`) REFERENCES `categories` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `constant_options`
--
ALTER TABLE `constant_options`
  ADD CONSTRAINT `constant_options_constant_id_foreign` FOREIGN KEY (`constant_id`) REFERENCES `constants` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `governance_translations`
--
ALTER TABLE `governance_translations`
  ADD CONSTRAINT `governance_translations_governance_id_foreign` FOREIGN KEY (`governance_id`) REFERENCES `governances` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `info_career_translations`
--
ALTER TABLE `info_career_translations`
  ADD CONSTRAINT `info_career_translations_info_career_id_foreign` FOREIGN KEY (`info_career_id`) REFERENCES `info_careers` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `member_translations`
--
ALTER TABLE `member_translations`
  ADD CONSTRAINT `member_translations_member_id_foreign` FOREIGN KEY (`member_id`) REFERENCES `members` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `model_has_permissions`
--
ALTER TABLE `model_has_permissions`
  ADD CONSTRAINT `model_has_permissions_permission_id_foreign` FOREIGN KEY (`permission_id`) REFERENCES `permissions` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `model_has_roles`
--
ALTER TABLE `model_has_roles`
  ADD CONSTRAINT `model_has_roles_role_id_foreign` FOREIGN KEY (`role_id`) REFERENCES `roles` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `page_lists`
--
ALTER TABLE `page_lists`
  ADD CONSTRAINT `page_lists_page_id_foreign` FOREIGN KEY (`page_id`) REFERENCES `pages` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `page_list_translations`
--
ALTER TABLE `page_list_translations`
  ADD CONSTRAINT `page_list_translations_page_list_id_foreign` FOREIGN KEY (`page_list_id`) REFERENCES `page_lists` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `page_translations`
--
ALTER TABLE `page_translations`
  ADD CONSTRAINT `page_translations_page_id_foreign` FOREIGN KEY (`page_id`) REFERENCES `pages` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `productivity_translations`
--
ALTER TABLE `productivity_translations`
  ADD CONSTRAINT `productivity_translations_productivity_id_foreign` FOREIGN KEY (`productivity_id`) REFERENCES `productivities` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `products`
--
ALTER TABLE `products`
  ADD CONSTRAINT `products_product_type_id_foreign` FOREIGN KEY (`product_type_id`) REFERENCES `product_types` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `product_category`
--
ALTER TABLE `product_category`
  ADD CONSTRAINT `product_category_category_id_foreign` FOREIGN KEY (`category_id`) REFERENCES `categories` (`id`) ON DELETE CASCADE,
  ADD CONSTRAINT `product_category_product_id_foreign` FOREIGN KEY (`product_id`) REFERENCES `products` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `product_images`
--
ALTER TABLE `product_images`
  ADD CONSTRAINT `product_images_product_id_foreign` FOREIGN KEY (`product_id`) REFERENCES `products` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `product_translations`
--
ALTER TABLE `product_translations`
  ADD CONSTRAINT `product_translations_product_id_foreign` FOREIGN KEY (`product_id`) REFERENCES `products` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `product_type_translations`
--
ALTER TABLE `product_type_translations`
  ADD CONSTRAINT `product_type_translations_product_type_id_foreign` FOREIGN KEY (`product_type_id`) REFERENCES `product_types` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `role_has_permissions`
--
ALTER TABLE `role_has_permissions`
  ADD CONSTRAINT `role_has_permissions_permission_id_foreign` FOREIGN KEY (`permission_id`) REFERENCES `permissions` (`id`) ON DELETE CASCADE,
  ADD CONSTRAINT `role_has_permissions_role_id_foreign` FOREIGN KEY (`role_id`) REFERENCES `roles` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `slider_translations`
--
ALTER TABLE `slider_translations`
  ADD CONSTRAINT `slider_translations_slider_id_foreign` FOREIGN KEY (`slider_id`) REFERENCES `sliders` (`id`) ON DELETE CASCADE;

--
-- Constraints for table `stoke_price_translations`
--
ALTER TABLE `stoke_price_translations`
  ADD CONSTRAINT `stoke_price_translations_stoke_price_id_foreign` FOREIGN KEY (`stoke_price_id`) REFERENCES `stoke_prices` (`id`) ON DELETE CASCADE;
COMMIT;

/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
